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CHAPTER 1 
BACKGROUND 
1.1    Introduction 
 Therapeutic drugs are crucial in the fight against infectious diseases caused by 
many viruses, bacteria, parasites and fungi.  In recent years, there have been an increasing 
number of microbial resistances against many commonly used drugs e.g. anti-biotic, anti-
malaria, anti-tuberculosis, anti-HIV, anti-retrovials.  Although, over the last decade, 
genetics and molecular biology have advanced at a rapid pace in an attempt to alleviate 
various drug resistance issues, the number of new antibiotic or antimicrobial drugs that 
can cure microbial infection has decreased.1  Diversity-oriented synthesis (DOS) aims to 
generate structural and skeletal diversity from simple and common starting precursors to 
provide libraries of compounds that increase the statistical likelihood of finding new drug 
candidates with improved potency. 
Although, many bioactive natural compounds are not assembled with desired 
pharmacokinetic properties and efficacy, they represent a suitable class of molecules for 
the discovery of new drugs.  Most prescribed drugs are either small, natural products, 
derivatives thereof, or designer synthetic small molecules.  A majority of these drugs are 
cyclic, often contain “privileged scaffolds” and numerous hetero atoms.2  Despite recent 
advancement in combinatorial and synthetic chemistry, heterocyclic building blocks 
including those that are suitably functionalized, are not easy to access.  With all that 
being said, there is a need to develop new synthetic strategies that can rapidly generate 
libraries of diverse drug-like molecules in few transformations with column 
chromatography kept to a minimum.2  Amongst many strategies employed to generate 
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molecular diversity, to date, multicomponent coupling reactions (MCCRs) have emerged 
as a very efficient and powerful strategy that incorporate the new ethos for library 
development.3  Hence, there are concerted efforts among the scientific community to 
develop new MCCRs and design strategies incorporating existing MCCRs to generate 
skeletal and structural diversity that may or may not contain a “privileged scaffold”.3 
 
1.1.    Multicomponent Coupling Reactions: A Tandem Sequential Reaction 
Natural products are an invaluable source of inspiration for the development of 
new reaction methodologies and strategies.  Over the last two decades, modern organic 
syntheses have advanced dramatically.  However, the synthesis of complicated natural 
products requires multistep, protection-deprotection strategies at times, costly reagents 
and throughout the endeavor cumbersome purification processes.  Although, natural 
product synthesis is an indispensable part for the advancement of organic chemistry and 
drug discovery, the encompassing concepts of effective, economical “ideal organic 
synthesis” have yet to be fully modernized. 
 
Ideal Synthesis
Simple
One Pot
Time-Saving
Environmetally Benign
Readily Available Starting Materials
Total conversion
100% yield
 
Figure 1. Schematic representation of an ideal organic synthesis (inspired from Wender 
et al.)4 
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 According to Wender, an ideal synthesis (Figure 1) should provide the target 
compound in fewest possible steps, in high yield, using cheap, environmentally benign 
reagents and should produce the least amount of waste.4  In contrast to traditional organic 
reactions, domino/cascade reactions are more atom-economical and can provide a wide 
array of complex molecules in an efficient, stereocontrol manner.  According to 
Nicolaou, the classification of tandem, cascade, sequential or domino reactions are not 
well defined in literature and often indistinguishable from one another.5 
Tietze has defined a cascade (domino) reaction in which two or more bond-
forming events take place based on prior formed functionalities without changing 
reaction conditions and additional reagents, catalysts, or additives.6,7  Furthermore, 
Denmark defined that most cascade (domino) reactions fall under the broader category of 
tandem processes: (a) cascade or domino reactions; (b) consecutive reactions; (c) 
sequential reactions.8 
A tandem cascade reaction, as suggested by Denmark, follows the same criteria as 
defined by Tietze, i.e., the reaction should occur without the change of reaction 
conditions and addition of extra reagents or additives or even catalysts.  In addition, the 
intermediates are non-isolatable and bring forth required structural change for the 
following steps (Scheme 1).9 
 
 
Scheme 1.  Example of a tandem cascade reaction. 
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In contrary to tandem cascade reaction, intermediates are isolatable in a tandem 
consecutive reaction and they contain the requisite functionality for the next desired step.  
However, the next step usually has higher activation energy and additional energy in the 
form of light or heat or catalyst is required.  As shown in Scheme 2, additional activation 
energy in the form of heat is required to drive the reaction to the final product B8 from the 
isolatable intermediates B6 and B7.10 
 
 
Scheme 2.  Example of a tandem consecutive reaction. 
 
A tandem sequential reaction requires the addition of extraneous reagents and 
potential changes in conditions.  The intermediates contain requisite functionalities for 
the next step and may be isolated.  However, isolation of the intermediate it is not 
necessarily a requirement.  As shown in Scheme 3, the intermediate B10 is isolatable and 
requires addition of B11 and a change in reaction conditions to provide B12.11 
 
 
Scheme 3.  Example of a tandem sequential reaction. 
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 According to the classification of tandem reactions suggested by Tietze and 
Denmark, multicomponent coupling reactions (MCCRs) are a special class of tandem 
sequential reactions in which at least three starting materials or coupling 
partners/components react together to form a product in such a way that the maximum 
number of atoms of the reacting components can be found in the target molecule.12  In a 
typical MCCR, the coupling partners do not react concurrently in a single step; instead in 
sequential elementary steps.  Many of the MCCRs often involve an irreversible step that 
drives the overall reaction in favor of the final product. 
 MCCRs can be further classified into three categories depending upon different 
types of equilibrium involved.  Type-I MCCRs are those in which the equilibrium 
between reacting components, intermediates and products are changeable.  In general, 
type-I MCCRs are incomplete and vulnerable to side product formation that lead to 
extraneous isolation protocols.  The Strecker reaction is an example of type-I MCCR. 
 On the other hand, in type-II MCCRs, the reacting components and intermediates 
are in equilibrium and lead to partial reactivity.  However, the last highly exothermic and 
irreversible step drives the overall reaction to the product side.  The exothermic step 
usually involves a change in oxidation state of carbon (CII→CIV),13 ring closure, or an 
aromatization event.  The Biginelli, Passerini and Ugi reactions are the most widely 
studied and successful type II MCCRs. 
 Reactions in which each elementary step is irreversible are known as type-III 
MCCRs.  Most biomimetic reactions fall into this highly selective category.  An example 
of type-III MCCR is the ATP coupling during phosporylation. 
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 Depending upon the functional groups present in the coupling partners, MCCRs 
can be further categorized as imine-based MCCRs (IMCCRs), isocyanide-based MCCRs 
(ICMCCRs) and carbene-based MCCRs (CMCCRs).  For example, the Passerini three 
component coupling reaction (P-3CCR) is an ICMCCR, whereas the Ugi four component 
coupling reaction (U-4CCR) belongs to both IMCCRs and ICMCCRs. 
By employing a few multifunctional starting materials, alternative source of 
energy and altering the sequence of addition of coupling partners; a single synthetic 
transformation can provide diverse array of products.  Moreover, “off-the-shelf” starting 
materials can be used in many known MCCRs and many other common starting materials 
are easily accessible.  Thus, many known MCCRs have emerged as an effective tool for 
environmentally benign and atom economic syntheses of diverse small, complex 
architectures in a single operation by virtue of their convergent nature, high yield, facile 
execution and generation of less waste materials.14  Consequently, in comparison to 
multistep total synthesis, rationally, the MCCRs are a close fit to the concept of an “ideal 
synthesis” as suggested by Wender. 
 160 years ago, Strecker had reported that condensation of the benzaldehyde, 
potassium cyanide and ammonium chloride generates the α-amino cyanide (B14) which 
upon subsequent hydrolysis provides the desired α-amino acid B15 (Scheme 4).15  The 
reaction is generally accepted to be the first MCCR and commonly described as S-3CCR 
after Strecker.  However, in 1838, Laurent and Gerhardt had isolated a product called 
hydrocyanic acid-containing benzaldehyde (B16) that reacted with ammonia, giving 
aminobenzyl cyanide (B14) via a S-3CCR (Scheme 5).16 
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Scheme 4. Strecker α-amino acid synthesis: the 1st MCCR 
 
 
Scheme 5. The purported 1st MCCR. 
 Over the past century, many new MCCRs were discovered and employed in the 
synthesis of many heterocycles.  Among those MCCRs the Asinger reaction (A-4CCR)17, 
Radziszewski reaction (R-3CCR)18, Hanztsch dihydropyridine (H-4CCR) synthesis19, 
Hantzsch pyrrole synthesis,20 Bignelli reaction (B-3CCR)21, Mannich reaction (M-
3CCR)22, Passerini (P-3CCR) reaction23, Ugi (U-4CCR) reaction24, Bucherer-Bergs (BB-
4CCR) reaction25, Kabachnik-Field (KF-3CCR) reaction26, Petasis (Pt-3CCR) reaction27, 
Gewald reaction (G-3CCR)28, Groebke-Blackburn-Bienyeme reaction (GBB-3CCR)29, 
Passerini-Smiles reaction (PS-3CCR)30, Ugi-Smiles reaction (US-4CCR)31 have become 
very useful in combinatorial chemistry as well as in diversity-oriented synthesis for 
diversification of libraries and have helped to increase chemical space.  It is noteworthy 
that isocyanides have been found to be a versatile coupling partner in many of the 
aforementioned MCCRs.12 
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1.2.    History of Isonitriles/Isocyanides 
 In 1859, Leike had synthesized the first isonitrile (allyl isonitrile) while he was 
studying the conversion of nitriles into corresponding carboxylic acids.32  Isonitriles are 
also known as isocyanides and often times the scientific community will intermix their 
terminology.  Other than few stable carbenes e.g. the N-heterocyclic carbenes (NHCs), 
the ICs are the only known organic compounds having divalent (CII) carbon and quite 
stable.  Due to their very unusual valence shell electron configuration they exhibit 
extraordinary reactivity and thus, fundamentally differ from other functional groups.33  
Their versatile reactivity made them very useful functional handles not only in MCCRs 
but also in a variety of organic reactions including free radical addition34a, Ferrier 
rearrangement,34b organometallic transformation like the Pauson-Khand reaction35 and 
polymerizations.36 
It has been widely described that most commercially available isocyanides are 
volatile and carry repulsive odor “which is reminiscent of artichokes and phosphorous at 
the same time.”37  Ugi admits “The development of the chemistry of isonitriles has 
probably suffered through the characteristic odor of volatile isonitriles, which has been 
described by Hofmann and Gautier as ‘highly specific, almost overpowering’, ‘horrible’, 
and ‘extremely distressing’”.  Demhardter et al. further noted that very long-term 
inhalation of volatile isocyanides e.g., the allyl, benzyl, methyl, or tert-butyl isocyanides 
can lead to sensory disorder and intense dreams.3a 
 
A few liquid ICs e.g., the isomeric picolyl isocyanides do not smell and the L-
phenylglycine methyl ester has the smell of rhubarb plant.  Notably, most solid 
isocyanides have been found to be very less repulsive or odorless. 
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Over 3000 isocyanides are known and several methods for their synthesis have 
been developed in the past few decades.38 Due to their very offensive odor and 
preparative difficulty, only few isocyanides are commercially available.  This limits the 
scope of routine experimentations and thereby rapid generation of molecular diversity.  
Thus, over the past decade, the scientific community has continued to devise 
preparatively easy routes for the synthesis of isonitriles/isocyanides (Table 1).39-43 
 
Table 1. Recently developed methods for isocyanides/isonitriles synthesis. 
Kitano (1998)39 
 
McCarthy (1998)40 
 
Pirrung (2003)41 
 
Porcheddu (2005)42 
 
Mukaiyama (2005)43 
 
 
 Furthermore, scientific community showed interest in developing fragrant 
smelling isocyanides to avoid their repulsive odor during experimentation.  In addition, 
the U-4CCR products derived from most ‘off-the-shelf’ isocyanides, typically can not be 
modified at the N-terminal of the dipeptide without using harsh reaction conditions which 
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are not usually compatible with many commonly used functional groups.  Despite 
profound advancement of the art of organic synthesis, selective hydrolysis of secondary 
amide functional groups is a nontrivial task in highly functionalized organic compounds.  
This further limits the scope of generating molecular diversity by post-Ugi modification.  
Thus, in recent years, there has been a growing interest among the scientific community 
to develop fragrant-like ‘convertible isocyanides’ (CICs).  These new CICs (Figure 2) by 
virtue of their selective cleavage ability, have been found to be useful for the synthesis of 
diverse small molecules as well as complex natural products having biological activities 
related to human health.44 
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Figure 2. Convertible isocyanides employed in MCCRs. 
 
1.3.    Multicomponent Name Reactions 
 Among many MCCRs, the isocyanide/isonitrile-based P-3CCR and U-4CCR have 
been most widely used in combinatorial synthesis.  In recent years, there is a revival of 
interest in devising new variations of these MCCRs as exemplified in this section. 
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(a) Passerini Reaction:  In 1921, Italian scientist Mario Passerini had discovered that an 
aldehyde (or ketone), isocyanide and carboxylic acid can condense together to provide α-
acyloxycarboxamides in one step (Scheme 6).23  Typically, the reaction has been reported 
to accelerate in aprotic solvents and thus possibly non-ionic intermediates are involved.45  
Many pharmaceutically active compounds contain the α-acyloxycarboxamide moiety 
(B43).  The reaction has been named after Passerini and generally described as P-3CCR. 
 
 
Scheme 6. The P-3CCR for synthesis of α-acyloxycarboxamides. 
 
 
Scheme 7. Mechanism of the P-3CCR. 
 
 The most widely accepted mechanism of the P-3CCR is depicted in Scheme 7.  
Initially, the carbonyl compound B40 and a carboxylic acid B41 forms an adduct B44 via 
hydrogen-bonding.  The isocyanide attacks the electrophilic carbonyl carbon, following 
which the carboxylate attacks the terminal electrophilic carbon of the isocyanide to 
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provide the α-addition intermediate B46 via a cyclic transition state. The non-isolatable α-
addition intermediate B46 then provides more stable α-acyloxy carboxamide B43 via an 
intramolecular transacylation. 
(b) Ugi Reaction:  In 1959, German chemist Ivar Karl Ugi discovered that an amine, 
aldehyde, carboxylic acid and isocyanide condense together to provide α-
acylaminoamide (Scheme 8).24  Typically, the Ugi reaction requires protic polar solvents 
e.g. methanol.  In general, the reaction works well with high concentration of starting 
materials.  McFarland noted that the reactivity of the isocyanides is primarily influenced 
by electronic effects and reactant concentration plays more of an important role than the 
properties of the solvent.46  The reaction has been named after Ugi and commonly 
described as U-4CCR.  The U-4CCR generates one new C-C bond and several carbon-
hetero atom bonds are concommitantly formed. 
 
 
Scheme 8. The U-4CCR. 
 
In Scheme 9, two postulated mechanisms of the U-4CCR are shown.47  
Condensation of the amine B47 and the oxo compound B48 (aldehyde or ketone) forms 
imine B50 in the first step of two pathways.  The nitrogen of the imine, thus increases the 
electrophilicity of the C=N bond.  The next step involves the protonation of imine that 
leads to formation of iminium-carboxylate ion-pair B51 (depending upon solvent) 
followed by nucleophilic attack of isocyanide carbon atom onto the electrophilic iminium 
carbon atom and nucleophilic attack of the carboxylate anion onto the electrophilic 
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isocyanide carbon atom to form B53.  Alternatively, the formation of ester B54 can take 
place via nucleophilic attack of the carboxylate anion, followed by SN2 attack of B42 onto 
the α-carbon to form B53.  However, because of competing reactions and other equilibria 
involved, detail experimentations to support the formation of intermediate B52 versus B54 
have not been reported.47  Although, the debate still rages over possible intermediates, 
formation of intermediate B52 has been widely accepted by the scientific community. 
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Scheme 9. Mechanism of the U-4CCR. 
 
Intramolecular acylation of nitrogen derived from the amine component provides 
the intermediate B55.  This type of intramolecular acylation is known as the Mumm 
rearrangement.48  The Mumm rearrangement has been widely accepted as the rate 
determining step of the U-4CCR.  After the intramolecular acylation, the hydroxylamine 
converts to stable amide to provide the final U-4CCR α-acylaminoamide B49 (Scheme 9). 
Although, the P-3CCR and U-4CCR are closely related, stereochemical control of 
the U-4CCR has proven to be difficult despite the development of chiral Lewis acid 
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catalysts for the P-3CCR.49  Use of Lewis acid catalysts, chiral starting materials, low 
temperature or low concentration of the isocyanides in the U-4CCR provided low 
enantioselectivity (<11:1).50 
 
 
Figure 3.  Bifunctional substrate and chiral auxiliaries employed in the U-4CCR. 
 
Several chiral auxiliaries e.g. chiral amine auxiliaries and bifunctional substrates  
have been developed to control the stereoselectivity of the U-4CCR and many of them 
provided good-to-excellent enantioselectivity (<99:1) and yield (43-91%) respectively 
(Figure 3).51  Kunz and co-workers have reported that when pivaloyl 
galactopyranosylamine B58 and zinc chloride etherate were employed in stoichiometric 
amounts, the U-4CCR provided R-configured products; on the other hand 
arabinosylamine (not shown) provided the corresponding S-configured products.  Both 
the chiral amines provided excellent enantioselectivity (>99:1), good-to-excellent yields 
and can be cleaved in two additional steps.52  Most recently, Kunz and co-workers have 
developed, chiral thio-xylopyranosyl amine auxiliary B59 which provided both R- or S- 
configured products in good diatereoselectivity (96:4) and yield (92%) and can be 
cleaved under mild conditions.53 
 
(d) Passerini-Smiles Reaction:  Recently, Grimaud and coworkers30 discovered that 
phenolic compounds having strong electron-withdrawing groups are sufficiently acidic to 
replace carboxylic acid in the P-3CCR and can provide similar type of products (Scheme 
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10).  Various substituted o-nitrophenol as well as o-nitro substituted hydroxyquinolines, 
pyridines and 4-hydroxypyrimidines provides desired products in moderate yield. 
 
Scheme 10. The Passerini-Smile three component reaction (PS-3CCR). 
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Scheme 11. Postulated mechanism of the PS-3CCR. 
 
 A postulated mechanism of the PS-3CCR is shown in Scheme 11.  Protonation of 
the carbonyl forms the activated intermediate B62 and nucleophilic attack by isocyanide 
B42 onto the electrophilic α-carbon of B62 generates the intermediate B63.  The 
nucleophilic phenolate ion then attacks the electrophilic carbon of the isocyanide and 
traps the nitrilium intermediate to form imidate B64 which then undergoes Smiles 
rearrangement54 to provide the desired product B61. 
(e) Ugi-Smiles reaction:  Laurent El Kaim’s group from France has modified the Ugi 
reaction by replacing the carboxylic acid component with phenolic derivatives having 
strong electron-withdrawing groups to couple with the Smiles rearrangement.  Thus, an 
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amine, aldehyde, phenolic compound and isocyanide condense to provide the Ugi-Smiles 
product 79 (Scheme 12).30b,31  Phenolic compounds act as proton donor-like carboxylic 
acids and generally require the presence of a strong electron withdrawing group at the 
para or ortho position to the hydroxyl group of the phenol.  The reaction works well in 
polar protic solvents like methanol at elevated temperature. 
 
 
Scheme 12. The Ugi-Smiles four component reaction (US-4CCR). 
 
 
Scheme 13. Mechanism of the US-4CCR. 
 
 The mechanism of the Ugi-Smiles reaction (Scheme 13) is quite similar to that of 
the Ugi reaction (Scheme 9).  The amine and aldehyde condense to form the imine B50.  
The phenolic compound protonates the imine B50 and activates the carbon atom of the 
C=N bond.  The isocyanide attacks the electrophilic carbon of the activated imine-
phenolate ion-pair B66 and the phenolate ion attacks the electrophilic carbon of the 
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isocyanide in the intermediate B52.  Smiles rearrangement54 of the α-adduct B67 provides 
the final product B65 (Scheme 13). 
 The versatility of MCCRs is often referred to its exploratory power (EN).  All 
multicomponent reactions do not have the same EN.  For example, if the number of 
starting materials in a MCCR is N for each of the four components (e.g. U-4CCR or 
Povarov 4CCR), the exploratory power EN = N4 = 10004 = 1×1012; which means that 
1000 trillion products could be potentially accessible from only 4000 starting materials.55  
Thus, a 7-CCR would have more exploratory power than a 3-CCR; would provide more 
potentially accessible products when 7 starting materials are variable.  For example, the 
synthesis of 1,3-oxathiolan via three component reaction of epoxides, sulfur and carbon 
dioxide developed by Sonoda, is an example of MCCR having low EN since two 
components (sulfur and carbon monoxide) are not variable (Scheme 14).55e 
 
 
Scheme 14. 1,3-oxathiolan synthesis via Sonoda’s 3-CCR. 
 
In recent years, there is a growing tendency among the scientific community to 
combine two or more MCCRs to increase dimensionality and access diverse and complex 
products.  Thus, the Asinger-Ugi (Ugi-Dömling) reaction (U-8C-7CCR),56 U-5CCR,57 
Interrupted Ugi reaction,58 Ugi-Ugi reaction (U-8CCR),59 Tandem Ugi-Passerini reaction 
(U-7C-6CCR),60 Petasis-Ugi reaction (U-7C-6CCR).61 have been developed over the 
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years to increase EN.  In addition, MCCRs have been used in conjunction other reaction 
such as Diels-Alder, Heck reaction, RCM and others.62 
 
1.4.    Application of Multicomponent Reactions in Natural Product Total Synthesis 
In recent years there have been a number of applications of MCCRs in total 
synthesis.  Interestingly, in several cases other traditional methods failed to provide the 
desired product in appreciable yield, but selective MCCRs provided the desired product 
in good yield.  Moreover, MCCRs have been employed as key step in many total 
syntheses. 
 The Eurystatins A and B are isolated from Streptomyces eurythermus R353-21.  
These 13-membered macrocyclic compounds have shown to strongly inhibit the serine 
protease prolyl endopeptidase (PEP).  Semple and co-workers have reported a short total 
synthesis of Eurystatin A (B76) employing the P-3CCR/amine deprotection/acyl 
migration (PADAM) strategy (Scheme 15).63 
 
 
Scheme 15.  Total synthesis of Eurystatin A using the P-3CCR. 
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 Dömling and co-workers have developed a de novo strategy for the first total 
synthesis of tubulysin V (B82) and U (B83) employing Lewis acid catalyzed Passerini-type 
3CCR using Schöllkopf’s isocyanide (B79) (Scheme 16).  The first step works best when 
the reaction is carried out at -78 oC under inert atmosphere.64 
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Scheme 16. Total synthesis of tubulysin V and U employing P-3CCR type reaction. 
 
 
Scheme 17. Application of the U-4CCR in the total synthesis of Ecteinascidin 743. 
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 The antitumor antibiotic Ecteinascidine 743 (B89) of the marine tunucate, 
Ecteinascidia turbinate, is currently undergoing advanced clinical trials and has been 
approved for the treatment of soft tissue sarcomas in Europe.65  The total synthesis of B89 
was achieved by the Fukuyama group in 37 steps utilizing a planned U-4CCR as a key 
reaction that generated the important precursor B88 containing significant architecture as 
part of the final target molecule (Scheme 17).66 
 Similarly, Fukuyama et al.67 have employed the U-4CCR in the stereocontrolled 
synthetic approach (Scheme 18) for the total synthesis of antitumor antibiotic 
tetrahydroisoquinoline alkaloid (-)-Lemonomycin (B95) which was isolated from the 
fermentation broth of Streptomyces candidus (LL-AP191).68  Zhu and coworkers are also 
studying the synthesis of B95 using U-4CCR as a key step in the their strategy (Scheme 
18) as well.69  Several other biologically relevant natural products have been synthesized 
using MCCR as a key step in their synthetic strategy.70 
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Scheme 18. Utilization of U-4CCR in the synthesis of (-)-Lemonomycin. 
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1.5.    Application of MCCRs in Drug Discovery 
 Although, in the last decade MCCRs have not been utilized much in drug 
discovery process, recent advancement of high-throughput-screening (HTS) have led the 
scientific community in pharmaceutical companies as well as in academia to apply 
MCCRs in particular IMCCRs for rapid identification of drug-like molecules.  Among 
several known MCCRs, the U-4CCR was first applied for the synthesis of local 
anesthetic XylocaineTM (114) by the pharmaceutical company AB Astra (Scheme 19).71 
 
Scheme 19. Synthesis of Xylocaine using U-4CCR. 
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 Merck research has utilized the U-4CCR as a key step for the large scale synthesis 
of CrixivanTM (B106) which is currently marketed as an HIV-1 aspartyl protease 
inhibitor.72  Researchers in the Hofmann and LaRoche company recently found two 
desirable thrombin inhibitors B111, B112 using the U-4CCR (Scheme 20).73 
In recent years, MCCRs have become a rapid platform in the drug discovery 
process and many MCCR-derived small molecules showed promising results in clinical 
trials.  For example, tubulin inhibitor B113, kinase inhibitor B114, aspartyl-protease 
inhibitor B115, serine-protease inhibitor B116, phosphatase inhibitor B117, metallo-protease 
inhibitor B118, CCR5 antagonist B119, antituberculosis B120, antiproliferative B121, protein-
protein interaction inhibitor B122 and cystine protease inhibitor B123 to name a few 
(Figure 4).70b, 74 
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1.6.    Diversity-Oriented Synthesis of Small Molecules 
Small molecules are known to interact with the active site of proteins, enzymes 
and disrupt biological events.  Thus they have been used frequently by chemists to study 
various complicated biological systems in order to develop new therapeutic agents.75  
However, many naturally occurring small molecules do not induce the desired biological 
response and thus further structural modifications are required. 
 In target-oriented synthesis (TOS), a specific target molecule in chemical space is 
usually deconstructed in a backward direction via a retrosynthetic analysis pioneered by 
Woodward and Corey;76 then reconstructed in the forward direction.  Whereas, in 
diversity-oriented synthesis (DOS), wide arrays of structurally and skeletally diverse, 
complex molecules can be synthesized in the forward direction from simple, readily 
available starting materials via “split-pool” concept of combinatorial synthesis (Scheme 
5).77  Since, DOS has the ability to generate structurally as well skeletally rigid and 
complex molecules (spirocycles, fused-polycycles, macrocycles etc.), it has emerged as a 
very powerful tool to provide a diverse library of compounds that can be screened against 
an entire collection of enzymes or proteins.78 
 
 
Figure 5. Schematic representation of TOS, traditional combinatorial synthesis and DOS 
(adapted from Spring et al. with permission from Prof. Spring).79 
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 Since the mantra of DOS strategy does not provide identical compounds and 
incorporates structural diversity, any racemic synthesis of diverse compounds can also be 
classified as DOS.  The DOS strategy is designed in such way that it incorporates both 
diversity and complexity.  Since the number of all possible “drug-like” molecules is 
calculated to be astronomical, it is quite impossible to synthesize the entire chemical 
space.80  Hence, ideal goal of DOS is to cover maximum possible chemical space that 
will not only include “drug-like” but also skeletally diverse molecules.80 
There are four key types of diversity strategies those must be incorporated in 
designing a DOS: (a) appendage diversity (employing various suitably functionalized 
precursors); (b) stereochemical diversity (employing chiral reagents); (c) functional 
group diversity; (iv) skeletal diversity.81  Among these, the skeletal diversity is the most 
important strategy in DOS.81b  Skeletal diversity can be achieved via  branching pathways 
or folding pathways (Figure 6).  In a branching pathway, different reagents are used to 
convert a specific starting material into various scaffolds using various reagents.  Thus, 
branching pathway is often referred to as “reagent-based approach”.  On the other hand, 
in the folding pathway, similar reagents are used to obtain varying scaffolds from pre-
encoded starting materials from MCCRs or others (σ-elements) and are often referred to 
as a “substrate-based approach”. 
 
Figure 6. Pathways of skeletal diversity (adapted from Spring et al. with permission from 
Prof. Spring).79 
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 Branching pathways can be achieved via either pluripotent functionality strategy 
or multiple group pair strategy.  Recently, Schreiber and co-workers have described a 
build/couple/pair strategy which combines many essentials from the above described 
approaches.82  The required chiral starting units are “built” from chiral pool reagents and 
they are then transformed into densely functionalized molecules through coupling 
condensation reactions (e.g. MCCRs).  Specific transformations of the densely 
functionalized molecules generate various structural motifs (Scheme 21).83 
 
Scheme 21. An example of build/couple/pair strategy in DOS.122 
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1.7.    Microwave-Assisted Organic Synthesis for Diversity in MCCRs 
 During the World War II, Percy LeBaron Spencer accidentally discovered that 
microwave (µwave) energy could cook food while experimenting with radar waves 
during his tenure at the Raytheon company.84  Further exploration showed that 
microwaves could increase the internal temperature of foods much quicker than a 
conventional oven and the first commercial microwave oven for home was introduced in 
1954.  However, the effects of microwave irradiation in organic synthesis were not 
explored until Giguere and coworkers as well as Gedye, Westway reported on the use of 
microwave-assisted organic synthesis (MAOS) in 1986 (Scheme 22).85  Following this 
report, industrial and academic multi-mode as well as single-mode microwaves have been 
developed.  They are featured with corrosion-resistant stainless steel cavities, reinforced 
doors, real-time temperature and pressure monitoring, and automatic safety controls. 
 
 
Scheme 22. Example of the first MAOS.85b 
 
 Understanding the basic theory behind microwaves might help the scientific 
community to apply this powerful and reliable energy source to any synthetic route and 
thereby discover novel reaction pathways.  A µwave is a form of electromagnetic energy 
(Figure 7) that falls between the infrared and radio frequency regions (300-300,000 MHz) 
of the electromagnetic spectrum (Figure 8).  Although the microwave energy consists of 
an electric and a magnetic field component, only the electric component of the 
electromagnetic field interacts with matters to heat the substance in chemical synthesis.86 
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Figure 7. Electric and magnetic components of microwave (Reproduced after permission 
from Prof. Kappe, Copyright: Wiley-Blackwell Publishing Group).88 
 
 
Figure 8.  Microwave region in the electromagnetic spectrum. 
 
To avoid interference between different applications, all domestic microwave 
ovens and dedicated microwave reactors available today for heating purposes, operate at 
a frequency of 2.45 GHz corresponding to a wavelength 12.2 cm.  The energy of 
microwave at frequency of 2.45 GHz is 1.6×10-3 eV or the energy of microwave photons 
is 0.037 kcal per mole.  On the other hand, typical energy required to cleave molecular 
bonds lies between 80-120 kcal/mole. Consequently, it is quite understandable from the 
data in Table 2 that the microwave energy is too low to cleave molecular bonds and thus 
can not affect molecular structure of organic compounds; however it can affect molecular 
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rotation.84a, 87  Hence, microwaves can not induce chemical transformation by direct 
absorption of electromagnetic radiation, similar to ultraviolet and visible radiation.  
Microwave absorption is completely kinetic during molecular excitation. 
 
Table 2.  Comparison of radiation type and bond energy88 
Radiation Type Frequency 
(MHz) 
Quantum Energy 
(eV) 
Bond Type 
 
Bond Energy 
(eV) 
Gamma rays 3.0×1014 1.24×106 C-C  3.61 
X-rays 3.0×1013 1.24×105 C=C 6.35 
Ultraviolet 1.0×109 4.1 C-O 3.74 
Visible light 6.0×108 2.5 C=O 7.71 
Infrared light 3.0×106 0.012 C-H 4.28 
Microwaves 2450 0.0016 O-H 4.80 
Radiofrequencies 1 4.0×10-9 Hydrogen bond 0.04-0.44 
 
 Traditional organic synthesis has been carried out through conductive heating 
process, typically by heating glass vessels emerged in a silicone-based oil-bath with an 
external heat source e.g. hot-plate or heating mantle.  The oil-bath heating process is 
inherently slow because the heat passes first through the walls of the vessel and then 
reaches the solvent and reacting components.  Moreover, the transfer of energy through 
the walls of the vessels depends on the thermal conductivity of the various materials.  
Consequently, a temperature difference between the inner and outer walls of the vessel 
occurs (Figure 9).  This introduces another temperature differences between the inner 
walls of the vessel and the reaction mixture.  These events make the measurement of 
actual temperature of reaction mixture inaccurate unless otherwise the temperature is 
being monitored by emerging a thermometer into the reaction mixture.  Thus, conductive 
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heating is relatively insufficient method of transferring energy in the form of heat.  In 
addition, the oil-bath heating process can take hours to reach a specific temperature. 
 
 
Figure 9.  A comparison of temperature (Kelvin) gradients between microwave and oil-
bath heating processes: (a) in microwave heating, the temperature of the entire reaction 
mixture volume increases simultaneously, (b) in the oil bath heating, only the reaction 
mixture volume in contract with the vessel wall is increased first.(adapted from Kappe et 
al. after permission from Prof. Kappe).88 
 In MAOS, on the other hand, microwaves interact directly with the solvent and 
reacting components present in the reaction vessel.  Thus, microwave heating leads to 
rapid increase in temperature because the heating process is independent of the thermal 
conductivity of vessel materials which is nearly microwave-transparent (Figure 10).  As a 
result, microwave heating can provide instantaneous localized superheating of reaction 
mixture.  There are two fundamental mechanisms by which the electric component of an 
electromagnetic field transfers energy from microwaves to reaction mixture being heated: 
dipolar polarization and ionic conduction.88, 89 
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Figure 10.  Temperature profile of microwave and oil-bath heating of ethanol 
(Reproduced with permission from Prof. Kappe, Copyright: Nature Publishing Group)88 
 
 
Figure 11.  Dipolar polarization (reproduced with permission from Dr. Ioannidis, 
Biotage, Sweden AB) [Copyright: Biotage, Sweden).90 
 
 The dipolar polarization mechanism is a phenomenon in which the electric field 
component interacts with the matrix or components of reaction mixture (Figure 11).  
Thus, in order to generate heat upon microwave irradiation, a substance must possess 
dipole moment.  When a sample is exposed to microwaves, the dipoles try to align in the 
direction of the applied electric field.  As the applied electromagnetic field oscillates, the 
dipole of the sample tries to realign with the alternating electric field.  Due to this 
rotational motion of the molecules of the sample some energy is lost through molecular 
friction and dielectric loss and results in the transfer of energy in the form of heat.  Thus, 
the amount of heat that will be generated by this process is directly proportional to the 
ability of the molecules to align themselves with the frequency of applied field.  The 
efficiency of this dipolar coupling depends on a number of factors; however, polar 
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solvents will also encounter this mechanism of energy transfer.  The extent of interaction 
between microwave irradiation and a particular solvent depends upon the average 
rotational frequency or its inverse, the average relaxation time (τ).  Debye postulated that 
τ is dependent on the nature of various intermolecular forces present in solution as well as 
molecular size.  Thus, the average relaxation time of a molecule is dependent on the 
average time of the molecules to attain a random orientation when microwave irradiation 
is turned off.  Thus τ is defined as τ = 4πr3η/kT, where r3 represents the size of the 
molecules and η is the viscosity which represents the intermolecular forces.  Viscosity 
clearly depends upon the strength of intermolecular forces in a complex way because the 
dipole-dipole, induced dipole-dipole and hydrogen bonding may contribute to 
intermolecular forces.  The relaxation time is also dependent on temperature because 
molecules can rotate faster at higher temperature.  The ability of any solvent to absorb 
microwave energy and convert into thermal energy (heat) at the applied frequency is 
called the loss tangent or energy dissipation factor.  The loss tangent is defined as: tan δ = 
ε"/ε', where ε" is the loss factor that reflects the conductance of the material and ε' is the 
dielectric constant of the solvent.  Since the interaction of electromagnetic field from 
microwave irradiation with matter is dependent upon absorption, transmission and 
reflection, polar solvents with high dielectric constant e.g. H2O, EtOH, MeOH etc will 
absorb microwave energy readily and ensue rapid heating of the medium.  On the other 
hand, since non-polar solvents have low dielectric constant, they are not capable of 
absorbing microwave energy readily (Table 3). 
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Table 3.  Physical properties of selected common solvents.89b 
Solvent Bp (oC) Dielectric 
constant (ε')
Loss factor 
(ε") 
tan δ Viscosity 
(η) 
Water 100 80.4 9.889 0.123 10.1 
Formic acid 100 58.5 42.237 0.722 15.7 
DMSO 189 45 37.125 0.825 2.45 
DMF 153 37.7 6.070 0.161 0.85 
Acetonitrile 82 37.5 2.325 0.062 3.8 
Nitromethane 101 36 2.304 0.064 0.61 
Nitrobenzene 202 34.8 20.497 0.589  
Methanol 65 32.6 21.483 0.659 5.5 
NMP 215 32.2 8.855 0.275 16.7 
Ethanol 78 24.3 22.866 0.941 10.8 
Isobutanol 108 15.8 8.248 0.522 3.95 
1,2-Dichloroethanne 83 10.4 1.321 0.127 0.84 
Dichloromethane 40 9.1 0.382 0.042 0.44 
THF 66 7.4 0.348 0.047 0.55 
Ethyl acetate 77 6.0 0.354 0.059 0.45 
Chlorobenzene 132 2.6 0.263 0.101 0.80 
Toluene 111 2.4 0.096 0.040 0.59 
 
 The second way to transfer microwave energy is through ionic conduction which 
occurs if there are free ions or ionic species present in the substance being heated (Figure 
12).  When the sample is heated, the ions oscillate back and forth and in the event they 
collide with their neighboring ions, molecules or atoms; this results agitations or motions 
that generate heat.  Furthermore, at higher temperature, the rate of collision increases 
which leads to efficient transfer of energy in the form heat. 
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Figure 12. Ionic conduction mechanism (reproduced with permission from Dr. Ioannidis, 
Biotage, Sweden AB) [Copyright: Biotage, Sweden]90 
 
 Since the microwave reaction vessels are usually made of microwave transparent 
materials quartz or Teflon, uniform increase in temperature is more likely to occur.  It is 
quite evident from recent literature reports that microwaves definitely accelerate the rate 
of organic reactions.  However, it is not fully understood how microwaves accelerate 
reaction rates in general.  Among the scientific community, some believe that this rate 
acceleration is due to the distinct wave-material interaction that leads to a decrease in the 
required activation energy.  Others believe that the rate acceleration is due to the rapid 
heating which enables to reach high temperature very quickly or due to a “specific 
microwave effect”. 
 According to the Arrhenious equation, the rate constant of a particular reaction, к 
= Ae-Ea/RT.  Thus, for a particular reaction the rate constant is dependent on the frequency 
of collisions between molecules having correct spatial orientation (A) and the fraction of 
those molecules having minimum energy needed to overcome the activation energy 
barrier (e-Ea/RT).  Although, some speculates that microwave affects the orientation of the 
molecular collisions as well as the activation energy, there is currently a lack of concrete 
evidence in support of these arguments.91  Thus, an increase in temperature causes 
molecules to move around rapidly which leads to increased number of energetic 
collisions.  This phenomenon occurs at a much faster rate under microwave irradiation 
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than traditional oil bath heating.  Although the debate currently looms, microwave 
technology has become a powerful and efficient tool in organic synthesis, medicinal 
chemistry as well as drug discovery. 
1.8.    Principle of Green Chemistry 
 In the last decade, there has been a growing interest among scientists as well 
governments around the world in ‘sustainable chemistry or green chemistry’.  The United 
States Environmental Protection Agency (US EPA) had started the green chemistry 
movement in 1990s to encourage scientists in chemical industry and academia to use 
chemistry in order to prevent pollution of environment.  Thereafter, the American 
Chemical Society (ACS) and the US EPA have jointly developed a set of 12 guiding 
principles of green chemistry.92  In summary, these principles are: 
(a) Minimization of waste materials 
(b) Synthetic strategy should be devised in such a way that most starting materials 
can be incorporated into the target product. 
(c) Synthetic methods should be devised to minimize the use of hazardous chemicals 
(d) Synthetic method should be devised to avoid unnecessary use of solvents or 
auxiliaries. 
(e) Synthetic methods should generate chemicals those have less toxicity. 
(f) All chemical synthetic strategy should be designed to increase energy efficiency. 
(g) Whenever possible renewable materials should be used in chemical processes. 
(h) Whenever possible, derivatization of chemicals should be minimized. 
(i) Use of catalyst is better than stoichiometric reagents. 
(j) Synthetic strategy should be designed to generate degradable products. 
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(k) All chemical processes should be monitored in real-time to prevent hazardous 
materials formation. 
(l) Safer chemical methods should be designed to prevent accidents 
Thus, employing MCCRs in chemical synthesis fulfils many criteria of green 
chemistry.  Organic solvents have been used for routine experimentation and scale-up 
process in chemical industry as well academia due to critical ‘enabling’ role in 
solubilization, chelation etc.  However, many of them are carcinogenic and are significant 
sources of air and water pollution.  In order to solve these problems, recently reactions 
have been carried out without any solvent or in solvents those are environmentally benign 
such as water.  In terms of a synthetic application, water, to date, has been a much under-
utilized solvent despite being cheap and safe for various reaction processes.  Unlike other 
solvents, water exhibits higher ionic product at elevated temperature.  Consequently, 
water exhibits stronger acid-base character at elevated temperature and thus behaves 
more likely to that of an organic solvent.  Moreover, water is abundant and causes no 
pollution.  Hence, water is a worthy candidate to consider as a solvent in designing 
synthetic strategy especially those reactions requiring high temperature.93  In various 
monographs, it has been established that microwave irradiation can reduce reaction time 
courses as well.  Thus, utilization of microwave irradiation in the synthetic design can 
subsequently reduce energy consumption.  Therefore, according to the principles of green 
chemistry set up by the EPA and ACS, dedicated microwave irradiated reactions in water 
can be considered as valuable contributions for their stated missions.93b, 94 
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CHAPTER 2 
 
Microwave-Influenced Diversity-Oriented Synthesis of Biologically 
Relevant Small Molecules via Multicomponent Coupling Reactions 
and Development of New Methodology 
 
2. Introduction 
MCCRs have been frequently used by synthetic chemists as a facile means to 
generate molecular diversity from multifunctional substrates that can sequentially react in 
intramolecular processes.95  Devising new strategies employing MCCRs that achieve the 
formation of multiple bonds in a single operation is one of the major challenges in 
modern-day organic synthesis.96  Perhaps the most promising, efficient and powerful 
method for covering maximum chemical space by generating skeletal diversity are the 
MCCRs.97.  In particular, the MCCRs should be versatile so that any combinations of 
functional groups can be incorporated in starting materials and those functional groups 
would be compatible for subsequent derivatization.  By virtue of their simple execution in 
one-pot, they are well suited for automated synthesis which allows for maximum 
exploration of novel chemical space. 
 In order to facilitate the high throughput screening (HTS)98 of small molecules 
against proteins, enzymes, and macromolecules, rapid generation of libraries is essential.  
In recent years microwave irradiation has emerged as an alternative and powerful tool 
over traditional heating processes and is becoming widely accepted by the scientific 
community for discovery in microwave-assisted organic synthesis (MAOS) which offers 
 38
(a) reduced reaction time, (b) cleaner products, (c) avoids purifications and handling, (d) 
less waste material.99 
 Designing a synthetic strategy that will not only retain the mantra of DOS, but 
also employ sustainable/green chemistry is a significant challenging problem amongst the 
scientific community. 
 
2.1. Goal of the Research 
 The short-term goal of the project was to develop very efficient and 
environmentally benign methodology that would provide access to a wide variety of 
biologically relevant small and highly complex molecules via multicomponent coupling 
reactions in conjunction with microwave irradiation from cheap and readily available 
starting materials.  The long-term goal was to apply the novel methodologies to achieve 
structural and skeletal diversity; extend into other areas of chemistry to develop further 
new chemistry, establish a discovery platform and conduct structure-activity relationships 
(SARs) studies to find potential hits. 
 In order to achieve these goals, we questioned (i) if the novel method(s) could 
provide structural and skeletal diversity by tuning reacting components?, (ii) the 
possibility to establish a new paradigm of diversity-activity relationships (DARs)?, (iii) 
the conventional use of microwave irradiation as rate-accelerating tool (could it be used 
as a reagent in synthesis?), (iv) the influence of microwave irradiation on molecular 
properties/reactivities?, (v) if it was possible to find a common platform that would 
enable us to achieve both the short-term and long-term goals?. 
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2.2. Results and Discussion 
 While we were planning to execute an efficient synthetic strategy for small 
molecule synthesis, we came across a literature which reported that the U-4CCR between 
p-methoxy benzylamine (1), fumaric acid monoethyl ester (2), bezyl isocyanide (3) and 
furan-2-aldehyde (4) provided a (4π +2π) Diels-Alder (DA) cycloaddition adduct 6 at 
ambient temperature (Scheme 23).100  It is noteworthy that the Ugi product (±)-5 was not 
isolable because of rapid intramolecular bond construction from the diene and 
dienophile.100  We envisioned that the proposed olefinic acyclic intermediate could, 
however, be engineered to gain access to various other structural motifs.  After a 
thorough literature survey it became evident that thiophene usually does not undergo (4π 
+ 2π) DA cycloaddition reactions under normal conditions; it prefers to undergo (2π +2π) 
cycloaddition reaction.101  In some cases where the sulfur atom of thiophene was 
converted to a sulfoxide or if the reaction was performed under extremely high pressure, 
then thiophene did provide the (4π +2π) DA cycloaddition product.102 
 
 
Scheme 23.  Furan-2-aldehyde provides Diels-Alder product at ambient temperature. 
 
Hence, we speculated that we could isolate a thiophene-derived U-4CCR product 
using similar reaction substrates and conditions.  To our expectation, acyclic (±)-7 was 
isolated in excellent yield (87%) yet did not spontaneously undergo a [4π + 2π] DA 
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cycloaddition at ambient temperature (Scheme 24).  To explain this, one must understand 
that although furan and thiophene obey Hückel’s rule for aromaticity, in terms of 
reactivity in a [4π + 2π] DA cycloaddition, thiophene will undergo this type of reaction 
only when forced to do so with extreme heat and an immense amount of pressure.  In 
fact, it requires, in some instances, over 120,000 psi to do so.  A likely explanation for 
this could be that thiophene is more aromatic that furan due to large differences in 
LUMO energy.  Furthermore, longer C-S vs C-O bond (1.73 cm vs 1.43 cm) might 
increase the TS energy.  Even in a sealed tube, run at 140 oC, thiophene does not undergo 
DA cycloadditions. 
 
 
Scheme 24.  The U-4CCR using thiophene-2-aldehyde results in an isolatable acyclic 
Ugi product (7) at ambient temperature. 
 
 We then decided to explore the use of microwaves as a tool and observe how it 
would affect the reaction for new bond formation.  We speculated that in presence of a 
suitable Lewis acid, the isolated Ugi product 7 might undergo Fridel-Craft alkylation to 
provide 1,4-dihydroisoquinolinone 10 via an 5-exo-trig intermediate 9 (Scheme 25).  
However, when AlCl3 and FeCl3 were used as Lewis acid, either degradation of 7 
occurred or unreacted 7 was isolated.  Literature precedent revealed that a number of rate 
accelerated Fridel-Crafts alkylation reactions had been accomplished using microwave 
irradiation and an appropriate additive.103  Unfortunately, when these literature protocols 
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were employed in our system, the aforementioned problems were not negated.  Thus, we 
switched our focus to alternative possibilities. 
 
Scheme 25.  Proposed synthesis of isoquinolinones under Lewis acid conditions. 
 
2.2.1. Effect of Solvents under Microwave Irradiation 
 When the acyclic Ugi product (±)-7 was dissolved in DMF without any Lewis 
acid additives and irradiated under microwave (CEM Discover, 300 W, 220oC, and 17 
bar) for 30 min, to our delight, it provided a 9:1 diastereomeric mixture of [4π + 2π] 
Diels-Alder cycloaddition product (±)-8 in 15% yield.  On the other hand, when the 
reaction was carried out in CH3OH under similar conditions, an intramolecular 6-exo-trig 
aza-Michael reaction ensued to reveal a 1.5:1 diastereomeric mixture of a biologically 
validated scaffold104 2,5-diketopiperazine (±)-11 in 70% yield (Scheme 26).  
Diastereomeric ratios were determined using 1H NMR from the crude reaction mixture in 
CDCl3.  In the case of pathway B, the major diastereoisomer had a trans relationship 
between the aldehyde and acid component and the stereochemistry was confirmed by 
nOe studies.  With these initial promising results in hand, we then decided to explore the 
effect(s) of different solvents that might shed more indepth insight into the reaction.  As 
shown in Table 4, it was observed that aprotic (polar/non-polar) solvents like DMF, 
dichloromethane, dichloroethane favor the [4π + 2π] DA cycloaddition (pathway A) and 
 42
protic polar solvents like methanol and water favor the 6-exo-trig aza-Michael reaction 
(pathway B).  It is well worth noting that the two pathways do not overlap and the 
outcome of the reaction is completely solvent controlled.  This dependency could be 
explained by the fact that 6-exo-trig aza-Michael reactions are stabilized through ionic 
intermediates and use of protic polar solvents assist in this regard.  On other hand, [4π + 
2π] DA cycloaddition proceeds through non-ionic intermediates and aprotic non-polar 
solvents assist in the stabilization.  This result is totally contrary to Breslow’s report on 
the enhancement of the DA reaction in water.101 
 
 
Scheme 26.  Pathway selectivity of the microwave-influenced reaction. 
 
Table 4.  Effect of solvents on microwave-influenced reaction of 7a. 
Yield (%)b  
Entry 
 
Solvent Type A Type B 
1 DMF 15 0 
2 CH2Cl2 20 0 
3 DCE 30 0 
4 MeOH 0 30 
5 MeOH/H2O 0 65 
6 H2O 0 85 
aMicrowave was equilibrated to 300 W, 220 oC, 17 bar for 30 min; bIsolated yield 
 
 
 
 43
2.2.2. Effect of Temperature, Pressure and Power  
 With our noted solvents for the two pathways, we then elected to screen various 
microwave-based temperature, pressure and power ranges to further explore the optimum 
condition for our observed pathways (A and B).  From our data, it was observed that 
microwave power (W), temperature (oC) and pressure (bar) have correlating 
relationships.  For a given power setting, the temperature and pressure adjust accordingly.  
At lower power settings, desired temperature and pressure can not be achieved.  On the 
other hand, at high power settings, desired temperature and pressure are achievable. In 
our examples, the reactions were found to be completely controlled by temperature and 
pressure.  When the microwave power was set to 50 W, the temperature and pressure 
reached 110 oC and 1.5 bar respectively yet there was no conversion.  Whereas at a 
microwave power of 100 W, the temperature and pressure were 138 oC and 4.1 bar 
respectively and corresponding yield was 10%.  At a higher microwave power 200 W, the 
temperature and pressure were 160 oC and 6 bar respectively and the corresponding yield 
was 20%.  When we had set a microwave power 250 W, the temperature and pressure 
were 200 oC and 15 bar respectively and corresponding yield was 70%.  Finally after 
tuning the power, temperature and bar, a microwave setting at 300 W, 200 oC and 18 bar 
provided the best yield (85%) (Table 5).  It must be noted that the reaction does not 
provide the desired product when it was thermally refluxed under similar conditions.  
Primarily, microwaves work on the Arrhenious equation concept and according to ideal 
gas law (pV = nRT), temperature (T) is directly proportional to pressure (P).  On the 
other hand, according to Stefan-Boltzman Law (eq. 1) and Wein’s Displacement Law of 
emission (eq. 2), power (W) is directly proportional to temperature with a factor of 4.  
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Thus, if power (W) goes down by a factor 16, temperature (oC) and pressure (bar) will go 
down by a factor of 2. 
 
 
 
Table 5.  Optimization of µwave-influenced 6-exo-trig aza-Michael reaction leading to 
11. 
Entry Solvent Time (min) Power (W) Temp (oC) Pressure (bar) Yield (%) 
1 H2O 30 300 100a 1.5 0 
2 H2O 30 300 140a 4 11 
3 H2O 30 300 150a 5 15 
4 H2O 30 300 170 9 45 
5 H2O 30 300 175a 9 50 
6 H2O 30 300 200a 18.5 85 
7 H2O 30 250 200a 15 70 
8 H2O 30 200 160b 6 20 
9 H2O 30 150 151b 5.1 15 
10 H2O 30 100 138b 4.1 10 
11 H2O 30 50 110b 1.5 0 
12 H2O 25 300 200a 18 85 
13 H2O 20 300 200a 18 85 
aObserved temperature (set at 100 oC), bObserved temperature (set at 200 oC). 
 
2.3.3. Scope: Effect of Substituents on Amine and Isocyanide Components 
 Various isocyanides and amines were also screened.  We were interested in how 
the electronic nature of substituents on benzyl groups pertaining to the amine component 
affected the reaction outcome.  It was observed that weak or moderately strong electron-
donating groups (e.g. OMe, CH3) or electron-withdrawing groups (e.g. Cl, CF3) at para, 
meta or ortho position on the amine component do not have any effect on the reaction 
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outcome and yield (Table 10).  However, when we changed the methoxy group (-OMe) 
with a stronger electron-donating hydroxyl group (-OH) (1b) on the benzyl group of the 
amine component and used 2,6-dimethylphenyl isocyanide (3b), the Ugi reaction 
provided 2, 5-diketopiperazine (±)-12 as the major product and p-hydroxyl benzyl (PHB) 
alcohol as the minor product under the optimized microwave reaction conditions 
(Scheme 27).  The stereochemistry of the 2,5-diketopiperazine (±)-12 was determined by 
nOe experiment.  Identity of (±)-12 and 14104h were unequivocally confirmed by X-ray 
structure analysis (Figure 14 and 15 respectively). 
 
 
Scheme 27.  Formation of p-hydroxy benzyl alcohol from acyclic Ugi product. 
 
 Formation of the minor product 14 was quite unexpected and we envisioned that 
the pathway could be further tuned by taking advantage of this side reaction.  Thus, when 
we used p-hydroxy benzylamine (1b), isopropyl aldehyde (4c), tert-butyl isocyanide (3c) 
and monoethyl ester of fumaric acid (2a); the one-pot microwave reaction afforded 
biologically validated scaffold 2-azaspiro[4.5]deca-6,9-diene-3,8-diones105 exclusively  
under the optimized conditions (Scheme 28).  The structure and identification of 16 was 
determined by 1H, 13C, GDQFCOSY, GHMQC spectral analysis and unequivocally 
confirmed by X-ray crystal structure analysis (Figure 16).106 
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Scheme 28.  Formation of 2-azaspiro[4.5]deca-6,9-diene-3,8-dione scaffold from single-
pot U-4CCR using μwave irradiation. 
 
 In order to examine the effect of a spacer on the amine component in the 
microwave-influenced reaction, we elected to use 2-(4-hydroxyl phenyl)ethylamine (1c), 
trimethylacetaldehyde (4b), monoethyl ester of fumaric acid (2a) and tert-butyl 
isocyanide (3c).  However, the expected product 3-azaspiro[5.5]deca-7,10-diene-2,9-
dione (±)-19 was not observed and the reaction provided only acyclic Ugi product (±)-18 
(Scheme 29).  Replacement of the aldehyde coupling partner (e.g. isopropyl and 2-
napthyl) did not have an effect on the reaction.  Although, Baldwin’s rule107 favors a 6-
exo-trig ring closure, however 6-exo-trig Michael pathway is not favored under the 
reaction conditions mentioned.  A plausible explanation could be that the Michael-
acceptor is not in close proximity. 
 
Scheme 29.  Effect of spacer on the intramolecular Michael reaction. 
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Table 6.  Effect of substituents on isocyanide on reaction outcome. 
 
Yield/dra  
Entry 
 
R4 23a-f 25a-f 
1 t-butyl (3c) 60/3:1 - 
2 cyclohexyl (3d) 82/1:1 5/20:1 
3 cyclopentyl (3e) 81/2:1 7/18:1 
4 isopropyl (3f) 80/2:1 10/15:1 
5 benzyl (3a) 5/2:1 91/10:1 
6 n-butyl (3g) - 92/15:1 
aDetermined from 1H NMR of unpurified reactions. 
 
 Next we examined the effect of substituents on isocyanides on the reaction.  We 
chose p-hydroxy benzylamine (1b), trimethylacetaldehyde (4b), monoethyl ester of 
fumaric acid (2a) and different isocyanides to examine their on the reaction outcome 
(Table 6).  Thus, when we used tert-butyl isocyanide (3c), the reaction afforded 2-
azaspiro[4.5]deca-6,9-diene-3,8-dione (±)-16 exclusively.  Replacement of t-butyl 
isocyanide (3c) with cyclohexyl isocyanide (3d) in the reaction provided 82% of 23c and 
5% of 25c.  On the other hand, n-butyl isocyanide (3g) provided 92% of 25f.  The 
bulkyness of substituents on the isocyanides increases in the order n-
butyl<isopropyl<cyclopentyl<cyclohexyl<tert-butyl and the yield of 25 decreases in the 
same order.  In general, it has been observed that bulky isocyanides provide 2-
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azaspiro[4.5]deca-6,9-diene-3,8-dione 23 as the major product and less bulky isocyanides 
provide 2, 5-diketopiperazine 25 as the major product.106 
 
2.2.4. Scope: Effect of Substituents on Carboxylic Acid Component 
 Different carboxylic acid components were also screened in the coupling reaction 
(Scheme 30).  Electron withdrawing groups (R = CO2Et, COCH3; Y = Me) provided 2, 5-
diketopiperazines (Type B) in good to excellent yield.  When, R = CO2Et and Y = Me 
(2c), the expected product 26 was not observed in the 1H NMR of the unpurified reaction 
mixture.  A probable explanation could be that 6-exo-trig cyclization is not favored under 
this condition probably due to steric effects.  However, when R = COCH3 and Y = H 
(2d), the reaction provided 28 good yield (80%). 
 
 
Scheme 30.  Effect of substituents on carboxylic acid component of the U-4CCR. 
 
 To further examine the carboxylic acid substrate scope, 3-oxo-cyclohexene-1-
carboxylic acid (2e) was synthesized from methyl ester of cyclohexene carboxylic acid.  
Allylic oxidation of 30 in the presence of CrO3 and AcOH108 provided methyl 3-oxo-1-
cyclohexene-1-carboxylate 31 in 80% yield.  Saponification of 31 with aqueous Na2CO3 
afforded the desired 3-oxo-cyclohexene-1-carboxylic acid 2e in quantitative yield 
(Scheme 31). 
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Scheme 31.  Synthesis of 3-oxo-cyclohexene-1-carboxylic acid (2e). 
 
 With 2e in hand, we examined the possibility of forming spiro-2, 5-
diketopiperazine109 and dispirocyclohexadienone.  Thus, the U-4CCR of benzylamine 
(1d), trimethylacetaldehyde (1d), 3-oxo-cyclohexene-1-carboxylic acid (2e) benzyl 
isocyanide (4a) provided acyclic product (±)-32.  Varying temperature, pressure and time 
were screened to find the right reaction conditions (Table 7).  However, none of the 
conditions provided the desired spiro-2,5-diketopiperazine (±)-33 (Scheme 32). 
 
Scheme 32.  Efforts toward the synthesis spiro-2,5-diketopiperazines (spiro-DKP). 
 
Table 7.  Microwave conditions toward the synthesis of spiro-DKP. 
Entry Power (W) Temp (oC) Pressure (bar) Time (min) Yield (%) of 33 
1 300a 200 18 30 0 
2 800b 200 27 35 0 
3 1600b 215 41 65 0 
aCEM Discover Microwave; bMARS Microwave 
 
Next, we synthesized acyclic Ugi product 34 from the reaction between p-
hydroxy benzylamine (1b), trimethylacetaldehyde (4b), 3-oxo-cyclohexene-1-carboxylic 
acid (2e) and tert-butyl isocyanide (3c) (Scheme 33).  However, when the acyclic product 
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34 was subjected to microwave reaction conditions, the desired product 35 was not 
obtained using various conditions (Table 8). 
 
 
Scheme 33.  Efforts toward the synthesis of aza-dispirocyclohexadienone. 
 
Table 8.  Microwave conditions for the synthesis of aza-dispirocyclohexadienone (±)-
35a. 
Entry Power (W) Temp (oC) Pressure (bar) Time (min) Yield (%) of 35 
1 300 192 18 30 0 
2 300 192 18 60 0 
3 300 198 18 75 0 
4 300 210 18.5 90 0 
5 300 220 19 120 0 
aCEM Discover Microwave 
 
To invoke a SN2/ or SN2 type pathway that will provide 2, 5-diketopiperazines and 
the method can be applied for the synthesis of billion (>10) dollar drug Cialis and its 
derivatives for ED treatment (Figure 13, 36)110, few carboxylic acid components were 
also screened initially.  Thus, U-4CCR of p-methoxy benzylamine (1a), 
trimethylacetaldehyde (4b), (E)-4-bromo-2-butenoic acid (2f) and benzyl isocyanide (3a) 
provided (±)-37a and that of p-methoxy benzylamine (1a), trimethylacetaldehyde (4b), 2-
iodoacetic acid (2g) and benzyl isocyanide (3b) provided (±)-37b.  However, none of the 
microwave conditions (Table 9) provided the desired products (±)-38 and (±)-39; instead 
displacement acyclic products (±)-40 (R = 3-hydroxy propene), (±)-41 (R = 3-
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methoxypropene), (±)-42 (R = hydroxyl) and (±)-43 (R = methoxy) were obtained in 
protic solvents (e.g. H2O, MeOH) whereas in aprotic solvent (e.g. CH2Cl2) only acyclic 
products were recovered (Scheme 34). 
 
Figure 13. Retrosynthetic analysis for the ED treatment drug Cialis. 
 
Scheme 34.  SN2 and SN2/ pathways for the synthesis of 2, 5-diketopiperazines. 
 
Table 9.  Microwave reaction conditions for SN2 and SN2/ pathway.a 
Yield (%) Entry Solvent Power 
(W) 
Temp 
(oC) 
Pressure 
(bar) 
Time 
(min) 38 39 40 41 42 43 
1 H2O 300 200 18 25 0 0 95 0 96 0 
2 MeOH 300 210 18 30 0 0 0 94 0 95 
3 CH2Cl2 300 170 15 30 0 0 0 0 0 0 
aCEM Discover Microwave. 
 
 52
 In order to examine the possibility of a 7-endo-trig aza-Michael pathway, acyclic 
Ugi product 44 was synthesized from the U-4CCR between p-methoxy benzylamine (1a), 
trimethyl acetaldehyde (4d), acrylic acid (2c) and benzyl isocyanide (3a).  However, the 
desired diazepine product 45 was not obtained using various conditions (Scheme 35).  A 
probable explanation could be that the Michael acceptor is either not in close proximity 
or it is deactivated due to lone pair delocalization from nitrogen onto the amide carbonyl 
group. 
 
Scheme 35.  Approach toward 7-endo-trig aza-Michael pathway. 
 
 
Scheme 36.  General molecular diversity from a single-pot microwave reaction. 
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Table 10. Substrate scope of microwave-influenced syntheses of small molecules. 
aIsolated. bDetermined from the 1H NMR of unpurified reaction mixture. 
Compd type/%yielda/drbEnt
ry 
R1 R2 R3 R4 
H2O CH2Cl2 dr 
1 2-thienyl (4a) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) See entry 2 A (8)/25 10:1 
2 2-thieny l(4a) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (11)/83 See entry 1 7:1 
3 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) 2,6-dimethylphenyl (3b) B (12)/85 acyclic (15/91 9:1 
4 isopropyl (4c) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) tert-butyl (3c) C (16)/60 acyclic (17)/92 3:1 
5 tert-butyl (4b) Ethoxycarbonyl (2a) 2-(4-hydroxyphenyl)ethyl (1c) tert-butyl (3c) Acyclic (18)/90  
6 piperonyl (4d) Ethoxycarbonyl (2a) 2-(4-hydroxyphenyl)ethyl (1c) tert-butyl (3c) Acyclic (20)/91  
7 Isopropyl (4c) Ethoxycarbonyl (2a) 2-(4-hydroxyphenyl)ethyl (1c) tert-butyl (3c) Acyclic (22)/91  
8 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) tert-butyl (3c) C (23a)/60 acyclic (24a)/85 1:1 
9 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Cyclohexyl (3d) C (23b)/82 acyclic (24b)/89 1:1 
10 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Cyclopentyl (3e) C (23c)/81 acyclic (24c)/90 2:1 
11 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Isopropyl (3f) C (23d)/80 Acyclic (24d)/90 2:1 
12 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Benzyl (3a) C (23e)/5 acyclic (24e)/93 2:1 
13 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) n-butyl (3g) B (25f)/92 acyclic (24f)/91 15:1 
14 tert-butyl (4b) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (27/94) acyclic (27b/92) 10:1 
15 tert-butyl (4b) Methylcarbonyl (2b) 4-methoxybenzyl (1a) Benzyl (3a) B (28)/85 acyclic (29)/92 1:1 
16 tert-butyl (4b) 3-oxocyclohexene (2c) Benzyl (1d) Benzyl (3a) Acyclic (32)/89  
17 tert-butyl (4b) 3-oxocyclohexene (2c) 4-hydroxybenzyl (1b) tert-butyl (3c) Acyclic (34)/87  
18 tert-butyl (4b) 3-bromopropene (2d) 4-methoxybenzyl (1a) Benzyl (3a) Acyclic (37a, 40, 41)/93, 95  
19 tert-butyl (4b) Iodine (2e) 4-methoxybenzyl (1a) Benzyl (3a) Acyclic (37b, 42, 43)/91, 96  
20 tert-butyl (4b) Hydrogen (2f) 4-methoxybenzyl (1a) Benzyl (3a) Acyclic (44)/90  
21 tert-butyl (4b) Ethoxycarbonyl (2a) Benzyl (1d) Benzyl (3a) B (46)/96 acyclic (47)/97 11:1 
22 tert-butyl (4b) Ethoxycarbonyl (2a) Cyclohexylmethyl (1e) Benzyl (3a) B (48)/88 Acyclic (49)/92 20:1 
23 Isopropyl (4c) Ethoxycarbonyl (2a) Benzyl (1d) 4-methoxyphenyl (3h) B (50)/85 Acyclic (51)/90 6:1 
24 Isopropyl (4c) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) 4-methoxyphenyl (3h) B (52)/81 Acyclic (53)/82 7:1 
25 tert-butyl (4b) Benzoyl (2g) Benzyl (1d) Benzyl (3a) B (54)/98 Acyclic (55)/98 2:1 
26 tert-butyl (4b) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) n-butyl (3g) B (56)/92 Acyclic (57)/90 15:1 
27 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Benzyl (3a) B (25e)/83 See entry 12 12:1 
28 2-thienyl (4a) Ethoxycarbonyl (2a) 3.5-dimethoxybenzyl (1e) Benzyl (3a) B (58)/87 See entry 32 7:1 
29 2-thienyl (4a) Benzoyl (2g) 4-bromophenyl (1f)) n-butyl (3g) B (59)/83 See entry 33 7:1 
30 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxy-3-methoxybenzyl (1g) tert-butyl (3c) C (60)/60 Acyclic (61)/80 3:1 
31 tert-butyl (4b) Ethoxycarbonyl (2a) 4-hydroxybenzylmethyl (1h) tert-butyl (3c) C (62)/95 Acyclic (63)/96 3:1 
32 2-thienyl (4a) Ethoxycarbonyl (2a) 3.5-dimethoxybenzyl (1e) Benzyl (3a) See entry 28 A (64)/23 8:1 
33 2-thienyl (4a) Ethoxycarbonyl (2a) 4-Bromophenyl (1f) Benzyl (3a) See entry 29 A (65)/25 10:1 
34 tert-butyl (4b) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) tert-butyl (3c) Acyclic (66)/92  
35 Isopropyl (4c) Ethoxycarbonyl (2a) 3,4-dimethoxybenzyl (1h) tert-butyl (3c) B (67)/93 Acyclic (67a)/95 12:1 
36 Isopropyl (4c) Ethoxycarbonyl (2a) Benzyl (1d) tert-butyl (3c) Acyclic (68)/90  
37 Cyclopropyl (4e) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (69)/88 Acyclic (70)/90 4:1 
38 Phenyl (4f) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (71)/90 Acyclic (72)/93 6:1 
39 tert-butyl (4b) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Cyclohexyl (3d) Acyclic (73)/88  
40 Isopropyl (4c) Ethoxycarbonyl (2a) 4-chlorobenzyl (1i) tert-butyl (3c) Acyclic (74)/90  
41 Isopropyl (4c) Ethoxycarbonyl (2a) 4-trifluoromethylbenzyl (1j) tert-butyl (3c) Acyclic (75)/93  
42 Isopropyl (4c) Ethoxycarbonyl (2a) 3,5-dimethoxybenzyl (1e) tert-butyl (3c) Acyclic (76)/92  
43 Isopropyl (4c) Ethoxycarbonyl (2a) 3,4-methylenedioxybenzyl (1k) tert-butyl (3c) Acyclic (77)/91  
44 Isopropyl (4c) Ethoxycarbonyl (2a) 4-methylthiobenzyl (1l) tert-butyl (3c) Acyclic (78)/90  
45 2-thienyl (4a) Hydrogen (2ef 4-methoxybenzyl (1a) tert-butyl (3c) Acyclic (79)/91  
46 Isopropyl (4c) Ethoxycarbonyl (2a) 4-methoxyphenylethyl (1m) tert-butyl (3c) Acyclic (80)/92  
47 2-thienyl (4a) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) tert-butyl (3c) C (81)/89 –  
48 Isopropyl (4c) Hydrogen (2f) 4-methoxybenzyl (1a) tert-butyl (3c) Acyclic (82)/90  
49 2-thienyl (4a) Ethoxycarbonyl (2a) 3-methoxybenzyl (1o) Benzyl (3c) B (83)/93 – 5:1 
50 Isopropyl (4c) Ethoxycarbonyl (2a) 1-(4-methoxyphenyl)ethyl (1p) tert-butyl (3c) Acyclic (84)/89  
51 Isopropyl (4c) Ethoxycarbonyl (2a) 3-hydroxybenzyl (1q) tert-butyl (3c) Acyclic (85)/93  
52 Isopropyl (4c) Ethoxycarbonyl (2a) 4-hydroxybenzyl (1b) Benzyl (3a) B (86)/89 Acyclic (87)/92 11:1 
53 Isopropyl (4c) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Cyclohexyl (3d) Acyclic (88)/91  
54 Cyclopentyl (4g) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (89)/85 Acyclic (90)/91 10:1 
55 Cyclohexyl (4h) Ethoxycarbonyl (2a) 4-methoxybenzyl (1a) Benzyl (3a) B (91)/83 Acyclic (92)/90 7:1 
56 tert-butyl (4b) Ethoxycarbonyl (2a) 1-(4-methoxyphenyl)ethyl (1p) Benzyl (3a) B (93)/93 Acyclic (94)/93 10:1 
57 Isopropyl (4c) Ethoxycarbonyl (2a) 3,4-methylenedioxybenzyl (1k) Benzyl (3a) B (95)/91 Acyclic (96)/92 9:1 
58 Isopropyl (4c) Ethoxycarbonyl (2a) 4-methylthiobenzyl (1l) Benzyl (3a) B (97)/90 Acyclic (98)/92 11:1 
59 Isopropyl (4c) Ethoxycarbonyl (2a) 3-hydroxybenzyl (1q) Benzyl (3a) B (99)/92 Acyclic (100)/93 13:1 
60 Isopropyl (4c) Ethoxycarbonyl (2a) 6-methoxynapthylmethyl (1r) Benzyl (3a) B (101)/93 Acyclic (102)/95 8:1 
61 2-napthyl (4d) Ethoxycarbonyl (2a) 4-methoxyoxylbenzyl (1a) Benzyl (3a) B (103)/91 Acyclic (103a)/90 35:1 
62 tert-butyl (4b) Ethoxycarbonyl (2a) 2-(4-hydroxyl phenyl)ethyl (1s) tert-butyl (3c) Acyclic (104)/92  
63 Isopropyl (4c) Ethoxycarbonyl (2a) 2-(4-hydroxyl phenyl)ethyl (1s) tert-butyl (3c) Acyclic (105)/90  
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Figure 14.  X-ray crystal structure of major diastereomer of diketopiperazine (±)-12. 
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Figure 15.  X-ray crystal structure of 4-hydroxybenzyl alcohol (14) from μwave reaction. 
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Figure 16. X-ray crystal structure of 2-azaspiro[4.5]deca-6,9-diene-3,8-dione (±)-16. 
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2.2.5.  Mechanism of the Microwave-Influenced One-Pot Reaction 
 The substrate scope of the microwave-influenced one-pot reaction provided 
insight into the mechanism of different pathways.  At very high temperatures (180-220 
oC), lone pairs on the hydroxyl group of p-hyrdoxy benzylamine become activated and 
formed the acyclic intermediate 106 along with the quinonemethide intermediate 107.  
Nucleophilic attack by water on the quinonemethide intermediate (107) formed the 
phenolic intermediate 109 which finally provided 14 (Scheme 37). 
 
 
Scheme 37.  Mechanism of formation of 14 from acyclic U-4CCR product 15 under 
µwave irradiation. 
 
When R4 ≠ t-Bu (e.g. Bn), 2, 5-diketopiperazines arose from a 6-exo-trig aza-
Michael reaction forming a zwitterionic intermediate (±)-111 (Scheme 38) which is 
believed to be stabilized by hydrogen bonding in water and provided 2, 5-
diketopiperazine (±)-53.  When R4 = tert-butyl (3c), the reaction does not provide 2, 5-
diketopiperazines, instead it undergoes a 5-exo-trig Michael reaction to form zwitterionic 
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intermediate (±)-110 which is believed to be stabilized by hydrogen bonding in water to 
provide 2-azaspiro[4.5]deca-6,9-diene-3,8-dione (±)-57. 
 
Scheme 38.  Mechanism of Microwave-influenced Michael and aza-Michael reaction. 
 
We argued that steric effects of the substituents (R4), in the transition state of the 
reaction, leads to pathway C and this is evident from the trend of yields referring to Type-
B products (Table 6).  When R4 = Bn (3a) and R3 = PHB (1b), the reaction provides 2, 5-
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diketopiperazine; whereas when R4 = tert-butyl (3c) and R3 = PHB (1b), the reaction 
provides 2-azaspiro[4.5]deca-6,9-diene-3,8-dione.  This result indicates that the 6-exo-
trig aza-Michael reaction process is faster and preferred over the 5-exo-trig Michael 
process; likely due to the fact that during a 5-exo-trig Michael process there is loss of 
aromaticity which requires a higher energy of activation. 
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Scheme 39.  Mechanism of Diels-Alder reaction leading tricyclic lactam (±)-8. 
 
2.3.6.  Extension Toward the Synthesis of Spiro-β-Lactams 
 Apart from being antibacterial agents111, β-lactams have been found to be very 
useful synthons for the preparation of a variety of molecules of biological and medicinal 
interest.112  In particular, the spiro β-lactams have become the center of attention among 
the scientific community as they can behave as β-turn mimetics113 and are precursor of 
α,α-disubstituted β-amino acids.114  In addition, the spirocyclic β-lactam motif is also 
present in the chartellin family of marine natural products115 that are known to have a 
wide variety of biological activity.116 
Although, to date, there is no precedence of spiro-β-lactam formation under 
microwave irradiation, we anticipated that p-hydroxy aniline (1t) might have similar 
reactivity like p-hydroxyl benzylamine (1b) that would undergo a 4-exo-trig Michael 
process.  Thus p-hydroxyl aniline, 2-napthaldehyde (4c), monoethyl fumarate (2a) and 
tert-butyl isocyanide (3b) under the microwave irradiation (300 W, 200 oC,18 bar, 20 
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min) provided spiro-β-lactam (±)-113 in about 20% yield (Scheme 40) which was proved 
to be inseparable from the acyclic U-4CCR 112.  Further optimization of reaction 
conditions might provide higher yields.  By employing substituted p-hydroxy aniline, 
different aldehydes, acids and other bulky isocyanides, a library of similar types of spiro-
β-lactam can be generated to screen against various biological events. 
 
Scheme 40.  Synthesis of spiro β-lactam via microwave irradiation. 
 
2.2.7. Extension Toward the Synthesis of 1,4-Benzodiazepine-3-Ones For 
Anti-Cancer Therapy and Anti-Depressants 
 Benzodiazepines (BDZs) are psychoactive drugs whose chemical structure is the 
fusion of a benzene ring and a diazepine ring.  The first BDZ was discovered by Leo 
Sternbach of the Hoffmann La Roche Company and was marketed as Librium 
(chlordiazepoxide, 114, Figure 17).117  Over the past decade, BDZ have attracted a 
considerable interest among the scientific community as well as pharmaceutical 
companies due to their wide spread biological activities e.g. hypnotic (sleep-inducing), 
anxiolytic (anti-anxiety), anticonvulsant, muscle relaxant, amnesic, sedative, fibrinogen 
receptor antagonist, anticancer.118, 119, 120, 121, 122  As a result a number of BDZ drugs have 
been marketed by many pharmaceutical companies (Figure 17).  In recent years, several 
synthetic approaches toward 1,4-benzodiazepin-3-ones have been reported including a 
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CuI-catalyzed Ullmann aryl amination,123 addition/elimination nucleophilic substitution 
of primary or secondary amines,124 and retro-Michael/amidation,125 and an intramolecular 
1,3-dipolar cycloaddition.126  However, a majority of these synthesis are lengthy and 
require costly reagents.  Although, these reported methods can provide substrate 
diversity, they do not provide regiochemical substitution on the diazepine ring. 
 
Figure 17.  Commercialized BDZ drugs. 
 
 It has been well established that BDZs increase the efficiency of gamma amino 
butyric acid (GABA) – a natural brain neurotransmitter.  The excitability of neurons thus 
decreases.  Consequently, this phenomenon reduces the ability of neurons to 
communicate with each other and renders a calming effect on normal brain functions.  
The excitation of neurons is controlled by the binding of GABA to the protein complex 
GABAA receptor which is located in the synapses of neurons.127  The heteromeric 
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GABAA receptor is composed of five subunits, most commonly two α units, two β units 
and one γ (α2β2γ) unit.  All GABAA receptors contain two binding sites for GABA 
located at the interface of α and β subunits; one binding site for BDZs located at the 
interface of α and γ subunits; and a center chloride ion channel that allows transportation 
of chlorides ions across the neuronal cell membranes (Figure 18).  The binding of BDZs 
at the interface of α and γ subunits requires the presence of histidine amino acid residue 
in α subunits.  Thus, BDZs do not have affinity toward arginine containing α4 and α6 
subunits.  Binding of BDZs to the BDZ-binding site promotes binding of GABA.  This 
results in an increased conduction of chloride ions across the neuronal cell membranes 
and raises the membrane potential of the neuron itself.  Consequently, the process inhibits 
neuronal firing.  Hence, activation of GABA binding to the GABAA receptor by BDZs 
may provide distinct pharmacological events that might allow to develop new BDZs as 
therapeutic drug.128, 129 
 
GABA
site
BZD
site
GABA
site
Cl-
pore
2
1 1
2
 
Figure 18.  A schematic representation of the (α1)2(β2)2(γ2)2 GABAA receptor complex. 
 
 We became interested in 1,4-BDZ-3-ones primarily because in recent years they 
have found to be useful adjuncts to cancer chemotherapy122b and many commercialized 
BDZ drugs have severe side-effect.  Moreover, recently 1,4-BDZ-3-ones have been 
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reported to be fibrinogen receptor antagonist.118  Thus, we envisioned that 1, 4-
benzodiazepin-3-ones could be synthesized utilizing the U-4CCR in conjunction with 
μwave irradiation to rapidly access differentially substituted motifs in a one-pot130 
protocol utilizing environmentally benign reagents.  We speculated that use of o-
nitrobenzylamine and o-nitrobenzaldehyde in the U-4CCR could provide acyclic 
products that could undergo tandem reduction and 7-exo aza-Michael cyclization in 
presence of a suitable catalyst to provide differentially substituted 1,2,4,5-tetrahydro-1,4-
benzodiazepin-3-ones (Scheme 41). 
 
 
Scheme 41.  Proposed synthetic route for 1,4-benzodiazepin-3-ones. 
 
Thus, we chose 2-nitro-4-(trifluromethyl)phenyl (4i), p-bromoaniline (1f), 
fumaric acid monotheyl ester (2a) and tert-butyl isocyanide (3c) to synthesize the acyclic 
Ugi product (±)-122 and isolated the compounds according to Pirrung’s method.131  The 
acyclic product was subjected to reduction conditions and it was observed that benzyl-
based substrates did not fair well under hydrogenolysis conditions with palladium or 
platinum.  Although tin (II) chloride worked reasonably well for the aryl nitro reduction, 
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we elected to use the two electron reducing conditions of Fe (0)132 and NH4Cl in an 
aqueous media due to its mild nature and the fact that iron has a high functional group 
tolerance.133 
 
Table 11.  7-exo-trig aza-Michael cyclization yielding C2, N4, C5 substitution of 1,4-
BDZ-3-ones. 
 
% Yield Entry Conditions 
123 124 
1 rt, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 48 h 0 0 
2 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 5 h <1c >98c 
3 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 24 h <1c >98c 
4 Sealed tube, 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 4 h <1c,d >98c 
5 μwave, 140 oCb, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 1h 70e 30e 
6 μwave, 140 oCb, Fe/NH4Cl (15:1), EtOH/H2O (4:1), 1h 70e 30e 
7 μwave, 140 oCb, Fe/NH4Cl (10:1), EtOH/H2O (3:1), 1h 70e 30e 
8 μwave, 150 oCb, Fe/NH4Cl (10:1), EtOH/H2O (3:1), 45 min 75e 25e 
a Denotes oil bath temperature. bMicrowave equilibrated to 300 W, 10 bar. c Determined 
by 1H NMR. d At temperature exceeding 200 oC, <10% product observed. e Isolated. 
 
Different temperatures and solvent conditions were screened to find the optimum 
reaction yield.  Stirring the acyclic product (±)-122 in a 5:1 mixture of ethanol and water 
in the presence of Fe/NH4Cl (20:1 mol ratio) did not provide any product. The reaction 
mixture was heated at 140 oC in an silicone-based oil bath for 5-24 h and only ~1% 
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conversion was observed by GC-MS and 1H NMR.  Heating the same reaction mixture in 
a sealed tube under similar conditions did not provide a better result.  However, when a 
solution of 122 in a 5:1 mixture of ethanol and water in presence of Fe/NH4Cl (20:1 mol 
ratio) was irradiated at a microwave setting of 300 W, 180 oC, 18 bar, 60 min, the desired 
product (±)-123 was obtained in about 60% yield.  Further optimization of solvent (3:1), 
catalyst loading (10:1 mol ratio) temperature (150 oC), pressure (10 bar) and time (45 
min) provided good yield (75%) of (±)-123.134 
 It must be noted that when the reaction was run in a sealed tube or microwave 
vial, when temperatures exceeding 200 oC, extensive decomposition of starting material 
was observed.  However, at the optimized microwave condition, both the cyclized (123) 
and reduced acyclic anilne (124) products were isolated in quantitative yield, indicating 
that product degradation did not occur.  It is important to note that compound 122 or 124 
would not undergo an aza-Michael cyclization unless microwave irradiation was applied. 
A similar study was conducted to optimize a 7-exo-trig aza-Michael cyclization 
for C2, N4 substituted 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones.  A purified Ugi 
product 125 arising from isobutyraldehyde (4d), o-nitrobenzylamine (1t), fumaric acid 
monoethyl ester (2a) and tert-butyl isocyanide (3b), was used as the starting material.  
Stirring the acyclic product 125 in a 51 mixture of ethanol and water in the presence of 
Fe/NH4Cl (20:1 mol ratio) did not provide any product. The reaction mixture was heated 
at 140 oC in oil bath for 5-24 h and a moderate yield (55-73%) was observed by GC-MS 
and 1H NMR.  Heating the same reaction mixture in a sealed tube under similar 
conditions provided a better result but not satisfactory.  However, when a solution of 125 
in a 5:1 mixture of ethanol and water in presence of Fe/NH4Cl (20:1 mol ratio) was 
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irradiated at a microwave setting of 300 W, 180 oC, 18 bar, 60 min, the desired product 
126 was obtained in about 85% yield.  Further optimization of solvent ratio (3:1), catalyst 
loading (10:1 mol ratio) temperature (150 oC), pressure (10 bar) and time (45 min) 
provided excellent yield (90%) of 126 along with 7% of reduced acyclic aniline product 
127.134 
 
Table 12.  Optimization of 7-exo-trig aza-Michael cyclization yielding C2, N4 
substitution of 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-one. 
 
% Yield Entry Conditions 
126 127 
1 rt, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 48 h 0 0 
2 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 5 h 55c 40c 
3 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 24 h 73c 22c 
4 Sealed tube, 140 oCa, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 4 h 80c,d 17c 
5 μwave, 140 oCb, Fe/NH4Cl (20:1), EtOH/H2O (5:1), 1h 85e 12e 
6 μwave, 140 oCb, Fe/NH4Cl (15:1), EtOH/H2O (4:1), 1h 85e 12e 
7 μwave, 140 oCb, Fe/NH4Cl (10:1), EtOH/H2O (3:1), 1h 85e 12e 
8 μwave, 150 oCb, Fe/NH4Cl (10:1), EtOH/H2O (3:1), 45 min 90e 7e 
a Denotes oil bath temperature. b Microwave equilibrated to 300 W, 10 bar. c Determined 
by 1H NMR. d At temperature exceeding 200 oC, <10% product observed. e Isolated. 
 
 We were then encouraged to develop a one-pot protocol for the synthesis of 
1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones based on our results with the 7-exo Michael 
cyclization described in Tables 11 and 12.  We selected to use isobutyraldehyde (4c), 2-
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nitrobenzylamine (1t), fumaric acid monoethyl ester (2a) and benzyl isocyanide (3a) as 
our intitial set of starting substrates leading to BDZ of type B (Table 13).  Protic solvents 
such as aqueous methanol or ethanol gave the desired Ugi product in high yield (>98%) 
after being subjected to microwave irradiation for 1 h at 60 oC.  Fe(0) and NH4Cl were 
then added to the reaction flask, and the mixture was further subjected to microwave 
irradiation until all starting materials were converted to 128 and 129.  The structure of 
compound 128 was unequivocally confirmed by X-ray analysis (Figure 19).134 
 
Table 13.  Optimization of conditions for one-pot synthesis of BDZ. 
 
Entry Solvent Time (min) T (oC) % yield of 128a % yield of 129b 
1 EtOH 30 150 77 10 
2 H2O 30 150 73 5 
3 EtOH/H2O, 3:1 30 150 85 3 
4 EtOH/H2O, 3:1 15 180 71 7 
5 EtOH/H2O, 3:1 75 140 82 3 
6 EtOH/H2O, 3:1 100 120 80 3 
7 EtOH/H2O, 3:1 180 110 81 3 
a Isolated. b Determined by 1H NMR 
 
 The reduction worked best in the microwave at 150 oC for 30 min in a 3:1 ratio of 
EtOH/H2O.  It is important to note that in the absence of microwave irradiation or other 
heat sources in the one-pot protocol, only the acyclic Ugi product could be isolated 
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(approximately 80% yield in 18 h, refer to Table 12 for cyclization conditions) suggesting 
that a high energy of activation for nitro group reduction with Fe (0).134 
 We next turned our attention to examining the scope of the one-pot protocol.  As 
noted in Table 14, entries 1-5, BDZs of the type A were formed in 70-80% yield with 
high diastereomeric ratios.  In fact, compounds 135 and 137 (Table 14, entries 4 and 5) 
were obtained as single diastereomers, as determined by 1H NMR.  NOe data assisted in 
elucidating a 2,5-cis relationship between the acid and aldehyde components of the 
coupling products.134 
 These data correspond nicely with literature precedent in which similar types of 
1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones were synthesized.124b  Diastereomers are 
rationalized to arise from the E olefin geometry of the fumaric acid component.  Using 2-
nitrobenzylamine (1t) as a substrate in the U-4CCR gave benzodiazepines of the type B 
following the one-pot protocol (Table 14, entries 6-7). Although we observed higher 
yields of C2, N4 substituted 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones, diastereomeric 
raios were determined to be, at best, 1.5:1 (1H NMR).  The diastereomeric mixture 
proved difficult to separate and required a silica gel column of considerable length.  In a 
similar fashion (Table 14, entry 8), when acrylic acid (2f) was used as coupling 
component and subjected to the one-pot cyclization conditions, a 8-endo-trig aza-Michael 
cyclization leading to an eight-membered ring was not observed and only the acyclic 
aniline U-4CCR product 139 was isolated.  The structure of 139 was unequivocally 
confirmed by X-ray analysis (Figure 20). 
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Scheme 42.  General route toward the synthesis of regiochemically substituted BDZs. 
Table 14.  Scope of the one-pot microwave-assisted synthesis of regiochemically 
differentiated 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-one. 
Entry R1 R2 R3 R4 Compd typea/ 
% yieldb/drc 
1 2-Nitro-4-(trifluorometthyl)- 
phenyl (4i) 
4-Bromophenyl 
(1f) 
tert-butyl 
(3c) 
Ethoxycarbonyl 
(2a) 
A (123)/75/5:1 
2 2-Nirophenyl (4j) Benzyl 
(1d) 
tert-butyl 
(3c) 
Ethoxycarbonyl 
(2a) 
A (131)/75/20:1 
3 4,5-dimethoxy-2-nitrophenyl 
(4k) 
Allyl 
(1u) 
Cyclohexyl 
(3d) 
Benzoyl 
(2g) 
A (133)/70/20:1 
4 2-Nitrophenyl (4j) Piperonyl 
(1v) 
tert-butyl 
(3c) 
Ethoxycarbonyl 
(2a) 
A (135)/73/ 
single 
5 2-Nitrophenyl (4j) 4-aminoacetophenone 
(1w) 
cyclopentyl 
(3e) 
4-methylbenzoyl 
(2h) 
A (137)/78/ 
single 
6 Isopropyl 
(4c)l 
2-Nitrobenzyl 
(1t) 
tert-butyl 
(3c) 
Ethoxycarbonyl 
(2a) 
B (126)/90/1.5:1 
7 Isopropyl 
(4c) 
2-Nitrobenzyl 
(1t) 
Benzyl 
(3a) 
Ethoxycarbonyl 
(2a) 
B 
(128d,e)/85/1.5:1 
8 Isopropyl 
(4c) 
2-Nitrobenzyl 
(1t) 
tert-butyl 
(3c) 
H 
(2f) 
Acyclic 
(139d,f)/100 
aCompound number denoted in parentheses. b Isolated. c Determined by using an 
unpurified sample with 1H NMR. d X-ray structure. e At temperature >180 oC the major 
product was 2,5-diketopiperazine. f Isolated the acyclic aniline U-4CCR product. 
 
 At high μwave intensity, a one-pot 6-exo aza-Michael cyclization occurred to 
from 2,5-diketopiperazines 140 and 141 as illustrated in Scheme 43.106  This potentially 
competing reaction pathway could readily be suppressed by reduction of μwave intensity 
to exclusively form BDZ 128.  This transformation indicates that a 6-exo aza-Michael 
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cyclization, from an amide occurs faster than the zero valent iron metal reduction.  Our 
results suggest that compound 141 resulted from the direct reduction of 140 and not from 
prior –NO2 → –NH2 reduction. 
 
 
Scheme 43.  Microwave intensity controls pathway selectivity. 
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Figure 19. X-ray structure of (±)-128. 
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Figure 20.  X-ray structure of compound (±)-139. 
 
 As a part of our interest in spiro-cyclic motifs, we next embarked on devising 
synthetic route for spiro-benzodiazepines as they have become attractive synthetic target 
due to their biological activity.135  A thorough literature survey revealed that aza-Michael 
reactions had not been utilized to construct spiro-BDZ motifs and there were few reports 
that described the synthesis of these motifs.  However, we envisioned that use of 
previously synthesized (Scheme 31) 3-oxo-cyclohexene-1-carboxylic acid (2e) in the U-
4CCR might provide spirocyclic 1,4-benzodiazepine-3-ones.  Thus, Ugi acyclic product 
142 was synthesized from a coupling reaction of 2-nitrobenzylamine (1t), 
trimethylacetaldehyde (4b), 3-oxo-cyclohexene-1-carboxylic acid (2e) and tert-butyl 
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isocyanide (3c).  When 142 was subjected to microwave irradiation under previously 
established reaction conditions (Table 12), spirocyclic 1,4-benzodiazepin-3-one 143 and 
octahydrodibenzodiazocine-1,5-dione 144 were obtained in 35% and 50% respectively.  
The identity of 143 and 144 was confirmed by 1H NMR as well as nOe studies.  It is 
noteworthy that 144 was less polar than 143 (Scheme 44). 
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Scheme 44.  Synthesis of spiro-1,4-benzodiazepine and octahydrodibenzodiazocine-1,5-
dione. 
 
2.2.8. Extension Toward the Synthesis of Spiro-2,5-Diketopiperazines to 
Develop CCR5 Antagonist 
 
 2,5-Diketopiperazines are the simplest member of cyclic dipeptides.  In other 
words, cyclic peptides are surrogates of simple amino acids.  Consequently, spirocyclic 
amino acids might have the ability to restrict conformational flexibility when they are 
incorporated into bioactive peptide frameworks.  Potentially, they can provide critical 
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information on the spatial requirement of peptide receptors.136  More importantly, such 
pseudopeptides often display several advantages over natural peptides including 
improved bio-stability and selectivity toward specific biological target. 
Spiro-2,5-diketopiperazines (Spiro-DKP) are the cyclic dipeptides containing α, 
α-disubstituted amino acid moieties with wide range of pharmacological activities which 
includes neuroprotection, anti-proliferative, anti-inflammatory, anti-allergic and also 
prevent immune diseases.137  These bioactivities make the spiro-DKP motif an attractive 
core in medicinal chemistry.  Recently, spiro-DKPs have gained wide spread attention 
among scientific community since it has emerged as potential antagonist of HIV (human 
immunodeficiency virus) receptor CCR5.  Chemokines are chemotactic cytokines that 
play a key role in leukocyte migration, adhesion, and activation involved in inflammation 
and immune cell differentiation.138  The chemokines receptors, belong to the family of 
seven transmembrane (7TM) G-protein-coupled receptors (GPCRs), are broadly 
classified into two families based on their cytocine residue structure: CC and CXC.  
Similarly, their corresponding receptors are also classified into two groups: CCR and 
CXCR respectively.  In the HIV (human immunodeficiency virus) infection process of 
target cells requires viral binding to the chemokine receptors CCR5 and CXCR4.139  In 
particular, the entry of R5 tropic strains of HIV-1, HIV-2 and simian immunodeficiency 
virus (SIV) requires the CCR5 co-receptor.  Consequently, preventing or disrupting the 
HIV-chemokine receptor binding could lead to potential route for the development of 
inflammatory drugs, antiallergic drugs, immunosuppressants, and/or antiviral drugs for 
HIV infection.  Moreover, they are monoamine oxidase inhibitors and calcium channel 
blockers. 
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To date, only few literatures are available which reported the synthesis of spiro-
DKPs.  However, many of these syntheses require either multiple steps or external 
additives which are not environmentally benign.140  We envisioned that use of cyclic 
ketones in the U-4CCR in conjunction with microwave irradiation might provide an 
environmentally benign route for the synthesis of spiro-DKPs.  Thus, acyclic U-4CCR 
product 145 was obtained from four component coupling reaction of p-methoxy 
benzylamine (1a), cyclopentanone (4l), fumaric acid monoethyl ester (2a) and n-butyl 
isocyanide (3g).  When 145 was subjected to microwave irradiation under previously 
established conditions (Table 2, entry 13), a 6-exo-trig aza-Michael reaction provided 
compound 146 in about 50% yield (scheme 46).  Further optimization of reaction 
conditions provided 146 in about 85% yield.  We then examined the substrate scope of 
this spiro-DKP synthesis using various cyclic ketones, amines and isocyanides (scheme 
47).  Majority of the substrates provided good to excellent yields.  In general it has been 
observed that spiro-DKPs formation requires longer reaction time compared to DKPs 
probably due to ring strain of the resulting products 
 
 
Scheme 45.  Synthesis of spiro-DKP under microwave irradiation. 
 
 
 
 
 
 76
Table 15.  Optimization of microwavea reaction conditions leading to spiro-DKP. 
Entry Solvent Time (min) Power (W) Temp (oC) Pressure (bar) Yield 
(%)b 
1 H2O 20 300 200 18 50 
2 H2O 30 300 200 18 60 
3 H2O 30 300 200 18.5 65 
4 H2O 40 300 200 18.5 70 
5 H2O 50 300 200 18.5 80 
6 H2O 60 300 200 18.5 85 
a CEM Discover Microwave. b Isolated 
 
  While we were working on the project, astonishingly, a thorough literature survey 
revealed that cyclopropanone and cyclobutanone have been used in the IMCCRs in very 
few cases.141  Therefore, we decided to use commercially available cyclobutanone 4l as 
coupling partner in the U-4CCR.  Gratifyingly, the U-4CCR reaction between benzyl 
amine 1d, cyclobutanone 4l, fumaric acid monoethyl ester 2a and benzyl isocyanide 3a 
provided the desired spiro-DKP 154 in excellent yield.  During the progress of the 
project, Pirrung and coworkers reported that cyclobutanones work well in Ugi and 
Passerini reactions and reasoned that the lack of past reports was due to the unusual 
reaction course of cyclobutanones.142  It is quite noteworthy that in our hand, the 
cyclobutane ring opening does not occur in the presence of microwave irradiation under 
high temperature and pressure, although there was speculation that due to ring strain, it 
might undergo ring opening.143 
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Scheme 46.  General scheme for microwave-influenced spiro-DKP synthesis. 
 
Table 16.  Substrate scope of microwave-influenced synthesis of spiro-DKPs. 
Entry R1 R2 R3 R4 Compd/% yielda 
1 Cyclopentyl 
(4l) 
Ethoxycarbonyl 
(2a) 
4-Methoxybenzyl 
(1a) 
n-butyl 
(3g) 
146/85 
2 Cyclohexyl 
(4m) 
Ethoxycarbonyl 
(2a) 
4-Methoxybenzyl 
(1a) 
n-butyl 
(3g) 
148/80 
3 4-Thio-pyran 
(4n) 
Ethoxycarbonyl 
(2a) 
3,4-Dimethoxybenzyl 
(1f) 
Benzyl 
(3a) 
150/82 
4 4-pyran  
(4o) 
Ethoxycarbonyl 
(2a) 
3,4-
methylenedioxybenzyl 
(1j) 
Benzyl 
(3a) 
152/83 
5 Cyclobutane 
(4p) 
Ethoxycarbonyl 
(2a) 
Benzyl 
(1d) 
Benzyl 
(3a) 
154/98 
6 3-methyl- 
Cyclopentane 
(4q) 
Tolylcarbonyl 
(2h) 
4-bromophenyl 
(1f) 
n-butyl 
(3g) 
 
156/n.db 
7 1-phenethyl- 
Piperidine 
(4r) 
Ethoxycarbonyl 
(2a) 
Propargyl 
(1x) 
n-butyl 
(3g) 
 
158/n.db 
aIsolated. bNot determined 
 
2.2.9. Extension Toward the Synthesis of Tetrahydro-Isoquinolinones 
 
 Isoquinolinone is a very important heterocyclic privileged scaffold and present in 
wide range of natural products that possesses a broad spectrum of biological activities 
e.g., anticancer, antileukemic, antitumor, antiulcer, antidepressant, anti-inflammatory, 
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analgesic, hypolipidemic, antihypertensive as well as inhibits PARP-1 and 
topoisomerase-1.  A large number of syntheses of isoquonolinone (IQ) motifs have been 
reported.  Because of the therapeutic value of such motifs in various bioactive molecules, 
there has been an increasing interest among the scientific community to construct these 
motifs.  Since it was discovered over 75 year ago,144 scientific community have 
extensively studied the  acid catalyzed dienone-phenol rearrangement (DPR)145 and 
widely reviewed.146  However, there is lack of study on the rearrangement of 
corresponding 4,4-disubstituted 2-alkoxycyclohexa-2,5-dien-1-ones.147  Primarily, the C-
4 substituents have been observed to migrate almost exclusively to C-5.148  When the C-5 
is substituted in these α-keto enol ethers, migration to C-3 is observed only. 
We envisioned that previously synthesized 2-azaspiro-[4.5]deca-6,9-diene-3,8-
dienone 61 can undergo DPR in presence of a suitable acid catalyst to provide 
isoquinolinones.105d  Thus, we screened various Lewis acid and Bronsted acid catalysts 
and nitromethane was used as solvent as there are literature precedents.105d  In view of 
some recent reports that lanthanide-based catalyst are water stable and can catalyze many 
reactions; we also screened lanthanide-based catalyst in water.  Moreover, there is 
minuscule literature precedence of using microwave irradiation to perform DPR.  Thus, 
we were interested to study microwave irradiation on DPR.  It has been found that 1.5 
equiv. of BF3.OEt2 and TMSOTf were the best catalyst and provided 90% yield of 159 
where as TiCl4, FeCl3 and Bronsted acids lead to decomposition of starting material 
(when the microwave was equilibrated to 300 W, 150 oC, 20 min, 16 bar).  However, the 
reaction gave no recognizable amount (or at best a trace amount) of compound 160 
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(Scheme 47).  The identity of 159 was confirmed by 1H, GQFCOSY, nOe study and mass 
spectrometry (HRMS). 
 
Scheme 47.  Synthesis of tetrahydroisoquinolinone under microwave irradiation. 
 
Table 17.  Screening of Lewis/Bronsted Acids for DPR under microwave irradiationa 
Entry Lewis/Bronsted Acid Solvent % yield of 159b % yield of 160 
1 BF3.OEt2 CH3NO2 100 0 
2 Yb(Otf)3 CH3NO2 NR 0 
3 Yb(OTf)3 H2O NR 0 
4 Sc(OTf)3 CH3NO2 NR 0 
5 Sc(OTf)3 H2O NR 0 
6 AlCl3 CH3NO2 NR 0 
7 InCl3 CH3NO2 NR 0 
8 CuI CH3NO2 NR 0 
9 FeCl3 CH3NO2 Decomposition 0 
10 TiCl4 CH3NO2 Decomposition 0 
11 Ti(i-PrO)4 CH3NO2 NR 0 
12 ZnCl2 CH3NO2 NR 0 
13 AgI CH3NO2 NR 0 
14 TMSOTf CH3NO2 100 0 
15 PTSA CH3NO2 Decomposition 0 
16 CSA CH3NO2 Decomposition 0 
17 HCl CH3NO2 Decompostion 0 
a Microwave was equilibrated to 300 W, 150 oC, 16 bar for 20min. b Based on TLC 
 
 Next we screened various solvents for DPR in presence of BF3.OEt2 and 
TMSOTf.  It has been observed that polar aprotic solvents (e.g., CH3NO2 and CH3CN) 
except DMF and DMSO highly favored the DPR, whereas polar protic solvents e.g., 
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MeOH gave no recognizable (or at best a trace amount) of DPR product 159.  A plausible 
explanation could be that the DPR involves a carbocationic intermediate and polar protic 
solvents might act as proton source leading to protonation of the intermediate which 
prevents the final irreversible rearrangement step. 
 
Table 18.  Solvent effects on DPR under microwave irradiation.a 
Entry Lewis Acid Solvent % yield of 159b 
1 CH3CN 89 
2 CH3NO2 90 
3 CH2Cl2 15 
4 DMF NR 
5 DMSO NR 
6 MeOH NR 
7 
 
 
 
BF3.OEt2 
THF NR 
8 CH3CN 90 
9 CH3NO2 90 
10 CH2Cl2 10 
11 DMF NR 
12 DMSO NR 
13 MeOH NR 
14 
 
 
 
TMSOTf 
THF NR 
a Microwave was equilibrated to 300 W, 150 oC, 16 bar for 20 min. b Isolated 
 
 Having best solvents and catalysts in hand, we elected to use CH3NO2 as solvent 
and BF3.OEt2 as the Lewis acid catalyst for the optimization of microwave reaction 
conditions.  When microwave was equilibrated to 300 W, 100 oC, 10 bar for 10 min, the 
reaction provided the best result (96% yield of 159).  A series of acyclic Ugi products 
(Table 21) have been synthesized and currently, we are performing the spiro cyclization 
(Table 2) and resulting spiro compounds will be subjected to DPR (Table 21) conditions 
to study substrate scope of this novel method. 
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Table 19.  Optimization of microwave reaction conditions for the DPR.a 
Entry Power (W) Temperature (oC) Pressure (bar) Time (min) % yield of 159b 
1 300 150 16 20 90 
2 300 140 14 20 91 
3 300 130 13 20 92 
4 300 110 10 10 94 
5 300 100 10 10 96 
a CH3NO2 was used as solvent and BF3.OEt2 (1.5 equiv.) was used as Lewis acid catalyst. b Isolated 
 
Table 20.  Substrate scope of the microwave-assisted synthesis isoquinolinones via DPR. 
 
Compd/% yield/dr Entry R1 R2 R3 X Y 
Acyclic Spiro IQ 
1 t-butyl (4b) Ethoxycarbonyl 
(2a) 
t-butyl (3b) OMe 
(1c) 
H 61/80 60/60/1:
2 
159/96a/1:1.5 
2 t-butyl (4b) Tolylcarbonyl (2h) t-butyl (3b) OMe H –/82 161/70 162/65b/1:2 
3 t-butyl (4b) benzoyl (2f) t-butyl (3b) OMe H –/85 163/75 164/68b/n.d 
4 4-fluorophenyl 
(4s) 
Ethoxycarbonyl (2a) t-butyl (3b) OMe 
(1y) 
OMe 165/81 166/73 167/67c/n.d 
5 Piperonyl (4t) Ethoxycarbonyl (2a) Cyclohexyl 
(3b) 
OMe 
(1c) 
H – 168/87 169/n.dc/n.d 
6 4-fluorophenyl 
(4s) 
Ethoxycarbonyl (2a) Cyclohexyl 
(3c) 
OMe 
(1c) 
H 170/84 171/ndc 172/ndc 
7 t-butyl (4b) Ethoxycarbonyl (2a) Cyclopentyl 
(3g) 
H 
(1b) 
H 24c/90 23c/81 173/85 
a Isolated yield. b based on crude 1H NMR, not isolated yield. c reaction will be performed 
 
 As shown in table 20 (entry 2, 3, 5), the U-4CCR provided the 2-azaspiro-
[4.5]deca-6,9-diene-3,8-dienone when the reaction was carried out at room temperature 
and warmed upto 70 oC.  The probable explanation could be that the π-cloud of aromatic 
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groups of the U-4CCR products stack together and the π-stacking effect149 (Figure 21) 
might help to bring the reacting centers closer; lowers the activation barrier for 5-exo 
Michael pathway leading to 161, 163 and 168. 
 
 
Figure 21.  Possible π-stacking effect led to the spiro-cyclization via 5-exo-trig Michael 
pathway. 
 
 The C-5 regioselectivity in methoxy/hydroxy dienones (e.g., 60) in DPR can be 
simply rationalized by considering the electron density at C-3 vs C-5. in the coordinated 
form of 60 with Lewis acid.147l  It should be clear that while the coordinated carbonyl 
induces a partial positive charge at both carbons, represented by resonance structures 176 
(177) and 182 (183), the overall charge at C-3 is neutralized to a large extent by the 
electron donation of the enol ether moiety, as shown in structure 185 (Scheme 48).  Since 
it is the positive charge character of C-3 or C-5 that induces this rearrangement, it is their 
relative sizes that control the overall regioselectivity.149  The potential migrating groups 
(C-3׳ and C-5׳) are in the same steric environment, held conformationally rigid on either 
side of the planner dienone ring, so their setric effects in the rearrangement are 
minimized.  The C-3׳ is a 1o carbon and C-5׳ is a 2o carbon, thus C-5׳ has higher 
migratory aptitude and will migrate (1,2-shift) preferentially.  Furthermore, resulting 
carobocation intermediate after 1,2-shift is resonance stabilized by the methoxy group at 
the C-2 position.  The large driving force for the rearrangement is the aromatization of 
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Scheme 48.  Proposed mechanism of the microwave-assisted DPR. 
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 Understanding the mechanism of the DPR can provide some shed on the solvent 
effect on the reaction.  As shown in Table 19, polar nucleophilic protic solvents did not 
provide any product.  The probable explanation is that the rearrangement involves 
carbocation intermediates that might capture a good nucleophile e.g. MeOH.  On the 
other hand, polar aprotic solvents with no nucleophlic character (e.g. CH3NO2) or very 
low nucleophilic character (e.g. CH3CN) favors the DPR because the carbocationic 
intermediate can avoid any short of nucleophilic attack. 
 It is quite noteworthy that under the reaction conditions, the t-Bu-NH group from 
61 (derived from tert-Butyl isocyanide) spontaneously cleaved to provide corresponding 
acid 159.  We speculated that, in presence of a nucleophilic solvent, we might be able 
tune the reaction.  Thus we decided to revisit our single-step synthesis effort (Scheme 25) 
and chose to subject the acyclic precursor of 61 under the same microwave irradiation 
conditions in 3:1 mixture o CH3CN and MeOH using BF3.OEt2 (Scheme 49).  To our 
surprise, compound 186 was obtained with concurrent loss of the tert-butyl-NH (derived 
from tert-butyl isocyanide) and 3-methoxy-4-hydroxy benzyl groups.  Identity of 
compound 186 was confirmed by 1H NMR, 13C and HRMS. 
 
 
Scheme 49.  Conversion of an amide into an ester under microwave irradiation. 
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 Thus, tert-butyl isocyanide can act as convertible isocyanide (CIC)44 in presence 
of BF3.OEt2 under microwave irradiation.  During the progress of the project, Kravasin 
and coworkers also reported that tert-butyl isocyanide acts as a CIC in presence of TFA 
under microwave irradiation.150  Next, we decided to explore the outcome of this reaction 
and study whether other commercial ‘off-the-shelf’ isocyanides can be cleaved and can 
act as CICs.  A series of acyclic Ugi products were synthesized employing commercial 
‘off-the-shelf’ isocyanides.  Purified acyclic Ugi products 24b was subjected to the 
microwave irradiation using BF3.OEt2 (1 .5 equiv., 2 equiv. and 2.5 equiv.).  Gratifyingly, 
the removal of cyclohexyl amine was observed and the reaction provided best yield of 
187 when 2 equiv. of BF3.OEt2 was used.151  Thus, we decided to use 2 equiv. of 
BF3.OEt3 for other precursors.  In general, it has been observed that all of the commercial 
‘off-the-shelf’ isocyanides can act as CICs under our reaction conditions.152 
 
Table 21.  Scope of ‘off-the-shelf’ isocyanides as CICs. 
 
Entry R1 R2 R4 % Yielda/ 
(U-4CCR pdt) 
% Yield/ 
(Deprotected pdt) 
1 t-butyl hydroxyl cyclohexyl 89/(24b) 90a/(187) 
2 t-butyl hydroxyl cyclopentyl 90/(24c) 70b/(188) 
3 t-butyl hydroxyl isopropyl 90/(24d) 75b/(189) 
4 t-butyl hydroxyl benzyl 93/(24e) 69b/(190) 
5 t-butyl hydroxyl n-butyl 91/(24f) 72b/(191) 
6 isopropyl hydrogen 4-methoxyphenyl 90/(51) 65b/(192) 
a Isolated. b Based on crude 1H NMR 
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Scheme 50.  Possible mechanism for the formation of compound 187. 
 
 A possible mechanism for the formation of compound 187 is shown in Scheme 
50.  Nucleophilic attack of the carbonyl group (from the carboxylic acid component) onto 
the carbonyl group (derived from isocyanide component) forms the müchanone.  The 
müchanone is further stabilized resonance structure (187b-187d) and finally nucleophilic 
attack onto the ester carbonyl of 187a provides the observed product 187.  
 From Table 11, it is quite clear that microwave irradiation can influence 
electronic property of molecules and can be used as a reagent to construct new bonds.  It 
must be noted that a hydroxyl group is a stronger electron-donating group than a methoxy 
group.  Although, a p-methoxy group does undergo spiro-cyclization under other 
conditions,153 we think that it might form a spiro-intermediate like 193, but under the 
neutral reaction conditions the methyl group of the OMe does not fall off spontaneously.  
Consequently, the intermediate collapse and follow an alternative 6-exo-trig aza-Michael 
pathway to form DKP (Scheme 51). 
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Scheme 51.  Methyl group does not fall off spontaneously under neutral conditions. 
 
 We decided that it would be interesting to study how microwave irradiation can 
influence other functional groups e.g. N-acetyl group at the para positon of phenyl ring 
and alter the reaction course.  Thus, we elected to use 4-acetamidobenzaldehyde in the 
one-pot U-4CCR.  Gratifyingly, when benzylamine 1d, 4-acetamidobenzaldehyde 4u, 
furmaic acid monoethyl ester 2a and t-butyl isocyanide 3c was subject to U-4CCR under 
microwave conditions as shown in scheme 69, IQ 195 was obtained in about 60% yield 
 88
via non-isolatable U-4CCR product 194.  For spectroscopic comparison, the acyclic Ugi 
product 194 was separately synthesized at room temperature. 
 Employing other 4-amidobenzaldehydes, amines, acids and bulky isocyanides a 
library of these 1,4-dihydroisoquinolinones can be envisioned in one-pot. 
 
 
Scheme 52.  Microwave-influenced one-pot synthesis of IQ via cascade 
Ugi/Michael/DPR-type rearrangement. 
 
 A probable mechanism for the formation of IQ 195 via cascade 
Ugi/Michael/DPR-type pathway is shown in scheme 53.  Initial 5-exo-trig Michael 
addition form the spiro acyliminium intermediate 196 which upon proton loss form 
intermediate 197.  Delocalization of double bond forms the carbocationic spiro 
intermediate 198 which then undergoes a 1,2-shift to form 199.  Protonation provides the 
final IQ product 195.  By employing various substituted 4-acetamidobenzaldehydes, 
other acids amines and bulky isocyanides a library of these amino IQs can generated for 
conducting SAR study. 
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Scheme 53.  Proposed mechanism for the formation of IQ via Cascade 
Ugi/Michael/DPR-type rearrangement. 
 
2.3. Materials and Methods 
 All Reagents were purchased from Aldrich unless otherwise mentioned.  4-
Hydroxybezylamine was purchased from Matrix Scientific.  4-Hydroxy-3-
methoxybenzylamine hydrochloride was purchased from Alfa Aesar.  6-
Nitroveratraldehyde and 4-aminoacetophenone were purchased from Alfa Aesar.  Allyl 
amine was purchased from Acros.  2-Nitrobenzylamine was obtained from 2-
nitrobenzylamine hydrochloride.  Except as otherwise indicated, reactions were carried 
out under argon.  Microwave reactions were carried out in a capped vial on CEM 
Discover System.  All reactions were monitored by thin layer chromatography using 0.25 
mm Dynamic Adsorbents, L.L.C. precoated silica gel (particle size 0.03-0.07 mm, 
catalog no. 84111.  Column chromatography was perfomed using Whatman Purasil 60 Ǻ 
(230-400 mesh ASTM) silica gel.  Yields refer to chromatographically and 
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spectroscopically pure compounds, except as noted.  Diasteremeric ratio was determined 
from 1H NMR spectra of crude reactions.  Proton and carbon-13 NMR spectra were 
recorded on Varian Mercury 400, Varian Unity 500 and Varian 500 Direct Drive System 
spectrometers.  The residual CDCl3 singlet at δ 7.26 ppm and δ 77 ppm were used as the 
standard for 1H NMR and 13C NMR spectra respectively.  Mass spectra were recorded on 
Micromass GCT at 70 eV.  IR spectra were recorded on Varian/Digilab Excalibur 3100 
High Resolution FT-IR.  Automatic LC-MS was performed on a WATERS LCT 
PREMIER XE ELECTROSPRAY TOF with waters BEH C18 column (2.1 mmx 50 mm, 
1.7 µm).  The eluent was mixture of acetonitrile and water containing 0.05% HCOOH 
with linear gradient from 10:90 (v:v) acetonitrile-water to 90:10  acetonitrile-water within 
10 minutes at 0.7 mL/min. UV absorption detection was conducted at 254 nm. 
 
2.3.1. General Procedure 1 for 2,5-diketopiperazines or 2-
azaspirocyclohexadienones synthesis (Starting with four separate substrates) 
To a 10 mL vial (CEM Discover System) equipped with magnetic stirring bar, 15 
mg (0.14 mmol) of Benzyl amine, 12 mg (0.14 mmol) of Trimethyl acetaldehyde, 25 mg 
(0.14 mmol) of trans-3-Benzoylacrylic acid and 17 μL (0.14 mmol) of Benzyl isocyanide 
were taken in a mixture of 1.5 mL LiCl and 1 mL MeOH.  The vial was capped properly 
and placed in the microwave.  Then the microwave was run at two stages: (a) 1 hr at 50 
oC, 10 Bar and 300 W (b) 20-25 min, 210 oC, 18 Bar and 300 W.  After cooling the vial 
at room temperature, ethyl acetate was added and shaken thoroughly.  The organic layer 
was separated and the aqueous layer was extracted with ethyl acetate twice (2 mL each).  
The organic layers were combined and washed with NaHCO3 (3 mL each), 1 N HCl (3 
mL each), Brine (3 mL each).  The organic layer was separated.  All aqueous layers were 
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combined and extracted with 3 mL ethyl acetate.  The organic layers were combined and 
dried over Na2SO4 and filtered.  The filtrate was dried under vacuum and purified by 
silica gel column chromatography using 1:2 mixture of ethyl acetate and hexane as 
eluent. 
2.3.1.1. General Procedure 2 for 2,5-diketopiperazines or 2-
azaspirocyclohexadienones synthesis (Starting from the acyclic Ugi product) 
To a 10 mL vial (CEM Discover System) equipped with magnetic stirring bar, 50 
mg of acyclic Ugi starting material was taken and 2.5 mL of distilled water was added to 
it.  The vial was capped properly and placed in the microwave.  Then microwave was run 
for 20-25 min at 210 oC, 18 Bar and 300 W.  After cooling the vial at room temperature, 
ethyl acetate was added and shaken thoroughly.  The organic layer was separated and the 
aqueous layer was extracted with ethyl acetate twice (2 mL each).  The organic layers 
were combined, dried over Na2SO4 and filtered.  The filtrate was dried under vacuum and 
purified by silica gel column chromatography using 1:2 mixture of ethyl acetate and 
hexane as eluent. 
2.3.1.2. Modified General Procedure 2 for the synthesis of tricyclic lactam (Starting 
from the acyclic Ugi product). 
To a 10 mL vial (CEM Discover System) equipped with magnetic stirring bar 
under argon, 50 mg of acyclic Ugi starting material was taken and 2.5 mL of dry CH2Cl2 
was added to it.  The vial was capped properly and placed in the microwave.  Then 
microwave was run for 20-25 min at 210 oC, 18 Bar and 300 W.  After cooling the vial at 
room temperature, ethyl acetate was added and shaken thoroughly.  The organic layer 
was separated and the aqueous layer was extracted with ethyl acetate twice (2 mL each).  
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The organic layers were combined, dried over Na2SO4 and filtered.  The filtrate was dried 
under vacuum and purified by silica gel column chromatography using 1:2 mixture of 
ethyl acetate and hexane as eluent. 
2.3.1.3. General Procedure 3 (for acyclic intermediates): 
To a 10 mL RB flask 0.3 g (2.19 mmol) of 4-Methoxybenzylamine was dissolved 
in 3 mL LiCl (or 3 mL MeOH) and 0.24 mL (2.19 mmol) of Trimethyl acetaldehyde was 
added.  The mixture was stirred for 10 min.  Then 0.32 g (2.19 mmol) of Fumaric acid 
monoethyl ester and 0.27 mL (2.19 mmol) were added respectively.  The resulting 
solution was allowed to stir overnight at room temperature and quenched with 1mL of 1N 
HCl.  To the mixture CH2Cl2 was added and stirred well.  The organic layer was 
separated and aqueous layer was extracted twice with CH2Cl2 (2 mL each).  The organic 
layers were collected and dried over Na2SO4 and filtered.  The filtrate was dried under 
vacuum and purified by silica gel column chromatography using a 1:2 mixture of ethyl 
acetate and hexane as eluent. 
2.3.1.4. General Procedure for the synthesis of carboxylic acid 2e: 
 To a 50 mL dry RB flask containing 3.02 mL of acetic anhydride (Ac2O), 3.85 g 
(38 mmol) of chromium trioxide (CrO3) was added slowly.  When all CrO3 was dissolved 
completely, 6.05 mL of glacial acetic acid (AcOH) was added slowly.  The resulting 
oxidizing solution was added dropwise to a stirred, cooled (11-14 oC) solution of 2 g 
(14.3 mmol) methyl-1-cyclohexene-1-carboxylate in 28 mL of dry dichloromethane over 
45 min.  The resulting solution was allowed to stir for additional 15 min and slowly 
added to ice-cold 19.8 mL KOH (12.5 M).  The organic layer was separated and the 
aqueous layer was then extracted twice with diethyl ether (20 mL).  The organic layers 
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were combined and washed with saturated NaHCO3, brine respectively and separated 
again. The organic layer was then dried over Na2SO4 and concentrated on rotary 
evaporator.  The crude 1H NMR was >97% clean and the product was used in next step 
without further purification. 
 Next, 1.75 g (11.4 mmol) of the enone carboxylate was stirred with 1.48 g (14 
mmol) in 14 mL water for 7 h at room temperature.  The reaction mixture was then 
acidified with 10% HCl to maintain pH 2 and immediately extracted with 
dichloromethane (15 mL × 3).  After evaporation on rotary evaporator, the residue was 
dissolved in 2.8 mL of dichloromethane and precipitated by addition of 14 mL of 
pentane.  The 1H NMR of the acid 2e was in excellent agreement with reported values 
and also it’s identity was confirmed by HRMS.  The acid was used directly in the next 
step without further purification 
2.3.2. General Procedure 1 (One-pot, two-steps synthesis of 1,2,4,5-tetrahydro-1,4-
benzodiazepin-3-ones) 
In a 10 mL vial (CEM Discover System) equipped with a magnetic stir bar, 2-
nitrobenzylamine (15 mg, 0.099 mmol), 2,2-dimethylpropanal (7 mg, 0.099 mmol), 
fumaric acid monoethyl ester (14 mg, 0.099 mmol) and tert-butyl isocyanide (8 mg, 
0.099 mmol) were added to a mixture of 1.8 mL of ethanol and 0.6 mL of distilled water 
(3:1 ratio).  The vial was capped and placed in the microwave.  The microwave was then 
run at 300 W, 60 oC, for 60 min.  After cooling the vial to room temperature, 10 
equivalent of Fe(0) powder (40 mess, 55 mg, 0.99 mmol) followed by 0.5-1.0 equivalent 
of NH4Cl (5 mg, 0.099 mmol) were added to the same vial (assume the multicomponent 
acyclic Ugi reaction went to completion).  The microwave was then run at 300 W, 150 
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oC, 10 bar for 30-45 min.  Then the vial was cooled to room temperature, filtered through 
a pad of celite and washed with ethyl acetate (3 x 5 mL) followed by saturated NaHCO3 
(5 mL).  The filtrate was then transferred to a separatory funnel and the mixture was 
shaken thoroughly.  The organic layer was separated and the aqueous layer was extracted 
with ethyl acetate (3 x 2.5 mL).  The organic layers were combined, dried with Na2SO4 
and filtered.  The filtrate was concentrated under vacuum and the residue was purified by 
silica gel column chromatography using a 1:3 mixture of ethyl acetate to hexane as the 
eluent.  
 
2.3.2.1. General Procedure 2 for the synthesis of 1,4-BDZ-3-ones(Two-step 
reaction): Step 1 (Four component acyclic Ugi reaction):  
In a 10 mL round-bottomed flask, 2-nitrobenzylamine (0.5g, 3.3 mmol) was 
dissolved in 5 mL of MeOH and 2,2-dimethylpropanal (0.237 mg, 3.3 mmol) was added.  
The mixture was stirred for 10 min.  Then fumaric acid monoethyl ester (0.473 g, 3.3 
mmol) and tert-butyl isocyanide (0.273 mg, 3.3 mmol) were added consecutively.  The 
resulting solution was allowed to stir overnight at room temperature and then quenched 
with 1 mL of 1N HCl.  To the mixture, 5 mL of CH2Cl2 was added and the reaction was 
vigorously stirred.  The organic layer was separated and the aqueous layer was extracted 
with CH2Cl2 (3 x 5 mL).  The organic layers were collected, dried over Na2SO4 and 
filtered.  The filtrate was concentrated under vacuum and the residue was purified by 
silica gel column chromatography using a 1:3 mixture of ethyl acetate to hexane as the 
eluent. 
2.3.2.2. Step 2 (Synthesis of 1,2,4,5-tetrahydro-1,4-benzodiazepin-3-ones): 
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To a 10 mL vial (CEM Discover System) equipped with a magnetic stir bar, 50 
mg of the acyclic Ugi product from step 1 was added along with 1.8 mL of ethanol and 
0.6 mL of distilled water.  Then 10 equivalent of Fe(0) powder (40 mess) followed by 
0.5-1.0 equivalent of NH4Cl were added to the same vial.  The vial was capped and 
placed in the microwave.  The microwave was then run for 30-45 min at 150 oC, 10 bar 
and 300 W.  Then the vial was cooled to room temperature and filtered through a pad of 
celite and washed with ethyl acetate (3 x 5 mL) followed by saturated NaHCO3 (5 mL).  
The filtrate was then transferred to a separatory funnel and the mixture was shaken 
thoroughly.  The organic layer was separated and the aqueous layer was extracted with 
ethyl acetate (3 x 2.5 mL).  The organic layers were combined, dried with Na2SO4 and 
filtered.  The filtrate was concentrated under vacuum and the residue was purified by 
silica gel column chromatography using a 1:3 mixture of ethyl acetate to hexane as the 
eluent.  
2.3.2.3. Sealed Tube Reaction Condition for the Synthesis of 1,2,4,5-tetrahydro-1,4-
benzodiazepin-3-ones): 
To a 20 mL sealed tube equipped with a magnetic stir bar, 50 mg of the acyclic 
Ugi product (5) from step 1 was added along with 1.8 mL of ethanol and 0.6 mL of 
distilled water.  Then 10 equivalent of Fe(0) powder (40 mess) followed by 0.5-1.0 
equivalent of NH4Cl were added to the same sealed tube.  The sealed tube was placed in 
the silicone oil bath and heated at 200-205 oC for one hour.  Then the sealed tube was 
cooled to room temperature and filtered through a pad of celite and washed with ethyl 
acetate (3 x 5 mL) followed by saturated NaHCO3 (5 mL).  The filtrate was then 
transferred to a separatory funnel and the mixture was shaken thoroughly.  The organic 
layer was separated and the aqueous layer was extracted with ethyl acetate (3 x 2.5 mL).  
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The organic layers were combined, dried with Na2SO4 and filtered.  The filtrate was 
concentrated under vacuum and the residue was purified by silica gel column 
chromatography using a 1:3 mixture of ethyl acetate to hexane as the eluent. 
2.3.3. General procedure for the synthesis of 1,2,3,4-tetrahydroisoquinolinones from 
2-azaspirocyclohexadienones: 
 To a 10 mL vial (CEM Discover System) equipped with magnetic stirring 
bar, 50 mg of acyclic Ugi starting material was taken and 2.5 mL of dry nitromethane 
(CH3NO2) or acetonitrile (CH3CN) was added to it under Argon.  The vial was capped 
properly and 14 µL of dry BF3.OEt2 or TMSOTf was added carefully.  The vial was 
capped with a new cap very quickly and placed in the microwave cavity.  Then 
microwave was run for 10-15 min at 100 oC, 16 Bar and 300 W.  After cooling the vial at 
room temperature, the reaction mixture was transferred to a 25 mL RB flask and 
concentrated on rotary evaporator.  The residue was purified by gradient silica gel 
column chromatography using mixture of ethyl acetate and hexane (1:4 to 1:1) as the 
eluent. 
 
2.3.3.1. General Procedure for the ‘off-the-shelf’ convertible isocyanides: 
 To a 10 mL vial (CEM Discover System) equipped with magnetic stirring 
bar, 50 mg of acyclic Ugi starting material was taken and 2.5 mL of dry nitromethane 
(CH3NO2) or acetonitrile (CH3CN) was added to it under Argon.  The vial was capped 
properly and 14 µL of dry BF3.OEt2 was added carefully.  The vial was capped with a 
new cap very quickly and placed in the microwave cavity.  Then microwave was run for 
10-15 min at 100 oC, 16 Bar and 300 W.  After cooling the vial at room temperature, the 
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reaction mixture was transferred to a 25 mL RB flask and concentrated on rotary 
evaporator.  The residue was purified by gradient silica gel column chromatography 
using mixture of ethyl acetate and hexane (1:4 to 1:1) as the eluent. 
2.3.3.2. General procedure for the one-pot synthesis of 1,2,3,4-
tetrahydroisoquinolinones (starting from four separate substrates): 
 To a 10 mL vial (CEM Discover System) equipped with magnetic stirring 
bar, 15 mg (0.14 mmol) of Benzyl amine, 12 mg (0.14 mmol) of 4-
acetamidobenzaldehyde, 25 mg (0.14 mmol) of trans-3-Benzoylacrylic acid and 17 μL 
(0.14 mmol) of Benzyl isocyanide were taken in a mixture of 1.5 mL LiCl and 1 mL 
MeOH.  The vial was capped properly and placed in the microwave.  Then the 
microwave was run at two stages: (a) 1 hr at 50 oC, 10 Bar and 300 W (b) 20-25 min, 210 
oC, 18 Bar and 300 W.  After cooling the vial at room temperature, ethyl acetate was 
added and shaken thoroughly.  The organic layer was separated and the aqueous layer 
was extracted with ethyl acetate twice (2 mL each).  The organic layers were combined 
and washed with NaHCO3 (3 mL each), 1 N HCl (3 mL each), Brine (3 mL each).  The 
organic layer was separated.  All aqueous layers were combined and extracted with 3 mL 
ethyl acetate.  The organic layers were combined and dried over Na2SO4 and filtered.  
The filtrate was dried under vacuum and purified by silica gel column chromatography 
using 1:2 mixture of ethyl acetate and hexane as eluent. 
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2.4. Experimental Data 
1. (E)-Ethyl 4-((2-(benzylamino)-2-oxo-1-(thiophen-2-yl)ethyl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.21-7.36 (m, 7 H, Ph , thienyl and –CH=CH- overlap)), 
7.08 (d, 1 H, J = 3.2 Hz, thienyl), 7.01 (d, 2 H, J = 8.8 Hz, Aryl), 6.91 (dd, 1 H, J = 5.2, 4 
Hz, thienyl), 6.87 (d, 1 H, J = 15.2 Hz, -CH=CH-), 6.77 (d, 2 H, J = 8.4 Hz, Aryl), 6.33 
(t, 1 H, J = 5.6 Hz, -NH), 5.95 (s, 1 H, Ha), 4.69 (dd, 2 H, J = 24.4, 17.2 Hz, -NCH2Ar), 
4.44 (ddd, 2 H, J = 48.0, 14.8, 5.6 Hz, -NCH2Ar), 4.19 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 
3.76 (s, 3 H, OMe), 1.26 (t, 3 H, J = 7.3 Hz, -OCH2CH3) 
 
13C NMR (100 MHz, CDCl3): δ 168.3, 166.2, 165.5, 159.2, 137.9, 136.1, 133.8, 132.9, 
130.2, 128.9, 128.6, 128.3, 128.2, 127.8, 127.7, 126.8, 125.1, 114.3, 61.3, 59.2, 55.5, 
50.4, 44.0, 14.3. 
 
HRMS (EIMS, M+): calcd for C28H29NO5S 491.1766, found 491.1769. 
 
2. Thiophene-derived tricyclic lactam 
N
EtO O
O
HgN O
Hf
S
He
OMe
HaHb
Hc Hd
( )-8  
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1H NMR (500 MHz, CDCl3): δ 7.28-7.38 (m, 3H, aryl), 7.19-7.24 (m, 2H, aryl), 7.10 (d, 
2H, J = 8.6 Hz, aryl), 6.81 (d, 2H, J = 8.6 Hz, aryl), 6.48 (d, 1H, J = 6.1 Hz, Hb), 6.32 
(dd, 1H, J = 3.6, 6.1 Hz, Hc), 6.30 (br t, 1H, Hg), 4.93 (d, 1H, J = 14.7 Hz, bn), 4.41-4.46 
(m, 3H, bn and Hd overlap), 4.14 (q, 2H, J = 7.1 Hz, –OCH2CH3), 3.98 (s, 1H, Ha), 3.94 
(d, 1H, J = 14.7 Hz, bn and He overlap), 3.92 (t, 1H, J = Hz, He and bn overlap), 3.78 (s, 
3H, OCH3), 3.42 (d, 1H, J = 3.6 Hz, Hf), 1.25 (t, 3H, J = 7.1 Hz, CH3). 
 
13C NMR (125 MHz, CDCl3): δ 173.5, 170.5, 166.9, 159.5, 136.9, 136.6, 129.9, 128.9, 
127.9, 127.8, 126.8, 114.3, 71.3, 62.3, 61.4, 55.3, 54.9, 54.3, 51.7, 45.9, 43.9, 29.7, 14.2. 
 
HRMS: EIMS (M+) calcd for C27H28N2O5S 492.1719, found 492.1713. 
 
2. Ethyl 2-((2S,5S)-1-benzyl-4-(4-methoxybenzyl)-3,6-dioxo-5-(thiophen-2-
yl)piperazin-2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.42 (m, 1H), 7.3-7.36 (m, 3H), 7.14-7.2 (m, 4H), 7.06-
7.12 (m, 2H), 6.86-6.9 (m, 2H), 5.52 (d, 1H, J=14.4 Hz), 5.37 (d, 1H, J=15.6 Hz), 4.26 
(m, 1H), 4.12-4.18 (m,1H), 4.02-4.08 (m, 1H), 3.99 (d, 1H, J=15.6 Hz), 3.85 (s, 3H), 
3.64 (d, 1H, J=14.4 Hz), 3.32 (dd, 1H, J=3, 17.4 Hz), 2.96 (dd, 1H, J=4.8, 17.4 Hz), 1.21 
(t, 3H, J=7.2 Hz). 
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13C NMR (125 MHz, CDCl3): δ 169.4, 165.1, 165.0, 159.3, 139.9, 134.9, 130.2, 128.9, 
127.9, 127.8, 127.1, 126.4, 113.9, 61.0, 58.4, 55.2, 54.5, 46.7, 46.6, 34.5, 14.0. 
 
HRMS (EIMS, M+): calcd for C27H28N2O8S 492.1719, found 492.1721. 
 
3. Ethyl 2-((2S,5R)-5-(tert-butyl)-1-(2,6-dimethylphenyl)-4-(4-hydroxybenzyl)-3,6-
dioxopiperazin-2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.39 (br s, 1 H, -OH), 7.12-7.18 (t, 1 H, J = 7.6 Hz, Ar), 
7.02-7.10 (m, 4 H, Ar), 6.58 (d, 2 H, J = 8.5 Hz, Ar), 5.56 (d, 1 H, J = 14.3 Hz, -CH2Ar), 
5.30 (dd, 1 H, J = 7.9, 5.5 Hz, Hb), 4.03 (s, 1 H, Ha), 3.90-4.06 (m, 2 H, -OCH2CH3), 3.83 
(d, 1 H, J = 14.3 Hz, -CH2Ar), 2.80 (dd, 1 H, J = 16.2, 7.9 Hz, Hc), 2.24 (s, 3 H, -CH3), 
2.25 (dd, 1 H, J = 16.2, 5.5 Hz, Hc), 1.80 (s, 3 H, -CH3), 1.30 (s, 9 H, t-Bu), 1.13 (t, 3 H, J 
= 7.3 Hz, -OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 170.4, 167.9, 167.5, 156.7, 136.7, 136.1, 135.4, 129.8, 
129.0, 128.9, 128.8, 126.9, 115.6, 69.6, 61.0, 55.9, 51.4, 39.5, 34.0, 28.9, 19.1, 18.1, 13.9 
HRMS: EIMS (M+) calcd for C27H34N2O5 466.2468, found 466.2466. 
 
4. Ethyl 2-(2-(1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
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1H NMR (400 MHz, CDCl3): δ 6.62 (m, 2H), 6.32 (m, 2H), 5.79 (br s, 1H, NH), 4.07 (m, 
2H, –OCH2CH3), 3.95 (d, 1H, J = 11 Hz, Ha), 3.78 (d, 1H, J = 10.4 Hz, He), 3.53 (d, 1H, 
J = 10.4 Hz, He), 3.39 (dd, 1H, J = 6.1, 7.6 Hz, Hb), 2.65 (dd, 1H, J = 6.1, 16.6 Hz, Hc), 
2.09 (dd, 1H, J = 7.6, 16.8 Hz, Hc), 1.20 (t, 3H, J = 7.3 Hz, CH3), 0.95 (d, 3H, J = 6.1 Hz, 
CHCH3), 0.90 (d, 3H, J = 4.9 Hz, CHCH3). 
 
13C NMR (100 MHz, CDCl3): δ 184.9, 172.6, 171.3, 168.2, 149.2, 145.9, 131.4, 130.9, 
62.8, 61.1, 50.8, 50.1, 48.1, 47.4, 30.3, 28.6, 27.3, 19.3, 19.3, 14. 
 
HRMS: EIMS (M+) calcd for C22H32N2O5 404.2311, found 404.2317. 
 
5. (E)-ethyl 6-(tert-butylcarbamoyl)-5-(4-hydroxybenzyl)-7-methyl-4-oxooct-2-
enoate 
 
1H NMR (500 MHz, CDCl3) : δ 8.12 (bs, 1H), 7.3 (d, 1H, J=15.2 Hz), 6.89 (d, 2H, J=8.6 
Hz), 6.81 (d, 1H, J=15.2 Hz), 6.6 (d, 2H, J=8.6 Hz), 4.74 (d, 1H, J=16.7 Hz), 4.5 (d, 1H, 
J=16.7 Hz), 4.19 (q, 2H, J=7.1 Hz), 2.5 (bs, 1H), 1.26 (t, 3H, J=7.1 Hz), 0.94 (d, 3H, 
J=6.6 Hz), 0.81 (d, 3H, J=6.6 Hz). 
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13C NMR (125 MHz, CDCl3) : δ 169.5, 166.9, 165.4, 156.3, 134.1, 132.1, 127.8, 127.1, 
115.7, 61.2, 51.4, 28.7, 28.5, 27.3, 19.5, 18.9, 14.0. 
 
HRMS: EIMS (M+) calcd for C23H33NO5 403.2359, found 403.2357. 
 
6. (E)-Ethyl 4-((2-(tert-butylamino)-1-(naphthalen-2-yl)-2-oxoethyl)(4-
hydroxyphenethyl)amino)-4-oxobut-2-enoate 
N
OHN
t-Bu
O
-20
OH
CO2Et
Ha
O
O
 
1H NMR (400 MHz, CDCl3): δ 7.81-7.99 (m, 4 H, Aryl), 7.48-7.59 (m, 3 H, Aryl), 7.36 
(d, 1 H, J = 15.4 Hz, -CH=CH-), 6.85 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.59 (s, 2 H, -
OCH2O-), 6.19 (s, 1 H, Ha), 5.89 (s, 1 H, -NH), 5.77 (s, 1 H, -OH), 4.26 (q, 2 H, J = 7.3 
Hz, -OCH2CH3), 3.55-3.71 (m, 2 H, -NCH2CH2Ar), 2.42-2.57 (m, 1 H, -NCH2CH2Ar), 
2.0-2.12 (m, 1 H, -NCH2CH2Ar), 1.36 (s, 9 H, t-Bu), 1.32 (t, 3 H, J = 7.3 Hz, -
OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 168.6, 166.5, 163.0, 155.7, 149.3, 147.7, 135.7, 132.0, 
130.2, 130.2, 127.5, 126.7, 115.8, 114.7, 112.9, 101.2, 71.0, 61.4, 60.0, 47.3, 33.7, 29.2, 
14.2. 
HRMS: EIMS (M+) calcd for C30H34N2O5 502.2468, found 502.2468. 
 
7. Ethyl 2-(2-(1-(cyclohexylamino)-3,3-dimethyl-1-oxobutan-2-yl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 6.81-6.93 (m, 2H), 6.33-6.47 (m, 2H), 5.62 (d, 1H, J = 
7.6 Hz, –NH ), 4.25 (s, 1H, Ha), 4.08 (dq, 2H, J = 1.4, 7.2 Hz, –OCH2CH3), 3.69-3.78 (m, 
3H, He and Hd overlap), 3.29 (dd, 1H, J = 6.1, 7.6 Hz, Hb), 2.90 (dd, 1H, J = 5.9, 16.6 Hz, 
Hc), 2.13 (dd, 1H, J = 7.6, 16.8 Hz, Hc), 1.83-1.97 (m, 3H, Cy), 1.66-1.77 (m, 3H, Cy), 
1.57-1.65 (m, 2H, Cy), 1.30-1.41 (m, 2H, Cy), 1.20 (t, 3H, J = 7.3 Hz, –OCH2CH3). 
 
13C NMR (125 MHz, CDCl3) : δ 185.1, 173.8, 171.3, 166.6, 149.7, 146.1, 131.4, 131.3, 
64.1, 61.1, 53.9, 48.5, 47.5, 46.6, 36.1, 33.1, 32.9, 30.7, 27.6, 25.4, 24.8, 24.7, 14.1. 
 
HRMS (EIMS, M+): calcd for C25H36N2O5 444.2624, found 444.2632. 
 
8. (E)-Ethyl 4-((1-(cyclohexylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (300 MHz, CD3OD): δ 7.20 (d, 1 H, J = 15.8 Hz, -CH=CH-), 6.86 (d, 2 H, J = 
8.6 Hz, Aryl), 6.62 (d, 2 H, J = 8.6 Hz, Aryl), 6.44 (d, 1 H, J = 15.3 Hz, -CH=CH-), 5.43 
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(d, 1 H, J = 17.7 Hz, -NCH2Ar), 5.07 (s, 1 H, Ha0, 4.68 (d, 1 H, J = 17.7 Hz, -NCH2Ar), 
4.07 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.32-3.50 (m, 1 H, Hb), 1.45-1.86 (m, 8 H, Cy), 
1.09-1.32 (m, 5 H, Cy and –OCH2CH3 overlap), 1.01 (s, 9 H, t-Bu). 
 
13C NMR (75 MHz, CD3OD): δ 169.7, 169.0, 166.7, 157.6, 136.4, 131.5, 131.3, 128.2, 
116.3, 64.2, 62.1, 50.3, 49.7, 38.1, 33.7, 33.4, 28.0, 26.6, 26.1, 14.4. 
 
HRMS (EIMS, M+): calcd for C25H36N2O5 444.2624, found 444.2619. 
 
9. Ethyl 2-(2-(1-(cyclopentylamino)-3,3-dimethyl-1-oxobutan-2-yl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 6.89 (m, 2H), 6.36 (m, 2H), 5.94 (d, 1H, J = 7.3 Hz, –NH 
), 4.28 (s, 1H, Ha), 4.12-4.18 (m, 1H, Hd), 4.07 (q, 2H, J = 7.3 Hz, –OCH2CH3).. 3.70 (dd, 
2H, J = 11.4, 14.6 Hz, He), 3.30 (dd, 1H, J = 6.5, 8.1 Hz, Hb), 2.67 (dd, 1H, J = 6.1, 16.7 
Hz, Hc), 2.12 (dd, 1H, J = 7.3, 16.2 Hz, Hc), 1.88-2.23 (m, 2H, Cp), 1.51-1.72 (m, 4H, 
Cp), 1.29-1.44 (m, 2H, Cp), 1.20 (t, 3H, J = 7.3 Hz, –OCH2CH3), 1.05 (s, 9H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 185.1, 173.3, 171.4, 168.2, 149.3, 145.9, 131.5, 130.9, 
63.1, 61.1, 52.6, 51.2, 47.6, 47.0, 35.1, 33.0, 32.9, 30.4, 27.8, 27.6, 23.7, 14.0. 
 
HRMS: EIMS (M+) calcd for C24H34N2O5 430.2488, found 430.2487. 
 
10. Ethyl 2-(2-(1-(isopropylamino)-3,3-dimethyl-1-oxobutan-2-yl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 6.89 (m, 1H), 6.63 (m, 1H), 6.36 (m, 2H), 5.65 (d, 1H, J 
= 7.3 Hz, –NH), 4.33 (s, 1H, Ha), 4.17 (d, 1H, J = 10.4 Hz, He), 4.00-4.12 (m, 3H, Hd and  
– OCH2CH3 overlap), 3.74 (d, 1H, J = 10.4 Hz, He), 3.38 (dd, 1H. J = 6.4, 7.6 Hz, Hb), 
2.64 (dd, 1H, J = 5.8, 16.7 Hz, Hc), 2.07 (dd, 1H, J = 7.6, 16.7 Hz, He), 1.20 (t, 3H, J = 
7.3 Hz, –OCH2CH3), 1.16 (d, 3H, J = 6.1 Hz, i-Pr), 1.15 (d, 3H, J = 6.1 Hz, i-Pr), 1.07 (s, 
9H, t-Bu). 
 
13C NMR (125 MHz, CDCl3) : δ 185.1, 173.3, 171.4, 167.7, 149.3, 145.9, 131.5, 131.0, 
63.2, 61.1, 52.6, 47.6, 47.0, 41.5, 35.1, 30.4, 27.8, 22.6, 14.0. 
 
HRMS: EIMS (M+) calcd for C22H32N2O5 404.2311, found 404.2308. 
 
11. (E)-Ethyl 4-((4-hydroxybenzyl)(1-(isopropylamino)-3,3-dimethyl-1-oxobutan-2-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.19 (d, 1 H, J = 15.3 Hz, -CH=CH-), 6.83 (d, 2 H, J = 
8.5 Hz, Aryl), 6.76 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.55 (d, 2 H, J = 8.5 Hz, Aryl), 5.36 
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(d, 1 H, J = 17.1 Hz, -NCH2Ar), 4.96 (s, 1 H, Ha), 4.66 (d, 1 H, J = 17.1 Hz, -NCH2Ar), 
4.17 (dq, 2 H, J = 7.3 Hz, -OCH2CH3), 3.84 (sept, 1 H, J = 6.7 Hz, Hb), 1.26 (t, 3 H, J = 
7.3 Hz, -OCH2CH3), 1.11 (d, 3 H, J = 6.7 Hz, i-Pr), 1.08 (s, 9 H, t-Bu), 0.91 (d, 3 H, J = 
6.7 Hz, i-Pr). 
 
13C NMR (125 MHz, CDCl3): δ 167.7, 165.4, 155.3, 135.1, 134.0, 132.8, 131.9, 127.1, 
114.6, 61.2, 41.4, 37.1, 27.5, 22.5, 22.1, 14.1. 
 
HRMS (EIMS, M+): calcd for C22H32N2O5 404.2311, found 404.2321. 
 
12. Ethyl 2-(2-(1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.22-7.37 (m, 5 H, Ph), 6.86 (dd, 1 H, J = 10.1, 3.1 Hz, 
Hg), 6.34 (dd, 1 H, J = 10.1, 1.8 Hz, Hg), 6.30 (dd, 1 H, J = 3.1 Hz, 3.1 Hz, Hf), 6.22 (dd, 
1 H, J = 10.4, 1.8 Hz, Hf), 6.15 (t, 1 H, J = 6.1 Hz, -NH), 4.61 (s, 1 H, Ha), 4.44 (dd, 1 H, 
J = 14.7, 6.1 Hz), He), 4.35 (dd,1 H, J = 5.8, 14.7 Hz, He), 4.05-4.12 (m, 2 H, -
OCH2CH3), 4.04 (d, 1 H, J = 10.1 Hz, -NHCH2Ph), 3.75 (d, 1 H, J = 10.4 Hz, -
NHCH2Ph), 3.36 (dd, 1 H, J = 7.3, 6.1 Hz, Hb), 2.59 (dd, 1 H, J = 16.8, 6.1 Hz, Hc), 2.01 
(dd, 1 H, J = 16.8, 7.6 Hz, Hc), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.09 (s, 9 H, t-Bu). 
 
HRMS (EIMS, M+): calcd C26H32N2O5 452.2311, found 452.2317. 
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13. (E)-Ethyl 4-((1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.5-7.7 (bs, 1H), 7.1-7.38 (m, 6H), 6.78 (d, 2H, J = 8.1 
Hz), 6.66 (d, 1H, J =  15.2 Hz), 6.49 (d, 2H, J = 8.1 Hz), 5.34 (d, 1H, J = 15.2 Hz), 5.05-
5.26 (bs, 1H), 4.68 (d, 1H, J = 15.2 Hz), 4.38 (dd, 1H, J = 6.1, 14.7 Hz), 4.15 (m, 2H), 
4.02 (d, 1H, J = 12.7 Hz), 1.24 (t, 3H, J = 7.1 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 168.8, 167.6, 165.4, 155.4, 137.3, 134.1, 131.7, 128.6, 
127.8, 127.5, 126.9, 115.6, 61.2, 43.5, 36.9, 27.6, 13.9. 
 
HRMS (EIMS, M+) calcd for C26H32N2O5 452.2311, found 452.2314. 
 
14. (3R,6S)-1-benzyl-3-(tert-butyl)-4-(4-hydroxybenzyl)-6-(2-oxopropyl)piperazine-
2,5-dione 
( )-25e
N
N
O
O
t-Bu
OH
EtO2C
HaHb
Hc Hc
 
1H NMR (500 MHz, CDCl3): δ 7.56 (bs, 1H, –OH), 7.24-7.37 (m, 3H, aryl), 7.20 (m, 2H, 
aryl), 7.08 (d, 2H, J = 8.1 Hz, aryl), 6.63 (d, 2H, J = 8.6 Hz), 5.56 (d, 1H, J = 15.2 Hz, 
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Bn), 5.16 (d, 1H, J = 15.2 Hz, Bn), 4.53 (dd, 1H, J = 4.1, 5.6 Hz, Hb), 4.32 (d, 1H, J = 
15.7 Hz, Bn), 3.98-4.16 (m, 2H, –OCH2CH3), 3.88 (d, 1H, J = 15.2 Hz, Bn), 3.17 (dd, 
1H, J = 3.6, 17.2 Hz, Hc), 2.97 (dd, 1H, J = 6.1, 17.2 Hz, Hc), 1.18 (t, 3H, J = 7.3 Hz, –
OCH2CH3), 1.12 (s, 9H, t-Bu). 
 
13C NMR (125 MHz, CDCl3) : δ 170.1, 167.7, 167.5, 156.4, 136.1, 129.5, 128.9, 127.8, 
127.6, 126.3, 115.7, 67.7, 61.0, 55.8, 51.3, 47.0, 40.1, 34.6, 28.3, 14.0. 
 
HRMS (EIMS, M+): calcd for C26H32N2O5 452.2311, found 452.2314. 
 
15. (E)-Ethyl 4-((1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.1-7.35 (m, 6H, aryl), 6.96 (d, 2H, J = 8.1 Hz, aryl), 6.75 
(d, 2H, J = 8.6 Hz, aryl), 6.62 (d, 1H, J = 15.2 Hz, HC=CH), 5.27 (d, 1H, J = 17.2 Hz, 
bn), 4.96-5.18 (br, 1H,), 4.72 (d, 1H, J = 17.2 Hz, bn), 4.35 (dd, 1H, J = 5.6, 14.2 Hz), 
4.03-4.22 (m, 3H), 3.8 (s, 3H, OCH3), 1.24 (t, 3H, J = 7.1 Hz, CH3), 1.1 (s, 9H, t-butyl). 
 
13C NMR (125 MHz, CDCl3): δ 168.7, 167.2, 165.3, 158.6, 137.6, 134.2, 131.4, 128.7, 
127.9, 127.5, 127.2, 114.1, 60.9, 55.2, 43.4, 36.7, 27.6, 14.0. 
 
HRMS: EIMS (M+) calcd for C27H34N2O5 466.2468, found 466.2481. 
 
16. (3R,6S)-1-benzyl-4-(4-methoxybenzyl)-3-(4-nitrophenyl)-6-(2-
oxopropyl)piperazine-2,5-dione 
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1H NMR (400 MHz, CDCl3): δ 8.32 (d, 1 H, J = 8.9 Hz, Aryl), 7.72 (d, 1 H, J = 8.9 Hz, 
Aryl), 7.44 (d, 1 H, J = 8.9 Hz, Aryl), 7.22-7.34 (m, 5 H, Ph), 7.02 (d, 2 H, J = 8.1 Hz, 
Aryl), 6.81 (d, 2 H, J = 8.1 Hz, Aryl), 5.47 (d, 1 H, J = 14.6 Hz, -NCH2Ar), 5.43 (d, 1 H, 
J = 14.6 Hz, -NCH2Ar), 5.23 (s, 1 H, Ha), 4.67 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 4.65 (dd, 
1 H, J = 5.7, 4.1 Hz, Hb), 4.50 (d, 1 H, J = 14.6 Hz, -NCH2Ar), 3.81 (s, 3 H, OMe), 3.27 
(dd, 1 H, J = 15.4, 3.2 Hz, Hc), 3.10 (dd, 1 H, J = 18.7, 4.9 Hz, Hc), 2.10 (s, 3 H, -COMe). 
 
13C NMR (100 MHz, CDCl3): δ 206.9, 170.2, 166.3, 158.4, 146.9, 143.2, 136.7, 132.1, 
129.1, 128.9, 128.6, 128.2, 127.9, 127.2, 114.4, 70.3, 61.3, 55.9, 50.9, 49.1, 43.1, 29.4. 
 
HRMS (EIMS, M+): calcd for C28H27N3O6 501.1900, found 501, 1910. 
 
17. (E)-Ethyl 4-((1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.1-7.35 (m, 6H), 6.96 (d, 2H, J = 8.1 Hz), 6.75 (d, 2H, J 
= 8.6 Hz), 6.62 (d, 1H, J = 15.2 Hz), 5.27 (d, 1H, J = 17.2 Hz), 4.96-5.18 (bs, 1H), 4.72 
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(d, 1H, J = 17.2 Hz), 4.35 (dd, 1H, J = 5.6, 14.2 Hz), 4.03-4.22 (m, 3H), 3.8 (s, 3H), 1.24 
(t, 3H, J = 7.1 Hz), 1.1 (s, 9H). 
 
13C NMR (125 MHz, CDCl3) : δ 168.7, 167.2, 165.3, 158.6, 137.6, 134.2, 131.4, 128.7, 
127.9, 127.5, 127.2, 114.1, 60.9, 55.2, 43.4, 36.7, 27.6, 14.0. 
 
HRMS (EIMS, M+): calcd for C27H34N2O5 466.2468, found 466.2471. 
 
18. Methyl 3-oxocyclohex-1-enecarboxylate 
 
1H NMR (500 MHz, CDCl3): δ 6.73 (s, 1 H, Ha), 3.82 (s, 3 H, OMe), 2.58 (dt, 2 H, J = 
5.8, 1.5 Hz, Hb), 2.44 (t, 2 H, J = 7.0 Hz, Hd), 2.05 (quintet, 2 H, J = 6.7 Hz, Hc). 
 
13C NMR (125 MHz, CDCl3): δ 200.0, 166.9, 148.7, 133.1, 52.6, 37.7, 24.8, 22.1. 
 
HRMS (EIMS, M+): calcd for C8H10O3 154.0630, found 154.0641. 
 
19. 3-Oxocyclohex-1-enecarboxylic acid 
O
OH
O
2e
HaHb
Hc
Hd
 
1H NMR (500 MHz, CDCl3): δ 11.3 (br s, 1 H, -CO2H), 6.80-6.84 (m, 1 H, Ha), 2.55-2.61 
(m, 1 H, Hb), 2.44-2.50 (m, 2 H, Hd), 2.03-2.10 (m, 2 H, Hc). 
 
13C NMR (125 MHz, CDCl3): δ 200.6, 171.2, 148.5, 134.1, 37.5, 24.4, 21.9. 
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HRMS (EIMS, M+): calcd for C7H8O3 140.0473, found 140.0482. 
 
20. N-Benzyl-N-(1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)-3-oxocyclohex-1-
enecarboxamide 
 
1H NMR (400 MHz, CDCl3): δ 7.12-7.38 (m, 10 H, 2 × Ph), 6.83 (t, 1 H, J = 5.6 Hz, -
NH), 5.99 (s, 1 H, Hb), 5.44 (d, 1 H, J = 16.2 Hz, -NCH2Ph), 5.02 (s, 1 H, Ha), 4.53 (d, 1 
H, J = 16.2 Hz, -NCH2Ph), 4.46 (dd,1 H, J = 14.6, 5.7 Hz, -NCH2Ph), 4.34 (dd, 1 H, J = 
14.6, 5.7 Hz, -NCH2Ph), 2.01-2.28 (m, 4 H, Hc and He overlap), 1.59-1.74 (m, 1 H, Hd), 
1.32-1.44 (m, 1 H, Hd), 1.15 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 199.2, 172.5, 168.8, 156.4, 138.8, 137.6, 128.8, 128.1, 
127.6, 127.5, 127.2, 125.5, 63.1, 51.4, 43.5, 37.0, 36.9, 27.6, 25.8, 21.9. 
 
HRMS (EIMS, M+): calcd for C27H32N2O3 432.2413, found 432.2422. 
 
21. N-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-N-(4-hydroxybenzyl)-3-
oxocyclohex-1-enecarboxamide 
t-Bu N
O
O NH
t-Bu
OH
Ha
( )-34
O
Hb
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1H NMR (500 MHz, CDCl3): δ 6.81 (d, 2 H, J = 8.2 Hz, Aryl), 6.66 (d, 2 H, J = 8.2 Hz, 
Aryl), 5.99 (s, 1 H, Hb), 5.42 (s, 1 H, -NCH2Ar), 4.78 (br s, 1 H, -OH), 4.40 (d,1 H, J = 
15.6 Hz, -NCH2Ar), 2.10-2.40 (m, 3 H, cyclohexenone), 1.57-1.85 (m,1 H, 
cyclohexenone), 1.20-1.42 (m, 11 H, t-Bu and cyclohexenone overlap), 1.12 (s, 9 H, t-
Bu). 
 
13C NMR (125 MHz, CDCl3): δ 199.6, 172.8, 168.5, 156.8, 155.7, 128.7, 125.2, 115.7, 
51.8, 37.1, 37.0, 28.5, 27.6, 26.1, 22.1. 
 
HRMS (EIMS, M+): calcd for C24H34N2O4 414.2519, found 414.2527. 
 
22. (E)-N-(1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)-4-bromo-N-(4-
methoxybenzyl)but-2-enamide 
 
1H NMR (500 MHz, CDCl3): δ 7.18-7.32 (m, 5 H, Ph), 6.97 (d, 2 H, J = 8.6 Hz, Aryl), 
6.77 (d, 2 H, J = 8.9 Hz, Aryl), 6.71 (dt, 1 H, J = 14.7, 7.3 Hz, Hc), 6.24 (d, 1 H, J = 14.7 
Hz, Hb), 5.10-5.31 (m, 2 H, -NCH2Ph and Ha overlap), 4.72 (d, 1 H, J = 17.1 Hz, -
NCH2Ph), 4.45 (ddd, 1 H, J = 27.8, 14.9, 5.8 Hz, Hd ), 4.39 (dd, 1 H, J = 14.9, 6.1 Hz, -
NCH2Ar), 4.15 (dd, 1 H, J = 14.7, 5.2 Hz, -NCH2Ar), 3.99 (dd, 1 H, J = 7.0, 1.1 Hz, Hd), 
3.59 (s , 3 H. OMe), 1.15 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 169.0, 167.7, 158.4, 139.7, 137.9, 128.5, 127.9, 127.2, 
126.9, 124.7, 113.9, 55.2, 48.9, 43.2, 36.5, 29.9, 27.6. 
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HRMS (EIMS, M+): calcd for C25H31BrN2O3 486.1518, found 486.1527. 
 
23. N-benzyl-2-(2-iodo-N-(4-methoxybenzyl)acetamido)-3,3-dimethylbutanamide 
 
1H NMR (500 MHz, CDCl3): δ 7.21-7.38 (m, 5 H, Ph), 6.96 (d, 2 H, J = 8.5 Hz, Aryl),  
6.77 (d, 2 H, J = 8.5 Hz, Aryl), 5.41 (d, 1 H, J = 17.4 Hz, -NCH2Ar), 5.11 (br s, 1 H, Ha), 
4.60 (d, 1 H, J = 17.4 Hz, -NCH2Ar), 4.32 (dd, 1 H, J = 14.7, 5.8 Hz, -NCH2Ar), 4.22 
(dd, 1 H, J = 14.7, 5.5 Hz, -NCH2Ar), 3.78 (s, 3 H, -OMe), 3.53 (d, 1 H, J = 9.8 Hz, Hb), 
3.33 (d, 1 H, J = 9.5 Hz, Hb), 1.12 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 170.9, 168.6, 158.6, 137.9, 128.7, 128.6, 128.1, 127.9, 
127.3, 126.2, 114.3, 82.2, 55.2, 43.3, 37.5, 27.6, 26.2, -2.0. 
 
HRMS: EIMS (M+) calcd for C23H29IN2O3 508.1223, found 508.1221. 
 
24. (E)-methyl 2-(4-methoxy-N-(4-methoxybenzyl)but-2-enamido)-3,3-
dimethylbutanoate 
 
1H NMR (400 MHz, CDCl3): δ 7.04 (d, 2 H, J = 8.1 Hz, Aryl), 6.91 (dt, 1 H, J = 15.4, 4.1 
Hz, Hc), 6.83 (d, 2 H, J = 8.9 Hz, Aryl), 6.33 (d, 1 H, J = 14.6 Hz, Hb), 5.24 (s, 1 H, Ha), 
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4.93 (d, 1 H, J = 17.8 Hz, -NCH2Ar), 4.70 (d, 1 H, J = 17.8 Hz, -NCH2Ar), 3.89-4.04 (m, 
2 H, Hd), 3.77 (s, 3 H, OMe), 3.42 (s, 3 H, OMe), 3.17 (s, 3 H, OMe), 1.08 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 170.3, 167.9, 158.6, 142.7, 129.9, 127.2, 120.7, 113.9, 
71.4, 62.9, 58.3, 55.2, 51.3, 49.7, 36.5, 27.5. 
 
HRMS (EIMS, M+): calcd for C20H29NO5 363.2046, found 363.2053. 
 
25. N-benzyl-2-(2-hydroxy-N-(4-methoxybenzyl)acetamido)-3,3-
dimethylbutanamide 
 
1H NMR (500 MHz, CDCl3): δ 7.23-7.38 (m, 5 H, Ph), 7.11 (d, 2 H, J = 8.6 Hz, Aryl), 
6.86 (d, 2 H, J = 8.6 Hz, Aryl), 6.58 (t, 1 H, J = 1.8 Hz, -NH), 5.59 (d, 1 H, J = 14.9 Hz, -
NCH2Ar), 4.94 (d, 1 H, J = 16.8 Hz, Aryl), 4.73 (d, 1 H, J = 16.8 Hz, -NCH2Ar), 4.46 
(ddd, 1 H, J = 25.0, 14.6, 6.1 Hz, -NCH2Ar), 3.75-3.83 (m, 6 H, OMe, Ha and Hb 
overlap), 1.15 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 165.2, 164.7, 159.6, 137.9, 129.4, 128.7, 127.9, 127.6, 
114.6, 79.6, 67.9, 66.4, 55.3, 50.3, 39.5, 27.9. 
 
HRMS (EIMS, M+): calcd for C23H30N2O4 398.2206, found 398. 2213. 
 
26. N-Benzyl-2-(N-(4-methoxybenzyl)acrylamido)-3,3-dimethylbutanamide 
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1H NMR (400 MHz, CDCl3): δ 7.68 (t, 1 H, J = 1.8 Hz, -NH), 7.15-7.29 (m, 5 H, Ph), 
6.98 (d, 2 H, J = 8.9 Hz, Aryl), 6.75 (d, 2 H, J = 8.9 Hz, Aryl), 6.36 (dd, 1 H, J = 17.0, 
10.5 Hz, Hb), 6.14 (dd, 1 H, J = 17.0, 2.0 Hz, Hc), 5.48 (dd,1 H, J = 10.4, 2.0 Hz, Hc), 
5.31 (br s, 1 H, Ha), 5.27 (d, 1 H, J = 17.0 Hz, -NCH2Ph), 4.75 (d, 1 H, J = 17.8 Hz, -
NCH2Ph), 4.32 (dd,1 H, J = 14.6, 5.7 Hz, -NCH2Ar), 4.16 (dd,1 H, J = 15.4, 5.7 Hz, -
NCH2Ar), 3.75 (s, 3 H, OMe), 1.10 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 169.1, 168.4, 158.2, 138.1, 130.7, 128.3, 128.3, 127.8, 
127.0, 126.8, 62.3, 55.1, 48.8, 43.1, 36.5, 27.6. 
 
HRMS (EIMS, M+): calcd for C24H30N2O3 394.2256, found 394.2263. 
 
27. Ethyl 2-((2S,5R)-1,4-dibenzyl-5-(tert-butyl)-3,6-dioxopiperazin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.20-7.37 (m, 10H, aryl), 5.64 (d, 1H, J = 15.4 Hz, bn), 
5.11 (d,1H, J = 15.4 Hz, bn), 4.49 (dd, 1H, J = 4.1, 5.7 Hz, Hb), 4.29 (d, 1H, J = 15.4 Hz, 
bn), 4.0-4.15 (m, 2H, –OCH2CH3), 3.29 (d, 1H, J = 15.4 Hz, bn), 3.78 (s, 1H, Ha), 3.16 
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(dd, 1H, J = 4.1, 17 Hz, Hc), 2.96 (dd, 1H, J = 5.7, 17.4 Hz, Hc), 1.20 (t, 3H, J = 7.3 Hz, 
CH3), 1.11 (s, 9H, t-butyl) 
 
13C NMR (100 MHz, CDCl3): δ 169.9, 167.7, 166.6, 136.5, 135.6, 128.8, 128.7, 127.9, 
127.8, 127.7, 127.6, 68.1, 60.8, 55.6, 51.4, 46.9, 40.0, 34.8, 28.3, 14 
HRMS (EIMS, M+): calcd for C26H32N2O4 436.2362, found 436.2372. 
 
28. (E)-Ethyl 4-(benzyl(1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-
oxobut-2-enoate 
 
1H NMR (300 MHz, CDCl3): δ 7.18-7.39 (m, 8 H, Ph), 7.17 (d, 1 H, J = 15.4 Hz, -
CH=CH-), 6.89-7.16 (m, 2 H, Ph), 6.60 (d, 1 H, J = 15.4 Hz, -CH=CH-), 5.39 (d, 1 H, J = 
17.1 Hz, -NCH2Ph), 5.10 (s, 1 H, Ha), 4.77 (d,1 H, J = 17.7 Hz, -NCH2Ph), 4.63 (t, 1 H, J 
= 1.8 Hz, -NH), 4.31 (dd, 1 H, J = 14.7, 6.1 Hz, -NCH2Ph), 4.04-4.16 (m, 3 H, -
OCH2CH3 and –NCH2Ph overlap), 1.20 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.08 (s, 9 H, t-
Bu). 
 
13C NMR (75 MHz, CDCl3): δ 168.6, 167.3, 165.3, 138.3, 137.6, 133.9, 131.6, 128.7, 
128.6, 127.9, 127.4, 127.1, 125.8, 60.9, 50.6, 43.4, 36.7, 27.5, 13.9. 
 
HRMS (EIMS, M+): calcd for C26H32N2O4 436.2362, found 436.2375. 
 
29. 2-((2S,5R)-1-benzyl-5-(tert-butyl)-4-(cyclohexylmethyl)-3,6-dioxopiperazin-2-
yl)acetate 
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( )-48
N
N
O
O
t-Bu
EtO2C
HaHb
Hc Hc H
d
 
1H NMR (400 MHz, CDCl3): δ 7.21-7.35 (m, 5H, aryl), 5.14 (d, 1H, J = 15.4 Hz, bn), 
4.32 (dd, 1H, J = 3.3, 5.7 Hz, Hb), 4.23-4.30 (m, 2H), 3.99-4.17 (m, 3H), 3.77 (s, 1H, Ha), 
3.15 (dd, 1H, J = 4.1, 17.4 Hz, Hc), 2.9 (dd, 1H, J = 6.5, 17.0 Hz, Hc), 2.50 (dd, 1H, J = 
9.7, 13.8 Hz), 1.45-1.85 (m, 8H, cyclohexyl), 1.21 (t, 3H, J = 7.3 Hz, CH3), 1.05 (s, 9H, 
t-butyl), 0.75-0.93 (m, 2H, cyclohexyl) 
 
13C NMR (100 MHz, CDCl3): δ 169.8, 167.1, 166.8, 136.5, 128.8, 127.8, 127.7, 71.5, 
60.8, 56.9, 55.9, 46.9, 40.2, 35.6, 35.1, 31.2, 30.6, 28.0, 26.4, 25.7, 14.1 
 
HRMS (EIMS, M+): calcd for C26H38N2O4 442.2832, found 442.2841. 
 
30. (E)-Ethyl 4-((1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-
yl)(cyclohexylmethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.35 (d,1 H, J = 15.4 Hz, -CH=CH-), 7.18-7.31 (m, 5 H, 
Ph), 6.69 (d,1 H, J = 15.4 Hz, -CH=CH-), 4.63 (t, 1 H, J = 1.9 Hz, -NH), 4.48 (dd, 1 H, J 
= 14.6 Hz, 6.5 Hz, -NCH2Ph), 4.18-4.31 (m, 4 H, -OCH2CH3, Ha and –NCH2Ph overlap), 
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3.70 (br s, 1 H, -NCH2Cy), 3.25 (br s, 1 H, -NCH2Cy), 1.38-1.74 (m, 7 H, Cy), 1.30 (t, 3 
H, J = 7.3 Hz, -OCH2CH3), 0.96-1.16 (m, 11 H, t-Bu and Cy overlap), 0.70-0.94 (m, 2 H, 
Cy). 
 
13C NMR (100 MHz, CDCl3): δ 169.5, 166.7, 165.5, 137.9, 134.6, 131.1, 128.5, 127.8, 
127.2, 43.4, 36.8, 30.8, 29.6, 28.0, 26.0, 25.8, 25.7, 14.1. 
 
HRMS (EIMS, M+): calcd for C26H38N2O4 442.2832, found 442.2839. 
 
31. Ethyl 2-((2S,5R)-4-benzyl-5-isopropyl-1-(4-methoxyphenyl)-3,6-dioxopiperazin-
2-yl)acetate 
 
1H NMR (400 MHz, CD2Cl2): δ 7.30-7.45 (m, 5H, aryl), 7.03-7.10 (m, 2H, aryl), 6.92-
6.98 (m, 2H, aryl), 5.44 (d, 1H, J = 15.4 Hz, bn), 4.81 (t, 1H, J = 4.1 Hz, Hb), 4.09 (d, 1H, 
J = 15.4 Hz, bn), 4.03 (q, 2H, J = 7.3 Hz, –OCH2CH3), 3.84 (d, 1H, J = 4.9 Hz, Ha), 3.82 
(s, 3H, OCH3), 2.98 (dd, 1H, J = 4.1, 17 Hz, Hc), 2.64 (dd, 1H, J = 5.3, 17.4 Hz, Hc), 
2.32-2.46 (m, 1H, Hd), 1.16 (t, 3H, J = 7.3 Hz, CH3), 1.12 (d, 3H, J = 6.5 Hz, CHCH3), 
1.1 (d, 3H, J = 6.5 Hz, CHCH3) 
 
13C NMR (100 MHz, CD2Cl2): δ 170.3, 166.1, 165.9, 136.4, 131.1, 129.5, 129.1, 128.4, 
128.0, 114.8, 65.1, 60.9, 57.7, 55.8, 48.5, 35.9, 32.5, 20.2, 17.7, 14.2 
 
HRMS: EIMS (M+) calcd for C25H30N2O5 438.2155, found 438.2162.  
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32. (E)-ethyl 4-(benzyl(1-((4-methoxyphenyl)amino)-3-methyl-1-oxobutan-2-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 8.70 (br s, 1 H, -NH), 7.10-7.32 (m, 8 H, Aryl, -CH=CH- 
overlap), 6.82 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.79 (d, 2 H, J = 8.9 Hz, Aryl), 4.77 (t 
from dd, 2 H, J = 17.0 Hz, -NCH2Ph), 4.55 (br s, 1 H, Ha), 4.16 (q, 2 H, J = 7.3 Hz, -
OCH2CH3), 3.76 (s, 3 H, -OMe), 2.50-2.66 (m, 1 H, Hb), 1.24 (t, 3 H, J = 7.3 Hz, -
OCH2CH3), 1.10 (d, 3 H, J = 6.5 Hz, i-Pr), 0.85 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 167.4, 166.9, 164.9, 156.2, 136.6, 133.7, 132.3, 130.6, 
128.6, 127.4, 126.4, 121.7, 66.3, 60.9, 55.3, 49.1, 26.9, 19.6, 18.7, 13.9. 
 
HRMS (EIMS, M+): calcd for C25H30N2O5 438.2155, found 438.2169. 
 
33. Ethyl 2-((2S,5R)-5-isopropyl-4-(4-methoxybenzyl)-1-(4-methoxyphenyl)-3,6-
dioxopiperazin-2-yl)acetate 
( )-52
N
N
O
O
i-Pr
EtO2C
HaHb
Hc Hc
MeO
OMe
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1H NMR (400 MHz, CDCl3) : δ 7.24-7.30 (m, 2H), 7.0-7.06 (m, 2H), 6.85-6.95 (m, 4H), 
5.48 (d, 1H, J=14.6 Hz), 4.78 (t, 1H, J=4.5 Hz), 4.04 (q, 2H, J=7.3 Hz), 3.97 (d, 1H, 
J=15.4 Hz), 3.89 (d, 1H, J=4.1 Hz), 3.81 (s, 3H), 3.80 (s, 3H), 3.02 (dd, 1H, J=3.5, 17.4 
Hz), 2.63 (dd, 1H, J=4.9, 17 Hz), 2.35-2.42 (m, 1H), 1.16 (t, 1H, J=7.3 Hz), 1.11 (d, 3H, 
J=6.5 Hz), 1.08 (d, 3H, J=6.5 Hz). 
 
13C NMR (100 MHz, CDCl3) : δ 170.3, 166.0, 165.9, 159.7, 159.5, 131.2, 130.0, 129.4, 
128.1, 114.8, 114.4, 64.7, 60.8, 57.7, 55.8, 55.5, 47.9, 35.9, 32.5, 20.2, 17.6, 14.2. 
 
HRMS (M+) calcd for C26H32N2O6 468.2260, found 468.2273. 
 
34. (E)-Ethyl 4-((4-methoxybenzyl)(1-((4-methoxyphenyl)amino)-3-methyl-1-
oxobutan-2-yl)amino)-4-oxobut-2-enoate 
N
O
O NH
Ha
( )-53
EtO2C
OMe
OMe
Hb
 
1H NMR (400 MHz, CDCl3): δ 8.79 (br s, 1 H, -NHAr), 7.32 (d, 1 H, J = 15.4 Hz, -
CH=CH-), 7.27 (d, 2 H, J = 8.9 Hz, Ar), 7.05 (d, 2 H, J = 8.1 Hz, Ar), 6.81 (d, 1 H, J = 
15.4 Hz, -CH=CH-), 6.78 (d, 2 H, J = 8.9 Hz, Ar), 6.72 (d, 2 H, J = 8.1 Hz, Ar), 4.68 (s, 2 
H, -NCH2Ar), 4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.72 (s, 3 H, OMe), 3.69 (s, 3 H, 
OMe), 2.48-2.70 (m, 1 H, Hb), 1.24 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.99 (d, 3 H, J = 6.5 
Hz, i-Pr), 0.82 (d, 3 H, J = 6.5 Hz, i-Pr). 
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13C NMR (100 MHz, CDCl3): δ 167.6, 166.9, 165.1, 158.9, 156.2, 133.8, 132.4, 130.8, 
128.3, 128.1, 121.6, 114.1, 113.9, 67.8, 61.1, 55.3, 55.1, 48.7, 26.8, 19.8, 18.9, 14.0. 
 
HRMS (EIMS, M+): calcd for C26H32N2O6 468.2260, found 468.2273. 
 
35. (3R,6S)-1,4-dibenzyl-3-(tert-butyl)-6-(2-oxo-2-phenylethyl)piperazine-2,5-dione 
 
1H NMR (400 MHz, CDCl3): δ 7.8-7.89 (m, 2H, aryl), 7.52-7.61 (m, 1H, aryl), 7.05-7.49 
(m, 12H, aryl), 5.65 (d, 1H, J = 14.6 Hz, bn), 4.89 (d, 1H, J = 15.4 Hz, bn), 4.87 (dd, 1H, 
J = 4.1, 5.7 Hz, Hb), 4.41 (d, 1H, J=15.4 Hz, bn), 4.03 (d, 1H, J = 14.6 Hz), 3.86 (s, 1H, 
Ha), 3.79 (dd, 1H, J = 4.9, 17.8 Hz, Hc), 3.61 (dd, 1H, J = 4.9, 17.8 Hz, Hc), 1.18 (s, 9H, 
CH3) 
 
13C NMR (100 MHz, CDCl3): δ 195.9, 168.2, 166.8, 137.1, 136.3, 133.4, 128.9, 128.7, 
128.6, 128.0, 127.9, 127.3,68.5, 55.5, 51.6, 47.2, 39,9, 38,6, 28.5. 
 
HRMS: EIMS (M+) calcd for C30H32N2O3 468.2413, found 468.2408. 
 
36. (E)-N-benzyl-N-(1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)-4-oxo-4-
phenylbut-2-enamide 
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1H NMR (400 MHz, CDCl3): δ 7.68-7.82 (m, 3H), 7.52-7.59 (m, 1H), 7.37-7.45 (m, 2H), 
7.14-7.34 (m, 9H), 7.07-7.12 (m, 2H), 5.40 (d, 1H, J = 17.8 Hz), 5.15 (bs, 1H), 4.85 (d, 
1H, J = 17.8 Hz), 4.37 (dd, 1H, J = 5.7, 14.6 Hz), 4.15 (dd, 1H, J = 5.7, 14.6 Hz), 1.14 (s, 
9H) 
 
13C NMR (100 MHz, CDCl3): δ 189.9, 168.6, 167.7, 138.3, 137.6, 136.7, 134.9, 133.5, 
132.9, 128.7, 128.6, 128.0, 127.6, 127.2, 125.6, 43.5, 36.7, 27.6. 
 
HRMS: EIMS (M+) calcd for C30H32N2O3 468.2413, found 468.2411. 
 
37. Ethyl 2-((2S,5R)-5-(tert-butyl)-1-butyl-4-(4-methoxybenzyl)-3,6-dioxopiperazin-
2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.15 (d, 2H, J = 8.9 Hz, aryl), 6.83 (d, 2H, J = 8.6 Hz, 
aryl), 5.57 (d, 1H, J = 14.9 Hz, Bn), 4.54 (dd, 1H, J = 4.3, 5.8 Hz, Hb), 4.08-4.21 (m, 2H, 
–OCH2CH3), 3.93-4.03 (m, 1H, n-Bu), 3.88 (d, 1H, J = 14.9 Hz, Bn), 3.77 (s, 3H, OCH3), 
3.65 (s, 1H, Ha), 3.17 (dd, 1H, J = 4.1, 16.9 Hz, Hc), 3.01 (dd, 1H, J = 6.1, 16.9 Hz, Hc), 
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2.78-2.87 (m, 1H, n-Bu), 1.26-1.56 (m, 4H, n-Bu), 1.23 (t. 3H, J = 7.3 Hz, –OCH2CH3), 
1.09 (s, 9H, t-Bu), 0.92 (t, 3H, J = 7.3 Hz, –CH2CH2CH2CH3). 
 
13C NMR (125 MHz, CDCl3) : δ 170.1, 167.5, 165.9, 159.2, 129.4, 127.6, 114.2, 67.6, 
60.9, 55.2, 55.1, 50.9, 42.9, 39.9, 35.1, 29.4, 20.3, 14.1, 13.7. 
 
HRMS: EIMS (M+) calcd for C24H36N2O5 432.2624, found 432.2625 
 
38. (E)-Ethyl 4-((1-(butylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.18 (d, 1 H, J = 15.2 Hz, -CH=CH-), 6.98 (d, 2 H, J = 
8.5 Hz, Aryl), 6.93 (br s, 1 H, -NH), 6.76 (d, 2 H, J = 8.5 Hz, Aryl), 6.62 (d, 1 H, J = 15.2 
Hz, -CH=CH-), 5.34 (d, 1 H, J = 17.1 Hz, -NCH2Ar), 5.11 (br s, 1 H, Ha), 4.70 (d, 1 H, J 
= 17.1 Hz, -NCH2Ar), 4.12 (dq, 2 H, J = 7.3, 1.8 Hz, -OCH2CH3), 3.72 (s, 3 H, OMe), 
2.90-3.18 (m, 2 H, Hb), 1.24-1.41 (m, 4 H, Hc and Hd overlap). 1.20 (t, 3 H, J = 7.3 Hz, -
OCH2CH3), 1.06 (s, 9 H, t-Bu), 0.83 (t, 3 H, J = 7.3 Hz, He). 
 
13C NMR (125 MHz, CDCl3): δ 168.7, 167.1, 165.2, 158.5, 134.5, 131.1, 130.5, 127.0, 
113.9, 60.9, 55.1, 38.9, 36.6, 31.1, 27.5, 20.0, 13.9, 13.6. 
HRMS (EIMS, M+): calcd for C24H36N2O5 432.2624, found 432.2633. 
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39. Ethyl 2-((2S,5S)-1-benzyl-4-(3,5-dimethoxybenzyl)-3,6-dioxo-5-(thiophen-2-
yl)piperazin-2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.0-7.35 (m, 8H, aryl), 6.36-6.45 (m, 3H, aryl), 6.29 (s, 
1H, Ha), 5.55 (d, 1H, J = 14.9 Hz, bn), 5.32 (d, 1H, J = 15.6 Hz, bn), 4.22 (dd, 1H, J = 
2.8, 4.6 Hz, Hb), 4.02-4.15 (m, 2H, –OCH2CH3), 3.98 (d, 1H, J = 15.6 Hz, bn), 3.77 (s, 
6H), 3.56 (d, 1H, J = 14.9 Hz, bn), 3.32 (dd, 1H, J = 2.8, 17.5 Hz, Hc), 2.95 (dd, 1H, J = 
4.9, 17.5 Hz, Hc), 1.17 (t, 3H, J = 7.3 Hz, CH3). 
 
13C NMR (125 MHz, CDCl3): δ 169.5, 165.1, 164.9, 160.9, 139.8, 137.1, 134.9, 128.9, 
127.9, 127.1, 126.4, 106.2, 100.2, 60.9, 58.5, 55.2, 54.5, 47.1, 46.7, 34.4, 13.9. 
 
HRMS: EIMS (M+) calcd for C28H30N2O6S 522.1825, found 522.1829. 
 
40. Ethyl 2-((2S,5S)-4-(4-bromophenyl)-1-butyl-3,6-dioxo-5-(thiophen-2-
yl)piperazin-2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.76 (d, 2 H, J = 7.3 Hz, Aryl), 7.59 (t, 1 H, J = 7.3 Hz, 
Aryl), 7.51 (d, 2 H, J = 8.9 Hz, Aryl), 7.38-7.49 (m, 4 H, Aryl), 7.28 (d, 1 H, J = 8.9 Hz, 
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thienyl), 7.11-7.14 (m, 1 H, thienyl), 7.05-7.08 (m, 1 H, thienyl), 5.72 (s, 1 H, Ha), 5.08 
(dd, 1 H, J = 7.3, 3.4 Hz, Hb), 3.73-3.81 (m, 1 H, Hd), 3.47 (dd, 1 H, J = 17.4, 3.7 Hz, 
Hc), 3.18 (dd, 1 H, J = 17.4, 7.3 Hz, Hc), 2.97-3.06 (m, 1 H, Hd), 1.64-1.75 (m, 1 H, He), 
1.42-1.54 (m, 1 H, He), 1.32 (sextet, 2 H, J = 7.3 Hz, Hf), 0.90 (t, 3 H, J = 7.3 Hz, Hg). 
 
13C NMR (125 MHz, CDCl3): δ 195.4, 167.3, 164.2, 139.5, 138.3, 135.9, 133.8, 132.4, 
128.8, 128.1, 127.4, 127.1, 126.6, 121.1, 63.8, 56.2, 45.6, 43.6, 29.0, 19.9, 13.7. 
 
HRMS (EIMS, M+): calcd for C26H25BrN2O3S 524.0769, found 524.0762. 
 
41. (E)-N-(4-bromophenyl)-N-(2-(butylamino)-2-oxo-1-(thiophen-2-yl)ethyl)-4-oxo-
4-phenylbut-2-enamide 
 
1H NMR (500 MHz, CDCl3): δ 7.89-8.02 (m, 3 H, Aryl), 7.58 (t, 1 H, J = 7.3 Hz, Aryl), 
7.36-7.49 (m, 5 H, Aryl), 7.29 (d, 1 H, J = 4.9 Hz, thienyl), 7.27 (d, 1 H, J = 15.7 Hz, -
CH=CH-), 6.86-6.98 (m, 2 H, thienyl), 6.74 (d,1 H, J = 14.9 Hz, -CH=CH-), 6.24 (s, 1 H, 
Ha), 6.08 (t, 1 H, J = 5.2 Hz, -NH), 3.24-3.38 (m, 2 H, Hb), 1.49 (quintet, 2 H, J = 7.3 Hz, 
Hc), 1.31 (sextet, 2 H, J = 7.3 Hz, Hd), 0.90 (t, 3 H, J = 7.3 Hz, He). 
 
13C NMR (125 MHz, CDCl3): δ 189.4, 167.9, 164.7, 138.0, 136.7, 135.3, 134.9, 133.7, 
132.6, 132.5, 131.4, 130.2, 128.8, 128.7, 128.3, 126.6, 123.1, 61.2, 39.8, 31.4, 20.0, 13.7. 
 
HRMS (EIMS, M+): calcd for C26H25BrN2O3S 524.0769, found 524.0775. 
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42. Ethyl 2-(2-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-7-methoxy-3,8-
dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 6.91 (dd, 1H, J = 2.7, 10.1 Hz), 6.38 (d, 1H, J = 10.1 Hz), 
5.57 (d, 1H, J = 2.7 Hz), 5.51 (br s, 1H, NH), 4.31 (d, 1H, J = 10.1 Hz, Hd),, 4.28 (s, 1H, 
Ha), 4.08 (m, 2H, –OCH2CH3), 3.78 (d, 1H, J = 10.1 Hz, Hd), 3.61 (s, 3H, OCH3), 3.39 
(dd, 1H, J = 5.8, 7.4 Hz, Hb), 2.66 (dd, 1H, J = 6.1, 16.6 Hz, Hc), 2.09 (dd, 1H, J = 7.3, 
16.8 Hz, Hc), 1.34 (s, 9H, t-butyl), 1.21 (t, 3H, J = 7.3 Hz, CH3), 1.08 (s, 9H, t-butyl). 
(Major Isomer) 
 
13C NMR (125 MHz, CDCl3): δ 180.4, 173.9, 171.6, 167.1, 152.7, 146.4, 130.7, 116.5, 
64.2, 61.2, 55.1, 54.8, 51.9, 48.3, 47.3, 36.2, 30.4, 28.6, 27.6, 14.0. (Minor Isomer) 
 
HRMS: EIMS (M+) calcd for C24H36N2O6 448.2573, found 448.2582. 
 
43. (E)-Ethyl 4-((1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-hydroxy-3-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
 127
1H NMR (400 MHz, CDCl3): δ 7.16 (d, 1H, J = 14.6 Hz), 6.4-6.74 (m, 4H), 5.38 (d, 1H, 
J = 17 Hz), 4.98 (bs, 1H), 4.65 (d, 1H, J = 17 Hz), 4.06 (q, 2H, J = 7.3 Hz), 3.73 (s, 3H), 
1.18 (t, 3H, J = 7.3 Hz). 
 
13C NMR (100 MHz, CDCl3): δ167.9, 167.2, 165.3, 146.8, 144.6, 134.1, 134.0, 131.3, 
118.4, 114.5, 108.8, 60.9, 60.2, 55.7, 51.2, 36.9, 28.1, 27.4, 13.8. 
 
HRMS: EIMS (M+) calcd for C24H36N2O6 448.2573, found 448.2578. 
 
44. Ethyl 2-(2-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-7-methoxy-1-
methyl-3,8-dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.12 (d, 1 H, J = 8.1 Hz, Hg), 7.07 (d, 1 H, J = 8.1 Hz, 
Hg), 6.71-6.79 (m, 1 H, Hf), 6.58-6.67 (m, 1 H, Hf), 4.02-4.15 (m, 2 H, -OCH2CH3), 3.93 
(q, 1 H, J = 6.5 Hz, He), 3.49 (s, 1 H, Ha), 3.48 (dd, 1 H, J = 12.3, 6.5 Hz, Hb), 3.18 (dd, 1 
H, J = 8.1, 4.9 Hz, Hc), 2.65 (dd, 1 H, J = 7.3, 4.9 Hz, Hc), 1.34 (d, 3 H, J = 6.5 Hz, -Me), 
1.29 (s, 9 H, t-Bu), 0.90 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 184.9, 172.6, 171.3, 169.5, 165.5, 145.9, 131.4, 130.9, 
62.8, 61.1, 50.8, 50.1, 48.1, 47.4, 30.3, 28.6, 27.3, 19.3, 19.3, 14.1. 
 
HRMS (EIMS, M+): calcd for C24H36N2O5 432.2624, found 432.2621. 
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45. (E)-ethyl 4-((1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)(1-(4-
hydroxyphenyl)ethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 8.46 (s, 1 H, -NH), 7.62 (d, 1 H, J = 15.4 Hz, -CH=CH-), 
7.01 (d, 2 H, J = 8.1 Hz, Aryl), 6.82 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.63 (d, 2 H, J = 
8.2 Hz, Aryl), 5.41 (q, 1 H, J = 6.5 Hz, Hb), 4.28 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.29 (s, 
1 H, Ha), 1.60 (d, 3 H, J = 6.5 Hz, -Me), 1.32 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.22 (s, 9 
H, t-Bu), 1.13 (s, 9 H, t-Bu). 
13C NMR (100 MHz, CDCl3): δ 170.6, 167.8, 165.3, 157.6, 136.2, 131.5, 129.9, 128.8, 
126.8, 116.0, 72.4, 61.4, 58.1, 35.1, 29.7, 28.6, 17.2, 14.1. 
HRMS (EIMS, M+): calcd for C24H36N2O5 432.2624, found 432.2631. 
 
46. (E)-Ethyl 4-((2-(benzylamino)-2-oxo-1-(thiophen-2-yl)ethyl)(3,5-
dimethoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.17-7.34 (m, 6H, aryl), 7.12 (m, 1H, aryl), 6.90-6.95 (m, 
1H, aryl), 6.87 (d, 1H, J = 14.7 Hz, HC=CH), 6.23-6.33 (m, 4H), 5.96 (s, 1H), 4.71 (s, 
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2H), 4.52 (dd, 1H, J = 5.5, 14.9 Hz, bn), 4.40 (dd, 1H, J = 5.6, 15.2 Hz, bn), 4.19 (q, 2H, 
J = 7.1 Hz, –OCH2CH3), 3.7 (s, 6H, OCH3), 1.26 (t, 3H, J = 7.1 Hz, CH3). 
 
13C NMR (125 MHz, CDCl3) : δ 167.9, 166.1, 165.2, 161.0, 138.9, 137.7, 135.9, 133.4, 
132.8, 130.1, 128.7, 128.2, 127.6, 127.5, 126.7, 104.3, 99.8, 61.1, 59.1, 55.3, 50.8, 43.8, 
14. 
 
HRMS: EIMS (M+) calcd for C28H30N2O6S 522.1825, found 522.1816. 
 
47. (E)-Ethyl 4-((1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.18 (d, 1H, J=15.2 Hz, –CH=CH–), 7.01 (d, 2H, J=8.6 
Hz, aryl), 6.78 (d, 2H, J=8.6 Hz, aryl), 6.70 (d, 1H, J=15.2 Hz, –CH=CH–), 5.77 (bs, 1H, 
–NH), 5.36 (d, 1H, J=16.7 Hz, Bn), 4.91 (bs, 1H, Ha), 4.68 (d, 1H, J=17.2 Hz, Bn), 4.09-
4.21 (m, 2H, –OCH2CH3), 1.24 (t, 3H, J=7.1 Hz, –OCH2CH3), 1.22 (s, 9H, N-t-Bu), 1.09 
(s, 9H, C-t-Bu). 
 
13C NMR (125 MHz, CDCl3) : δ 168.1, 167.2, 165.4, 158.6, 134.3, 131.4, 127.2, 113.9, 
60.9, 55.2, 51.6, 37.0, 28.6, 28.4, 27.5, 26.2, 14.1. 
 
HRMS (M+) calcd for C24H36N2O5 432.2624, found 432.2632. 
 
48. Ethyl 2-((2S,5R)-1-benzyl-4-(3,4-dimethoxybenzyl)-5-isopropyl-3,6-
dioxopiperazin-2-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 7.20-7.34 (m, 5 H, Ph), 6.99 (s, 1 H, Aryl), 6.79 (s, 2 H, 
Aryl), 5,54 (d, 1 H, J = 15.2 Hz, -NCH2Ar), 5.11 (d, 1 H, J = 15.2 Hz, -NCH2Ar), 4.14-
4.24 (m, 2 H, Ha and -NCH2Ar overlap), 3.65-4.03 (m, 9 H; Hb, -OCH2CH3, OMe, OMe 
overlap), 3.29 (dd, 1 H, J = 17.2, 2.5 Hz, Hc), 2.90 (dd,1 H, J = 17.2, 5.1 Hz, Hc), 2.26-
2.40 (m, 1 H, i-Pr), 1.13 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.11 (d, 3 H, J = 6.5 Hz, i-Pr), 
0.94 (d, 3 H, J = 6.5 Hz, i-Pr). 
13C NMR (125 MHz, CDCl3): 168.9, 166.6, 165.3, 148.9, 148.4, 134.1, 131.9, 129.5, 
119.1, 111.0, 110.2, 78.3, 61.9, 61.1, 55.9, 51.2, 50.9, 35.9, 27.5, 27.4, 19.0, 14.2. 
HRMS (M+) calcd for C27H34N2O6 482.2417, found 482.2427. 
 
49. (E)-Ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(3,4-
dimethoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.24-7.32 (d, 1H, –CH=CH–), 6.66-6.82 (m, 4H, aryl 
overlap with –CH=CH–), 4,73 (d, 1H, J=16.7 Hz, Bn), 4.61 (d, 1H, J=17.2 Hz, Bn), 4.27 
(br s, 1H, –NH ), 4.23 (bs, 1H, Ha), 4.12-4.21 (m, 2H, –OCH2CH3), 3.81 (s, 6H, –OCH3), 
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2.32-2.45 (m, 1H, Hb), 1.21-1.27 (m, 12H, t-Bu and –OCH2CH3 overlap), 0.93 (d, 3H, 
J=6.6 Hz, i-Pr), 0.78 (d, 3H, J=6.6 Hz, i-Pr). 
 
13C NMR (125 MHz, CDCl3) : δ 168.9, 166.6, 165.3, 148.9, 148.4, 134.1, 131.9, 129.5, 
119.1, 111.0, 110.2, 61.1, 55.8, 51.2, 28.5, 27.4, 19.5, 19.0, 14.0. 
 
HRMS (M+) calcd for C27H34N2O6 482.2417, found 482.2424. 
 
50. (E)-Ethyl 4-(benzyl(1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)amino)-4-
oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.09-7.26 (m, 6H, aryl overlap with –CH=CH– ), 6.74 (d, 
1H, J=15.7 Hz, –CH=CH–), 6.37 (bs, 1H, –NH), 4.84 (d, 1H, J=17.8 Hz, Bn), 4.64 (d, 
1H, J=17.2 Hz, Bn), 4.4 (d, 1H, J=8.6 Hz, Ha), 4.08-4.16 (m, 2H, –OCH2CH3 ), 2.31-2.42 
(m, 1H, Hb), 1.21 (s, 9H, t-Bu), 1.19 (t, 3H, J=7.1 Hz, –OCH2CH3), 0.92 (d, 3H, J=6.6 
Hz, i-Pr), 0.78 (d, 3H, J=6.6 Hz, i-Pr). 
 
13C NMR (125 MHz, CDCl3) : δ 168.5, 166.5, 165.1, 137.2, 133.9, 131.9, 128.5, 127.3, 
126.5, 60.9, 51.2, 28.3, 27.4, 19.4, 18.7, 13.9. 
 
HRMS (M+) calcd for C22H32N2O4 388.2362, found 388.2359 
 
51. Ethyl 2-((2S,5R)-1-benzyl-5-cyclopropyl-4-(4-methoxybenzyl)-3,6-
dioxopiperazin-2-yl)acetate 
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1H NMR (500 MHz, CDCl3) : δ 7.16-7.37 (m, 7H), 6.8-6.89 (m, 2H), 5.4 (d, 1H, J = 15.4 
Hz), 5.35 (d, 1H, J = 15.4 Hz), 4.26 (dd, 1H, J = 3.2, 5.7 Hz), 4.21 (d, 1H, J = 14.6 Hz), 
4.0-4.17 (m, 2H), 3.8 (s, 3H), 4.05 (d, 1H, J = 14.6 Hz), 3.36 (d, 1H, J = 8.9 Hz), 3.21 
(dd, 1H, J = 3.2, 17 Hz), 2.93 (dd, 1H, J = 5.7, 17 Hz), 1.19 (t, 3H, J = 7.3 Hz), 1.05 (m, 
1H), 0.75 (m, 3H), 0.48 (m, 1H). 
 
13C NMR (125 MHz, CDCl3) : δ 169.7, 167.0, 165.7, 159.1, 135.7, 129.2, 128.9, 128.7, 
127.9, 127.8, 127.6, 127.5, 114.1, 62.1, 60.9, 55.3, 54.5, 46.6, 46.4, 34.4, 14.6, 14.1, 6.1, 
1.9. 
 
HRMS (M+) calcd for C26H30N2O5 450.2155, found 450.2154 
 
52. (E)-Ethyl 4-((2-(benzylamino)-1-cyclopropyl-2-oxoethyl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.19-7.35 (m, 5H), 7.10-7.19 (m, 2H), 6.75-6.89 (m, 3H), 
4.76 (dd, 2H, J = 17.5, 40 Hz), 4.42 (ddd, 2H, J = 5.6, 14.7, 30.4 Hz), 4.19 (q, 2H, J = 7.1 
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Hz), 3.96 (d, 1H, J = 10.1 Hz), 1.38 (m, 1H), 1.26 (t, 3H, J = 7.1 Hz), 0.69 (m, 1H), 0.34 
(m, 2H), 0.15 (m, 1H). 
 
13C NMR (125 MHz, CDCl3) : δ 169.8, 166.3, 165.3, 158.9, 138.0, 133.7, 132.6, 128.9, 
128.6, 127.8, 127.5, 127.3, 114.0, 64.5, 61.1, 55.2, 49.3, 43.4, 14.1, 10.5, 5.6, 4.7. 
 
HRMS (EIMS, M+): calcd for C26H30N2O5 450.2155, found 450.2157. 
 
53. Ethyl 2-((2S,5R)-1-benzyl-4-(4-methoxybenzyl)-3,6-dioxo-5-phenylpiperazin-2-
yl)acetate 
 
1H NMR (500 MHz, CDCl3) : δ 7.37-7.45 (m, 3H), 7.23-7.31 (m, 5H), 7.03-7.11 (m, 4H), 
6.78-6.85 (m, 2H), 5.44 (d, 1H, J = 14.6 Hz), 5.26 (d, 1H, J = 15.4 Hz), 4.24 (dd, 1H, J = 
3.2, 4.9 Hz), 4.06-4.16 (m, 1H), 3.95-4.04 (m, 1H), 3.95 (d, 1H, J = 15.4 Hz), 3.39 (d, 
1H, J = 14.6 Hz), 3.27 (dd, 1H, J = 2.4, 17.0 Hz), 2.93 (dd, 1H, J = 4.9, 17.0 Hz), 1.16 (t, 
3H, J = 7.3 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 169.8, 166.7, 165.9, 156.2, 135.6, 129.7, 128.9, 127.9, 
127.8, 126.2, 115.7, 63.7, 54.9, 47.9, 46.8, 34.7, 31.7, 19.9, 17.5, 13.9. 
 
HRMS (M+) calcd for C29H30N2O5 486.2155, found 486.2153. 
 
54. (E)-Ethyl 4-((2-(benzylamino)-2-oxo-1-phenylethyl)(4-methoxybenzyl)amino)-4-
oxobut-2-enoate 
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1H NMR (500 MHz, CDCl3) : δ 7.16-7.4 (m, 11H), 6.92 (d, 2H, J = 8.6 Hz), 6.85 (d, 1H, 
J = 15.2 Hz) 6.71 (d, 2H, J = 8.1 Hz), 4,76 (d, 1H, J = 17.2 Hz), 4.54 (d, 1H, J = 17.2 Hz), 
4.46 (ddd, 2H, J = 5.6, 14.7, 30.4 Hz), 4.19 (q, 2H, J = 7.1 Hz), 1.26 (t, 3H, J = 7.1 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 169.0, 166.3, 165.4, 158.8, 137.8, 134.2, 133.9, 132.4, 
129.8, 128.9, 128.6, 127.7, 127.6, 127.4, 113.9, 63.6, 61.0, 55.2, 49.81, 43.7, 14.1. 
 
HRMS (EIMS, M+): calcd for C29H30N2O5 486.2155, found 486.2157. 
 
55. (E)-Ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(4-
(trifluoromethyl)benzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.54 (d, 2 H, J = 8.2 Hz, Aryl), 7.27 (d, 2 H, J = 8.2 Hz, 
Aryl), 7.12 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.80 (d,1 H, J = 15.4 Hz, -CH=CH-), 6.18 
(br s, 1 H, -NH), 4.97 (d, 1 H, J = 17.7 Hz, -NCH2Ar), 4.74 (d, 1 H, J = 17.7 Hz, -
NCH2Ar), 4.51 (d, 1 H, J = 10.1, Ha), 4.17 (dq, 2 H, J = 7.3, 1.8 Hz, -OCH2CH3), 2.30-
2.43 (m, 1 H, Hb), 1.25 (s, 9 H, t-Bu), 1.27 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.97 (d, 3 H, 
J = 6.5 Hz, i-Pr), 0.85 (d, 3 H, J = 6.5 Hz, i-Pr). 
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13C NMR (125 MHz, CDCl3) : δ 168.5, 166.5, 165.2, 141.6, 133.3, 132.7, 126.7, 125.6, 
125.6, 123.6 (JC-F = 272.2 Hz), 61.2, 51.5, 28.4, 27.5, 19.4, 18.7, 13.9. 
 
19F NMR (376 MHz, CDCl3): δ - 63.55. 
 
HRMS (EIMS, M+): calcd for C29H30N2O5 486.2155, found 486.2157. 
 
56. (E)-Ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(3,4-
dimethoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.24-7.32 (m, 1H, -CH=CH-), 6.66-6.82 (m, 4H, Aryl 
and –CH=CH- overlap), 4,73 (d, 1H, J = 16.7 Hz, -NCH2Ar), 4.61 (d, 1H, J = 17.2 Hz, -
NCH2Ar), 4.27 (br s, 1H, Ha), 4.12-4.21 (m, 2H), 2.26-2.34 (m, 1 H, i-Pr)1.21-1.27 (m, 
12H, t-Bu and –OCH2CH3 overlap), 0.93 (d, 3H, J=6.6 Hz), 0.78 (d, 3H, J=6.6 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 168.9, 166.6, 165.3, 148.9, 148.4, 134.1, 131.9, 129.5, 
119.1, 111.0, 110.2, 61.1, 55.8, 51.2, 28.5, 27.4, 19.5, 19.0, 14.0. 
 
HRMS (EIMS, M+): calcd for C24H36N2O6 448.2573, found 448.2581. 
 
57. (E)-Ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(4-
methoxyphenethyl)amino)-4-oxobut-2-enoate 
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1H NMR (500 MHz, CDCl3): δ 7.30 (d, 1 H, J = 15.4 Hz, -CH=CH-), 7.10 (d, 2 H, J = 
8.9 Hz, Ar), 6.78 (d, 2 H, J = 8.9 Hz, Ar), 7.20 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.36 (br 
s, 1 H, -NH), 4.22 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.66-3.77 (m, 4 H, OMe and Hb 
overlap), 2.76-2.88 (m, 2 H, -NCH2CH2Ar), 2.59-2.71 (m, 2 H, -NCH2CH2Ar), 1.32 (s, 9 
H, t-Bu), 1.30 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.95 (d, 3 H, J = 6.5 Hz, i-Pr), 0.75 (d, 3 
H, J = 6.5 Hz, i-Pr). 
 
13C (125 MHz, CDCl3): δ 169.1, 165.7, 165.3, 158.4, 133.0, 131.4, 129.8, 129.7, 113.9, 
65.8, 60.9, 55.0, 51.2, 47.8, 35.8, 28.4, 26.5, 19.4, 18.3, 14.0. 
 
HRMS (EIMS, M+): calcd for C24H36N2O5 432.2624, found 432.2631. 
 
58. Ethyl 2-(2-(2-(tert-butylamino)-2-oxo-1-(thiophen-2-yl)ethyl)-3,8-dioxo-2-
azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.78 (t, 1 H, J = 4.1 Hz, -NH), 7.14-7.18 (m, 2 H), 6.99-
7.04 (m, 1 H), 6.91-6.96 (m, 1 H), 6.81-6.86 (m, 1 H), 6.67-6.73 (m, 2 H), 5.67 (s, 1 H, 
Ha), 5.0 (d, 1 H, J = 14.6 Hz, He), 4.30 (d, 1 H, J = 14.6 Hz, He), 4.14 (q, 2 H, J = 7.3 Hz, 
-OCH2CH3), 3.93 (dd, 1 H, J = 12.2, 3.2 Hz, Hb), 2.72 (dd, 1 H, J = 15.4, 3.2 Hz, Hc), 
2.34 (dd, 1 H, J = 18.7, 12.2, Hz, Hc), 1.09-1.15 (m, 12 H, t-Bu and –OCH2CH3 overlap). 
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13C NMR (100 MHz, CDCl3): δ 185.1, 172.8, 171.6, 168.3, 149.8, 145.9, 131.4, 130.9, 
127.1, 126.9, 125.6, 71.2, 62.8, 61.1, 50.8, 50.1, 48.1, 47.4, 30.3, 28.6, 27.3, 19.3, 19.3, 
14. 
 
HRMS (EIMS, M+): calcd for C23H28N2O5S 444.1719, found 444.1729. 
 
59. (E)-Ethyl 4-((2-(tert-butylamino)-2-oxo-1-(thiophen-2-yl)ethyl)(4-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.27 (d, 1 H, J = 15.4 Hz, -CH=CH-), 7.24 (d, 1 H, J = 
5.7 Hz, thienyl), 7.25 (d, 1 H, J = 2.4 Hz, thienyl), 6.90 (t, 1 H, J = 5.7 Hz, thienyl), 6.87 
(d, 2 H, J = 8.9 Hz, Aryl), 6.82 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.66 (d, 2 H, J = 8.9 Hz, 
Aryl), 6.05 (s, 1 H, Ha), 5.80 (s, 1 H, -OH), 4.60 (dd, 2 H, J = 50.3, 17.0 Hz, -NCH2Ar), 
4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 1.28 (s, 9 H, t-Bu), 1.24 (t, 3 H, J = 7.3 Hz, -
OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): 167.5, 166.0, 165.4, 156.0, 136.1, 133.9, 132.3, 129.6, 
127.9, 127.7, 127.5, 126.5, 115.6, 65.8, 61.1, 59.2, 51.8, 49.9, 28.4, 15.1, 14.0. 
 
HRMS (EIMS, M+): calcd for C23H28N2O5S 444.1719, found 444.1727. 
 
60. Ethyl 2-((2S,5S)-1-benzyl-4-(3-methoxybenzyl)-3,6-dioxo-5-(thiophen-2-
yl)piperazin-2-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 7.3-7.36 (m, 3 H, Aryl), 7.14-7.2 (m, 4 H, Aryl), 7.06-
7.12 (m, 2 H, Aryl), 6.86-6.9 (m, 2H, Aryl), 5.52 (d, 1 H, J = 14.4 Hz, -NCH2Ar), 5.37 
(d, 1 H, J = 15.6 Hz, -NCH2Ar)), 4.26 (m, 1 H), 4.12-4.18 (m,1 H), 4.02-4.08 (m, 1 H), 
3.99 (d, 1 H, J = 15.6 Hz, -NCH2Ar)), 3.85 (s, 3 H), 3.64 (d, 1 H, J = 14.4 Hz, -
NCH2Ar)), 3.32 (dd, 1 H, J = 17.4, 3.0 Hz, Hc), 2.96 (dd, 1 H, J = 17.4, 4.8 Hz, Hc), 1.21 
(t, 3 H, J = 7.2 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 169.5, 165.2, 165.1, 159.9, 139.9, 136.4, 134.9, 128.9, 
127.9, 127.8, 127.1, 126.4, 113.9, 61.0, 58.4, 55.2, 54.5, 46.7, 46.6, 34.5, 14.0. 
 
HRMS (EIMS, M+): calcd for C27H28N2O8S 492.1719, found 492.1721. 
 
61. Ethyl 2-((2S,5R)-1-benzyl-4-(4-hydroxybenzyl)-5-isopropyl-3,6-dioxopiperazin-
2-yl)acetate 
N
N
O
O
i-Pr
EtO2C
HaHb
Hc Hc
( )-86
OH
 
 139
1H NMR (500 MHz, CDCl3) : δ 7.18-7.4 (m, 5H), 7.1 (d, 2H, J = 8.1 Hz), 6.69 (d, 2H, J = 
8.1 Hz), 5.36 (d, 1H, J = 15.2 Hz), 5.21 (d, 1H, J = 15.2 Hz), 4.29 (dd, 1H, J = 3.5, 5.1 
Hz), 4.18 (d, 1H, J = 15.2 Hz), 4.04-4.14 (m, 1H), 3.94-4.03 (m, 1H), 3.9 (d, 1H, J = 15.2 
Hz), 3.89 (d, 1H, J = 5.1 Hz), 3.22 (dd, 1H, J = 3.6, 17.2 Hz), 2.94 (dd, 1H, J = 5.6, 17.2 
Hz), 1.15 (t, 3H, J = 7.6 Hz), 1.12 (d, 3H, J = 6.6 Hz), 0.96 (d, 3H, J = 6.6 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 169.8, 166.7, 165.9, 156.2, 135.6, 129.7, 128.9, 127.9, 
127.8, 126.2, 115.7, 63.7, 61.0, 54.9, 47.9, 46.8, 34.7, 31.7, 19.9, 17.5, 13.9. 
 
HRMS (M+) calcd for C25H30N2O5 438.2155, found 438.2161. 
 
62. (E)-Ethyl 4-((1-(benzylamino)-3-methyl-1-oxobutan-2-yl)(4-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.99 (br s, 1 H, -NH), 7.33 (d, 1 H, J = 15.2 Hz, -
CH=CH-), 7.21-7.32 (m, 3 H, Aryl), 7.18 (d, 2 H, J = 7.1 Hz, Aryl), 6.86 (d, 2 H, J = 8.1 
Hz, Aryl), 6.78 (d, 1 H, J = 15.2 Hz, -CH=CH-), 6.55 (d, 2 H, J = 8.1 Hz, Aryl), 4.68 (d, 
1 H, J = 16.7, -NCH2Ar), 4.56 (d, 1 H, J = 16.7 Hz, -NCH2Ar), 4.41 (dd, 1 H, J = 14.7, 
6.1 Hz, -NCH2Ar), 4.31 (br s, 1 H, Ha), 4.15-4.24 (m, 3 H, -NCH2Ar and –OCH2CH3 
overlap), 2.51-2.64 (m, 1 H, Hb), 1.27 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.98 (d, 3 H, J = 
6.5 Hz, i-Pr), 0.84 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (125 MHz, CDCl3) : δ 170.3, 166.9, 165.4, 156.2, 137.5, 133.9, 132.3, 128.6, 
127.9, 127.6, 127.4, 115.7, 61.3, 43.5, 27.0, 19.7, 18.9, 14.0. 
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HRMS (M+) calcd for C25H30N2O5 438.2155, found 438.2166. 
 
63. Ethyl 2-((2S,5R)-1-benzyl-5-cyclopentyl-4-(4-methoxybenzyl)-3,6-
dioxopiperazin-2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.14-7.36 (m, 7 H, Ph and Aryl overlap), 6.86 (d, 2 H, J = 
8.9 Hz, Aryl), 5.45 (d, 1 H, J = 15.2 Hz, -NCH2Ar), 5.21 (d, 1 H, J = 15.7 Hz, -NCH2Ar), 
4.35 (d, 1 H, J = 5.6, 3.6 Hz, Hb), 4.12 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 4.05 (d, 1 H, J = 
3.4 Hz, Ha), 3.80 (s, 3 H, OMe), 3.16 (dd, 1 H, J = 17.2, 3.6 Hz, Hc), 2.93 (dd, 1 H, J = 
17.3, 6.1 Hz, Hc), 1.25 (t, 3 H, J = 7.3 Hz-OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): 171.3, 165.4, 165.3, 158.9, 136.7, 131.7, 128.9, 128.5, 
127.9, 127.2, 114.2, 72.1, 61.7, 61.2, 56.1, 50.9, 50.5, 40.1, 35.9, 29.5, 24.7, 14.2. 
 
HRMS (EIMS, M+): calcd for C28H34N2O5 478.2468, found 478.2473. 
 
64. (E)-Ethyl 4-((2-(benzylamino)-1-cyclopentyl-2-oxoethyl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
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1H NMR (500 MHz, CDCl3): δ 7.17-7.39 (m, 6 H, Ph and –CH=CH- overlap), 7.05 (d, 2 
H, J = 8.6 Hz, Aryl), 6.78 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.77 (d, 2 H, J = 8.6 Hz, 
Aryl), 4.66 (s, 2 H, -NCH2Ar), 4.64 (d, 1 H, J =3.6 Hz, Ha), 4.41 (dd, 1 H, J = 15.2, 6.1 
Hz, -NCH2Ar), 4.28 (dd, 1 H, J = 15.2, 6.3 Hz, -NCH2Ar), 4.21 (q, 2 H, J = 7.3 Hz, -
OCH2CH3), 1.28 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 169.9, 166.7, 165.2, 158.8, 138.0, 133.9, 132.0, 128.7, 
128.5, 127.9, 127.5, 127.2, 113.9, 61.0, 55.1, 43.1, 37.9, 30.3, 29.4, 25.5, 25.2, 13.9. 
 
HRMS (EIMS, M+): calcd for C28H34N2O5 478.2468, found 478.2475. 
 
65. Ethyl 2-((2S,5R)-1-benzyl-5-cyclohexyl-4-(4-methoxybenzyl)-3,6-dioxopiperazin-
2-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.18-7.38 (m, 5 H, Ph), 7.03 (d, 2 H, J = 8.1 Hz, Aryl), 
6.76 (d, 2 H, J = 8.5 Hz, Aryl), 5.37 (d, 1 H, J = 14.7 Hz, -NCH2Ar), 5.14 (d, 1 H, J = 
15.7 Hz, -NCH2Ar), 4.46 (dd, 1 H, J = 12.7, 6.1 Hz, Hb), 4.15-4.31 (m, 4 H, -OCH2CH3, 
Cy, -NCH2Ar overlap), 3.95 (d,1 H, J = 14.7 Hz, -NCH2Ar), 3.20 (dd,1 H, J = 7.2, 3.6 
Hz, Hc), 2.92 (dd, 1 H, J = 7.2, 5.6 Hz, Hc), 2.16-2.26 (m, 1 H, Cy), 1.43-1.93 (m, 6 H, 
Cy), 1.17 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.69-1.15 (m, 4 H, Cy). 
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13C NMR (125 MHz, CDCl3): δ 171.5, 166.1, 165.7, 159.1, 137.1, 132.2, 128.9, 128.7, 
127.9, 127.3, 114.2, 72.1, 60.9, 60.3, 55.6, 50.9, 50.4, 35.9, 30.1, 27.9, 27.1, 25.4, 14.2. 
 
HRMS (EIMS, M+): calcd for C29H36N2O5 492.2624, found 492.2633. 
 
66. (E)-Ethyl 4-((2-(benzylamino)-1-cyclohexyl-2-oxoethyl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.17-7.35 (m, 6 H, Ph and –CH=CH- overlap), 7.03 (d, 2 
H, J = 8.6 Hz, Aryl), 6.76 (d, 2 H, J = 8.6 Hz, Aryl), 6.73 (d, 1 H, J = 15.2 Hz, -CH=CH-
), 4.67 (dd, 2 H, J = 47.1, 16.7 Hz, NCH2Ar), 4.41 (dd, 1 H, J = 14.7, 6.1 Hz, -NCH2Ar), 
4.24 (dd,1 H, J = 14.7, 5.6 Hz, -NCH2Ar), 4.17 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 1.27 (t, 
3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 169.4, 166.6, 165.2, 158.8, 137.9, 134.0, 131.8, 128.9, 
128.5, 127.9, 127.6, 127.2, 113.9, 62.5, 60.9, 55.1, 48.3, 43.2, 36.1, 29.9, 29.2, 26.1, 25.5, 
13.9. 
 
HRMS (EIMS, M+): cacld for C29H36N2O5 492.2624, found 492.2632. 
 
67. Ethyl 2-((2S,5R)-1-benzyl-5-(tert-butyl)-4-((S)-1-(4-methoxyphenyl)ethyl)-3,6-
dioxopiperazin-2-yl)acetate 
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1H NMR (400 MHz, CDCl3) : δ 7.24-7.36 (m, 5H), 7.17-7.22 (m, 2H), 6.85-6.90 (m, 2H), 
5.07 (q, 1H, J = 7.3 Hz), 5.01 (d,1H, J = 16.2 Hz), 4.48 (dd, 1H, J = 4.1, 6.1 Hz), 4.31 (d, 
1H, J = 15.4 Hz), 4.10 (m, 2H), 3.06 (dd, 1H, J = 4.1, 17.03 Hz), 2.92 (dd, 1H, J = 5.7, 
17.03 Hz) 1.72 (d, 3H, J = 6.5 Hz), 1.25 (t, 3H, J = 7.3 Hz). 
 
13C NMR (125 MHz, CDCl3) : δ 170.2, 168.4, 167.6, 158.7, 136.8, 131.9, 128.8, 128.6, 
127.6, 127.5, 113.8, 69.6, 60.9, 59.9, 55.9, 55.2, 46.8, 37.8, 34.4, 28.8, 18.7, 14.1. 
 
HRMS (M+) calcd for C28H36N2O5 480.2624, found 480.2630. 
 
68. (E)-Ethyl 4-((1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl)((S)-1-(4-
methoxyphenyl)ethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3) : δ 7.24-7.36 (m, 5H), 7.10-7.22 (m, 6H, ), 7.03 (br s, 2H, 
Aryl), 6.79 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.70 (d, 2 H, J = 8.2 Hz, Aryl), 5.76 (t, 1 H, 
J = 4.8 Hz, -NH), 4.54 (dd, 1 H, J = 14.6, 4.5 Hz, -NCH2Ph), 4.10-4.44 (m, 5H; Ha, Hb, -
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OCH2CH3 and -NCH2Ph overlap), 3.76 (s, 3 H, OMe), 1.49 (d, 3 H, J = 6.5 Hz, -Me), 
1.31 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.15 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): 171.2, 167.4, 165.1, 136.7, 136.1, 128.3, 128.3, 127.7, 
127.6, 126.9, 126.3, 113.7, 63.5, 60.1, 54.9, 43.2, 29.6, 27.3, 20.8, 13.9. 
 
HRMS (M+) calcd for C28H36N2O5 480.2624, found 480.2633. 
 
69. Ethyl 2-((2S,5R)-4-(benzo[d][1,3]dioxol-5-ylmethyl)-1-benzyl-5-isopropyl-3,6-
dioxopiperazin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.20-7.36 (m, 5 H, Ph), 6.72-6.85 (m, 3 H, Aryl), 5.92 (s, 
2 H, -OCH2O-), 5.39 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 5.19 (d,1 H, J = 15.4 Hz, -
NCH2Ar), 4.23 (dd,1 H, J = 6.2, 3.2 Hz, Hb), 4.14 (d,1 H, J = 15.4 Hz, -NCH2Ar), 3.99-
4.15 (m, 2 H, -OCH2CH3), 3.88 (d,1 H, J = 15.4 Hz, -NCH2Ar), 3.86 (d,1 H, J = 2.l Hz, 
Ha), 3.22 (dd, 1 H, J = 7.2, 3.6 Hz, Hc), 2.92 (dd, 1 H, J = 7.2, 5.6 Hz, Hc), 2.21-2.36 (m, 
1 H, i-Pr), 1.17 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.12 (d, 3 H, J = 6.5 Hz, i-Pr), 0.94 (d, 3 
H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 169.8, 166.7, 165.9, 147.2, 145.3, 135.9, 129.7, 128.9, 
127.9, 127.8, 126.2, 110.5, 107.9, 101.6, 78.8, 62.7, 61.0, 52.9, 50.6, 35.9, 28.1, 19.2, 
14.2. 
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HRMS (M+) calcd for C25H30N2O5 466.2104, found 466.2111 
 
70. (E)-Ethyl 4-((benzo[d][1,3]dioxol-5-ylmethyl)(1-(benzylamino)-3-methyl-1-
oxobutan-2-yl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.19-7.35 (m, 6 H, Ph and –CH=CH- overlap), 6.89 (t, 1 
H, J = 1.8 Hz, -NH), 6.76 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.55-6.70 (m, 3 H, Aryl), 5.99 
(s, 2 H, -OCH2O-), 4.64 (dd, 2 H, J = 35.2, 8.8 hz, -NCH2Ar), 4.46 (dd, 1 H, J = 12.4, 8.3 
Hz, -NCH2Ar), 4.42 (dd, 1 H, dd, J = 12.4, 6.5 Hz, -NCH2Ar), 4.20 (q, 2 H, J = 7.3 Hz, -
OCH2CH3), 2.43-2.57 (m, 1 H, Hb), 1.27 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.97 (d, 3 H, J 
= 6.5 Hz, i-Pr), 0.82 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 171.1, 165.9, 163.2, 145.2, 145.1, 136.5, 136.2, 129.6, 
128.7, 127.8, 127.1, 126.9, 124.1, 110.6, 108.1, 101.4, 67.9, 61.8, 49.2, 42.9, 27.5, 19.1, 
14.2. 
HRMS (EIMS, M+): calcd for C26H30N2O6 466.2104, found 466.2112. 
 
71. Ethyl 2-((2S,5R)-1-benzyl-5-isopropyl-4-(4-(methylthio)benzyl)-3,6-
dioxopiperazin-2-yl)acetate 
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1H NMR (400 MHz, CDCl3): δ 7.16-7.34 (m, 5 H, Ph), 7.08 (d, 2 H, J = 8.9 Hz, Aryl), 
6.99 (d, 2 H, J = 8.3 Hz, Aryl), 5.39 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 5.18 (d, 1 H, J = 
15.4 Hz, -NCH2Ar), 4.24 (dd, 1 H, J = 6.2, 3.2 Hz, Hb), 4.15 (d, 1 H, J =15.4 Hz, -
NCH2Ar), 4.01-4.11 (m, 2 H, -OCH2CH3), 3.84 (d, 1 H, J = 4.1 Hz, Ha), 3.24 (dd,1 H, J = 
17.0, 3.2 Hz, Hc), 2.92 (dd,1 H, J = 17.0, 5.7 Hz, Hc), 2.47 (s, 3 H, SMe), 2.22-2.39 (m, 1 
H, i-Pr), 1.16 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.12 (d, 3 H, J = 6.5 Hz, i-Pr), 0.93 (d, 3 
H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 171.5, 165.8, 165.1, 138.7, 137.9, 134.2, 128.7, 128.3, 
127.9, 127.2, 75.1, 61.1, 61.4, 50.6, 50.2, 35.9, 27.5, 18.9, 14.9, 14.2. 
 
HRMS (EIMS, M+) cacld for C26H32N2O4S 468.2083, found 468.2093. 
 
72. (E)-Ethyl 4-((1-(benzylamino)-3-methyl-1-oxobutan-2-yl)(4-
(methylthio)benzyl)amino)-4-oxobut-2-enoate 
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1H NMR (400 MHz, CDCl3): δ 7.49 (br s, 1 H, -NH), 7.10-7.29 (m, 6 H, Ph and –
CH=CH- overlap), 7.05 (d, 2 H, J = 8.9 Hz, Aryl), 6.98 (d, 2 H, J = 8.3 Hz, Aryl), 6.62 
(d, 1 H, J = 15.4 Hz, -CH=CH-), 4.72 (dd, 2 H, J = 71.4, 17.0 Hz, -NCH2Ar), 4.64 (d, 1 
H, J = 3.4 Hz, i-Pr), 4.34 (dd, 1 H, J = 15.4, 6.5 Hz, -NCH2Ar), 4.18 (dd, 1 H, J = 14.6, 
5.7 Hz, -NCH2Ar), 4.12 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 2.23-2.45 (m, 4 H, i-Pr and 
SMe overlap), 1.21 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.94 (d, 3 H, J = 6.5 Hz, i-Pr), 0.79 
(d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 170.8, 166.5, 165.7, 138.9, 138.7, 134.2, 134.1, 132.4, 
128.8, 127.9, 127.5, 127.3, 126.9, 65.1, 61.5, 48.5, 43.3, 27.6, 19.8, 19.1, 15.9, 14.2. 
 
HRMS (EIMS, M+) cacld for C26H32N2O4S 468.2083, found 468.2091. 
 
73. Ethyl 2-((2S,5R)-1-benzyl-4-(3-hydroxybenzyl)-5-isopropyl-3,6-dioxopiperazin-
2-yl)acetate 
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1H NMR (400 MHz, CDCl3): δ 7.22-7.36 (m, 5 H, Ph), 6.70-6.87 (m, 3 H, Aryl), 5.38 (d, 
1 H, J = 15.4 Hz, -NCH2Ar), 5.24 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 4.26 (dd, 1 H, J = 3.3 
Hz, Hb), 4.15 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 4.05-4.15 (m, 2 H, -OCH2CH3), 3.98 (d, 1 
H, J = 15.4 Hz, -NCH2Ar), 3.88 (d, 1 H, J = 4.1 Hz, Ha), 3.25 (dd, 1 H, J = 17.0, 3.2 Hz, 
Hc), 2.93 (dd, 1 H, J = 17.0, 4.7 Hz, Hc), 2.26-2.37 (m, 1 H, i-Pr), 1.16 (t, 3 H, J = 7.3 Hz, 
-OCH2CH3), 1.13 (d, 3 H, J = 6.5 Hz, i-Pr), 0.96 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (125 MHz, CDCl3) : δ 170.1, 167.7, 167.5, 156.4, 136.1, 129.5, 128.9, 127.8, 
127.6, 126.3, 115.7, 67.7, 61.0, 55.8, 51.3, 47.0, 40.1, 34.6, 28.3, 14.0. 
 
HRMS (EIMS, M+): calcd for C26H32N2O5 452.2311, found 452.2314. 
 
74. (E)-Ethyl 4-((1-(benzylamino)-3-methyl-1-oxobutan-2-yl)(3-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
N
O
O NH
Bn
EtO2C
Ha
OH
( )-100
Hb
 
1H NMR (400 MHz, ): δ 7.17-7.32 (m, 6 H, Ph and –CH=CH- overlap), 6.99-7.06 (m, 1 
H, Aryl), 6.75 (d, 1H, J = 15.4 Hz, -CH=CH-), 6.52-6.66 (m, 3 H, -NH and Aryl 
overlap), 4.63 (dd, 2 H, J = 51.9, 17.8 Hz, -NCH2Ar), 4.42 (dd, 2 H, J = 14.6, 5.7 Hz, -
NCH2Ar), 4.24 (d, 1 H, J = 4.3 Hz, Ha), 4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 2.45-2.59 
(m 1 H, Hb), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.96 (d, 3 H, J = 6.5 Hz, i-Pr), 0.83 (d, 
3 H, J = 6.5 Hz, i-Pr). 
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13C NMR (100 MHz, CDCl3): δ 171.3, 166.5, 163.0, 156.8, 137.9, 137.8, 129.9, 128.5, 
126.9, 126.7, 120.5, 114.2, 113.6, 67.7, 61.4, 49.7, 43.6, 27.3, 18.8, 14.2. 
 
HRMS (EIMS, M+): calcd for C25H30N2O5 438.2155, found 438.2162. 
 
73. Ethyl 2-((2S,5R)-1-benzyl-5-isopropyl-4-((6-methoxynaphthalen-2-yl)methyl)-
3,6-dioxopiperazin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.66-7.74 (m, 3 H, Ar), 7.20-7.40 (m, 6 H, Ar), 7.08-7.16 
(m, 2 H, Ar), 5.56 (d, 1 H, J = 15.4 Hz, -NCH2Ar), 5.18 (d, 1 H, J = 14.6 Hz, -NCH2Ar), 
4.27 (dd, 1 H, J = 4.9, 3.2 Hz, Hb), 4.05-4.17 (m, 5 H, -NCH2Ar, -OCH2CH3 and Ha 
overlap), 3.90 (s, 3 H, OMe), 3.25 (dd, 1 H, J = 17.8, 3.3 Hz, Hc), 2.93 (dd, 1 H, J = 17.8, 
5.7 Hz, Hc), 2.30-2.43 (m, 1 H, Hd), 1.24 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.11 (d, 3 H, J 
= 6.5 Hz, i-Pr), 0.94 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
HRMS (EIMS, M+): cacld for C30H34N2O5 502.2468, found 502.2479. 
 
74. (E)-Ethyl 4-((1-(benzylamino)-3-methyl-1-oxobutan-2-yl)((6-
methoxynaphthalen-2-yl)methyl)amino)-4-oxobut-2-enoate 
 150
 
1H NMR (400 MHz, CDCl3): δ 7.48-7.68 (m, 3 H, Aryl), 7.08-7.36 (m, 9 H, Aryl and –
CH=CH- overlap), 6.96 (br s, 1 H, -NH), 6.77 (d,1 H, J = 15.4 Hz, -CH=CH-), 4.86 (dd, 
2 H, J = 47.2, 17.2 Hz, -NCH2Ar), 4.51 (d, 1 H, J = 3.4 Hz, Hb), 4.44 (dd, 1 H, J = 14.7, 
10.4 Hz, -NCH2Ar), 4.19 (dd, 1 H, J = 14.7, 10.4 Hz, -NCH2Ar), 4.14 (q, 2 H, J = 7.3 Hz, 
-OCH2CH3), 3.91 (s, 3 H, OMe), 2.48-2.63 (m, 1 H, Hb), 1.22 (t, 3 H, J = 7.3 Hz, -
OCH2CH3), 0.98 (d, 3 H, J = 6.5 Hz, i-Pr), 0.83 (d, 3 H, J = 6.5 Hz, i-Pr). 
 
13C NMR (100 MHz, CDCl3): δ 171.1, 166.6, 163.2, 156.3, 137.9, 135.8, 132.9, 133.1, 
129.4, 129.1, 128.7, 128.6, 127.6, 126.5, 126.1, 117.8, 108.5, 67.9, 61.3, 49.7, 43.7, 27.3, 
18.7, 14.1. 
 
HRMS (EIMS, M+): cacld for C30H34N2O5 502.2468, found 502.2476. 
 
75. Ethyl 2-((2S,5R)-1-benzyl-4-(4-methoxybenzyl)-5-(naphthalen-2-yl)-3,6-
dioxopiperazin-2-yl)acetate 
( )-103
N
N
O
O
EtO2C
HaHb
Hc Hc
OMe
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1H NMR (400 MHz, CD2Cl2) : δ 7.86-7.98 (m, 3H), 7.76 (s, 1H), 7.53-7.61 (m, 2H), 
7.38-7.45 (m, 1H), 7.24-7.35 (m, 3H), 7.05-7.19 (m, 4H), 6.80-6.89 (m, 2H), 5.43 (d, 1H, 
J=14.6 Hz), 5.11-5.21 (m, 2H), 4.33-4.38 (m, 1H), 3.98-4.17 (m, 3H), 3.8 (s, 3H), 3.42 
(d, 1H, J=14.6 Hz), 3.28 (dd, 1H, J=17.4 Hz), 2.98 (dd, 1H, J=5.3, 17.4 Hz), 1.20 (t, 3H, 
J=7.3 Hz). 
 
13C NMR (100 MHz, CD2Cl2) : δ 170.1, 166.1, 165.7, 159.7, 136.1, 135.1, 133.7, 133.6, 
130.5, 129.4, 129.2, 128.4, 128.3, 128.2, 128.0, 127.8, 127.6, 126.9, 125.1, 63.2, 61.4, 
55.6, 55.5, 47.2, 46.8, 35.3, 14.2. 
 
HRMS (M+) calcd for C38H32N2O5 536.2311, found 536.2317. 
 
76. (E)-Ethyl 4-((2-(benzylamino)-1-(naphthalen-2-yl)-2-oxoethyl)(4-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3) : δ 7.68-7.83 (m, 4H), 7.45-7.53 (m, 3H), 7.36-7.43 (m, 1H), 
7.19-7.35 (m, 6H), 6.84-6.94 (m, 3H), 6.6-6.67 (m, 2H), 6.19 (t, 1H, J=5.7 Hz), 6.15 (s, 
1H), 4.79 (d, 1H, J=17.8 Hz), 4.58 (d, 1H, J=17.8 Hz), 4.49 (ddd, 1H, J=5.7, 15.2, 38.8 
Hz), 4.19 (q, 2H, J=7.3 Hz), 3.68 (s, 3H), 1.26 (t, 3H, J=7.3 Hz). 
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13C NMR (100 MHz, CD2Cl2) : δ 170.1, 166.1, 165.7, 159.7, 136.1, 135.1, 133.7, 133.6, 
130.5, 129.4, 129.2, 128.4, 128.3, 128.2, 128.0, 127.8, 127.6, 126.9, 125.1, 63.2, 61.4, 
55.6, 55.5, 47.2, 46.8, 35.3, 14.2. 
 
HRMS (M+) calcd for C38H32N2O5 536.2311, found 536.2318. 
 
77. (E)-Ethyl 4-((2-(tert-butylamino)-1-(naphthalen-1-yl)-2-oxoethyl)(4-
hydroxyphenyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.69-7.81 (m, 5 H, Aryl), 7.65 (d, 2 H, J = 8.9 Hz, Aryl), 
7.42-7.52 (m, 3 H, Aryl), 7.16 (dd, 1 H, J = 8.9, 1.6 Hz, Aryl), 6.84 (dd, 2 H, J = 32.4, 
15.4 Hz, -CH=CH-), 6.58 (br s, 1 H, -NH), 6.10 (s, 1 H, Ha), 5.78 (br s, 1 H, -OH), 4.15 
(q, 2 H, J = 7.3 Hz, -OCH2CH3), 1.33 (s, 9 H, t-Bu), 1.23 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 168.7, 165.9, 165.1, 156.4, 134.6, 132.9, 131.7, 131.4, 
131.3, 130.8, 129.8, 128.2, 128.1, 127.6, 127.1, 126.7, 126.4, 66.5, 61.2, 51.9, 28.6, 14.0. 
 
HRMS (EIMS, M+): calcd for C28H30N2O5 474.2155, found 474.2167. 
 
78. Ethyl 2-((3R)-1-(2-(tert-butylamino)-1-(naphthalen-1-yl)-2-oxoethyl)-2,7-dioxo-1-
azaspiro[3.5]nona-5,8-dien-3-yl)acetate 
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1H NMR (300 MHz, CDCl3): δ 7.69-7.81 (m, 4 H, Aryl), 7.42-7.52 (m, 2 H, Aryl), 7.16 
(m, 2 H, Aryl and cyclohexadienone overlap), 6.60-6.90 (m, 3 H, cyclohexadienone), 
6.58 (br s, 1 H, -NH), 5.82 (s, 1 H, Ha), 4.15 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 4.03 (dd, 1 
H, J = 9.2, 4.9 Hz, Hb), 2.76 (dd, 1 H, J = 18.3, 3.7 Hz, Hc), 2.28 (dd, 1 H, J = 18.3, 12.2, 
Hz, Hc), 1.33 (s, 9 H, t-Bu), 1.23 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (75 MHz, CDCl3): δ 186.1, 171.2, 169.1, 168.9, 154.3, 134.6, 132.9, 131.7, 
131.4, 131.3, 130.8, 129.8, 128.2, 128.1, 127.6, 127.1, 126.7, 126.4, 68.1, 62.3, 61.8, 
59.6, 45.2, 35.2, 28.9, 14.0. 
 
HRMS (EIMS, M+): calcd for C28H30N2O5 474.2155, found 474.2152. 
 
79. (E)-Ethyl 4-((4-bromophenyl)(2-(tert-butylamino)-1-(2-nitro-4-(trifluoromethyl)phenyl)-
2-oxoethyl)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 8.13 (s, 1H, aryl), 7.64 (d, 2H, J = 8.9 Hz, aryl), 7.58 (d, 
1H, J = 8.1 Hz, aryl), 7.34 (d, 2H, J = 8.1 Hz, aryl), 7.10 (br s, 1H, -NH), 6.80 (d, 1H, J = 
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14.6 Hz, -CH=CH-), 6.70 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.54 (s, 1H, aryl), 6.00 (s, 1H, 
Ha), 4.16 (q, 2H, J = 8.0 Hz, -OCH2CH3), 1.27 (s, 9H, t-butyl), 1.25 (t, 3H, J = 7.3 Hz, -
OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 166.6, 165.3, 164.7, 149.9, 137.2, 133.3, 133.2, 133.1, 
133.0, 132.9, 132.7, 132.6, 131.6, 129.5, 129.4, 123.6 (JC-F = 272.2 Hz), 122.4, 122.3, 
61.5, 61.1, 52.5, 28.6, 14.3. 
 
19F NMR (376 MHz, CDCl3): δ - 63.51. 
 
HRMS: EIMS (M+) calcd for C25H25BrF3N3O6 599.0879 found 599.0889. 
 
IR (neat): 3322, 3070, 2968, 2933, 1714, 1690, 1664, 1542, 1486, 1362, 1324, 1298, 
1221, 1154, 1136, 1089, 1033, 975, 654. 
 
80. Ethyl 2-(4-(4-bromophenyl)-5-(tert-butylcaramoyl)-3-oxo-8-(trifluoromethyl)-2, 
3, 4, 5-tetrahydro-1H-benzo[e][1,4]diazepin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): (major) δ 8.43 (s, 1 H, aryl), 7.79 (d, 1 H, J = 8.1 Hz, aryl), 
7.46 – 7.38 (m, 3H, aryl), 7.30 – 7.24 (m, 2H, aryl), 5.92 (s, 1H, Ha), 4.58 (m, 1H, Hb), 
4.11 – 3.99 (m, 2H, -OCH2CH3), 2.43 (dd, 1H, J1 = 5.7 Hz, J2 = 16.2 Hz, Hc), 2.28 (dd, 
1H, , J1 = 8.1 Hz, J2 = 16.2 Hz, Hc), 1.23 (s, 9H, t-butyl), 1,17 (t, 3H, J = 7.3 Hz, -
OCH2CH3). 
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1H NMR (400 MHz, CDCl3): (minor) δ 8.32 (s, 1H, aryl), 7.43 (d, 1H, J = 8.1 Hz, aryl), 
7.46 – 7.38 (m, 3H, aryl), 7.30 – 7.24 (m, 2H, aryl), 6.88 (s, 1H, Ha), 4.58 (m, 1H, Hb), 
4.28 – 4.20 (m, 2H, -OCH2CH3), 3.29 (dd, 1H, J1 = 4.8 Hz, J2 = 17.2 Hz, Hc), 2.28 (dd, 
1H, , J1 = 7.3 Hz, J2 = 18.1 Hz, Hc), 1.31 (t, 3H, J = 7.3 Hz, -OCH2CH3), 1.21 (s, 9H, t-
butyl). 
 
13C NMR (100 MHz, CDCl3): (major and minor) δ 172.3, 169.7, 165.8, 165.6, 165.4, 
163.3, 150.0, 135.9, 135.7, 132.9, 132.8, 132.7, 130.6, 129.9, 129.8, 129.6, 128.4, 124.0 
(q, JC-F = 270.7 Hz), 123.0, 122.9,122.8, 119.1, 119.0, 118.4, 76.9, 71.5, 62.2, 61.6, 61.0, 
58.5, 53.4, 53.1, 31.9, 31.2, 29.9, 28.6, 28.5, 14.3, 14.2.  (JC-F for other diastereomer 
could not be detected clearly). 
 
19F NMR (282 MHz, CDCl3): δ – 63.50 (major), - 63.52 (minor). 
 
HRMS: EIMS (M+) calcd for C25H27BrF3N3O4 569.1137 found 569.1130. 
 
IR (neat): 3362, 3019, 2924, 1738, 1738, 1715, 1604, 1456, 1364, 1219, 1046, 968, 747, 
676. 
 
81. (E)-Ethyl 4-((1-(2-amino-4-(trifluoromethyl)phenyl)-2-(tert-butylamino)-2-
oxoethyl)(4-bromophenyl) amin o)-4-oxobut-2-enoate 
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1H NMR (500 MHz, CDCl3): δ 6.92 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.84 (m, 2H, aryl), 
6.74 (m, 3H, aryl), 6.65 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.56 (s, 1H, aryl), 6.24 (s, 1H, 
aryl ), 5.40 (s, 1H, Ha), 4.24 (s, 2H, -NH2), 4.16 (q, 2H, J = 8.0 Hz, -OCH2CH3), 1.27 (s, 
9H, t-butyl), 1.21 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 167.8, 167.0, 166.0, 137.6, 133.4, 133.3, 133.2, 133.1, 
133.0, 132.9, 132.8, 132.7, 132.2, 131.7, 131.6, 123.6, 119.4 (JC-F = 270.6 Hz), 118.7, 
61.5, 59.7, 47.9, 28.6, 19.5. 
 
19F NMR (376 MHz, CDCl3): δ – 63.51. 
 
HRMS: EIMS (M+) calcd for C25H27BrF3N3O4 569.1137 found 569.1139. 
 
IR (neat): 3402, 3270, 3068, 2963, 1716, 1681, 1367, 1244, 1159, 1064, 784, 751 
 
82. (E)-Ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(2-
nitrobenzyl)amino)-4-oxobut-2-enoate 
_( )-125
OHN
N
O
t-Bu
Ha
Hb
EtO2C
NO2
Hc
 
1H NMR (400 MHz, CDCl3): δ 8.13 (d,1H, J = 8.9 Hz, Hc), 7.51 (dd, 1H, J1 = 7.1 Hz, J2 
= 6.48 Hz, aryl), 7.41 (dd, 1H, J1 = 10.5, J2  = 7.3, aryl), 7.20 (d, 1H, J = 8.1 Hz, aryl), 
6.98 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.82 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.12 (br s, 1H, 
-NH), 5.30 (d, 1H, J = 18.7 Hz, Bn), 5.10 (d, 1H, J = 19.7 Hz, Bn), 4.55 (d, 1H, J = 10.5 
Hz, Ha), 4.13 (m, 2H, -OCH2CH3), 2.38 (m, 1H, CH(CH3)2, Hb), 1.20 (m, 12H, -
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OCH2CH3 and t-butyl overlap), 0.95 (d, 3H, J = 6.5 Hz, -CH(CH3)2), 0.90 (d, 3H,  J = 7.3 
Hz. -CH(CH3)2). 
 
13C NMR (100 MHz, CDCl3): δ 168.1, 166.7, 165.0, 133.8, 133.6, 133.2, 132.6, 128.2, 
128.0, 127.9, 125.6, 61.2, 51.5, 46.0, 28.5, 28.4, 27.9, 19.2, 18.6, 14.0. 
 
HRMS: EIMS (M+) calcd for C22H31N3O6  433.2213, found 433.2210. 
 
IR (neat): 3322, 3071, 2968, 2934, 1720, 1678, 1655, 11528, 1449, 1365, 1296, 1218, 
1178, 971, 731. 
 
83. Ethyl 2-(4-(1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)-3-oxo-2,3,4,5-
tetrahydro-1H-benzo[e][1,4]diazepin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): (major) δ 6.70 (t, 1H, J = 7.3 Hz, aryl), 6.65 (t, 1H, J = 7.3 
Hz, aryl), 6.53 (d, 1H, J = 7.2 Hz, aryl), 6.50 (d, 1H, J = 8.1 Hz, aryl), 5.64 (s, 1H, -NH), 
5.08 (d, 1H, J = 17.0 Hz, He), 5.00 (d, 1H, J = 7.3 Hz, Ha), 4.54 (d, 1H, J = 17.0 Hz, He),  
4.42 (dd, 1H, J1 = 11.4 Hz, J2 = 4.1 Hz, Hc), 4.16 (m, 2H, -OCH2CH3), 2.70 (dd, 1H, J1 = 
10.1 Hz, J2 = 5.7 Hz, Hd), 2.60 (dd, 1H, J1 = 11.0 Hz, J2 = 4.9 Hz, Hd), 2.20 (m, 1H, Hb), 
1.27 (t, 3H, J = 7.3 Hz, -OCH2CH3), 0.94 (s, 9H, t-butyl), 0.80 (d, 3H, J = 6.8 Hz,  -
CH(CH3)2), 0.50 (d, 3H, J = 6.8 Hz, -CH(CH3)2). 
 
1H NMR (400 MHz, CDCl3): (minor) δ 7.10 (t, 1H, J = 7.3 Hz, aryl), 7.00 (t, 2H, J = 7.3 
Hz, aryl),  6.90 (d, 1H, J = 8.1 Hz, aryl), 5.70 (s, 1H, -NH), 5.20 (d, 1H, J = 17.0 Hz, He),  
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5.10 (d, 1H, J = 17.0 Hz, He),  5.00 (d, 1H, J = 7.0 Hz, Ha), 4.42 (dd, 1H, J1 = 11.4 Hz, J2 
= 4.1 Hz, Hc), 4.16 (m, 2H, -OCH2CH3), 2.90 (dd, 2H, J1 = 15.8 Hz, J2 = 6.5 Hz, Hd), 
2.40 (m, 1H, Hb), 1.32 (s, 9H, t-butyl), 1.28 (t, 3H, J = 7.3 Hz, -OCH2CH3), 0.97 (d, 3H, 
J = 6.5 Hz, -CH(CH3)2), 0.90 (d, 3H, J = 6.5 Hz, -CH(CH3)2). 
 
13C NMR (100 MHz, CDCl3): (major and minor) δ 171.6, 171.3, 171.1, 170.5, 169.4, 
168.2, 144.9, 144.6, 131.2, 129.6, 128.8, 120.9, 119.8, 119.3, 119.1, 118.7, 117.3, 116.8, 
63.7, 62.8, 60.9, 60.8, 59.7, 52.3, 51.5, 51.4, 50.9, 46.6, 46.2, 36.17, 36.1, 29.6, 28.5, 
28.3, 28.0, 27.3, 25.9, 19.5, 18.6, 18.4, 14.2, 14.1. 
 
HRMS: EIMS (M+) calcd for C22H33N3O4 403.2471 found 403.2472. 
IR (neat): 3339, 3066, 2967, 2873, 1714, 1635, 1612, 1537, 1426, 1362, 1204, 1043, 752. 
 
84. (E)-ethyl-4((2-aminobenzyl)(1-(tert-butylamino)-3-methyl-1-oxobutan-2-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ  7.60 – 7.20 (M, 4H, aryl), 7.41 (dd, 1H, J1 = 10.5, J2  = 
7.3, aryl),  6.98 (d, 1H, J = 14.6 Hz, -CH=CH-), 6.83 (d, 1H, J = 14.6 Hz, -CH=CH-),  
5.25 (d, 1H, J = 18.7 Hz, Bn), 5.00 (d, 1H, J = 19.5 Hz, Bn), 4.40 (d, 1H, J = 10.6 Hz, 
Ha), 4.13 (m, 2H, -OCH2CH3), 3.20 (br s, 2H, -NH2),  2.42 (m, 1H, Hb), 1.20 (m, 12H, -
OCH2CH3 and t-butyl overlap), 0.95 (d, 3H, J = 6.5 Hz, -CH(CH3)2), 0.90 (d, 3H,  J = 7.3 
Hz, -CH(CH3)2). 
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13C NMR (100 MHz, CDCl3): δ 168.1, 166.8, 165.0, 131.8, 131.0, 130.9, 130.6, 130.3, 
129.5, 129.0, 128.6, 61.2, 61.1, 51.8, 46.0, 28.9, 28.2, 27.8, 19.2, 18.6, 14.2. 
 
HRMS: EIMS (M+) calcd for C22H33N3O4 403.2471 found 403.2480. 
 
IR (neat): 3452, 3400, 3021, 2814, 1690, 1600, 1537, 1290 1060. 
 
85. Ethyl 2-(4-(1-(benzylamino)-3-methyl-1-oxobutan-2-yl)-3-oxo-2,3,4,5-tetrahydro-
1H-benzo [e][1,4] diazepin-2yl)acetate 
 
1HNMR (400 MHz, CDCl3): (major and minor) δ 7.35 - 6.98 (m, 12H, aryl), 6.80 (bd, 
2H, J = 5.0 Hz, aryl), 6.70 (t, 2H, J = 7.3 Hz, aryl), 6.54 (dd, 2H, J1 = 8.1 Hz, J2 = 3.2 Hz, 
aryl), 6.28 (br t, 1H, J = 5.7 Hz, -NH), 6.00 (br s, 1H, -NH), 5.20 (d, 1H, J = 16.2 Hz, 
He), 5.10 – 4.95 (m, 3H, 2 x He , J = 16.2 Hz , J = 16.0 Hz and -NH overlap),  4.60 – 4.45 
(m, 3H, 2 x Hd and He overlap), 4.31 (dd, 1H, J1 = 14.6 Hz, J2 = 5.7 Hz, Bn), 4.23 (d, 1H, 
J = 16.2 Hz, Bn), 4.20 – 4.10 (m, 5H, Ha, -NH, -OCH2CH3 and Bn overlap), 4.01 (dd, 
1H, J1 = 14.6 Hz, J2 = 5.7 Hz, Bn), 3.98 (br d, 1H, J = 5.7 Hz, Ha), 2.96 – 2.90 (m, 2H, -
OCH2CH3), 2.63 (dd, 2H, J1 = 16.2 Hz, J2 = 6.5 Hz, Hd), 2.49 (m, 2H, Hd), 2.27 (m, 2H, 
2x Hb), 1.28 – 1.23 (m, 6H, -OCH2CH3), 0.99 (d, 3H, J = 6.5 Hz, -CH(CH3)2), 0.92 (d, 
3H, J = 6.5 Hz, -CH(CH3)2) , 0.87 (d, 3H, J = 6.5 Hz, -CH(CH3)2, 0.51 (d, 3H, J = 6.5 
Hz, -CH(CH3)2). 
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13C NMR (125 MHz, CDCl3): (major and minor) δ 172.2, 171.6, 171.4, 170.7, 170.1, 
169.4, 145.3, 145.0, 138.2, 137.9, 131.0, 130.0, 129.3, 129.1, 129.0, 128.9, 128.7, 128.6, 
128.5, 128.0, 127.8, 127.7, 127.4, 121.0, 120.1, 119.3, 119.1, 117.7, 117.3, 63.6, 61.2, 
61.2, 60.6, 52.6, 52.0, 47.2, 46.8, 43.4, 36.5, 36.4, 29.93, 27.4, 26.5, 21.3, 19.9, 19.8, 
18.9, 14.4, 14.3. 
 
HRMS: EIMS (M+) calcd for C25H31N3O4  437.2315 found 437.2328. 
 
IR (neat): 3331, 3030, 2965, 2933, 2873, 1715, 1644, 1494, 1452, 1365, 1221, 1174, 
1029, 969, 748, 700. 
 
86. (E)-Ethyl 4-((2-aminobenzyl)(1-(benzylamino)-3-methyl-1-oxobutan-2-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ  7.40 - 6.95 (m, 9H, aryl, and  -CH=CH-, J = 15.4 Hz,), 
6.80 (1H, J = 8.0 Hz, aryl),  6.70 (d, 1H, J = 15.4 Hz, -CH=CH-), 5.18 (d, 1H, J = 19.4 
Hz, Bn), 5.00 (d, 1H, J = 19.4 Hz, Bn), 4.72 (br d, 1H, J = 10.5 Hz, Ha), 4.33 (dd, 1H, J1 
= 14.6 Hz, J2 = 5.7 Hz, Bn), 4.12 (m, 3H, Bn and -OCH2CH3 overlap), 3.40 (br s, 2H, 
NH2), 2.44 (m, 1H, Hb), 1.23 (t, 3H, J = 7.3 Hz, -OCH2CH3), 0.95 (d, 3H, J = 6.5 Hz, -
CH2(CH3)2), 0.90 (d, 3H, J = 6.5 Hz, -CH2(CH3)2). 
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13C NMR (100 MHz, CDCl3): δ 169, 167.2, 165.3, 137.4, 133.3, 132.6, 131.6, 128.9, 
128.6, 128.5, 128.4, 128.1, 128.0, 127.8, 127.6, 127.3, 126.0, 64.8, 61.6, 46.2, 43.8, 27.8, 
19.1, 18.1, 14.1. 
 
HRMS: EIMS (M+) calcd for C25H31N3O4  437.2315 found 437.2321. 
 
IR (neat): 3552, 3395, 3000, 2965, 2933, 2873, 1781, 1644, 1367, 1360, 1215, 1166, 
1023, 900. 
 
87. (E)-Ethyl 4-((1-(benzylamino)-3-methyl-1-oxobutan-2-yl)(2-nitrobenzyl)amino)-
4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 8.10 (d, 1H, J = 8.1 Hz, Hc), 7.37 (t, 1H, J = 8.1 Hz, aryl), 
7.28 (m, 4H, aryl), 7.1 (br s, 1H, aryl), 7.00 (br s, 1H, aryl), 6.99 (br s, 1H, aryl), 6.95 (d, 
1H, J = 15.4 Hz, -CH=CH-), 6.70 (d, 1H, J = 15.4 Hz, -CH=CH-), 5.20 (d, 1H, J = 19.4 
Hz, Bn), 5.00 (d, 1H, J = 19.4 Hz, Bn), 4.60 (br d, 1H, J = 10.5 Hz, Ha), 4.30 (dd, 1H, J1 
= 14.6 Hz, J2 = 5.7 Hz, Bn), 4.14 (m, 3H, Bn and -OCH2CH3 overlap), 2.45 (m, 1H, Hb), 
1.22 (t, 3H, J = 7.3 Hz, -OCH2CH3), 0.97 (d, 3H, J = 6.5 Hz, -CH2(CH3)2), 0.91 (d, 3H, J 
= 6.5 Hz, -CH2(CH3)2). 
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13C NMR (100 MHz, CDCl3): δ 168.9, 167.1, 165.1, 147.5, 137.9, 133.9, 133.6, 133.4, 
133.3, 132.8, 128.9, 128.5, 128.1, 128.0, 127.9, 127.6, 125.9, 65.0, 61.6, 46.5, 43.5, 27.7, 
19.1, 18.9, 14.2. 
 
HRMS: EIMS (M+) calcd for C25H29N3O6 467.2056 found 467.2050. 
 
IR (neat): 3323, 3066, 3032, 2966, 2873, 1717, 1655, 1525, 1498, 1442, 1342, 1298, 
1174, 1164, 1031, 970, 727, 700. 
 
88. Ethyl 2-(4-benzyl-5-(tert-butylcarbamoyl)-3-oxo-2,3,4,5-tetrahydro-1H-
benzo[e][1,4]diazepin-2-yl) acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.39 – 7.23 (m, 5H, aryl), 7.11 (t, 1H, J = 7.3 Hz, aryl), 
6.82 (d, 1H, J = 7.3 Hz, aryl), 6.68 (t, 1H, J = 7.3 Hz, aryl), 6.64 (d, 1H, J = 8.1 Hz, aryl), 
5.52 (s, 1H, Ha), 4.85 (d, 1H, J = 15.4 Hz, Bn), 4.66 (d, 1H, J = 15.4 Hz, Bn), 4.45 – 4.41 
(m, 1H, Hb), 4.16 (m, 2H, -OCH2CH3), 3.04 (dd, 1H, J1 = 16.2 Hz, J2 = 6.5 Hz, Hc), 2.64 
(dd, 1H, J1 = 16.2 Hz, J2 = 6.5 Hz, Hc), 1.27 (t, 3H, J = 7.2 Hz, -OCH2CH3), 1.17 (s, 9H, 
t-butyl). 
 
13C NMR (125 MHz, CDCl3): δ 171.5, 170.37, 169.1, 144.2, 137.0, 132.7, 129.8, 129.3, 
129.2, 129.0, 128.9, 128.8, 128.2, 119.2, 118.7, 66.9, 61.1, 52.8, 52.6, 51.9, 36.1, 28.5, 
28.4, 28.2, 14.4. 
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HRMS: EIMS (M+) calcd for C25H31N3O4  437.2315  found 437.2323. 
 
IR (neat): 3318, 2928, 2856, 1714, 1682, 1515, 1451, 1240, 1096, 1047, 847, 750. 
 
89. (E)-Ethyl 4-(benzyl(2-tert-butylamino)-1-(2-nitrophenyl)-2-oxoethyl)amino)-4-
oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3):  δ 7.85 (d, 1H, J = 7.3 Hz, aryl), 7.57 – 7.49 (m, 2H, aryl), 
7.41 – 7.19  (m, 5H, aryl and -CH=CH- overlap), 7.02 (br d, 2H, J = 7.3 Hz, aryl),  6.92 
(d, 1H, J = 15.0 Hz -CH=CH-), 5.70 (s, 1H, Ha), 5.19 (s, 1H, -NH), 4.88 (d, 1H, J = 17.8 
Hz, Bn), 4.74 (d, 1H, J = 17.8 Hz, Bn), 4.19 (m, 2H, -OCH2CH3),  1.30 (m, 3H, -
OCH2CH3), 1.20 (s, 9H, t-butyl). 
 
13C NMR  (100 MHz, CDCl3): δ 166.9, 166.4, 165.5, 149.6, 136.5, 133.8, 133.4, 133.2, 
130.5, 129.9, 129.7, 129.4, 128.9, 128.7, 128.5, 127.8, 126.5, 125.4, 62.9, 61.4, 60.2, 
52.2, 50.6, 28.4, 14.3. 
 
HRMS: EIMS (M+) calcd for C25H29N3O6  467.2056 found 467.2048. 
 
IR (neat): 3325, 2969, 2930, 1720, 1678, 1644, 1620, 1525, 1453, 1418, 1363, 1348, 
1222, 1031, 976, 853, 790, 718. 
 
 164
90. 4-allyl-N-cyclohexyl-7,8-dimethoxy-3-oxo-2-(2-oxo-2-phenylethyl)-2,3,4,5-
tetrahydro-1H-benzo[e] [1,4 ] diazepine-5-carboxamide 
 
1H NMR (400 MHz, CDCl3): δ 7.96 – 7.92 (m, 2H, aryl), 7.51-7.41 (m, 4H, aryl), 6.61 (s, 
1H, aryl), 6.18 (s, 1H, Ha), 5.87 – 5.77 (m, 1H, Hf), 5.31 – 5.18 (m, 2H, Hg), 4.64 – 4.50 
(m, 2H, He), 4.20 (dd, 1H, J1 = 6.5 Hz, J2 = 7.3 Hz, Hb), 4.10 (br d, 1H, J = 4.8 Hz, -NH), 
3.90 (s, 3H, -OCH3), 3.70 (s, 3H, -OCH3), 3.66 – 3.58 (m, 2H, Hd and Hc overlap), 3.18 
(dd, 1H, J1 = 5.0 Hz, J2 = 16.4 Hz, Hc), 1.80 – 1.00 (m, 10H, Cy). 
 
13C NMR (100 MHz, CDCl3): δ 191.6, 166.8, 155.6, 146.6, 143.4, 133.2, 133.8, 132.0, 
129.2, 128.9, 128.8, 128.7, 127.6, 112.6, 112.7, 105.9, 104.0, 96.0, 65.9, 63.2, 56.7, 56.5, 
52.4, 49.2, 32.7, 32.6, 24.98, 24.9, 24.7. 
 
HRMS: EIMS (M+) calcd for C29H35N3O5 505.2577 found 505.2589. 
 
IR (neat): 3320, 2927, 2854, 1740, 1608, 1454, 1373, 1240, 1047, 969, 751. 
 
91. (E)-N-allyl-N-(2-(cyclohexylamino)-1-(4,5-dimethoxy-2-nitrophenyl)-2-oxoethyl)-
4-oxo-4-phenylbut-2-enamide 
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1H NMR (400 MHz, CDCl3): δ 8.00 – 7.90 (m, 3H, aryl), 7.60 – 7.57 (m, 2H, aryl), 7.51 
– 7.46 (m, 2H, aryl and CH=CH-), 7.36 (d, 1H, J = 15.0 Hz, -CH=CH-), 7.14 (s, 1H, Hg), 
6.55 (s, 1H, Ha), 5.91 (br d, 1H, J = 6.4 Hz, -NH), 5.66 – 5.59 (m, 1H, He), 5.12 (d, 1H, J 
= 17.0 Hz, Hf),  5.08 (d, 1H, J = 17.0 Hz, Hf), 4.15 (br s, 2H, Hd), 3.94 (s, 3H, -OCH3), 
3.91 (s, 3H, -OCH3), 3.70 (m, 1H, Hc), 1.91 – 1.10 (m, 10H, Cy). 
 
13C NMR (100 MHz, CDCl3): δ 189.4, 167.4, 166.4, 152.9, 148.8, 142.3, 136.7, 135.2, 
133.7, 133.4, 132.4, 128.8, 128.7, 124.3, 117.6, 112.1, 108.5, 58.9, 56.5, 56.4, 49.0, 48.9, 
32.5, 25.4, 24.7, 24.6. 
 
HRMS: EIMS (M+) calcd for C29H33N3O7 535.2319 found 535.2311. 
 
IR (neat): 3321, 3068, 2932, 2854, 1711, 1675, 1643, 1521, 1449, 1410, 1358, 1332, 
1275, 1217, 1063, 924. 
 
92. Ethyl 2-(4-(benzo[d][1,3]dioxol-5-ylmethyl)-5-(tert-butylcarbamoyl)-3-oxo-
2,3,4,5-tetrahydro-1H-benzo [e][1,4]diazepin-2-yl)acetate 
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1H NMR (400 MHz, CDCl3): δ 7.10 (m, 1H, aryl), 6.85 – 6.61 (m, 6H, aryl), 5.91 (s, 2H, 
He), 5.57 (s, 1H, Ha), 4.77 (d, 1H, J = 14.6 Hz, Hd), 4.52 (d, 1H, J = 14.6 Hz, Hd), 4.42 
(dd, 1H, J1 = 5.6 Hz, J2 = 6.5 Hz, Hb), 4.19 (m, 2H, -OCH2CH3), 3.02 (dd, 1H, J1 = 7.3 
Hz, J2 = 16.2 Hz, Hc), 2.62 (dd, 1H, J1 = 7.3 Hz, J2 = 16.2 Hz, Hc), 1.27 (t, 3H, J = 6.5 
Hz, -OCH2CH3), 1.20 (s, 9H, t-butyl). 
 
13C NMR (125 MHz, CDCl3): δ 171.4, 170.3, 169.1, 148.4, 147.6, 144.4, 132.7, 129.9, 
129.8, 126.6, 122.4, 119.1, 118.7, 109.2, 108.6, 101.3, 66.7, 61.1, 52.8, 52.2, 51.8, 36.1, 
28.5, 14.4. 
 
HRMS: EIMS (M+) calcd for C26H31N3O6 481.2213 found 481.2218. 
 
IR (neat):  3348, 2976, 2934, 1734, 1662, 1608, 1503, 1444, 1368, 1245, 1183, 1100, 
1039, 930, 808, 674. 
 
93. (E)-Ethyl 4-(benzo[d][1,3]dioxol-5-ylmethyl)(2-(tert-butylamino)-1-(2-
oxoethyl)amino-4-oxobut-2-enoate 
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1H NMR (400 MHz, CDCl3): δ 8.06 (d, 1H, J = 8.1 Hz, aryl), 7.63 – 7.24 (m, 3H, aryl 
and -CH=CH-), 7.02 – 6.85 (m, 2H, aryl and -CH=CH- overlap), 6.75 – 6.63 (m, 2H, 
aryl), 6.43 (s, 1H, aryl), 5.91 (s, 2H, Hb), 5.70 (s, 1H, Ha), 4.76 (d, 1H, J = 17.0 Hz, Bn), 
4.58 (d, 1H, J = 17.0 Hz, Bn), 4.21 (m, 2H, -OCH2CH3), 1.28 (t, 3H, J = 6.5 Hz, -
OCH2CH3), 1.22 (s, 9H, t-butyl). 
 
13C NMR (100 MHz, CDCl3): δ 166.9, 166.3, 165.5, 149.7, 148.3, 147.8, 147.3, 133.7, 
133.4, 133.3, 133.2, 130.3, 130.1, 129.5, 125.4, 122.4, 120.0, 108.6, 107.1, 101.4, 61.5, 
60.3, 52.3, 50.7, 28.5, 14.3. 
 
HRMS: EIMS (M+) calcd for C26H29N3O8 511.1955 found 511.1947. 
 
IR (neat):  3339, 3074, 2970, 1829, 1715, 1685, 1657, 1629, 1490, 1420, 1393, 1364, 
1296, 1243, 1223, 1173, 1095, 1037, 973, 926, 808, 657. 
 
94. 4-(4-acetylphenyl)-N-cyclopentyl-3-oxo-2-(2-oxo-2-p-tolylethyl)-2,3,4,5-
tetrahydro-1-H-benzo  [e][1,4 ] diazepine-5-carboxamide 
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1H NMR (400 MHz, CDCl3): δ 7.93 (d, 2H, J = 8.1 Hz, aryl), 7.86 (d, 2H, J = 8.9 Hz, 
aryl), 7.46 (d, 2H, J = 8.1 Hz, aryl), 7.25 (m, 2H, aryl), 7.19 (m, 1H, aryl), 7.02 (d, 1H, J 
= 7.3 Hz, aryl), 6.80 (t, 1H, J = 7.3 Hz, aryl), 6.70 (d, 1H, J = 8.0 Hz, aryl), 5.90 (d, 1H, J 
= 8.1 Hz, -NH), 5.06 (s, 1H, Ha), 4.76 (m, 1H, Hb), 4.19 (m, 1H, Hd), 3.76 (dd, 1H, J1 = 
17.0 Hz, J2 = 5.0 Hz, Hc), 3.20 (dd, 1H, J1 = 17.0 Hz, J2 = 7.0 Hz, Hc), 2.57 (s, 3H, -Mef), 
2.40 (s, 3H, -Mee), 1.96 – 1.87 (m, 2H, Cp), 1.60 – 1.49 (m, 4H, Cp), 1.36 – 1.24 (m, 2H, 
Cp). 
 
13C NMR (125 MHz, CDCl3): δ 197.9, 197.4, 170.1, 169.6, 148.5, 145.1, 144.7, 135.8, 
134.0, 132.0, 130.5, 129.8, 129.6, 128.6, 127.1, 119.6, 119.2, 119.0, 118.9, 118.8, 70.3, 
53.3, 52.4, 39.7, 33.1, 32.8, 26.8, 23.8, 21.9. 
 
HRMS: EIMS (M+) calcd for C32H33N3O4 523.2471 found 523.2466. 
 
IR (neat): 3348, 2957, 2870, 1735, 1679, 1601, 1508, 1494, 1426, 1406, 1224, 1203, 
1181, 824, 754. 
 
95. (E)-N-(4-acetylphenyl)-N-(2-(cyclopentylamino)-1-(2-nitrophenyl)-2-oxoethyl)-4-
oxo-4-p-tolylbut-2-enamide 
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1H NMR (500 MHz, CDCl3): δ 8.00 (d, 1H, J = 14.9 Hz, CH=CH-), 7.88 – 7.84 (m, 3H, 
aryl), 7.76 (d, 2H, J = 7.3 Hz, aryl), 7.39 – 7.33 (m, 5H, aryl), 7.24 (d, 2H, J = 7.0 Hz, 
aryl), 6.71 (d, 1H, J = 15.0 Hz, -CH=CH-), 6.67 (s, 1H, Ha), 5.94 (s, 1H, -NH), 4.24 (m, 
1H, Hb), 2.53 (s, 3H, -Mec), 2.40 (s, 3H, -Med), 2.03 – 1.91 (m, 2H, Cp), 1.68 – 1.53 (m, 
4H, Cp), 1.47 – 1.41 (m, 1H, Cp), 1.32 – 1.25 (m, 1H, Cp). 
 
13C NMR (125 MHz, CDCl3): δ 197.2, 188.9, 168.1, 164.9, 145.1, 142.7, 137.1, 135.4, 
135.3, 134.6, 134.5, 133.3, 133.2, 132.2, 132.1, 130.6, 130.2, 129.7, 129.4, 129.2, 129.1, 
129.0, 128.9, 128.5, 125.1, 60.7, 52.2, 33.0, 26.9, 24.0, 23.9, 22.0. 
 
HRMS: EIMS (M+) calcd for C32H31N3O6 553.2213 found 553.2218. 
 
IR (neat): 3309, 3067, 2916, 2869, 1712, 1684, 1647, 1599, 1526, 1443, 1407, 1350, 
1292, 1262, 1194, 1181, 1027, 1013, 969, 858, 789, 741, 704. 
 
96. 2-(N-(2-aminobenzyl)acrylamido)-N-tert-butyl-3-methylbutanamide 
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1H NMR (400 MHz, CDCl3): δ 7.20 (m, 1H, aryl), 7.10 (d, 1H, J = 7.5 Hz, aryl), 6.70 (m, 
1H, aryl), 6.65 (m, 3H, aryl and NH2 overlap), 5.80 (d, 1H, J = 19.0 Hz, Bn), 5.70 (m, 
1H, -CH=CH2), 5.60 (m, 1H, -CH=CH2), 5.50 (br s, 1H, -CH=CH2), 3.60 (d, 1H, J = 19.0 
Hz, Bn), 3.36 (d, 1H, J = 10.5 Hz, Ha),  2.55 – 2.60 (m, 1H, Hb), 1.10 (s, 9H, t-butyl), 
0.96 (m, 6H, 2x –CH(CH3)2). 
 
13C NMR (100 MHz, CDCl3): δ 169.6, 168.0, 131.2, 133.4, 130.6, 129.6, 128.2, 128.1, 
127.4, 119.4, 118.2, 60.6, 51.4, 44.8, 28.5, 23.8, 19.2. 
 
HRMS: EIMS (M+) calcd for C19H29N3O2 331.2260 found 331.2267. 
 
IR (neat): 3423.03, 3326.61, 2966.95, 2873.42, 1735.62, 1671.02, 1641.13, 1456.96, 
1221.68. 
 
97. N-tert-butyl-3-methyl-2-(N-(2-nitrobenzyl)acrylamido)butanamide 
 
1H NMR (400 MHz, CDCl3): δ 8.10 (d, 1H, J = 7.4 Hz, aryl ), 7.50 (t, 1H, J = 7.3 Hz, 
aryl), 7.40 (t, 1H, J = 7.3 Hz, aryl), 7.25 (m, 1H, aryl), 6.40 (d, 1H, J = 16.2 Hz, -
CH=CH2), 6.16 (m, 1H, -CH=CH2), 5.62 (d, 1H, J = 16.0 Hz, -CH=CH2), 5.24 (d, 1H, J 
= 19.5 Hz, Bn), 5.60 (d, 1H, J = 19.5 Hz, Bn), 4.60 (d, 1H, J = 10.5 Hz, Ha),  2.43 – 2.34 
(m, 1H, Hb), 1.22 (s, 9H, t-butyl), 0.96 (d, 3H, J = 6.5 Hz, -CH(CH3)2) , 0.91 (d, 3H, J = 
6.5 Hz, -CH(CH3)2). 
 171
13C NMR (100 MHz, CDCl3): δ 169.4, 169.0, 148.6, 133.4, 130.1, 128.2, 128.1, 127.9, 
127.1,  125.4, 59.6, 51.4, 45.8, 28.6, 28.4, 27.8, 19.3, 18.6. 
 
HRMS: EIMS (M+) calcd for C19H27N3O4 361.2002 found 361.2005. 
 
IR (neat): 3328, 3077, 2965, 2874, 1714, 1675, 1644, 1525, 1448, 1344, 1301, 1222, 
1194, 1060, 971, 861, 728,676. 
 
98. Ethyl 2-(1-benzyl-5-isopropyl-4-(2-nitrobenzyl)-3,6-dioxopiperazin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.93 (d, 1H, J = 7.9 Hz, aryl), 7. 69 – 7.59 (m, 2H, aryl), 
7.45 – 7.25 (m, 6H, aryl), 5.54 (d, 1H, J = 17.0 Hz, Bn), 5.28 (d, 1H, J = 15.2 Hz, Bn), 
4.62 (d, 1H, J = 17.0 Hz, Bn), 4.26 – 3.93 (m, 5H, Bn, Hb, Ha and –OCH2CH3 overlap), 
3.60 (dd, 1H, J1 = 3.0 Hz, J2 = 17.7 Hz, Hc), 2.94 (dd, 1H, , J1 = 5.0 Hz, J2 = 17.7 Hz, 
Hc), 2.34 (m, 1H, Hd), 1.19 (m, 6H, -OCH2CH3 and -CH(CH3)2 overlap), 0.98 (d, 3H, J = 
6.7 Hz, -CH(CH3)2). 
 
13C NMR (100 MHz, CDCl3): δ 169.9, 166.8, 165.9, 148.5, 136.0, 134.2, 134.1, 131.6, 
129.3, 129.1, 128.5, 128.2, 125.3, 125.2, 65.9, 61.2, 55.1, 47.1, 45.8, 34.6, 32.5, 20.2, 
17.6, 14.2. 
 
HRMS: EIMS (M+) calcd for C25H29N3O6  467.2056 found 467.2053. 
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IR (neat): 3309, 3065, 2965, 2934, 2876, 1733, 1660, 1526, 1446, 1294, 1222, 1192, 
1030, 727, 701. 
 
99. Ethyl 2-(4-(2-aminobenzyl)-1-benzyl-5-isopropyl-3,6-dioxopiperazin-2-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.30 -7.20 (m, 5H, aryl), 7.10 (t, 1H, J = 6.5 Hz, aryl), 
7.00 (d, 1H, J = 7.3 Hz, aryl), 6.70 (m, 2H, aryl), 5.38 (d, 1H, J = 14.6 Hz, Bn), 5.10 (d, 
1H, J = 15.4 Hz, Bn), 4.24 – 3.85 (m, 6H, Bn, Hb, Ha, and –OCH2CH3 overlap), 3.26 (dd, 
1H, J1= 17.0 Hz, J2 = 2.6 Hz, Hc), 2.90 (dd, 1H, J1= 17.0 Hz, J2 = 4.8 Hz, Hc), 2.37 – 
2.30 (m, 1H, Hd), 1.10 (m, 6H, –OCH2CH3 and -CH(CH3)2 overlap), 0.80 (d, 3H, J = 6.4 
Hz, -CH(CH3)2). 
 
13C NMR (100 MHz, CDCl3): δ 170.0, 166.4, 165.9, 146.5, 136.0, 132.0, 130.0, 129.0, 
128.3, 128.0, 117.8, 117.5, 116.1, 62.4, 61.2, 55.5, 47.1, 45.8, 35.4, 31.6, 20.1, 17.0, 14.1. 
 
HRMS: EIMS (M+) calcd for C25H31N3O4 437.2315 found 437.2312. 
 
IR (neat): 3447, 3367, 3251, 2965, 2935, 2876, 1732, 1652, 1584, 1496, 1445, 1374, 
1294, 1250, 1194, 1164, 1031, 919, 750, 736, 709. 
 
100. N-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-N-(2-nitrobenzyl)-3-
oxocyclohex-1-enecarboxamide 
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1H NMR (500 MHz, CDC3): δ 7.90-7.99 (m, 1 H, aryl), 7.49-7.58 (m, 1 H, aryl), 7.35-
7.42 (m, 1 H, aryl), 7.21-7.28 (m, 1 H, aryl), 6.25 (br s, 1 H, -NH), 5.78 (d, 1 H, J = 18.6 
Hz, -CH2Ar), 5.74 (s, 1 H, Hb), 5.0 (d, 1 H, J = 18.3 Hz, -CH2Ar), 4.92 (br s, 1 H, Ha), 
2.34-2.49 (m, 1 H, 3-oxocyclohex-1-ene), 2.20-2.30 (m, 2 H, 3-oxocyclohex-1-ene), 
1.81-1.90 (m, 1 H, 3-oxocyclohex-1-ene), 1.61-1.80 (m, 2 H, 3-oxocyclohex-1-ene), 1.20 
(s, 9 H, t-Bu), 1.11 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 197.9, 172.4, 167.5, 155.0, 147.9, 133.1, 128.1, 127.9, 
126.2, 125.0, 51.7, 37.6, 36.9, 28.3, 27.5, 26.6, 22.3. 
 
HRMS (EIMS, M+ + Na): calcd for C24H33N3O5Na 466.2318, found 466.2318. 
 
101. N-(tert-butyl)-2-(3,3'-dioxospiro[benzo[e][1,4]diazepine-2,1'-cyclohexan]-
4(1H,3H,5H)-yl)-3,3-dimethylbutanamide 
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1H NMR (500 MHz, CDC3): δ 7.28 (d, 1 H, J = 7.3 Hz, aryl), 7.15-7.20 (m, 1 H, aryl), 
6.93 (t, 1 H, J = 7.6 Hz, aryl), 6.83 (d, 1 H, J = 7.6 Hz, aryl), 5.52 (br s, 1 H, -NH), 4.92 
(d, 1 H, J = 13.7 Hz, -CH2Ar), 4.79 (s, 1 H, Ha), 4.78 (d, 1 H, J = 13.7 Hz, -CH2Ar), 3.10 
(d, 1 H, J = 14.3 Hz, Hb), 2.37-2.53 (m, 2 H, cyclohexanone), 2.22-2.32 (m, 1 H, 
cyclohexanone), 2.17 (d, 1 H, J = 14.3 Hz, Hb), 1.90-2.02 (m, 3 H, cyclohexanone), 1.24 
(s, 9 H, t-Bu), 1.11 (s, 9 H, t-Bu). 
 
HRMS (EIMS, M+ + H): calcd for 414.2757, found 414.2747. 
 
102. N-(tert-butyl)-2-(7,11-dioxo-7,7a,8,9,10,11,11a,12-
octahydrodibenzo[b,g][1,5]diazocin-6(5H)-yl)-3,3-dimethylbutanamide 
 
1H NMR (500 MHz, CDC3): δ 7.27-7.37 (m, 3 H, aryl), 7.07-7.16 (m 1 H, aryl), 5.38 (br 
s, 1 H, -NH), 5.10 (d, 1 H, J = 14.7 Hz, -CH2Ar), 4.50 (s, 1 H, Ha), 4.01 (d, 1 H, J = 14.4 
Hz, -CH2Ar), 2.90-2.99 (m, 1 H, Hb), 2.80-2.89 (m, 1 H, Hc), 2.61 (t, 2 H, J = 7.3 Hz), 
2.05 (sx, 2 H, J = 7.3 Hz, cyclohexanone), 1.21-1.34 (m, 2 H, cyclohexanone), 1.15 9s, 9 
H, t-Bu), 1.11 (s, 9 H, t-Bu). 
 
13C NMR (100 MHz, CDCl3): δ 208.3, 167.4, 166.6, 164.0, 146.8, 129.1, 128.9, 128.7, 
126.2, 125.6, 62.3, 51.6, 45.5, 43.0, 37.3, 36.6, 29.9, 28.5, 27.2, 20.5. 
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HRMS (EIMS, M+ + H): calcd for C24H35N3O3 414.2757, found 414.2744. 
 
103. (E)-ethyl 4-((1-(butylcarbamoyl)cyclopentyl)(4-methoxybenzyl)amino)-4-
oxobut-2-enoate 
 
1H NMR (500 MHz, CDC3): δ 7.17 (d, 1 H, J = 15.0 Hz, -CH=CH-), 7.14 (br d, 2 H, 
aryl), 6.88 (d, 2 H, J = 8.5 Hz, aryl), 6.81 (d, 1 H, J = 15.0 Hz, -CH=CH-), 4.66 (br s, 1 
H, -NH), 4.17 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.78 (s, 3 H, OMe), 3.09-3.27 (m, 2 H, n-
Bu), 2.50-2.69 (m, 2 H, cyclopentyl), 1.78-1.94 (m, 2 H, cyclopentyl), 1.56-1.68 (m, 4 H, 
n-Bu and cyclopentyl overlap), 1.35-1.48 (m, 2 H, n-Bu), 1.25-1.33 (m, 2 H, n-Bu), 1.23 
(t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.88 (t, 3 H, J = 7.3 Hz, -NHCH2CH2CH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 173.1, 167.4, 165.3, 158.9, 135.3, 132.3, 129.9, 127.0, 
114.4, 73.8, 61.0, 55.2, 50.3, 39.4, 35.8, 31.4, 23.1, 19.9, 14.0, 13.7. 
 
HRMS (EIMS): calcd for C24H34N2O5 430.2468, found 430.2474. 
 
104. Ethyl 2-(9-butyl-6-(4-methoxybenzyl)-7,10-dioxo-6,9-diazaspiro[4.5]decan-8-
yl)acetate 
N
N
O
OEtO2C
( )-146
Ha
Hb
Hb
OMe
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1H NMR (500 MHz, CDC3): δ 7.15 (d, 2 H, J = 8.6 Hz, aryl), 6.83 (d, 2 H, J = 8.6 Hz, 
aryl), 4.80 (d, 1 H, J = 15.0 Hz, -CH2Ar), 4.45 (t, 1 H, J = 5.5 Hz, Ha, dd overlap), 4.30 
(d, 1 H, J = 15.0 Hz, -CH2Ar), 4.10-4.21 (m, 2 H, -OCH2CH3), 3.74-3.82 (m, 4 H, OMe 
and n-Bu overlap), 3.02 (dd, 1 H, J = 16.5, 4.6 Hz, Hb), 2.96-3.04 (m, 1 H, n-Bu), 2.89 
(dd, 1 H, J = 16.5, 5.5 Hz, Hb), 2.26-2.40 (m, 2 H, cyclopentyl), 1.71-2.02 (m, 7 H, n-Bu 
and cyclopentyl overlap), 1.59-1.69 (m, 2 H, n-Bu), 1.44-1.55 (m, 1 H, n-Bu), 1.33 (sx, 
3H, n-Bu), 1.26 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.94 (t, 3 H, J = 7.3 Hz, -
NHCH2CH2CH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 171.2, 169.8, 166.4, 158.6, 130.1, 127.7, 113.9, 70.7, 
61.2, 56.3, 55.3, 46.5, 44.6, 39.9, 37.7, 37.6, 29.0, 27.2, 27.0, 20.1, 14.2, 13.8. 
 
HRMS (EIMS): calcd for C24H34N2O5 430.2468, found 430.2473. 
 
105. (E)-ethyl 4-((1-(butylcarbamoyl)cyclohexyl)(4-methoxybenzyl)amino)-4-oxobut-
2-enoate 
 
 
1H NMR (500 MHz, CDC3): δ 7.23 (d, 1 H, J = 15.2 Hz, -CH=CH-), 7.16 (d, 2 H, J = 8.2 
Hz, aryl), 6.86 (d, 2 H, J = 8.2 Hz, aryl), 6.75 (d, 1 H, J = 15.0 Hz, -CH=CH-), 6.50 (br s, 
1 H, -NH), 4.63 (s, 2 H, -CH2Ar), 4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.77 (s, 3 H, 
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OMe), 3.18 (q, 2 H, J = 6.7 Hz, n-Bu), 2.40 (d, 2 H, J = 13.4 Hz), 1.66-1.77 (m, 2 H), 
1.37-1.48 (m, 2 H), 1.18-1.33 (m, 9 H), 0.79-0.95 (m, 5 H). 
 
13C NMR (100 MHz, CDCl3): δ 172.6, 171.0, 167.4, 165.4, 158.9, 136.3, 131.8, 129.9, 
127.5, 114.3, 66.6, 60.9, 60.3, 55.2, 47.9, 39.3, 32.8, 31.5, 31.3, 25.2, 22.8, 22.6, 20.1, 
14.1, 14.0, 13.7. 
 
HRMS (EIMS): calcd for C25H36N2O5 444.2624, found 444.2629. 
 
106. Ethyl 2-(4-butyl-1-(4-methoxybenzyl)-2,5-dioxo-1,4-diazaspiro[5.5]undecan-3-
yl)acetate 
N
N
O
OEtO2C
( )-148
Ha
Hb
Hb
OMe
 
1H NMR (500 MHz, CDC3): δ 7.15 (d, 2 H, J = 8.6 Hz, aryl), 6.82 (d, 2 H, J = 8.6 Hz, 
aryl), 4.80 (d, 1 H, J = 15.6 Hz, -CH2Ar), 4.48-4.60 (m, 2 H, -CH2Ar and Ha overlap), 
4.19 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.77 (s, 3 H, OMe), 3.70-3.77 (m, 1 H), 2.97-3.05 
(m, 2 H), 2.94 (dd, 1 H, J = 10.7, 5.8 Hz, Hb), 2.10-2.24 (m, 1 H), 1.42-1.94 (m, 11 H), 
1.30-1.37 (m, 2 H), 1.27 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.02-1.14 (m, 1 H), 0.94 (t, 3 H, 
J = 7.3 Hz, -NHCH2CH2CH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 170.2, 168.9, 167.8, 158.5, 130.3, 127.8, 113.9, 62.6, 
61.2, 56.1, 55.2, 45.2, 44.5, 38.3, 34.9, 33.6, 29.1, 24.4, 22.9, 22.5, 20.1, 14.1, 13.8. 
 
HRMS (EIMS): calcd for C25H36N2O5 444.2624, found 444.2627. 
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107. (E)-ethyl 4-((4-(benzylcarbamoyl)tetrahydro-2H-thiopyran-4-yl)(3,4-
dimethoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDC3): δ 7.23-7.34 (m, 6 H, aryl and –CH=CH- overlap), 6.84 (d, 1 
H, J = 15.3 Hz, -CH=CH-), 6.67-6.76 (m 3 H, aryl), 6.21 (t, 1 H, J = 5.2 Hz, -NH), 4.66 
(s, 2 H, -CH2Ar), 4.42 (d, 2 H, J = 5.5 Hz, -CH2Ar), 4.24 (q, 2 H, J = 7.3 Hz, -
OCH2CH3), 3.85 (s, 3 H, OMe), 3.71 (s, 3 H, OMe), 3.12 (m, 1 H, thiopyran), 2.58-2.67 
(m, 2 H, thiopyran), 2.0-2.10 (m, 2 H, thiopyran), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 172.0, 166.8, 165.3, 149.6, 148.7, 138.1, 135.1, 133.1, 
129.9, 128.8, 127.9, 127.6, 118.2, 111.6, 109.1, 65.6, 61.3, 55.9, 55.8, 47.7, 44.0, 34.2, 
24.9, 14.1. 
 
HRMS (EIMS): calcd for C28H34N2O6S 526.2138, found 526.2142. 
 
108. Ethyl 2-(4-benzyl-1-(3,4-dimethoxybenzyl)-2,5-dioxo-9-thia-1,4-
diazaspiro[5.5]undecan-3-yl)acetate 
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1H NMR (500 MHz, CDC3): δ 7.29-7.37 (m, 3 H, Bn), 7.21-7.25 (m, 1 H, Bn), 6.76-6.85 
(m, 3 H, aryl), 5.19 (d, 1 H, J = 15.0 Hz, -CH2Ph), 4.74 (s, 2 H, -CH2Ar), 4.28 (t, 1 H, J = 
4.4 Hz, Ha, dd overlap), 4.16 (d, 1 H, J = 15.0 Hz, -CH2Ph), 4.07 (q, 2 H, J = 7.3 Hz, -
OCH2CH3), 3.84 (s, 3 H, OMe), 3.83 (s, 3 H, OMe), 3.49-3.64 (m, 2 H, thiopyran), 3.09 
(dd, 1 H, J = 17.1, 3.7 Hz, Hb), 2.89 (dd, 1 H, J = 17.1, 5.5 Hz, Hb), 2.39-2.56 (m, 3 H, 
thiopyran), 2.01-2.27 (m, 3 H, thiopyran), 1.21 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 169.7, 168.9, 166.7, 149.1, 147.9, 135.8, 130.5, 128.9, 
127.9, 127.8, 118.3, 111.1, 109.8, 61.7, 61.1, 55.9, 55.8, 55.1, 47.2, 45.8, 36.4, 35.3, 34.6, 
25.3, 14.1. 
 
HRMS (EIMS): calcd for C28H34N2O6S 526.2138, found 526.2136. 
 
109. (E)-ethyl 4-((benzo[d][1,3]dioxol-5-ylmethyl)(4-(benzylcarbamoyl)tetrahydro-
2H-pyran-4-yl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDC3): δ 7.22-7.34 (m 5 H, Bn), 7.15 (d, 1 H, J = 15.3 Hz, -
CH=CH-), 6.77 (d, 1 H, J = 15.3 Hz, -CH=CH-), 6.75 (m 1 H, aryl), 6.61-6.68 (m, 2 H, 
aryl), 5.97 (s, 2 H, -OCH2O-), 4.56 (s, 2 H, -CH2Bn), 4.45 (d, 2 H, J = 5.8 Hz, -CH2Ar), 
4.21 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.76-3.84 (m, 2 H, pyran), 3.55-3.67 (m, 2 H, 
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pyran), 2.68 (d, 2 H, J = 13.1 Hz, pyran), 1.9 (m, 2 H, pyran), 1.27 (t, 3 H, J = 7.3 Hz, -
OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 170.8, 167.8, 165.3, 148.5, 147.3, 138.2, 135.6, 132.9, 
131.3, 128.7, 127.7, 127.5, 119.0, 108.8, 106.3, 101.3, 64.8, 64.4, 61.2, 48.4, 43.8, 33.6, 
14.1. 
 
HRMS (EIMS): calcd for C27H30N2O7 494.2053, found 494.2059. 
 
110. Ethyl 2-(1-(benzo[d][1,3]dioxol-5-ylmethyl)-4-benzyl-2,5-dioxo-9-oxa-1,4-
diazaspiro[5.5]undecan-3-yl)acetate 
 
1H NMR (500 MHz, CDC3): δ 7.29-7.37 (m, 3 H, Bn), 7.21-7.25 (m, 2 H, Bn), 6.71-6.74 
(m, 2 H, aryl), 6.65-6.69 (m, 1 H, aryl), 5.92 (s, 2 H, -OCH2O-), 5.12 (d, 1 H, J = 15.3 
Hz, -CH2Ph), 4.78 (d, 1 H, J = 15.3 Hz, -CH2Ar), 4.58 (d, 1 H, J = 15.3 Hz, -CH2Ar), 
4.36 (t, 1 H, J = 4.9 Hz, Ha, dd overlap), 4.28 (d, 1 H, J = 15.3 Hz, -CH2Ph), 4.20-4.28 
(m, 1 H), 4.08-4.15 (m, 3 H, -OCH2CH3 and pyran overlap), 3.85-3.97 (m, 2 H, pyran), 
3.02 (dd, 1 H, J = 16.8, 3.9 Hz, Hb), 2.89 (dd, 1 H, J = 16.8, 5.2 Hz, Hb), 2.0-2.25 (m, 3 
H, pyran), 1.76 (d, 1 H, J = 14.0 Hz, pyran), 1.21 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
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13C NMR (100 MHz, CDCl3): δ 169.8, 169.4, 166.9, 147.9, 146.5, 135.8, 131.7, 128.9, 
127.9, 127.7, 119.4, 108.3, 107.1, 101.0, 64.9, 64.5, 61.2, 60.1, 55.5, 47.5, 45.6, 36.6, 
33.8, 33.6, 14.1. 
 
HRMS (EIMS): calcd for C27H30N2O7 494.2053, found 494.2049. 
 
111. (E)-ethyl 4-(benzyl(1-(benzylcarbamoyl)cyclobutyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDC3): δ 7.78 (b t, 1 H, J = 5.2 Hz, -NH), 7.16-7.40 (m, 10 H, Ph), 
7.09 ( d, 1 H, J = 15.3 Hz, -CH=CH-), 6.79 (d, 1 H, J = 15.3 Hz, -CH=CH-), 4.56 (s, 2 H, 
-CH2Ph), 4.40 (d, 2 H, -CH2Ph), 4.17 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 2.70-2.84 (m, 2 H, 
Ha), 2.27-2.40 (m, 2 H, Ha),  1.67-.184 (m, 2 H, Hb), 1.24 (t, 3 H, J = 7.3 Hz, -OCH2CH3) 
13C NMR (100 MHz, CDCl3): δ 172.4, 166.1, 165.1, 138.3, 137.1, 133.9, 132.6, 128.9, 
128.5, 127.6, 127.2, 127.1, 125.8, 66.0, 61.0, 49.2, 43.4, 31.2, 14.6, 13.9. 
HRMS (EIMS): calcd for C25H28N2O4 420.2049, found 420.2043 
 
112. Ethyl 2-(5,8-dibenzyl-6,9-dioxo-5,8-diazaspiro[3.5]nonan-7-yl)acetate 
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1H NMR (500 MHz, CDC3): δ 7.21-7.37 (m, 8 H, Ph), 7.16-7.21 (m, 2 H, Ph), 5.17 (d, 1 
H, J = 15.3 Hz, -CH2Ph), 5.10 (d, 1 H, J = 15.9 Hz, -CH2Ph), 4.70 (d, 1 H, J = 15.9 Hz, -
CH2Ph), 4.38 (t from dd overlap, 1 H, J = 5.5 Hz, Hc), 4.29 (d, 1 H, J = 15.3 Hz, -
CH2Ph), 4.10 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 2.85 (dd, 1 H, J = 16.2, 5.5 Hz, Hd), 2.80-
2.84 (m, 1 H, cyclobutane), 2.78 (dd, 1 H, J = 16.2, 5.5 Hz, Hd), 2.46-2.69 (m, 3 H, 
cyclobutane), 2.07-2.19 (m, 1 H, cyclobutane), 1.78-1.89 (m, 1 H, cyclobutane), 1.23 (t, 3 
H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 169.7, 169.6, 166.5, 137.8, 136.1, 128.9, 128.7, 127.9, 
127.2, 126.4, 63.1, 61.2, 56.2, 53.4, 48.0, 46.4, 37.1, 34.4, 31.2, 14.5, 14.1. 
 
HRMS (EIMS): calcd for C25H28N2O4 420.2049, found 420.2051 
 
113. (E)-1-(N-(4-bromophenyl)-4-oxo-4-(p-tolyl)but-2-enamido)-N-butyl-3-
methylcyclopentanecarboxamide 
 
1H NMR (500 MHz, CDC3): δ 7.80 (d, 4 H, J = 8.2 Hz, Ar), 7.73 (d, 1 H, J = 15.3 Hz, -
CH=CH-)7.70 (d, 4 H, J = 8.5 Hz, Ar), 6.64 (d, 1 H, J = 15.3 Hz, -CH=CH-), 6.18 (br t, J 
= 5.5 Hz, -NH), 3.29-3.39 (m, 2 H, n-Bu), 2.39 (s, 3 H, Ar-CH3), 1.34-1.73 (m, 9 H, n-Bu 
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and cyclopentyl overlap), 1.10-1.23 (m, 2 H, n-Bu), 0.94 (t, 3 H, J = 7.3 Hz, -
NHCH2CH2CH2CH3), 0.85 (d, 3 H, J = 6.4 Hz, -CH3). 
 
13C NMR (100 MHz, CDCl3): δ 189.1, 175.0, 166.0, 144.6, 138.4, 134.2, 133.9, 132.9, 
132.6, 132.3, 129.4, 128.9, 122.9, 67.7, 42.3, 39.7, 34.1, 33.9, 31.5, 29.4, 21.6, 20.1, 13.8. 
 
HRMS (EIMS): calcd for C28H33BrN2O3 524.1675, found 524.1671. 
 
114. (E)-ethyl 4-((4-(butylcarbamoyl)-1-phenethylpiperidin-4-yl)(prop-2-yn-1-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.41 (d, 1 H, J = 15.3 Hz, -CH=CH-), 7.24-7.32 (m, 3 H, 
Ph), 7.16-7.23 (m, 2 H, Ph), 6.78 (d, 1 H, J = 15.3 Hz, -CH=CH-), 6.54 (br t, 1 H, J = 5.5 
Hz, -NH), 4.27 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 4.17 (br s, 2 H, Ha), 3.23 (dd, 2 H, J = 
16.8, 7.0 Hz, -NHCH2CH2CH2CH3), 2.76-2.88 (m, 5 H), 2.53-2.68 (m, 7 H), 2.46 (t, 1 H, 
J = 1.5 Hz, Hb), 2.21-2.32 (m, 2 H), 1.41-1.48 (m, 2 H, n-Bu), 1.32 (t, 3 H, J = 7.3 Hz, -
OCH2CH3), 1.25-1.35 (m, 3 H), 0.89 (t, 3 H, J = 7.3 Hz, -NHCH2CH2CH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 171.7, 167.1, 165.3, 135.1, 132.5, 128.7, 128.4, 126.2, 
79.6, 74.3, 64.6, 61.3, 59.9, 53.4, 52.3, 50.1, 39.4, 35.1, 33.5, 32.4, 31.4, 20.1, 14.1, 13.7. 
 
HRMS (EIMS): calcd for C27H37N3O4 467.2784, found 467.2779. 
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115. 2-(4-(2-ethoxy-2-oxoethyl)-6-hydroxy-7-methoxy-3-oxo-3,4-dihydroisoquinolin-
2(1H)-yl)-3,3-dimethylbutanoic acid 
 
1H NMR (500 MHz, CDCl3): (Major diastereomer) δ 6.77 (s, 1 H, He), 6.69 (s, 1 H, Hf), 
5.66 (br s, 1 H, -OH), 5.10 (s, 1 H, Ha), 4.64 (d, 1 H, J = 14.9 Hz, Hd), 4.44 (d, 1 H, J = 
15.3 Hz, Hd), 4.17 (m, 2 H, -OCH2CH3), 3.95 (dd, 1 H, J = 13.4, 6.7 Hz, Hb), 3.87 (s, 3 
H, OMe), 3.09 (dd, 1 H, J1 = 16.0 Hz, J2 = 6.4 Hz, Hc), 2.88 (dd, 1 H, J1 = 16.0 Hz, J2 = 
3.1 Hz, Hc), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.07 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): (Major diastereomer) δ 173.1, 172.3, 171.8, 146.2, 144.5, 
126.5, 126.1, 111.7, 108.0, 60.9, 56.1, 43.4, 43.1, 35.8, 34.2, 27.9, 14.2. 
 
HRMS (EIMS, M+-H): calcd for C20H27NO7 393.1788, found 392.1799. 
1H NMR (500 MHz, CDCl3): (Minor diastereomer) δ 6.77 (s, 1 H, He), 6.72 (s, 1 H, Hf), 
5.66 (br s, 1 H, -OH), 5.10 (s, 1 H, Ha), 4.54 (dd, 2 H, J = 28.9, 15.3 Hz, Hd), 4.17 (m, 2 
H, -OCH2CH3), 3.95 (dd, 1 H, J = 13.4, 6.7 Hz, Hb), 3.87 (s, 3 H, OMe), 3.04 (dd, 1 H, J1 
= 15.9 Hz, J2 = 6.4 Hz, Hc), 2.85 (dd, 1 H, J1 = 7.6 Hz, J2 = 3.1 Hz, Hc), 1.25 (t, 3 H, J = 
7.3 Hz, -OCH2CH3), 1.12 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): (Minor diastereomer) δ 173.2, 173.2, 171.9, 146.2, 144.5, 
126.6, 126.1, 111.8, 108.2, 60.9, 56.1, 43.4, 43.1, 35.7, 34.5, 27.9, 14.2. 
 
HRMS (EIMS, M+-H): calcd for C20H27NO7 393.1788, found 392.1799. 
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116. Ethyl 2-(2-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-7-methoxy-3,8-
dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 6.91 (dd, 1 H, J1 = 10.1 Hz, J2 = 2.7 Hz, Hg), 6.38 (d, 1 H, 
J = 10.1 Hz, Hf), 5.57 (d, 1 H, J = 2.7 Hz, He), 5.52 (br s, 1 H, -NH), 4.32 (d, 1 H, J = 
10.1 Hz, Hd), 4.28 (s, 1 H, Ha), 4.04-4.13 (m, 2 H, -OCH2CH3), 3.77 (d, 1 H, J = 9.8 Hz, 
Hd), 3.66 (s, 3 H, OMe), 3.39 (dd, 1 H, J1 = 7.6 Hz, J2 = 6.1 Hz, Hb), 2.65 (dd, 1 H, J1 = 
16.6 Hz, J2 = 6.1 Hz, Hc), 2.08 (dd, 1 H, J1 = 16.8 Hz, J2 = 7.3 Hz, Hc). 1.39 (s, 9 H, t-
Bu), 1.21 (s, 3 H, J = 7.3 Hz, -OCH2CH3), 1.06 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 180.4, 173.3, 171.5, 168.4, 152.5, 149.9, 130.8, 112.6, 
63.2, 61.1, 55.0, 54.7, 53.6, 48.7, 47.8, 30.3, 28.5, 27.8, 13.9. 
 
HRMS (EIMS, M+): calcd for C24H36N2O6 448.2573, found 448.2584. 
 
117. Ethyl 2-(2-(1-(tert-butylamino)-3,3-dimethyl-1-oxobutan-2-yl)-7-methoxy-3,8-
dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
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1H NMR (500 MHz, CDCl3): (Minor Diastereomer) δ 6.89 (dd, 1 H, J1 = 10.1 Hz, J2 = 
2.8 Hz, Hg), 6.45 (d, 1 H, J = 10.1 Hz, Hf), 5.55 (d, 1 H, J = 2.5 Hz, He), 5.52 (br s, 1 H, -
NH), 4.32 (d, 1  H, J = 10.1 Hz, Hd), 4.28 (s, 1 H, Ha), 4.04-4.13 (m, 3 H, -OCH2CH3 and 
Hd overlap), 3.67 (s, 3 H, OMe),3.61 (d, 1 H, J = 9.8 Hz, Hd), 3.31 (dd, 1 H, J1 = 7.3 Hz, 
J2 = 6.4 Hz, Hb), 2.64 (dd, 1 H, J1 = 16.5 Hz, J2 = 6.1 Hz, Hc), 2.08 (dd, 1 H, J1 = 16.5 
Hz, J2 = 7.6 Hz, Hc). 1.40 (s, 9 H, t-Bu), 1.21 (s, 3 H, J = 7.3 Hz, -OCH2CH3), 1.05 (s, 9 
H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): (Minor Diastereomer) δ 180.3, 173.9, 171.6, 167.1, 
152.7, 146.4, 130.6, 116.5, 64.2, 61.2, 55.1, 54.8, 48.3, 47.3, 36.2, 30.4, 28.6, 27.6. 
 
HRMS (EIMS, M+): calcd for C24H36N2O6 448.2573, found 448.2586. 
 
118. N-(tert-butyl)-2-(7-methoxy-3,8-dioxo-4-(2-oxo-2-(p-tolyl)ethyl)-2-
azaspiro[4.5]deca-6,9-dien-2-yl)-3,3-dimethylbutanamide 
 
1H NMR (400 MHz, CDCl3): δ 7.75 (dd, 2H, J = 6.0, 8.2 Hz, aryl), 7.22 (d, 2H, J = 7.6 
Hz, aryl), 6.98 (m, 1H, vinyl), 6.34 (m, 1H, vinyl), 5.82 (m, 1H, vinyl), 5.55 (d, 1H, J = 
8.8 Hz, NH), 4.32 (s, 1H, Ha), 3.79 (m, 2H, Hd), 3.70 (m, 1H, Hb) 3.69 (s, 3H,-OMe), 
3.36 (m, 1H, Hc), 2.70 (m, 1H, Hc), 2.39 (s, 3H, -Me), 1.35 (s, 9H, t-butyl), 1.09 (s, 9H, t-
butyl). 
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13C NMR (100 MHz, CDCl3): δ 196.4, 180.4, 174.7, 168.5, 152.6, 150.4, 146.8, 144.2, 
133.8, 130.5, 129.2, 128.0, 117.1, 116.6, 113.0, 63.9, 55.2, 53.7, 51.6, 49.0, 48.0, 46.8, 
43.9, 36.2, 34.9, 28.4, 27.8, 21.5. 
 
HRMS: EIMS (M+) calculated for C29H38N2O5Na 517.2678, found 517.2677. 
 
119. N-(tert-butyl)-2-(7-methoxy-3,8-dioxo-4-(2-oxo-2-phenylethyl)-2-
azaspiro[4.5]deca-6,9-dien-2-yl)-3,3-dimethylbutanamide 
 
1H NMR (400 MHz, CDCl3): δ 7.86 (d, 2H, J = 7.2 Hz, aryl), 7.55 (t, 1H, J = 8.0 Hz, 
aryl), 7.43 (t, 2H, J = 8.0 Hz, aryl), 6.99 (m, 1H, vinyl), 6.36 (m, 1H, vinyl), 5.83 (m, 1H, 
vinyl), 5.56 (d, 1H, J = 9.6 Hz, NH), 4.23 (s, 1H, Hd), 3.80 (m, 2H, Hc), 3.71 (m, 1H, Hb) 
3.70 (s, 3H, -0Me), 3.39 (m, 1H, Ha), 2.70 (m, 1H, Ha), 1.35 (s, 9H, t-butyl), 1.09 (s, 9H, 
t-butyl). 
 
13C NMR (100 MHz, CDCl3): δ 196.8, 180.3, 174.4, 168.4, 152.6, 150.3, 146.7, 136.1, 
133.3, 130.5, 128.5, 117.0, 113.0, 63.8, 55.2, 53.6, 51.5, 49.0, 46.7, 36.2, 34.9, 33.8, 28.4, 
27.7. 
 
HRMS: EIMS (M+) calculated for C28H37N2O5 481.2702, found 481.2699 
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120. (E)-Ethyl 4-((2-(tert-butylamino)-1-(4-fluorophenyl)-2-oxoethyl)(4-hydroxy-3,5-
dimethoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (300 MHz, CDCl3): δ 7.49 (dd, 2H, J = 3.1, 5.5 Hz, aryl), 7.38 (d, 1H, J = 15.9 
Hz, vinyl), 7.09 (t, 2H, J = 8.6 Hz, aryl), 6.92 (d, 1H, J = 15.3, vinyl), 6.27 (s, 2H, aryl), 
6.06 (s, 1H, NH), 5.85 (s, 1H, Ha), 5.72 (bs, 1H, -OH), 4.77 (dd, 2H, J = 17.7, 28.2, 
benzyl), 4.29 (q, 2H, J = 7.2 Hz, -OCH2CH3), 3.84 (s, 6H, 2(-OCH3)), 1.44 (s, 9H, t-
butyl), 1.37 (t, 3H, J = 6.8 Hz, -OCH2CH3). 
 
HRMS: EIMS (M+) calculated for C27H33N2O7FNa 539.2169, found 539.2166. 
 
121. Ethyl 2-(2-(2-(tert-butylamino)-1-(4-fluorophenyl)-2-oxoethyl)-7,9-dimethoxy-
3,8-dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.34 (m, 2H, aryl), 7.08 (m, 2H, aryl), 6.30 (d, 1H, J = 
2.0, vinyl), 5.80 (d, 1H, J = 2.4, vinyl), 4.04 (m, 2H, -0CH2CH3), 4.0 (s, 1H, Hd), 3.61 (s, 
6H, 2(-OMe)), 3.33 (t, 1H, J = 2.8 Hz, Hb), 3.11 (d, 1H, J = 9.6 Hz, Hc), 2.91 (d, 1H, J = 
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10.8 Hz, Hc), 2.62 (m, 1H, Ha), 2.04 (m, 1H, Ha), 1.24 (s, 9H, t-butyl), 1.18 (m, 3H, -
0CH2CH3). 
 
13C (100 MHz, CDCl3): δ 190.7, 176.1, 172.8, 167.7, 164.0, 161.6, 152.2, 130.9, 116.6, 
114.7, 112.5, 107.0, 61.1, 58.1, 56.4, 55.4, 52.9, 48.7, 30.2, 14.1. 
 
HRMS: EIMS (M+) calculated for C27H33N2O7FNa 539.2169, found 539.2166. 
 
122. 2-(benzo[d][1,3]dioxol-5-yl)-N-cyclohexyl-2-(7-methoxy-3,8-dioxo-4-(2-oxo-2-
phenylethyl)-2-azaspiro[4.5]deca-6,9-dien-2-yl)acetamide 
 
1H NMR (400 MHz, CDCl3): δ 7.84 (d, 2H, J = 8.4 Hz, aryl), 7.54 (t, 1H, J = 7.6 Hz, 
aryl), 7.42 (t, 2H, J = 8.0 Hz, aryl), 7.02 (dd, 1H, J = 3.2, 10 Hz, vinyl), 6.85 (m, 3H, 
aryl), 6.28 (d, 1H, J = 9.6 Hz, vinyl), 5.98 (s, 2H, -OCH2O-), 5.82 (s, 1H, Hd), 5.56 (d, 
1H, J = 8.0 Hz, NH), 5.32 (d, 1H, J = 2.4 Hz, vinyl), 4.14 (m, 2H, Hc), 3.66 (s, 3H, -
OMe), 3.40 (m, 1H, He), 3.01 (dd, 1H, J = 2.4, 10.4 Hz, Hc), 2.69 (m, 2H, Ha), 1.91 (m, 
2H, cy), 1.66 (m, 3H, Cy), 1.36 (m, 2H, Cy), 1.15 (m, 3H, Cy) 
 
13C NMR (100 MHz, CDCl3 in CD3OD (3 drops)): δ 196.8, 180.5, 173.5, 167.5, 150.8, 
148.1, 136.1, 133.4, 129.9, 128.6, 122.2, 117.4, 113.1, 108.6, 101.4, 58.3, 54.6, 52.2, 
47.7, 46.7, 34.2, 32.5, 25.3, 24.6. 
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HRMS: EIMS (M+) calculated for C33H34N2O7Na 593.2264, found 593.2254. 
 
123. (E)-Ethyl 4-((2-(cyclohexylamino)-1-(4-fluorophenyl)-2-oxoethyl)(4-hydroxy-3-
methoxybenzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.36(t, 2H, J = 7.2 Hz, aryl), 7.27 (d, 1H, J = 14.4 Hz, 
vinyl), 6.97 (t, 2H, J = 9.2 Hz, aryl), 6.85 (d, 1H, J = 14.8 Hz, vinyl), 6.76 (d, 1H, J = 8.4 
Hz, aryl), 6.51 (m, 2H, aryl), 5.77 (s, 1H, Ha), 5.57 (d, 1H, J = 8.0 Hz, NH), 5.51 (s, 1H, -
OH), 4.62 (dd, 2H, J = 18.0, 81.4 Hz, benzyl), 4.19 (q, 2H, J = 7.2 Hz, -OCH2CH3), 3.79 
(m, 1H, cy, overlapping with -OMe) 3.76 (s, 3H, -OMe), 1.88 (m, 2H, cy), 1.64 (m, 3H, 
Cy), 1.32 (m. 2H, Cy) 1.26 (t, 3H, J =  7.2 Hz, -OCH2CH3), 1.09 (m, 3H, Cy). 
 
13C NMR (100 MHz, CDCl3): δ 167.8, 166.3, 165.3, 164.0, 161.5, 146.7, 144.9, 133.9, 
132.4, 131.7, 131.6, 130.7, 128.7, 119.4, 115.9, 115.7, 114.4, 109.1, 62.6, 61.1, 55.9, 
50.0, 48.6, 32.7, 25.4, 24.7, 24.6, 14.0 
 
19F NMR (376 MHz CDCl3) δ −112.8 
 
HRMS: EIMS (M+) calculated for C28H33N2O6FNa 535.2220, found 535.2211 
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124. Ethyl 2-(2-(2-(cyclohexylamino)-1-(4-fluorophenyl)-2-oxoethyl)-7-methoxy-3,8-
dioxo-2-azaspiro[4.5]deca-6,9-dien-4-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.39 (m, 1H, aryl), 7.31 (m, 1H, aryl), 7.10 (m, 2H, aryl), 
6.91 (dd, 1H, J = 2.4, 10.0 Hz, vinyl), 6.33 (dd, 1H, J = 1.6, 9.6 Hz, vinyl), 5.86 (s, 1H, 
Hd), 5.44 (d, 1H, J = 8.4 Hz, NH), 5.16 (d, 1H, J = 2.4 Hz, vinyl), 4.08 (m, 2H, -
OCH2CH3), 3.80 (m, 1H, He), 3.39 (s, 3H, -OMe), 3.33 (t, 1H, J = 2.4 Hz, Hb),3.11 (dd, 
1H, J = 10.0, 42.9 Hz, Hc), 2.95 (d, 1H, J = 10.4 Hz, Hc), 2.66 (m, 1H, Ha), 2.10 (m, 1H, 
Ha) 
 
13C NMR (100 MHZ CDCl3): δ 180.2, 172.7, 171.1, 167.2, 164.1, 161.6, 152.1, 149.8, 
147.7, 146.2, 116.4, 114.2, 112.2, 61.0, 58.0, 54.6, 52.0, 48.9, 47.6, 32.7, 30.4, 25.3, 14.0 
 
19F NMR (376 MHz CDCl3) δ -112.0 
 
HRMS: EIMS (M+) calculated for C28H33N2O6FNa 535.2220, found 535.2209 
 
125. (E)-Ethyl 4-((1-methoxy-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobut-2-
enoate 
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1H NMR ( 500 MHz, CDCl3): δ 6.96 (d, 1 H, J = 15.6 Hz, -CH=CH-), 6.82 (d, 1 H, J = 
15.3 Hz, -CH=CH-), 6.32 (d, 1 H, J = 9.2 Hz, -NH), 4.59 (d, 1 H, J = 9.8 Hz, Ha), 4.26 
(q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.75 (s, 3 H, OMe), 1.32 (t, 3 H, J = 7.3 Hz, -
OCH2CH3), 0.99 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 171.7, 165.4, 163.3, 135.7, 131.2, 61.2, 60.2, 52.0, 35.1, 
29.7, 26.5, 14.1. 
 
HRMS (EIMS, M+): calcd for C13H21NO5 271.1420, found 271.1432. 
 
126. (E)-Ethyl 4-((1-(4-acetamidophenyl)-2-(tert-butylamino)-2-
oxoethyl)(benzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.82 (s, 1 H, -NH), 7.36 (d, 2 H, J = 8.2 Hz, Aryl), 7.06-
7.25 (m, 6 H, Ph and –CH=CH- overlap), 6.92 (d, 2 H, J = 7.0 Hz, Aryl), 6.81 (d, 1 H, J 
= 15.3 Hz, -CH=CH-), 5.87 (s, 1 H, Ha), 5.72 (s, 1 H, -NH), 4.78 (d, 1 H, J = 17.4, -
NCH2Ph), 4.57 (d, 1 H, J = 17.7 Hz, -NCH2Ph), 4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 
2.10 (s, 3 H, -COMe), 1.30 (s, 9 H, t-Bu), 1.22 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 168.6, 168.4, 166.3, 165.3, 138.5, 137.2, 133.9, 132.3, 
130.4, 129.9, 128.4, 127.2, 126.2, 119.8, 62.9, 61.0, 51.8, 49.8, 28.5, 24.4, 14.1. 
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HRMS (EIMS, M+): calcd for C27H33N3O5 479.2420, 479.2414. 
127. Ethyl 2-(6-acetamido-2-benzyl-1-(tert-butylcarbamoyl)-3-oxo-1,2,3,4-
tetrahydroisoquinolin-4-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.48 (d, 1 H, Aryl), 7.16-7.42 (m, 7 H, Aryl), 5.49 (s, 1 H, 
Ha), 4.56 (d, 1 H, J = 15.9 Hz, -NCH2Ar), 4.17 (dd, 1 H, J1 = 6.7 Hz, J2 = 3.1 Hz, Hb), 
4.15 (q, 2 H, J = 7.3 Hz, -OCH2CH3) 4.04 (d, 1 H, J = 15.3 Hz, -NCH2Ar), 2.91 (dd,1 H, 
J1 = 18.0 Hz, J2 = 4.6 Hz, Hc), 2.79 (dd,1 H, J1 = 17.7 Hz, J2 = 9.8 Hz, Hc), 2.17 (s, 3 H, -
-COMe), 1.24 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.99 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 171.4, 169.5, 168.4, 168.2, 138.4, 136.6, 131.9, 131.5, 
129.0, 128.9, 128.5, 128.3, 127.9, 127.7, 119.9, 70.9, 61.1, 56.1, 51.7, 45.3, 31.0, 28.2, 
24.6, 14.1. 
HRMS (EIMS, M+): calcd for C27H33N3O5 479.2420, 479.2432. 
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CHAPTER 3 
 
A Microwave-Influenced, Diastereoselective Cascade Ugi/Michael/aza-
Michael Reaction In Water: Proximity Effect Leads To Natural-
Product-Like Diverse Aza-Spiro Tri- And Tetracycles 
 
3.  Introduction 
 Rapid construction of diverse complex molecular architectures especially 
spirocyclic frameworks, having all carbon quaternary centers154 in a regio- and 
stereospecific manner from simple substrates, continues to be a significant challenge in 
organic synthesis.4,155  To this extent, MCCRs involving cascade processes have been 
utilized in TOS as well DOS and have emerged as powerful tools for the construction of 
complex architectures as these reactions often provide excellent chemoselectivities.7, 156 
As a component of our on-going research in developing new cascade approaches 
using MCCRs to generate biologically relevant diverse small and complex molecules, we 
were particularly interested in spirocyclic scaffolds especially that of aza and/or oxa spiro 
[4.5]decanes157 which are typically synthesized using toxic hyper-valent iodine (e.g. 
PIFA, DIB), ICl, or expensive metal reagents.153, 158 
Over the past century, nearly 500 alkaloids have been isolated from the 
herbaceous Amaryllidaceae plant family.  Among these alkaloids (+)-Plicamine (200), 
(+)-Plicane (201), (-)-Obliquine (202), 3-epi-Plicane (203), 3-epi-Obliquine (204), (+)-
Pretazettine (205), (+)-Tazettine (206); Marine alkaloid (+)-Discorhabdin A (207); 
Lycopodium alkaloids Magellanine (208), Magellaninone (209) and Paniculatine (210); 
Simomenine (211), Erythratinone (212) have unique nitrogen-containing spiro-fused 
cyclic structures.159  We were particularly interested in the family of amaryllidaceae 
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alkaloids because of their extensive structural diversity and broad biological activities 
e.g. antitumor, antibacterial, antifungal, antimalarial, antiviral, analgesic and 
acetylcholinesterase (AChE) inhibitory activities.  In addition, they inhibit various cell 
cycles (e.g. Go/G1 phase in tumor progression, G2/M phase in HIV-1) and have found 
application in the therapeutic treatment of Schizophernia, Alzheimer’s diseases.160  The 
most notable structural feature common to all of these alkaloids is the presence of the 
sterically congested quaternary carbon center at the arylhydroindolone bridgehead, which 
represents one major challenge to their synthetic make-up. 
 
 
Figure 22.  Biologically relevant amaryllidaceae, marine and lycopodium alkaloids. 
 
 (+)-Plicamine (200), the first bis-nitrogen (two N atoms in the skeleton) 
containing alkaloid of the amaryllidaceae family, was isolated from extracts of the 
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Turkish Galanthus plicastus (subsp. Byzantinus).161  The most interesting feature of the 
tetracyclic structure of plicamine is the presence of a 6,6-spirocyclic core having three 
stereogenic centers.  Recently, Ley and coworkers162 have reported  the first total 
synthesis of (+)-plicamine and structurally related compounds in over 30 steps employing 
polymer supported phenyliodine (III) bis(trifluoroacetate) (PIFA) to construct the key 
6,6-spiro cyclic intermediate.  Although its biological property has not been entirely 
evaluated, in view of a recent literature report,163 structural modifications will alter 
biological and toxicological activities such that improved efficacy be realized.  Thus, the 
synthesis of structural motifs which are similar to (+)-Plicamine and its family are 
necessary to conduct SAR studies. 
 
3.1.  Results and Discussions 
 
3.1.1. A Cascade Ugi/Michael/aza-Michael Pathway Leads To Diazaspiro-
fused Tricycles and Tetracycles  
 We envisioned that a multicomponent coupling reaction, mainly the Ugi four 
component coupling reaction (U-4CCR), would provide an acyclic trifunctional precursor 
that would undergo a 5-exo Michael addition to form 2-azaspirocyclohexadienone106 
which could then undergo a 5-exo-trig/6-exo-trig aza-Michael reaction under microwave 
irradiation and bring forth structurally similar azasprio-fused polycyclic skeletons as 
those affiliated to the amaryllidaceae alkaloids. 
 The requisite substrates to test this hypothesis were p-hydroxy benzylamine 
(PHB, 1b), p-hydroxy benzaldehyde (213a), fumaric acid monethyl ester (2a) and tert-
butyl isocyanide (3c) (Scheme 54).  The U-4CCR afforded acyclic tetrafunctional 
precursor 214 in excellent yield (92%); it was then subjected to µwave irradiation in 
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water (300 W, 200 oC, 18 bar, 20 min).  To our delight, the desired diazaspiro-5,5,6-
fused-tricycle 215 was obtained via a 5-exo Michael addition followed by a 5-exo-trig 
aza-Michael in about 45% along with 2-azaspirocyclohexadienones 216 and 217.  
Although the reaction gave a moderate diastereoselectivity (1:3) for 215, we were quite 
satisfied with the result.  It must be noted that compound 217 (or structurally similar 16, 
23) did not undergo a 7-exo-trig aza-Michael addition to give any recognizable amount 
(or at best a trace amount) of diazaspiro-7,5,6-fused tricycle under microwave irradiation 
(Scheme 55). 
 
 
Scheme 54.  Synthesis of azaspiro-5,5,6-fused tricycle via Ugi/Michael/aza-Michael 
(UMAM) reaction under µwave irradiation. 
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Scheme 55.  7-exo-trig aza-Michael reaction does not occur. 
 
 Next, we focused on improving the reaction yield and replaced p-hydroxy 
benzylamine (1b) with benzyl amine (1d) in the U-4CCR.  The trifunctional acyclic 
precursor 219 was obtained in excellent yield (93%).  When 219 was subjected to 
 198
microwave irradiation under the previous conditions, an improved yield of diazaspiro-
5,5,6-fused tricycle 220 (65%) was obtained along with 2-azaspirocyclohexadienone 221.  
It is noteworthy that, isolated 221 can be converted to 220 upon further microwave 
irradiation (Scheme 56). 
 
 
Scheme 56.  Modified Ugi acyclic product provides excellent yield of (±)-220. 
 
Table 22.  Optimization of conditions for the synthesis of diazaspiro-5,5,6-fused tricycle. 
% yielda/drb Entry Time (min) Power (W) Temp (oC) Pressure (bar) 
220 221 
1 20 300 200 18 65/1:3 30/1:2 
2 20 300 220 18 60/1:3 23/1:2 
3 20 250 200 15 45/1:3 50/1:2 
4 20 200 160 6 25/1:3 25/1:2 
5 20 150 151 5.1 10/1:3 15/1:2 
6 20 100 138 4.1 0 7/1:2 
7 20 50 100 1.5 0 0 
8 25 300 200 18 70/1:3 25/1:2 
9 30 300 200 18 73/1:3 22/1:2 
10 30 300 200 18.5 77/1:3 15/1:2 
11 30 300 200 19 80/1:3 10/1:2 
a Isolated. b Determined from 1H NMR of crude reaction mixture. 
 
Next we examined different temperatures pressures, power and times to optimize 
the yield of 220.  After several trials (Table 22), when the microwave was equilibrated to 
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300 W, 200 oC, 18 bar for 30 min, the reaction gave a diastereomeric mixture of 220 in 
89% yield.  Diastereoselectivity was determined from the 1H NMR of the unpurified 
reaction mixture. 
With the optimized conditions in hand, we examined the substrate scope of this 
novel cascade UMAM reaction as a means to understand the process.  The majority of the 
substrates used, provided good to excellent yield (up to 99%) with moderate to excellent 
diastereoselectivities (up to 99:1).  It was observed that the reaction is highly sensitive to 
electronic nature of substituents on the phenyl ring of the aldehyde coupling partner (p-
hydroxy benzaldehyde).  Electron donating groups (e.g., OMe, Table 23) on p-hydroxy 
benzaldehyde highly favor the reaction.  However, 3,4-dimethyl benzaldehyde (Table 23, 
entry 18) did not provide expected diazaspiro-fused tricycle, only 2-
azaspirocyclohexadienone product was obtained most likely due to steric effect of the 
methyl groups which prevented the 5-exo-trig aza-Michael attack.  On the other hand, 
electron withdrawing groups (e.g., Br, NO2) disfavored the reaction and gave no 
recognizable amount (or at best a trace amount) of the desired product.  However, it is 
quite surprising that the use of 3-fluro-4-hydroxy benzaldehyde in the UMAM reaction 
provided a good yield (70%) of the desired product.  When 4-hydroxyl-1-napthaldehyde 
(213k) was used as a coupling partner, the reaction provided a quantitative yield and 
excellent diastereoselectivity (99:1).  It is noteworthy that 213k also provided 2-
azaspirocyclohexadienone 252 spontaneously at room temperature.  This unusual result 
could arise from the high reactivity of 4-hydroxy-1-napthaldehyde.  Moreover, refluxing 
213k along with other reacting partners in a sealed tube for 6 h provided 252 exclusively, 
and only a trace amount of 251 was observed on TLC.  It must be noted that, except 
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213k, other aldehydes afforded the acyclic U-4CCR product which did not undergo a 
UMAM convention upon refluxing in water in a oil-bath or in a sealed tube.  Use of the 
very bulky adamantyl isocyanide39, 164 (3i) provided only a single UMAM product, 
whereas the less bulky isocyanide e.g., cyclohexyl isocyanide (3d) provided a trace 
amount of 2,5-diketopiperazine 229 via 6-exo-trig aza-Michael pathway.144 
 
 
Scheme 57.  Synthesis of adamantyl (ada) isocyanide 3i. 
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Table 23.  Substrates scope of the microwave-influenced synthesis of azaspiro-fused 
tricycles. 
 
R1 Entry 
X Y W Z 
R2 R3 R4 Compd type/ 
%yielda/drb 
1 OMe H H H (213a) OEt (2a) p-hydroxylbenzyl (1b) t-Bu (3b) A(215)/35/1:2 
2 H H H H (213ª) OEt (2a) Benzyl (1d) t-Bu (3b) A(220)/80/1:3 
3 OMe H H H (213b) OEt (2a) Benzyl (1d) t-Bu (3b) A(222)/85/1:3 
4 OMe OMe H H (213c) OEt (2a) Benzyl (1d) t-Bu (3b) A(225)/89/1:3 
5 H H H H (213a) OEt (2a) Propargyl (1x) Cy (3c) A(228)/90/1:3 
C(229)/6/1:5 
6 OMe H H H (213b) OEt (2a) Benzyl (1d) Ada (3h) A(230)/65/single 
7 H H OMe H (213d) OEt (2a) Benzyl (1d) t-Bu (3b) A(233)85/1:3 
8 H H OMe OMe (213e) OEt (2a) Benzyl (1d) t-Bu (3b) A(236)/80/1:6 
9 Br H H H (213f) OEt (2a) Propargyl (1x) t-Bu (3b) – 
10 Br H H H (213f) OEt (2a) Propargyl (1x) Cy (3c) – 
11 NO2 H H H (213g) OEt (2a) Benzyl (1d) t-Bu (3b) – 
12 OMe NO2 H H (213b) OEt (2a) Benzyl (1d) t-Bu (3b) – 
13 F H H H (213h) OEt (2a) Benzyl (1d) t-Bu (3b) A(238)/70/1:3 
14 OMe H H H (213b) Ph (2f) Benzyl (1d) t-Bu (3b) A(240)/84/1:4 
15 OMe H H H (213b) Tol (2h) Benzyl (1d) t-Bu (3b) A(243)/83/1:4 
16 OMe H H H (213b) Tol (2h) 3,5-dimethoxybenzyl (1e) t-Bu (3b) A(246)/82/1:3 
17 H H H H (213a) OEt (2a) Benzyl (1d) Cy (3c) A (249)/85/1:4 
C (250)/5/1;3 
18 Me Me H H (213j) OEt (2a) Benzyl (1d) t-Bu (3b) – 
19 4-hydroxyl-1-napthaldehyde (213k) OEt (2a) Benzyl (1d) t-Bu (3b) B(251)/99/1:99 
20 4-hydroxyl-1-napthaldehyde (213k) OEt (2a) p-hydroxylbenzyl (1b) t-Bu (3b) B(253)/99/1:98 
21 4-hydroxyl-1-napthaldehyde (213k) OEt (2a) p-hydroxylbenzyl (1b) Bn (3a) B(255)/96/1:94 
a Isolated. b Determined from 1H NMR from the unpurified reaction mixture. 
 
In an attempt to examine whether less bulky or linear isocyanides could be used in 
the UMAM pathway, we took advantage of the spontaneous reactivity of 4-hydroxy-1-
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napthaldehyde and employed benzyl isocyanide (Table 23, entry 21) in the UMAM 
reaction at room temperature.  Gratifyingly, the reaction gave 2-aza-
spirocyclohexadienone 256 as a 94:1 disatereomeric mixture.  Having 256 in hand, we 
rationalized, based on previous results, that it could undergo a cascade Michael/aza-
Michael process to provide the highly complex diazaspiro-fused polycycles 259 and 260.  
However, upon microwave irradiation, 256 provided quantitative yield of 255 (Scheme 
58). 
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Scheme 58.  Benzyl isocyanide in U-4CCR provided diazaspiro-fused tetracycle. 
 
 Further substrate scope was also examined as a means to diversify the 
convention(s).  Thus, we chose to use p-hydroxy benzylamine (1b), 
trimethylacetaldehyde (4b), N-methylmaleic acid (2i) and tert-butyl isocyanide (3b) in 
the cascade process and to our delight the reaction afforded diazaspiro-6,5,6-fused 
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tricycle 261 in excellent yield (Scheme 59).  It is noteworthy that compound 261 have 
very similar structural core to that of (+)-plicamine. 
 
Scheme 59.  Synthesis of diazaspiro-6,5,6-fused tricycle via UMAM reaction. 
 
 
Scheme 60.  Proposed mechanism for the formation of diazaspiro-fused polycycles via 
UMAM pathway. 
 
 A proposed mechanism that accounts for the formation of diazaspiro-fused 
polycycles is depicted in Scheme 60.  We rationalized that the electron donating p-
hydroxy group on the benzaldehyde, under the influence of μwaves, led to the formation 
of zwitterionic intermediate 263 which is believed to be stabilized by hydrogen bonding 
with water.  Furthermore, zwitterionic character of the intermediate 263 probably helps to 
absorb μwave energy and thus might lower the activation energy barrier.  Upon 
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protonation and deprotonation, compound 263 formed 2-aza-spiro[4.5]deca-6,9-diene-
3,8-dione product 264 which under the influence of μwaves undergoes a 5-exo-trig aza-
Michael addition to form the zwitterionic intermediate 265.  Proton transfer finally 
provides the final products (Type A).  The mechanism of formation of Type B a is very 
similar to that of Type A. 
 The major isomer of 2-aza-spiro[4.5]deca-6,9-diene-3,8-diones has a trans 
relationship between the isocyanide and acid coupling partners as determined by nOe 
study, H-H COSY, HMQC, HMBC experiments and unequivocally confirmed by X-ray 
crystal structure analysis (Figure 23).  The stereochemistry of the major diastereomer of 
diazaspiro-fused polycycles was determined by nOe, 1H-1H GDQFCOSY, HMQC, 
HMBC experiments and unequivocally confirmed by X-ray crystal structure analysis 
(Figure 24). 
In our previous study, bulky substituents at R4 (e.g. tert-butyl) and p-hydroxy 
benzylamine at R3 led to the formation of 2-aza-spiro[4.5]deca-6,9-diene-3,8-diones 
probably due to the steric effect in the transition state and less bulky substituents at R4 
(e.g., benzyl) led to 2,5-diketopiperazine formation exclusively.144  Given this fact, one 
might not expect that in the presence of a bulky substituent at R4 (e.g., tert-butyl), 2-aza-
spiro[4.5]deca-6,9-diene-3,8-diones 264 would undergo a 5-exo-trig aza-Michael 
addition to afford the desired diazaspiro polycycles.  The possible explanation could be 
that the amide group with bulky substituent at R4 is in close proximity to the dienone 
Michael acceptor.  In fact, entry 5 (Table 23) shows that when R4 is cyclohexyl (3d), 2-
aza-spiro[4.5]deca-6,9-diene-3,8-diones 264 is the major product and only small amount 
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of 2,5-diketopiperazine 267 was obtained.  It must be kept in mind that 2-aza-
spiro[4.5]deca-6,9-diene-3,8-diones 217 does not undergo 7-exo aza-Michael addition. 
 
To confirm that spirocycle formation is driven by proximity effect,165 we decided 
to use 4-hydroxylbenzyl acetaldehyde (213l) instead of p-hydroxyl benzaldehyde (213a) 
(Scheme 61).  Initial attempt to synthesize 213l via pyridinium chloro chromate (PCC) or 
pyridinium dichromate (PDC) or 2-iodoxybenzoic acid (IBX) oxidation of 4-(2-
hydroxylethyl)phenol (268) only gave trace amount of product probably due to a oxa-
Pictet-Spengler side reaction leading to 275 as depicted in Scheme 62.166  However, 
Doering-Parikh oxidation167 of 268 (Table 24, entry 4) provided 65% yield of desired 
aldehyde 213l which was used without further purification. 
 
Scheme 61.  Synthesis of 4-hydroxylbenzyl acetaldehyde. 
 
Table 24.  Optimization of reaction conditions for the synthesis of 213l. 
Entry Conditions % yield of 213la 
1 PCC, CH2Cl2/EtOAc, 0 oC→rt, 6 h 10 
2 PDC, CH2Cl2/EtOAc, 0 oC→rt, 6 h 11 
3 IBX, DMSO, 0 oC → rt, 5 h 15 
4 SO3.Py, DMSO, Et3N, 0 oC → rt, 7 h 65 
a Isolated. 
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Scheme 62.  Mechanism of side product formation via oxa-Pictet-Spengler reaction. 
 
 Due to the sensitivity of the aldehyde 213l, the Ugi reaction between benzylamine 
(1d), 4-hydroxylphenyl acetaldehyde (213l, fumaric acid monoethyl ester (2a) and tert-
butyl isocyanide (3d) was carried out at room temperature and acyclic product 276 was 
obtained in 75% yield.  When 276 was subjected to microwave irradiation, neither a 6-
exo-trig Michael/6-exo-trig aza-Michael nor a 6-exo-trig Michael reaction occurred to 
give any recognizable (or at best a trace) amount of 277 or 278 respectively.  A probable 
explanation could be that the 6-exo-trig Michael addition did not occur because the 
Michael acceptor (ethyl acrylate) was not in close proximity of the p-hydroxy phenyl 
group.  Furthermore, six-membered ring formation is slower than five-membered rings.  
This further confirmed that azaspirocyclohexadienone and diazaspiro-fused polycycle 
formation is driven by proximity effect. 
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Scheme 63.  Further proof of proximity effect. 
 
 
Figure 23.  X-ray crystal structure of 2-aza-spiro[4.5]deca-6,9-diene-3,8-dione (±)-252. 
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Figure 24.  X-ray crystal structure of diazaspiro-fused polycycle (±)-251. 
 
3.1.2.  Synthetic Studies Toward The Synthesis of (+)-Plicamine Core 
 With a better understanding of our system, we next embarked on devising a 
strategy toward the synthesis of (+)-plicamine core.  Although as previously noted, 
acrylic acid did not provide any 7-membered diazepine rings via 7-exo-trig aza-Michael 
pathway (chapter 2, scheme 36), we speculated that it might exhibit different reactivity in 
the presence of a different set of substituents.  Thus, benzylamine 1d, 4-hydroxy-3-
methoxy-benzaldehyde 213b, acrylic acid 2f and t-butyl isocyanide 3c provided the 
acyclic Ugi product 279 in good yield.  However, when microwave irradiation was 
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employed, the desired product 280 was not obtained; rather formation the deprotected 
compound 281 was observed. 
 
Scheme 64.  Attempt to synthesize (+)-Plicamine core. 
 
 
Scheme 65.  Effect of electron withdrawing group on the amine component. 
 
 We reasoned that due to the lone pair donation from nitrogen to the amide 
carbonyl, the Michael acceptor itself was weak and it was not in close proximity.  Hence, 
we decided to replace benzylamine 1d with p-nitro aniline in the U-4CCR.  To our 
disappointment, only the deprotected products 286a and 286b were obtained. 
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Scheme 66.  Synthetic study toward (+)-Plicamine core. 
 
 Next, we decided to employ carboxylic acid salt 2j (Scheme 67) in the U-4CCR.  
Thus, 2j was synthesized from refluxing 2-cyano acetic acid 2i in benzene in presence of 
para-formaldehyde 4v, dicyclohexyl amine 1x and triethyl amine.168  The identity of 
compound 2j was confirmed by 1H NMR and HRMS.  However, when the acid 2j was 
employed in the U-4CCR, the desired Ugi product 287 was not obtained (Scheme 68). 
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Scheme 67.  Synthesis of acid 2j. 
 
 
Scheme 68.  Attempt to synthesize acyclic U-4CR product 287. 
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 Next, we speculated that amine 1y might be a better fit for the required proximity 
of the reacting centers to form 2-aza-spiro[5.5]deca-6,9-diene-8-ones.  Compound 1y was 
synthesized in 5 steps from P,P-dipenylphosphinic amide 288.  Initial attempt to convert 
288 into (E)-N-benzylidene-P,P-diphenylphosphinic amide 289 using TiCl4 as a catalyst 
provided moderate yields of 289 (Scheme 69).169 
 
 
Scheme 69.  Synthesis of amide 289. 
 
 
Scheme 70.  Synthesis of amine 1y. 
 
 Thus, we chose an alternative route for the synthesis of 1y (Scheme 70).  
Commercially available sodium salt of toluenesulfinic acid was converted to 
corresponding free acid by treating with conc HCl in a mixture of water and methyl tert-
butyl ether (MTBE) at room temperature.  Treatment of 288 with benzaldehyde 4f in the 
presence of p-toluenesulfinic acid in a 1:5 mixture of dichloromethane and ether afforded 
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a quantitative yield of 290.  Anhydrous K2CO3 mediated elimination of p-toluenesulfinate 
in dry CH3CN provided the amide 289 in excellent yield.170  The aza-Baylis-Hillman 
reaction of methyl vinyl ketone (MVK) with 289 in the presence of 10 mol% PPh3 
catalyst in anhydrous CH3CN afforded an excellent yield of the desired product 291.  
Hydrolysis of the phosphonamide 291 in the presence of conc HCl in methanol, followed 
by basification provided the amine 1y in good yield (Scheme 70).170, 171 
 With 1y in hand, we synthesized acyclic Ugi product 292 employing 4-hydroxy-
3-methoxy-benzaldehyde 213b, p-methoxy benzoic acid 2k and tert-butyl isocyanide 3c.  
However, when 292 was subjected to previously established microwave irradiation 
conditions, the desired product was not obtained (Scheme 71). 
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Scheme 71.  Alternative route for the synthesis of (+)-Plicamine core. 
 
 Next, we focused on applying the Passerini reaction to synthesize acyclic 
precursors that might lead to the formation of scaffolds similar to Pretazettine and 
Tazettine.  Thus, p-hydroxy benzaldehyde 213a, fumaric acid monoethyl ester 2a and 
tert-butyl isocyanide 3c was employed in the P-3CR, however, the desired product 294 
was not obtained.  Use of other solvents e.g. CH2Cl2, THF, PEG-400, H2O or other 
isocyanides did not provide a trace of the desired product 294 (Scheme 72). 
 213
 
Scheme 72.  Effort toward the synthesis of (±)-295 
 
 We speculated that the spontaneous reactivity of 4-hydroxy-1-napthadehyde 
(entry 15-17, Table 23) might help to obtain similar type of P-3CCR product.  However, 
to our disappointment, the desired product 296 was not obtained under any conditions 
explored (Scheme 73). 
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Scheme 73.  Effort toward the application of P-3CCR for complex molecule synthesis. 
 
 We speculated that the aldehydes (213a, 213k) used in the P-3CCR, were 
behaving like para-substituted nitro-phenols and undergoing a Passerini-Smile (PS-
3CCR) type of reaction.  Hence, we decided to employ silyl-protected p-hydroxy 
benzaldehyde in the P-3CCR (Scheme 74).  Unfortunately, trimethylsilyl (TMS) 
protected aldehyde 213m was too unstable under our reaction conditions probably due 
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the presence of the acid 2a.  Even when we used PEG-400, it did not provide any trace of 
the desired product 298. 
 
Scheme 74.  TMS-protected aldehyde in the P-3CCR. 
 
 Next, we decided to use a more acid stable silyl protecting group to protect the p-
hydroxyl group that would be removed under the same reaction conditions in one-pot.  
Thus, 4-tert-butyldimethylsilyloxy-3-methoxy benzaldehyde 213n was synthesized from 
aldehyde 213b using tert-butyldimethylsilyl chloride (TBDMSCl) and imidazole in DMF 
at room temperature (Scheme 75).172 
 
 
Scheme 75.  Synthesis of TBDMS protected aldehyde 213n. 
 
 When the TBDMS protected aldehyde 213n was employed in the P-3CCR, the 
expected product 299 was obtained in 50% yield along with 20% of the TBDMS 
deprotected aldehyde 213b (Scheme 76).  The P-3CCR product 299 was purified via 
gradient silica gel column chromatography and about 20% of unreacted TBDMS 
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protected aldehyde 213n was recovered.  Having 299 in hand, we speculated that the 
TBDMS group would fall off under the microwave reaction conditions and the resulting 
p-hydroxy product would undergo a cascade 5-exo-trig Michael/5-exo-trig aza-Michael 
reaction.  However, when prior microwave irradiation conditions were employed the 
desired product 300 was not obtained and only decomposition was observed (Scheme 
77). 
 
 
Scheme 76.  Synthesis of TBDMS-protected P-3CCR product (±)-299. 
 
 
Scheme 77.  Attempted synthesis of compound (±)-300. 
 
 Before trying other conditions and strategies, we decided to examine whether 
other P-3CCR products were suitable for microwave irradiation and can undergo Michael 
or aza-Micalel additions.  Thus, compound 301 was synthesized via the P-3CCR of 
isobutyraldehyde 4b, fumaric acid monoethyl ester 2a and benzyl isocyanide 3a.  
Gratifyingly, when 301 was subjected to microwave irradiation, biologically relevant 
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morpholin-3-one173 302 was obtained in 10% yield (Scheme 78).  The low yield could be 
attributed to the flexible ester bond bearing the Michael acceptor that might not easily 
come to proximity in the transition state. 
 
Scheme 78.  Synthesis of morpholin-3-one via P-3CR and 6-exo aza-Michael reaction. 
 
 Furthermore, we examined the utilization of P-3CCR products under our 
previously established tandem reduction/aza-Michael addition conditions (Table 13, 
Chapter 2).  Thus, we focused on synthesizing benzoxapines174 via P-3CCR and a 6-exo-
trig aza-Michael reaction.  The acyclic P-3CCR product 303 was synthesized from o-
nitro benzaldehyde 4j, fumaric acid monoethyl ester 2a and cyclohexyl isocyanide 3d in 
PEG-400 in about 70% yield.  However, when our previously established tandem 
reduction-cyclization conditions were employed, expected product 304 was not obtained, 
instead deprotected product 305 was isolated (Scheme 79). 
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Scheme 79.  Effort toward the synthesis of benzoxapines. 
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Hence, it can be concluded that the P-3CCR products are not suitable candidates 
for microwave irradiation chemistry in water.  However, they might be suitable 
candidates for exploration in other solvents in the presence of additives. 
 
3.1.3. Extension Toward the Synthesis β-Spiro-Indoles and Azaspiro-Fused 
Polycyclic Indoles 
 
 The pharmacophore indole nucleus has been found in many natural products and 
many of them exhibit wide range of biological activities.175  Thus, the chemistry of 
substituted indoles has received wide attention176 and there is a continuing search for 
synthetic methods to prepare new types of indoles for screening in medicinal and 
pharmaceutical programs among scientific community.  Due to their role in many cell 
cycle mechanisms, spiro-indoles and spiro-oxindoles represent very important 
“privileged” scaffolds among various indole derivatives.  Spirotyrptostatins A 306 which 
was isolated from Aspergillus fungigatus, is known to block cell growth via M-phase 
specific inhibition and microtubule disassembly.177  Horsfiline 307 and Elacomine 308 
are the simplest oxindole alkaloids that exhibit cell cycle inhibition.178  Chartellines (309, 
310, 311), isolated from marine bryozoan Chartella papyracea179; Phalarine (312), 
isolated from Phalaris coerulescens (blue canary grass)180; Kopsine (313), isolated from 
Malyan Kopsia fructicosa181 also contain embedded spirocyclic indole motifs.  Other β-
spiroindolenine moieties containing natural products are the Strychnos, Curare, 
Aspidosperma:182 (a) Strychnine (314), a potent central nervous system stimulant that 
inhibits inhibitory reflexes;183 (b) Aspidospermine (315), Aspidospermidine (316), are 
respiratory stimulants and exhibit atropine-like activity on smooth muscle;184 (c) 
Aspidospermidine (317); (d) Toxiferine-I (318), has the best potency among curare 
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alkaloids and causes selective paralysis of motor neuron endplates in skeletal muscle as 
well as autonomic ganglionic cells.185  Rhyncophylline (315) has been found to cause 
motor paralysis and inhibition of respiration in mice.  In addition, it causes miosis in 
frogs and hypertension in rabbits (Figure 25).186 
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Figure 25.  Azaspiro-indole containing natural products. 
 
 As a part of our interest in spirocylic motifs, the starting point would be to 
consider Horsfiline (307), Elacomine (308) and rhyncophylline (315) as they are the 
structurally simplest members of the β-spiro-indolenine family containing a second basic 
nitrogen incorporated in the five-membered exocyclic spiro ring.  A closely related 
compound 319 was synthesized187 as an analog of the reversible cholinesterase inhibitor 
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drug physostigmine.188  Surprisingly, 319 also exhibited cholinesterase-inhibiting 
properties. However, the observed activity was diminished to some extent (Figure 25). 
 
 
Scheme 80.  Electrophilic substitution and Michael addition reactions of 3-substituted 
indoles. 
 
 It has been reported that indoles can behave like enamines and undergo 
electrophilic substitution.  Furthermore, they are known to undergo Michael addition to 
electron-deficient alkenes.189  Typically, electrophilic substitution of 3-substituted indoles 
involves prior attack at the 3-position to give an indolenine 321 which undergoes 
rearrangement to the corresponding 2,3-disubstitued indole (Scheme 80).  Depending 
upon the relative migratory aptitude of the substituents (R vs E) at 3-position of 321, two 
possible products (322 or 333) might form.  Michael addition of indole to electron 
deficient alkene works in a similar way and thus when R = H, it undergoes 
rearomatization to provide 326.  However, it is not so well known about the fate of the 
intermediate 325 of the Michael addition of indole to electron deficient alkene when there 
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is a substituent (R ≠ H) present at the 3-position.  Taking consideration of the 
corresponding electrophilic substitution, two possibilities are : (a) either the R group will 
migrate to 2-position and rearomatize to provide 2,3-disubstituted indole 327 or (b) it 
might undergo a deprotonation-protonation process to provide 3,3-disubstituted 
indolenine 328 (Scheme 80). 
 
 
Scheme 81.  Speculated pathway of Michael addition of the Ugi product (±)-330. 
 
 A number of synthetic efforts have been reported190 for the synthesis of spiro-
indoles, many of them involve lengthy processes and use costly reagents.  We envisioned 
that a multicomponent reaction, namely the Ugi four component coupling reaction, 
involving indole-2-aldehyde 329, an amine 1, fumaric acid monoethyl ester 2a and an 
isocyanide 3 could provide acyclic Ugi product 330 (Scheme 81) that might undergo 5-
exo-trig Michael addition either at room temperature or upon heating or under microwave 
irradiation to provide intermediate 331.  We speculated that 331 might provide β-
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carboline-type products (334 or 336) via a 1,2-shift190i, 190k or β-spiro-indolenine 337 via a 
deprotonation-protonation process as shown in Scheme 81. 
 Thus, we elected to use benzylamine (1d), indole-2-aldehyde (329), furmaric acid 
monoethyl ester (2a) and tert-butyl isocyanide (3c) in the Ugi reaction.  The reaction was 
allowed to stir at room temperature for 24 h with occasional warming up to 60-70 oC.  
TLC and 1H NMR of the crude reaction mixture showed that three distinct compounds 
are present in the product and separated by gradient column chromatography using silica 
gel.  Further spectroscopic analysis (1H, H-H GDQFCOSY, HMQC, nOe) of the isolated 
fractions revealed the identity of azaspiro-indolenine 339190i, 190n, 190o and diazaspiro-fused 
tetracyclic indole 340 as shown in Scheme 82.  It is quite noteworthy that 340 resembles 
the ABCE tetracyclic framework of Strychnos alkaloids.190p 
 
 
Scheme 82.  Synthesis of azaspiroindolenine and diazaspiro-fused poycyclic indoles. 
 
 When the crude reaction mixture (containing 338, 339 and 340) was irradiated 
under microwave (300 W, 200 oC, 19 bar, 30 min), 92% of 340 was obtained as the major 
product.  Moreover, isolated azaspiroindolenine 339 under microwave irradiation gave 
quantitative yield of 340.  With these results in hand, we decided to run the Ugi reaction 
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in the presence of microwave irradiation in two stages: (a) stage 1 was run at 70 oC (b) 
stage 2 was run at 200 oC.  To our expectation, the reaction gave an excellent yield (92%) 
of 340 as a 98:1 mixture of diastereomers (Scheme 82). 
 Next, we replaced indole-3-aldehyde (329) with 1-methyl-indole-3-aldehyde 
(341) in the U-4CCR.  We anticipated that the presence of an electron donating methyl 
group on nitrogen (indole motif)  might help to stabilize intermediate 332 that would 
allow the 1,2-shift to occur.  In order to understand this new reaction and compare with 
the previous reaction conditions, we decided to run the Ugi reaction at room temperature 
and occasionally warm to 70 oC.  To our surprise, the reaction gave only acyclic Ugi 
product 342 which under microwave irradiation gave no significant amount (or a trace 
amount) of 1H-pyrido[4,3-b]indole-3-ones (343 and 344) and diazaspiro-fused tetracyclic 
indole 345.  Instead, the reaction gave fragmented products 346 and 347 (Scheme 83) as 
determined by 1H NMR. 
 
Scheme 83.  1-Methyl-indole-3-aldehyde (341) gave Ugi product 342 and did not 
undergo a µwave-asisted 5-exo-trig Michael addition. 
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Scheme 84.  Proposed mechanism for the formation of spiro-indolenine and diazaspiro-
fused tetracyclic indole. 
 
 A probable mechanism which accounts for the formation of azaspiroindolenine 
339 and diazaspiro-fused tetracyclic indole 340 is depicted in Scheme 84.  5-exo-trig 
Michael addition of 3-substituted indole led to the formation of intermediate 348 which is 
equilibrium with intermediate 349.  Intermediate 349 might also be in partial equilibrium 
with 350 and 352 (pathway a and pathway b respectively).  However, 1H-pyrido[4,3-
b]indole-3-ones (351 and 353) are kinetically controlled products191 derived from 
intermediates 350 and 352 respectively.  Consequently, at higher temperature (70 oC to 
200 oC), the equilibrium between 348, 350 and 352 lies largely in favor of 349.  The 
presence of electron donating methyl group on indole nitrogen does not help to stabilize 
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349 and thus the 1,2-shift can not take place.  Thus, 349 can undergo a deprotonation-
protonation process (pathway C) to form 354 or a competitive intramolecular 5-exo-trig 
aza-Michael reaction (pathway D) to form intermediate 356 that leads to the final product 
340. 
 
3.3. Material and Methods 
 All reagents were purchased from Aldrich unless otherwise noted.  4-
Hydroxybezaldehyde, 4-hydroxy-3-methoxybenzaldehyde, 4-hydroxy-3,5-
dimethoxybenzaldehyde, 4-hydroxy-3-bromobenzaldehyde, 4-hydroxy-3-methoxy-5-
nitrobenzaldehyde and 4-hydroxy-1-napthaldehyde were purchased from Alfa Aesar.  4-
Hydroxy-2-methoxybenzaldehyde was purchased from ASDI Product List, and 4-
hydroxy-2,6-dimethoxybenzaldehyde was purchased from Frinton Labs.  4-Hydroxy-2-
nitrobenzaldehyde was purchased from TCI America.  4-Hydroxy-2-fluorobenzaldehyde 
was purchased from Matrix Scientific.  tert-Butyl isocyanide was purchased from TCI 
America.  1-Adamantyl isocyanide was synthesized following a precedented literature 
procedure (Org. Lett. 2003, 5, 901-904).  Sodium p-toluenesulfinate and methyl vinyl 
ketone (MVK) were purchased from Alfa Aesar.  Except as otherwise indicated, reactions 
were carried out under argon.  Microwave reactions were conducted using a capped vial 
on CEM Discover System.  All reactions were monitored by thin layer chromatography 
using 0.25 mm Dynamic Adsorbents, L.L.C. precoated silica gel (particle size 0.03-0.07 
mm, catalog no. 84111).  Column chromatography was performed using Whatman 
Purasil 60 Ǻ (230-400 mesh ASTM) silica gel.  Yields refer to chromatographically and 
spectroscopically pure compounds, except as otherwise noted.  Diastereomeric ratios 
were determined from 1H NMR spectra of non-purified reaction mixtures.  Proton and 
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carbon-13 NMR spectra were recorded on Varian Mercury 400, Varian Unity 500 and 
Varian 500 Direct Drive System spectrometers.  The residual CDCl3 singlet at δ 7.26 
ppm and δ 77 ppm were used as the standard for 1H NMR and 13C NMR spectra 
respectively.  Mass spectra were recorded on Micromass GCT at 70 eV. 
3.3.1. General Procedure 1 – Commencing with four distinct Ugi substrates 
To a 10 mL vial (CEM Discover System) equipped with magnetic stirring bar, 
benzylamine (15 mg, 0.14 mmol), 4-hydroxybenzaldehyde(12 mg, 0.14 mmol), fumaric 
acid monoethyl ester (25 mg, 0.14 mmol)and tert-butyl isocyanide (17 μL, 0.14 mmol) 
were added sequentially to a mixture of 1.5 mL LiCl (1 M)  and 1 mL MeOH or 2.5 mL 
distilled water with a pH of 7.0.  The vial was capped according to manufacturer 
instructions and placed in the single-mode microwave cavity.  Then the microwave was 
run at two stages: (a) 1 hr at 50 oC, 10 Bar and 300 W (b) 25-30 min, 190 oC, 18.5 Bar 
and 300 W.  After allowing the vial to cool to room temperature, ethyl acetate (3 mL) 
was added and the 10 mL vial was shaken vigorously.  The organic layer was separated 
using a separatory funnel and the aqueous layer was extracted with ethyl acetate (2 x 2 
mL).  The organic layers were combined and washed with NaHCO3 (2 x 3 mL), 1N HCl 
(2 x 3 mL) and brine (2 x 3 mL).  The organic layer was separated.  All aqueous layers 
were combined and extracted one final time with ethyl acetate (3 mL).  The organic 
layers were combined, dried over Na2SO4 and filtered.  The filtrate was dried under 
vacuum and purified by gradient silica gel column chromatography using a mixture of 
ethyl acetate and hexane (1:5 to 1:1) as the eluent. 
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3.3.2. General Procedure 2 – Commencing from pre-formed acyclic Ugi 
product 
To a 10 mL vial (CEM Discover System) equipped with magnetic stirring bar, 50 
mg of acyclic Ugi product was taken-up in 2.5 mL of distilled water with a pH of 7.0.  
The vial was capped according to manufacturer’s instructions and placed in the single-
mode microwave cavity.  The microwave was run for 25-30 min at 190 oC, 18.5 Bar and 
300 W.  After allowing the vial to cool to room temperature, ethyl acetate (3 mL) was 
added and the 10 mL vial was shaken vigorously.  The organic layer was separated and 
the aqueous layer was extracted with ethyl acetate (2 x 2 mL).  The organic layers were 
combined, dried over Na2SO4 and filtered.  The filtrate was dried under vacuum and 
purified using gradient silica gel column chromatography employing a mixture of ethyl 
acetate and hexane (1:5 to 1:2) as the eluent. 
3.3.3. General procedure for sealed tube reaction: 
To a 20 mL sealed tube equipped with a magnetic stir bar, benzylamine (15 mg, 
0.14 mmol), 4-hydroxybenzaldehyde (12 mg, 0.14 mmol), fumaric acid monoethyl ester 
(25 mg, 0.14 mmol) and 17 μL (0.14 mmol) of tert-butyl isocyanide (17 μL, 0.14 mmol) 
were added sequentially to a mixture of 1.5 mL LiCl (1 M)  and 1 mL MeOH or 2.5 mL 
distilled water with a pH of 7.0..  The sealed tube was placed in a silicone-based oil bath 
and heated at 70 oC for one hour and then at 190 oC for 2-12 h.  The sealed tube was then 
cooled to room temperature and filtered through a pad of celite (Aldrich) and washed 
with ethyl acetate (3 x 5 mL) followed by saturated NaHCO3 (5 mL).  The filtrate was 
then transferred to a separatory funnel and the mixture was shaken vigorously.  The 
organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 x 
 227
2.5 mL).  The organic layers were combined, dried with Na2SO4 and filtered.  The filtrate 
was concentrated under vacuum and the residue was purified using gradient silica gel 
column chromatography employing a mixture of ethyl acetate and hexane (1:5 to 1:1) as 
the eluent. 
3.3.4. Synthesis of Isocyanide 3i: 
 To a 100 mL oven dried round bottom (RB) flask conataining magnetic stirrer 
under Argon, 5 g (33.04 mmol) of 1-adamantamine was taken.  66 mL of Ethyl formate 
followed by 22 mL of DMSO were added to the flask and a condenser was attached to 
the flask.  The mixture was then refluxed at 100 oC for 24 h and excess ethyl formate was 
removed on a rotary evaporator.  Ice-cold water was added to the residue and resulting 
solid was filtered.  Next, the solid was dissolved in dichloromethane and anhydrous 
sodium sulfate was added to remove traces of water. The dichloromethane solution was 
concentrated over rotavap to obtain the crude formamide (4.7 g, 79%).  The crude 
formamide was pure enough (confimed from 1H NMR) and used directly for the next step 
without further purification. 
 The crude N-1-adamantyl formamide (4.7 g, 26.3 mmol) was dried under high 
vacuum for overnight and kept under Argon. Magnetic stir bar was added to the flask and 
the solid was dissolved in dichloromethane.  After the solution was cooled to -40 oC, 
phosphoroyl chloride (POCl3, 9.16 g, 78.7 mmol) was added slowly.  To the resulting 
mixture, triethylamine (Et3N, 32.9 mL, 236.2 mmol) was added very slowly (caution: 
generates heat!!!).  The solution was then allowed to reach room temperature and stirred 
for 24 h.  The mixture was then poured slowly into ice-cold water (300 mL) and the 
entire mixture was transferred to a separatory funnel.  The organic layer was separated 
and aqueous layer was washed with dichloromethane (25 mL × 2).  The organic layers 
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were combined, washed with saturated NaHCO3, dried over sodium sulfate and 
concentrated over rotavap to obtain 3i as a brownish-yellow solid.  The crude 3i was then 
purified via column chromatography using silica gel as the stationary phase and 
dichloromethane to obtain pure isocyanide 3i (2.7 g, 58%). 
3.3.5. Synthesis of amine 1y: 
 Commercially available sodium p-toluenesulfenate (5 g, 20 mmol) was dissolved 
in water (25.5 mL) and methyl tert-butyl ether (MTBE, 25.5 mL) was added to the 
mixture.  Next, concentrated HCl (1.8 mL) was added dropwise to the mixture and stirred 
for 10 min at room temperature.  The mixture was transferred to a separatory funnel and 
the aqueous layer was separated. The aqueous layer was washed with MTBE (10 mL × 2) 
and the organic layers were combined.  The organic layer was dried over sodium sulfate 
and concentrated on rotavap to obtain p-toluenesulfinic acid as a white solid (4.3 g) 
which was further dried overnight under high vacuum. 
 To a 100 mL oven dried RB flask equipped with magnetic stir bar, 0.5 g (2.3 
mmol) of N,N,-diphenyl-phosphinic amide (288) was taken under Argon.  Then 19 mL of 
diethyl ether and 4 mL of dichloromethane were added to the flask.  To the mixture, 0.35 
mL (3.5 mmol) of benzaldehyde was added slowly followed by p-Toluenesulfinic acid 
(0.54 g, 3.5 mmol) in one portion.  The resulting solution was stirred at room temperature 
for 48 h, after which white precipitates were formed.  The reaction mixture was filtered 
over buckner funnel and the solid was washed with diethyl ether.  The white solid (289, 
1.09 g) was further dried overnight under high vacuum. 
 289 and anhydrous K2CO3 were taken in a oven-dried RB flask under Argon.  
Then anhydrous acetonitrile (CH3CN) was added to the flask and the resulting mixture 
was stirred at room temperature for 12-24 h.  After TLC showed complete conversion, 
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the reaction mixture was filtered thourgh a buckner funnel and the residue was washed 
with CH3CN (25 mL × 2).  The filtrate was concentrated on rotavap to obtain 290 as a 
while solid (0.67 g, 90%). 
 Imine 290 (0.42 g, 1.38 mmol) was taken in a oven-dried RB flask and dried 
further under high vacuum.  The flask was capped with a rubber septum and purged with 
for 5 min.  Tripehnyl phosphine (PPh3, 73 mg, 0.28 mmol) was added to the flask along 
with a steady stream of Argon was purged again.  The flask was capped well, wrapped 
well parafilm and anhydrous CH3CN (28 mL) was added at room temperature.  Methyl 
vinyl ketone (MVK, 0.12 g, 1.7 mmol) was added slowly to the solution and the reaction 
was stirred at room temperature for 48-96 h after which TLC showed complete 
consumption of imine 290.  The reaction mixture was transferred into a separatory funnel 
and washed with water (25 mL × 2).  The crude product was then extracted with 
dichloromethane (25 mL × 2), dried over Na2SO4 and concentrated on rotavap.  Pure 
product 291 was obtained via gradient column chromatography using silica gel as the 
stationary phase and a mixture of ethyl acetate-hexane (1:2 to 3:1) as the mobile phase. 
 Methanol (9.2 mL) was added to 291 (0.41 g, 1.1 mmol, taken in a RB flask.  To 
the solution, conc. HCl (2.1 mL) was dropwise and the resulting mixture stirred at room 
temperature for 12 h.  The solvent was removed under reduced pressure and the crude 
amine 1y was purified via gradient column chromatography using silica gel as the 
stationary phase and ethyl acetate-hexane (1:4 to 2:1) followed by dichloromethane-
methanol (10:1 to 1:5) mixtures as the mobile phase. 
3.3.6. Synthesis of the aldehyde 213n: 
 3-Methoxy-4-hydroxybenzaldehyde (0.5 g, 3.3 mmol) was taken in dry RB flask 
and anhydrous DMF (2.5 mL) was added. The mixture was then stirred to dissolve the 
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aldehyde and imidazole (0.67 g, 9.9 mmol) was added to the mixture at room 
tempertaure. After stirring for 5 minutes, tert-butyldimethylsilyl chloride (TBDMSCl, 
0.79 g, 5.3 mmol) and the resulting solution was stirred at room temperature for 3 h.  The 
reaction mixture was then diluted with diethyl ether (5 mL) and washed with water (50 
mL).  The organic layer was separated, dried over Na2SO4 and concentrated on rotavap.  
The crude product was purified via gradient column chromatography using silica gel as 
the stationary phase and mixture of ethyl acetate/hexane (1:5 to 1:2) as the mobile phase 
to afford TBDMS protected aldehyde 213n in 95% yield. 
3.3.7. General procedure for Passerini reaction: 
 4 Å molecular sieves (MS) was dried in oven for 24 h and then further dried under 
high vacuum with heating by a heat gun for 1 h.  After cooling, the MS (0.1 g) was 
transferred into a dry RB flask equipped with magnetic stir bar under Argon.  213n (0.15 
g, 0.57 mmol) was added to the flask and dissolved in anhydrous CH2Cl2 (3 mL).  Then 
fumaric monoethyl ester (2a, 0.083 g, 0.57 mmol) was added followed by tert-butyl 
isocyanide (0.05 mL, 0.57 mmol).  The resulting mixture was stirred at room temperature 
for 48 h under Argon and then TLC showed 70% conversion.  The reaction was diluted 
with CH2Cl2 (3 mL) and quenched by the addition of 1 N HCl (4 mL).  The organic layer 
was separated, dried over Na2SO4 and concentrated on rotavap.  Purification of the crude 
product via gradient column chromatography using silica gel as the stationary phase and 
mixture of ethyl acetate/hexane (1:5 to 1:1) as the mobile phase provided 50% of 299. 
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3.4. Experimental Data 
1. (E)-Ethyl 4-((2-(tert-butylamino)-1-(4-hydroxy-3-methoxyphenyl)-2-oxoethyl)(4-
hydroxybenzyl)amino)-4-oxobut-2-enoate 
 
 
1H NMR (500 MHz, CDCl3): δ 7.28 (d, 1 H, J = 15.2 Hz, -CH=CH-), 6.72-6.88 (m, 6 H, 
Aryl and –CH=CH- overlap), 6.62 (d, 2 H, J = 8.2 Hz, Aryl), 5.73 (s, 1 H, Ha), 5.64 (br s, 
1 H, -OH), 4.70 (d, 1 H, J = 17.4 Hz, -NCH2Ar), 4.49 (d, 1 H, J = 17.1 Hz, -NCH2Ar), 
4.18 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.72 (s, 3 H, OMe), 1.33 (s, 9 H, t-Bu), 1.26 (t, 3 
H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 168.7, 166.4, 165.4, 156.9, 146.4, 146.1, 137.6, 134.6, 
134.1, 132.4, 128.3, 127.1, 126.2, 126.0, 123.2, 115.4, 112.6, 62.9, 61.0, 55.8, 51.7, 49.6, 
28.6, 14.1. 
HRMS (EIMS): calcd for C26H32N2O7 484.2210, found 484.2223. 
 
2. Ethyl 2-((1S,5aR)-5-(tert-butyl)-3-(4-hydroxybenzyl)-8-methoxy-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.12 (d, 1H, J = 8.9 Hz, Aryl), 6.76 (d, 1H, J = 8.1 Hz, 
Aryl), 5.15 (d, 1H, J = 14.6 Hz, -CH2Ph), 5.11 (s, 1H, Hf), 4.84 (br s, 1H, -OH), 4.48 (dd, 
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1H, J = 11.4, 4.9 Hz; Hd), 4.26 (s, 1H, J = 14.6 Hz, -CH2Ph), 4.08 (q, 2H, J = 7.3 Hz,  -
OCH2CH3), 3.81 (s, 1H, Ha), 3.50 (s, 3H, -OMe), 3.27 (dd, 1H, J = 10.4, 3.2 Hz; Hb), 
3.10 (dd, 1H, J = 17.6, 3.2 Hz; He), 3.03 (dd, 1H, J = 15.2, 6.0 Hz; Hc), 2.44 (dd, 1H, J = 
17.6, 10.4 Hz; He), 2.42 (dd, 1H, J = 15.2, 2.8 Hz; Hc), 1.46 (s, 9H, tBu), 1.20 (t, 3H, J = 
7.3 Hz, -OCH2CH3). 
13C NMR (100 MHz, CDCl3): δ 189.9, 172.0, 171.9, 169.6, 156.1, 151.3, 130.0, 128.9, 
126.8, 119.9, 115.7, 115.4, 114.5, 109.4, 109.3, 74.1, 63.8, 61.3, 56.7, 55.8, 55.5, 55.2, 
46.5, 45.6, 45.3, 30.7, 28.6, 27.9, 14. 
HRMS (EIMS): calcd for C26H32N2O7 484.2210, found 484.2216. 
 
3. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(4-hydroxyphenyl)-2-oxoethyl)amino)-
4-oxobut-2-enoate 
HN
t-Bu
O
N
O
EtO2C
HO
Ha
( )-219  
1H NMR (500 MHz, CDCl3): δ 7.20 (d, 1H, J = 16.0 Hz, -CH=CH-), 7.07-7.17 (m, 5H, 
Ph), 6.9 (d, 2H, J = 6.7 Hz, Aryl), 6.79 (d, 1H, J = 15.3 Hz, -CH=CH-), 6.58 (d, 2H, J = 
8.5 Hz, Aryl), 5.82 (s, 1H, Ha), 5.74 (br s, 1H, -NH), 4.78 (d, 1H, J = 17.7 Hz, -CH2Ph), 
4.57 (d, 1H, J = 17.7 Hz, -CH2Ph), 4.16 (q, 2H, J = 7.3 Hz, -OCH2CH3), 1.31 (s, 9H, 
tBu), 1.24 (-OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 169.0, 166.5, 165.4, 156.7, 137.2, 134.0, 132.3, 131.3, 
128.4, 127.2, 126.3, 125.6, 115.8, 63.2, 61.1, 51.9, 49.8, 28.6, 14.1. 
 
 233
HRMS (EIMS): calcd for C25H30N2O5 438.2155, found 438.2163. 
4. Ethyl 2-((1S,5aR)-3-benzyl-5-(tert-butyl)-2,4,7-trioxo-2,3,3a,4,5,5a,6,7-octahydro-
1H-pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.21-7.38 (m, 5H, Ph), 6.43 (d, 1H, J = 10.5 Hz, Hg), 6.09 
(d, 1H, J = 10.5 Hz, Hf), 5.26 (d, 1H, J = 15.4 Hz, -CH2Ph), 4.58 (dd, 1H, J = 11.0, 5.7 
Hz; Hd), 4.41 (d, 1H, J = 14.6 Hz, -CH2Ph), 4.11 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.7 (s, 
1H, Ha), 3.29 (dd, 1H, J = 10.5, 3.2 Hz; Hb), 3.16 (dd, 1H, J = 17.8, 3.2 Hz; He), 2.97 (dd, 
1H, J = 15.4, 5.7 Hz; Hc), 2.43 (dd, 1H, J = 17.8, 10.5 Hz; He), 2.29 (dd, 1H, J = 15.4, 
11.4 Hz; Hc), 1.48 (s, 9H, tBu), 1.22 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 195.2, 171.8, 171.7, 169.0, 143.4, 135.3, 132.3, 132.3, 
130.2, 128.9, 128.5, 128.0, 62.5, 61.3, 57.3, 55.5, 45.9, 45.8, 45.5, 45.1, 30.7, 27.9, 14.1. 
 
HRMS (EIMS): calcd for C25H30N2O5 438.2155, found 438.2154. 
 
5. Ethyl 2-((1R,4S)-2-benzyl-1-(tert-butylcarbamoyl)-3,8-dioxo-2-azaspiro[4.5]deca-
6,9-dien-4-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.27-7.36 (m, 4H, Ph), 7.22-7.26 (m, 1H, Ph), 6.84 (dd, 
1H, J = 10.5, 3.24 Hz, He), 6.55 (dd, 1H, J = 10.5, 3.24 Hz; He), 6.29 (dd, 1H, J = 10.5, 
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1.6 Hz; Hf), 6.23 (dd, 1H, J = 9.7, 1.6 Hz, Hf), 5.5 (s, 1H, -NH), 5.05 (d, 1H, J = 14.6 Hz; 
J = 14.6Hz, -CH2Ph), 4.02-4.11 (m, 2H, -OCH2CH3), 3.92 (d, 1H, J = 14.6 Hz, -CH2Ph), 
3.74 (dd, 1H, J = 8.9, 5.7 Hz; Hb), 3.30 (s, 1H, Ha), 2.75 (dd, 1H, J = 17.0, 5.7 Hz; Hc), 
2.12 (dd, 1H, J = 16.2, 8.9 Hz; Hc), 1.31 (s, 9H, tBu), 1.19 (t, 3H, J = 7.3 Hz, -
OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 184.7, 176.9, 170.9, 165.9, 147.4, 146.4, 135.7, 131.3, 
130.5, 129.0, 128.8, 65.5, 60.9, 52.4, 48.0, 46.6, 45.5, 42.4, 30.8, 28.2, 14.0. 
 
HRMS (EIMS): calcd for C25H30N2O5 438.2155, found 438.2162. 
6. Ethyl 2-((1S,5aR)-3-benzyl-5-(tert-butyl)-8-methoxy-2,4,7-trioxo-2,3,3a,4,5,5a,6,7-
octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.22-7.38 (m, 5H, Ph), 5.28 (d, 1H, J = 14.6 Hz, -CH2Ph), 
5.15 (s, 1H, Hf), 4.50 (dd, 1H, J = 12.2, 5.7 Hz, Hd), 4.38 (d, 1H, J = 14.6 Hz, -CH2Ph), 
4.10 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.53 (s, 1H, Ha), 3.29 (dd, 1H, J = 10.5, 3.2 Hz; 
Hb), 3.14 (dd, 1H, J = 17.8, 3.2 Hz; He), 3.05 (dd, 1H, J = 15.4, 5.7 Hz; Hc), 2.47 (dd, 1H, 
J = 17.8, 10.5 Hz; He), 2.41 (dd, 1H, J = 15.4, 7.3 Hz; Hc), 1.47 (s, 9H, tBu), 1.22 (t, 3H, 
J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 189.9, 171.9, 169.4, 151.3, 135.6, 128.6, 128.5, 128.1, 
109.5, 63.8, 61.3, 56.6, 55.4, 55.2, 46.5, 45.8, 45.5, 45.4, 30.8, 28.2, 27.9, 14.1. 
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HRMS (EIMS): calcd for C26H32N2O6 468.2260, found 468.2272. 
7. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(4-hydroxy-3-methoxyphenyl)-2-
oxoethyl)amino)-4-oxobut-2-enoate 
HN
t-Bu
O
N
O
EtO2C
HO
Ha
MeO
( )-224  
1H NMR (500 MHz, CDCl3): δ 7.24 (d, 1H, J = 15.3 Hz, -CH=CH-), 7.09-7.17 (m, 3H, 
Aryl), 6.70-6.94 (m, 6H, -CH=CH- and Aryl  overlap), 5.88 (s, 1H, Ha), 5.60 (br s, 1H, -
OH), 4.80 (d, 1H, J = 17.7 Hz, -CH2Ph), 4.6 (d, 1H, J = 17.7 Hz, -CH2Ph), 4.16 (q, 2H, J 
= 7.3 Hz, -OCH2CH3), 3.68 (s, 3H, -OMe), 1.34 (s, 9H, tBu), 1.24 (t, 3H, J = 7.3 Hz, -
OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 168.7, 166.4, 165.4, 146.4, 146.1, 137.6, 134.6, 134.1, 
132.4, 128.3, 127.1, 126.2, 126.0, 123.2, 114.4, 112.6, 62.9, 61.0, 55.8, 51.7, 49.6, 28.6, 
14.1. 
HRMS (EIMS): calcd for C26H32N2O6 468.2260, found 468.2256. 
 
8. Ethyl 2-((1S,5aS,6S)-3-benzyl-5-(tert-butyl)-6,8-dimethoxy-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (400 MHz, CDCl3): δ 7.26-7.38 (m, 5H, Ph), 5.78 (d, 1H, J = 2.4 Hz, He), 5.52 
(s, 1H, Hf), 5.40 (d, 1H, J = 1.5 Hz, Hd), 3.97-4.08 (m, 2H, -OCH2CH3), 3.83 (d, 1H, J = 
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14.9 Hz, -CH2Ph), 3.81 (t from dd overlap, 1H, J = 5.7 Hz, Hb), 3.64 (s, 3H, -OMeh), 3.45 
(s, 3H, -OMeg), 3.27 (s, 1H, Ha), 2.69 (dd, 1H, J = 16.6, 4.9 Hz, Hc), 2.08 (dd, 1H, J = 
16.6, 8.9 Hz; Hc), 1.35 (s, 9H, tBu), 1.17 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 173.2, 171.3, 166.6, 152.0, 151.7, 135.5, 129.0, 128.8, 
128.4, 114.5, 113.7, 66.8, 60.9, 55.3, 55.2, 52.4, 47.2, 46.4, 30.6, 28.7, 13.9. 
 
HRMS (EIMS): calcd for C27H34N2O7 498.2366, found 498.2372. 
9. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(4-hydroxy-3,5-dimethoxyphenyl)-2-
oxoethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.24 (d, 1H, J = 14.6 Hz, -CH=CH-), 7.08-7.19 (m, 3H, 
Ph), 6.89-6.97 (m, 2H, Ph), 6.86 (d, 1H, CH=CH-), 6.50 (s, 2H, Aryl), 6.32 (br s, 1H, -
NH), 5.58 (s, 1H, Ha), 5.52 (br s, 1H, -OH), 4.80 (d, 1H, J = 17.4 Hz, -CH2Ph), 4.61 (d, 
1H, J = 17.4 Hz, -CH2Ph), 4.16 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.69 (s, 6H, 2 –OMe), 
1.34 (s, 9H, tBu), 1.23 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
13C NMR (100 MHz, CDCl3): δ 168.6, 166.3, 165.3, 146.9, 137.6, 134.9, 133.9, 132.4, 
128.3, 127.0, 126.1, 124.9, 106.9, 62.9, 61.0, 56.1, 51.7, 49.5, 28.5, 14. 
HRMS (EIMS): calcd for C27H34N2O7 498.2366, found 498.2376. 
 
10. Ethyl 2-((1S,5aR)-5-cyclohexyl-8-methoxy-2,4,7-trioxo-3-(prop-2-yn-1-yl)-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 5.34 (s, 1H, Hf), 4.77 (dd, 1H, J = 17.4, 2.5 Hz; Hg), 4.43 
(dd, 1H, J = 11.6, 5.8 Hz, Hd), 4.28 (s, 1H, Ha), 4.18 (dd, 1H, J = 17.4, 1.5 Hz; Hg), 4.09 
(q, 2H, J = 7.3 Hz, -OCH2CH3), 3.80-3.90 (m, 1H, Hi), 3.65 (s, 3H, -OMe), 3.12 (dd, 1H, 
J = 10.1, 4.0 Hz; Hb), 3.11 (dd, 1H, J = 15.6, 5.8 Hz; He), 3.04 (dd, 1H, J = 17.8, 4.0 Hz; 
Hc), 2.58 (dd, 1H, J = 15.6, 11.6 Hz; He), 2.44 (dd, 1H, J = 17.8, 11.0 Hz; Hc), 2.28 (t, 
1H, J = 2.54 Hz, Hh), 1.54-1.92 (m, 5H, Cy), 1.30-1.42 (m, 4H, Cy), 1.21 (t, 3H, J = 7.3 
Hz, -OCH2CH3), 1.08-1.19 (m, 1H, Cy). 
 
13C NMR (125 MHz, CDCl3): δ 189.9, 171.6, 171.1, 168.7, 151.6, 109.2, 72.9, 63.7, 61.3, 
55.9, 55.5, 52.9, 46.8, 46.0, 44.9, 32.0, 30.9, 30.1, 25.7, 25.6, 25.2, 14.1. 
 
HRMS (EIMS): calcd for C32H30N2O6 538.2104, found 538.2109. 
 
11. Ethyl 2-((2S,5R)-1-cyclohexyl-5-(4-hydroxy-3-methoxyphenyl)-3,6-dioxo-4-
(prop-2-yn-1-yl)piperazin-2-yl)acetate 
N
NO
O
CO2Et
HO
MeO
Hf
Ha
Hb
Hc HcHd
He
He
( )-229  
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1H NMR (500 MHz, CDCl3): δ 6.90 (d, 1H, J = 7.6 Hz, Aryl), 6.81 (s, 1H, Aryl), 6.80 (d, 
1H, J = 7.6 Hz, Aryl), 5.71 (s, 1H, -OH), 5.22 (s, 1H, Ha), 4.75 (dd, 1H, J = 17.1, 2.5; 
He), 4.37 (dd, 1H, J = 8.2, 5.5 Hz; Hb), 4.18 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.88 (s, 3H, 
-OMe), 3.44-3.53 (m, 1H, Hd), 3.29 (dd, 2H, J = 17.1, 2.5 Hz; He and Hc overlap), 2.95 
(dd, 1H, J = 17.4, 5.5, Hc), 2.21 (t, 1H, J = 2.5 Hz, Hf), 1.91-2.03 (m, 1H, Cy), 1.57-1.87 
(m, 8H, Cy), 1.26 (t, 3H, J = 7.3 Hz, -OCH2CH3), 1.02-1.17 (m, 1H, Cy). 
 
13C NMR (125 MHz, CDCl3): δ 169.6, 166.1, 165.7, 146.8, 146.0, 128.7, 120.8, 114.8, 
110.7, 76.8, 72.4, 63.4, 61.2, 58.7, 55.9, 55.8, 37.6, 33.5, 30.0, 29.8, 26.1, 26.0, 25.3, 
14.2. 
 
HRMS (EIMS): calcd for C32H30N2O6 538.2104, found 538.2109. 
 
12. (E)-Ethyl 4-(benzyl(2-(cyclohexylamino)-1-(4-hydroxyphenyl)-2-
oxoethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.20 (d, 1H, J = 15.4 Hz, -CH=CH-), 7.07-7.17 (m, 5H, 
Ph), 6.96 (d, 2H, J = 7.3 Hz, Aryl), 6.78 (d, 1H, J = 15.4 Hz, -CH=CH-), 6.68 (d, 2H, J = 
8.3 Hz, Aryl), 5.84 (br s, 1H, -OH), 5.80 (s, 1H, Ha), 4.77 (d, 1H, J = 17.8 Hz, -CH2Ph), 
4.56 (d, 1H, J = 17.8 Hz,  -CH2Ph), 4.16 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.69-3.82 (m, 
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1H, Hh), 1.80-1.92 (m, 2H, Cy), 1.50-1.68 (m, 3H, Cy), 1.25-1.37 (m, 2H, Cy), 1.24 (t, 
3H, J = 7.3 Hz, -OCH2CH3), 0.98-1.14 (m , 3H, Cy) 
13C NMR (100 MHz, CDCl3): δ 168.8, 166.4, 165.9, 137.0, 134.0, 132.2, 131.2, 128.5, 
127.3, 126.3, 125.4, 115.8, 63.1, 61.1, 49.9, 48.8, 32.6, 25.4, 24.7, 24.6, 14. 
HRMS (EIMS): calcd for C27H32N2O5 464.2325, found 464.2324. 
 
13. Ethyl 2-((1S,5aR)-3-benzyl-5-adamantyl-8-methoxy-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
( )-230
N
O
ON
O Bn
Ha
Hd
Hb
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EtO2CHf
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1H NMR (500 MHz, CDCl3): δ 7.28-7.36 (m, 5H, Ph), 5.27 (d, 1H, J = 14.7 Hz, -CH2Ph), 
5.16 (s, 1H, Hf), 4.52 (dd, 1H, J = 12.2, 5.5 Hz, Hd), 4.39 (d, 1H, J = 14.7 Hz, -CH2Ph), 
4.10 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.67 (s, 1H, Ha), 3.54 (s, 3H, -OMe), 3.30 (dd, 1H, 
J = 10.9, 3.2 Hz; Hb), 3.13 (dd, 1H, J = 18.0, 3.9 Hz, He), 3.07 (dd, 1H, J = 15.6, 5.5 Hz; 
Hc), 2.47 (dd, 1H, J = 18.0, 10.9 Hz; He), 2.43 (dd, 1H, J = 15.6, 12.2 Hz; Hc), 2.09-2.24 
(m, 9H, Ada), 1.65-1.75 (m, 6H, Ada), 1.22 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 190.1, 171.9, 171.8, 169.4, 151.3, 135.6, 128.9, 128.1, 
109.6, 64.0, 61.2, 56.8, 55.9, 55.2, 46.3, 45.8, 45.6, 41.5, 39.8, 36.1, 30.9, 29.6, 14.1. 
 
HRMS (EIMS): calcd for C32H30N2O6 538.2104, found 538.2109. 
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14. (E)-Ethyl 4-((2-((3s,5s,7s)-adamantan-1-ylamino)-1-(4-hydroxy-3-
methoxyphenyl)-2-oxoethyl)(benzyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.23 (d, 1H, J = 15.6 Hz, -CH=CH-), 7.10-7.19 (m, 3H, 
Aryl), 6.82-6.97 (m, 4H, Aryl and –CH=CH- overlap), 6.70-6.80 (m, 2H, Aryl), 5.87 (s, 
1H, Ha), 5.43 (br s, -OH), 4.80 (d, 1H, J = 17.8 Hz, -CH2Ph), 4.6 (d, 1H, J = 17.8 Hz, -
CH2Ph), 4.12-4.22 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.69 (s, 3H, -OMe), 1.95-2.12 (m, 
9H, Ada), 1.65 (s, 6H, Ada), 1.24 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 168.4, 166.3, 165.4, 146.4, 145.9, 134.1, 132.4, 128.3, 
127.0, 126.2, 123.2, 114.4, 112.6, 62.9, 61.0, 55.8, 52.5, 49.6, 41.3, 36.2, 29.4, 14.1. 
HRMS (EIMS, M+): calcd for C32H30N2O6 538.2104, found 538.2113. 
 
15. Ethyl 2-((1S,5aR)-3-benzyl-5-(tert-butyl)-9-methoxy-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 7.27-7.33 (m, 5H, Ph), 5.39 (s, 1H, Hf), 5.26 (d, 1H, J = 
14.7 Hz, -CH2Ph), 4.53 (dd, 1H, J = 11.9, 5.8 Hz; Hd), 4.37 (d, 1H, J = 14.7 Hz, -CH2Ph), 
4.07-4.17 (m, 2H, -OCH2CH3), 3.54 (s, 1H, Ha), 3.33 (dd, 1H, J = 9.5, 3.4 Hz, Hb), 3.18 
(dd, 1H, J = 18.3, 3.4 Hz, He), 2.90 (dd, 1H, J = 15.6, 5.8 Hz, Hc), 2.32 (dd, 1H, J = 18.3, 
9.5 Hz; He), 2.22 (dd, 1H, J = 15.6, 11.9 Hz; Hc), 1.48 (s, 9H, tBu), 1.24 (t, 3H, J = 7.3 
Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 193.8, 172.6, 172.4, 172.2, 168.9, 135.5, 129.0, 128.4, 
127.8, 103.8, 61.9, 61.2, 56.4, 56.0, 55.4, 48.5, 45.7, 45.2, 44.8, 30.6, 27.9, 14.2. 
 
HRMS (EIMS): calcd for C26H32N2O6 468.2260, found 468.2264. 
 
16. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(4-hydroxy-2-methoxyphenyl)-2-
oxoethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.15 (d, 1H, J = 15.4 Hz, -CH=CH-), 7.03-7.15 (m, 5H, 
Ph), 6.78-6.85 (m, 2H, Aryl), 6.75 (d, 1H, J = 15.4 Hz, -CH=CH-), 6.29-6.37 (m, 1H, 
Aryl), 6.12 (s, 1H, Ha), 6.01 (br  s, 1H, -NH), 5.81 (br s, 1H, -OH), 4.73 (d, 1H, J = 17.8 
Hz, -CH2Ph), 4.50 (d, 1H, J = 17.8 Hz, -CH2Ph), 4.16 (q, 2H, J = 7.3 Hz, -OCH2CH3), 
3.46 (s, 3H, -OMe), 1.30 (s, 9H, tBu), 1.23 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 170.2, 166.2, 165.5, 158.9, 158.7, 137.2, 134.1, 131.8, 
130.9, 127.9, 127.8, 126.7, 125.9, 113.3, 107.3, 98.6, 61.1, 57.4, 54.7, 51.7, 49.5, 28.5, 
14.0. 
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HRMS (EIMS): calcd for C26H32N2O6 468.2260, found 468.2262. 
 
17. Ethyl 2-((1S,5aS)-3-benzyl-5-(tert-butyl)-5a,9-dimethoxy-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.27-7.35 (m, 5H, Ph), 5.57 (s, 1H, Hg), 5.36 (s, 1H, He), 
4.80 (d, 1H, J = 14.4 Hz, -CH2Ph), 4.15 (d, 1H, J = 14.4 Hz, -CH2Ph), 4.06 (q, 2H, J = 
7.3 Hz, -OCH2CH3), 3.94 (t from dd overlap, 1H, J = 6.7 Hz, Hb), 3.77 (s, 1H, Ha), 3.65 
(s, 3H, -OMef), 3.30 (s, 3H, -OMed), 2.73 (dd, 1H, J = 17.0, 6.1 Hz; Hc), 2.05 (dd, 1H, J 
= 17.0, 7.6 Hz; Hc), 1.24 (s, 9H, tBu), 1.19 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 186.4, 174.5, 171.2, 170.2, 167.7, 165.6, 135.2, 129.7, 
128.8, 128.3, 103.8, 101.7, 66.9, 61.0, 56.2, 55.7, 51.9, 51.7, 47.9, 43.9, 30.5, 28.5, 14.0. 
 
HRMS (EIMS): calcd for C27H34N2O7 498.2366, found 498.2368. 
 
18. Ethyl 2-((1S,5aR)-3-benzyl-5-(tert-butyl)-8-fluoro-2,4,7-trioxo-2,3,3a,4,5,5a,6,7-
octahydro-1H-pyrrolo[2,3-c]indol-1-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 7.24-7.39 (m. 5H, Ph), 5.97 (d, 1 H, J = 12.9 Hz, Hf), 
5.25 (d, 1 H, J = 14.6 Hz, –CH2Ph), 4.64 (dd, 1 H, J = 11.4 ,5.7 Hz, Hd), 4.41 (d, 1 H, J = 
14.6 Hz, –CH2Ph), 4.13 (q, 2H, J = 7.3 Hz, -OCH2CH3), 3.75 (s, 1 H, Ha), 3.24-3.32 (m, 
1 H, Hb), 3.19 (dd, 1 H, J = 18.6, 3.2 Hz, Hc), 3.09 (dt, 1H, J = 15.4, 5.3 Hz, He), 2.45 
(dd, 1 H, J = 10.8, 4.6 Hz, He), 2.40 (dd, 1 H, J = 11.3, 8.1 Hz, Hc), 1.47 (s, 9 H, t-butyl), 
1.23 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 186,7, 171.9, 171.2, 168.9, 154.7, 152.0, 143.1, 135.2 
(JC-F = 48.5 Hz), 128.9, 128.5, 128.1, 119.6 (JC-F = 72.5 Hz), 62. 7, 62.7, 61.4, 56.6, 55.6, 
45.8, 45.4, 45.3, 45.3, 44.8, 30.8, 27.9, 14.1. 
 
19F NMR (282 MHz, CDCl3): δ – 124.9. 
 
HRMS (EIMS): calcd for C25H29FN2O5 456.2061, found 456.2065. 
 
19. (1S,5aR)-3-Benzyl-5-(tert-butyl)-8-methoxy-1-(2-oxo-2-phenylethyl)-3,3a,5a,6-
tetrahydro-1H-pyrrolo[2,3-c]indole-2,4,7(5H)-trione 
 
1H NMR (500 MHz, CDCl3): δ 7.90-7.99 (m, 2 H, Bz), 7.55-763 (m, 1 H, Bz), 7.42-7.51 
(m, 2 H, Bz), 7.31-7.39 (m, 5 H, Ph), 5.32 (d, 1 H, J = 14.6 Hz, -CH2Ph), 5.15 (s, 1 H, 
Hf), 4.70 (dd, 1 H, J = 5.7 Hz, Hd), 4.42 (d, 1 H, J = 14.6 Hz, -CH2Ph), 3.89 (dd, 1 H, J = 
18.7, 2.4 Hz, He), 3.73 (s, 1 H, Ha), 3.59 (m, 1 H, Hb), 3.41 (s, 3 H, OMe), 3.19 (dd, 1 H, 
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J = 18.7, 10.5 Hz, Hc), 3.06 (dd, 1 H, J = 15.4, 5.7 Hz, He), 2.41 (dd, 1 H, J = 15.4, 12.2 
Hz, Hc), 1.53 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 197.5, 189.9, 172.8, 169.6, 151.3, 135.9, 135.7, 133.7, 
128.8, 128.7, 128.5, 128.0, 109.8, 64.1, 56.5, 55.5, 55.1, 46.9, 45.9, 45.5, 44.3, 35.5, 27.9. 
 
HRMS (EIMS): calcd for C30H32N2O5 500.2311, found 500.2998. 
 
20. (1S,5aR)-3-Benzyl-5-(tert-butyl)-8-methoxy-1-(2-oxo-2-(p-tolyl)ethyl)-3,3a,5a,6-
tetrahydro-1H-pyrrolo[2,3-c]indole-2,4,7(5H)-trione 
( )-243
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1H NMR (500 MHz, CDCl3): δ 7.85 (d, 2 H, J = 8.2 Hz, aryl), 7.29-7.39 (m, 5 H, Ph), 
7.27 (d, 2 H, J = 7.9 Hz, aryl), 5.32 (d, 1 H, J = 15.0 Hz, -CH2Ph), 5.16 (s, 1 H, Hf), 4.72 
(dd, 1 H, J = 12.2, 5.8 Hz, Hd), 4.42 (d, 1 H, J = 14.7 Hz, -CH2Ph), 3.86 (dd, 1 H, J = 2.5 
Hz, Hc), 3.73 (s, 1H, Ha), 3.58 (m, 1 H, Hb), 3.42 (s, 3 H, OMe), 3.18 (dd, 1 H, J = 18.9, 
10.4 Hz, Hc), 3.06 (dd, 1 H, J = 15.6, 5.8 Hz, He), 2.41 (m, 4 H, He and Me overlap), 1.54 
(s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 197.1, 189.9, 172.9, 169.6, 151.3, 144.7, 135.8, 133.5, 
129.5, 128.8, 128.6, 128.2, 128.0, 109.9, 64.1, 56.5, 55.5, 55.2, 53.4, 46.9, 45.9, 45.5, 
44.3, 35.3, 27.9, 21.7. 
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HRMS (EIMS): calcd for C31H34N2O5 514.2468, found 514.2470 
 
21. (1S,5aR)-5-(tert-Butyl)-3-(3,5-dimethoxybenzyl)-8-methoxy-1-(2-oxo-2-(p-
tolyl)ethyl)-3,3a,5a,6-tetrahydro-1H-pyrrolo[2,3-c]indole-2,4,7(5H)-trione 
 
1H NMR (500 MHz, CDCl3): δ 7.84 (d, 2 H, J = 8.2 Hz, aryl), 7.25 (d, 2 H, J = 7.9 Hz, 
aryl), 6.42-6.46 (m, 2 H, aryl), 6.36-6.39 (m, 1 H, aryl), 6.23 (d, 1 H, J = 1.2 Hz, Hf), 5.22 
(d, 1 H, J = 15.0 Hz, -CH2Ph), 4.70 (dd, 1 H, J = 12.2, 5.5 Hz, Hd), 4.40 (d, 1 H, 15.0 Hz, 
-CH2Ph), 3.84 (dd, 1 H, J = 18.9, 2.4 Hz, Hc), 3.78 (s, 1 H, Ha), 3.77 (s , 6 H, OMe, 
OMe), 3.55 (m, 1 H, Hb), 3.13 (dd, 1 H, J = 18.6, 10.1 Hz, Hc), 2.98 (dd, 1 H, J = 15.3, 
5.8 Hz, He), 2.40 (s, 3 H, Me), 2.29 (dd, 1 H, J = 15.3, 12.2 Hz, He), 1.52 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 197.2, 195.7, 172.9, 169.5, 161.2, 144.6, 138.5, 137.9, 
137.1, 133.6, 129.4, 128.2, 106.3, 99.8, 63.0, 57.3, 55.4, 55.3, 46.5, 45.8, 45.4, 44.2, 35.2, 
27.9, 21.6, 15.9. 
 
HRMS (EIMS): calcd for C33H30N2O7 566.2053, found 566.2057. 
 
22. Ethyl 2-((5aR)-3-benzyl-5-(tert-butyl)-2,4,7-trioxo-2,3,3a,4,5,5a,6,7-octahydro-
1H-benzo[e]pyrrolo[2,3-c]indol-1-yl)acetate 
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1H NMR (500 MHz, CDCl3): δ 7.8 (dd, 1H, J = 7.6, 1.2 Hz; Aryl), 7.2-7.44 (m, 7h, 
Aryl), 6.76 (d, 1H, J = 7.3 Hz, Aryl), 5.32 (d, 1H, J = 14.3 Hz, -CH2Ph), 4.70 (dd, 1H, J 
= 12.5, 4.9 Hz; Hd), 4.49 (d, 1H, J = 14.3 Hz, -CH2Ph), 3.86-3.99 (m , 3H, -OCH2CH3 
and Ha overlap), 3.49 (dd, 1H, J = 10.1, 3.4 Hz, Hb), 3.14 (dd, 1H, J = 14.3, 4.9 Hz; He), 
3.00 (dd, 1H, J = 18.0, 3.4 Hz; Hc), 2.48 (dd, 1H, J = 13.7, 3.1 Hz, He), 2.04 (dd, 1H, J = 
18.0, 10.1 Hz, Hc), 1.54 (s, 9H, tBu), 1.03 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 194.7, 172.7, 171.9, 169.5, 139.0, 135.1, 134.1, 132.1, 
129.5, 128.7, 128.2, 128.0, 126.9, 126.7, 64.9, 60.9, 58.4, 55.5, 47.3, 47.2, 46.1, 30.9, 
27.9, 13.9. 
HRMS (EIMS): calcd for C29H32N2O5 488.2311, found 488.2314. 
 
23. Ethyl 2-((1S,2'R,4'S)-1'-benzyl-2'-(tert-butylcarbamoyl)-4,5'-dioxo-4H-
spiro[naphthalene-1,3'-pyrrolidin]-4'-yl)acetate (Spiro 11a) 
 
1H NMR (500 MHz, CDCl3): δ 7.73 (dd, 1H, J = 7.6, 1.2 Hz, Aryl), 7.27-7.39 (m, 6H, 
Aryl), 7.21-7.70 (m, 1H, Aryl), 7.08 (dd, 1H, J = 7.9, 0.6 Hz, Aryl), 6.99 (d, 1H, J = 10.4, 
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He), 6.41 (d, 1H, J = 10.4 Hz, Hd), 5.83 (s, 1H, -NH), 5.14 (d, 1H, J = 14.3 Hz, -CH2Ph), 
3.87-3.97 (m, 3H, -OCH2CH3 and –CH2Ph overlap), 3.73 (dd, 1H, J = 8.6, 5.8 Hz; Hb), 
3.64 (s, 1H, Ha), 2.48 (dd, 1H, J = 16.5, 6.1 Hz; Hc), 1.69 (dd, 1H, J = 16.5, 6.1 Hz, Hc), 
1.35 (s, 9H, tBu), 1.07 (t, 3H, J = 7.3 Hz, -OCH2CH3). 
13C NMR (125 MHz, CDCl3): δ 192.2, 183.7, 173.8, 170.9, 166.4, 150.6, 142.3, 140.2, 
134.5, 132.7, 130.2, 129.5, 129.3, 128.2, 128.1, 126.4, 125.1, 68.8, 60.7, 52.2, 47.5, 47.4, 
46.7, 30.6, 28.5, 13.8. 
 
HRMS (EIMS): calcd for C29H32N2O5 488.2311, found 488.2316. 
 
24. Ethyl 2-((1S,5aR)-5-(tert-butyl)-3-(4-hydroxybenzyl)-2,4,7-trioxo-
2,3,3a,4,5,5a,6,7-octahydro-1H-benzo[e]pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.78-7.83 (m, 1H, Aryl), 7.29-7.39 (m, 2H, Aryl), 7.25 (d, 
2H, J = 8.2 Hz, Aryl), 6.68-6.80 (m, 3H, Aryl), 6.1 (br s, 1H, -OH), 5.22 (d, 1H, J = 14.3 
Hz, -CH2Ph), 4.70 (dd, 1H, J = 12.6, 4.7 Hz; Hd), 4.49 (d, 1H, J = 14.3 Hz, -CH2Ph), 3.96 
(s, 1H, Ha), 3.87-3.95 (m, 2H, -OCH2CH3), 4.48 (dd, 1H, J = 10.4, 3.4 Hz; Hb), 3.14 (dd, 
1H, J = 14.4, 5.1 Hz; He), 2.98 (dd, 1H, J = 18.0, 3.7 Hz; Hc), 2.48 (t from dd overlap, 
1H, J = 14.4 Hz, He), 2.02 (dd, 1H, 1H, J = 18.0, 10.1 Hz; Hc), 1.53 (s, 9H, tBu), 1.05 (t, 
3H, J = 7.3 Hz, -OCH2CH3). 
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13C NMR (125 MHz, CDCl3): δ 194.7, 172.7, 171.9, 169.6, 155.9, 138.9, 134.2, 132.0, 
130.9, 128.3, 126.9, 115.6, 64.9, 61.0, 58.5, 55.6, 47.5, 47.3, 46.1, 45.6, 30.8, 27.9, 13.9. 
 
HRMS (EIMS): calcd for C29H32N2O6 504.2260, found 504.2272. 
 
25. Ethyl 2-((1S,11bS)-5-benzyl-3-(4-hydroxybenzyl)-2,4,7-trioxo-2,3,3a,4,5,5a,6,7-
octahydro-1H-benzo[e]pyrrolo[2,3-c]indol-1-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.71-7.75 (m, 1 H, J = 8.2 Hz, Aryl), 7.24-7.38 (m, 9 H, 
Aryl), 6.82 (d, 2 H, J = 7.9 Hz, Aryl), 6.70 (d, 1 H, J = 7.6 Hz, Aryl), 5.22 (d, 1 H, J = 
14.3 Hz, -NCH2Ar), 4.92 (d, 1 H, J = 14.9 Hz, -NCH2Ar), 4.50 (d, 1 H, J = 14.3 Hz, -
NCH2Ar), 4.36 (dd, 1 H, J1 = 11.3 Hz, J2 = 5.5 Hz, Hd), 4.18 (d, 1 H, J = 14.9 Hz, -
NCH2Ar), 4.17 (s, 1 H, Ha), 3.74 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.18 (dd, 1 H, J1 = 
10.8 Hz, J2 = 4.4 Hz, Hb), 3.02 (dd, 1 H, J1 = 14.3 Hz, J2 = 5.5 Hz, He), 2.78 (dd, 1 H, J1 
= 17.7, J2 = 4.4 Hz, Hc), 2.39 (dd, 1 H, J1 = 14.3 Hz, J2 = 11.3 Hz, He), 1.87 (dd, 1 H, J1 = 
17.7 Hz, J2 = 10.7 Hz, Hc), 0.93 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 194.4, 172.1, 171.1, 169.3, 156.2, 139.1, 134.9, 134.2, 
132.7, 131.3, 129.2, 128.3, 128.2, 126.8, 126.6, 126.4, 115.7, 65.1, 60.9, 59.8, 49.5, 46.2, 
45.5, 42.1, 31.6, 13.8. 
HRMS (EIMS, M+): calcd for C32H30N2O6 538.2104, found 538.2123. 
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26. N-(tert-butyl)-3,3-dimethyl-2-((3aR,6aR)-6-methyl-3,5,8-trioxo-3,3a,4,5,6,6a,7,8-
octahydropyrrolo[3,4-d]quinolin-2(1H)-yl)butanamide 
O
Hd
N
N
O
Me
O
t-Bu
N
H
Hb
Ha
Hc
Hc
O
t-Bu
Hh
Hg
He He
Hf
Hh
( )-261  
1H NMR (500 MHz, CDCl3): δ 6.80 (d, 1 H, J = 10.1 Hz, Hf), 6.09 (d, J = 10.1 Hz, Hg), 
5.89 (br s, 1 H, -NH), 4.22 (s, 1 H, Ha), 3.83 (d, 1 H, J = 11.0 Hz, Hh), 3.74 (d, 1 H, J = 
11.3 Hz, Hh), 3.65-3.68 (m, 1 H, Hd), 2.95 (s, 3 H, -NMe), 2.64-2.95 (m, 4 H, Hc and He 
overlap), 1.31 (s, 9 H, t-Bu), 1.07 (s, 9 H, t-Bu) 
13C NMR (125 MHz, CDCl3): δ 195.6, 174.4, 168.2, 167.3, 151.8, 128.1, 63.5, 60.0, 55.1, 
51.8, 44.0, 40.4, 39.9, 35.1, 33.8, 31.2, 28.4, 27.5. 
HRMS (EIMS): calcd for C22H33N3O4 403.2471, found 403.2475. 
 
27. 2-(4-hydroxyphenyl)acetaldehyde 
 
1H NMR (500 MHz, CDCl3): δ 9.71 (t, 1 H, J = 2.5 Hz, -CHO), 7.06 (d, 2 H, J = 8.5 Hz, 
Aryl), 6.83 (d, 2 H, J = 8.5 Hz, Aryl), 5.83 (br s, 1 H, -OH), 3.63 (d, 2 H, J = 2.1 Hz, -
CH2CHO). 
 
13C NMR (125 MHz, CDCl3): δ 200.6, 155.1, 130.8, 123.4, 115.9, 49.6. 
 
HRMS (EIMS, M+): calcd for C8H8O2 136.0524, found 136.0533. 
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28. (E)-Ethyl 4-(benzyl(1-(tert-butylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-
yl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 7.10-7.36 (m, 6 H, Ph and –CH=CH- overlap), 6.95 (d, 2 
H, J = 8.5 Hz, Aryl), 6.84 (d, 1 H, J = 15.3 Hz, -CH=CH-), 6.69 (d, 2 H, J = 8.2 Hz, 
Aryl), 5.01 (br s, 1 H, -OH), 4.91 (t, 1 H, J = 7.6 Hz, Ha), 4.78 (d, 1 H, J = 17.7 Hz, -
NCH2Ph), 4.65 (d, 1 H, J = 17.7 Hz, -NCH2Ph), 4.18 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 
3.15 (dd, 1 H, J1 = 13.4 Hz, J2 = 9.2 Hz, Hb), 2.87 (dd, 1 H, J1 = 13.7 Hz, J2 = 6.4 Hz, 
Hb), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 1.16 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 168.8, 166.6, 165.3, 155.1, 136.7, 133.6, 132.8, 130.2, 
129.8, 128.9, 128.7, 128.1, 127.7, 126.4, 115.5, 61.4, 61.2, 60.5, 51.4, 34.4, 28.4, 14.1. 
 
HRMS (EIMS, M+): calcd for C26H32N2O5 452.2311, found 452, 2324. 
 
29. N-benzyl-N-(2-(tert-butylamino)-1-(4-hydroxy-3-methoxyphenyl)-2-
oxoethyl)acrylamide 
 
1H NMR (500 MHz, CDCl3): δ 6.69-7.24 (m, 9 H; Ph, Aryl and vinyl overlap), 6.39-6.48 
(m, 2 H, vinyl and –NH overlap), 5.95 (s, 1 H, Ha), 5.83 (br s , 1 H, -OH), 5.60-5.68 (m, 2 
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H, vinyl), 4.78 (d, 1 H, J = 18.0 Hz, -NCH2Ph), 4.61 (d, 1 H, J = 18.0 Hz, -NCH2Ph), 
3.68 (s, 3 H, OMe), 1.33 (s, 9 H, t-Bu) 
 
13C NMR (125 MHz, CDCl3): δ 169.1, 167.9, 146.4, 145.9, 138.1, 129.3, 128.2, 128.1, 
126.7, 126.4, 125.9, 123.0, 114.4, 112.6, 62.5, 55.8, 51.6, 49.2, 28.6. 
 
HRMS (EIMS, M+): calcd for C23H28N2O4 396.2049, found 396.2057. 
 
30. N-benzylacrylamide 
 
1H NMR (500 MHz, CDCl3): δ 7.26-7.38 (m, 5 H, Ph), 6.34 (d, 1 H, J = 17.1 Hz, vinyl), 
6.13 (d, 1 H, J = 10.4 Hz, vinyl), 6.09 (d, 1 H, J = 10.4 Hz, vinyl), 5.82 (br s, 1 H, -NH), 
5.68 (d, 1 H, J = 10.4 Hz, vinyl), 4.53 (d, 2 H, J = 5.8 hz, -NCHPh). 
 
13C NMR (125 MHz, CDCl3): δ 165.3, 138.0, 130.6, 128.8, 127.9, 127.6, 126.9. 
 
HRMS (EIMS, M+): calcd for C10H11NO 161.0841, found 161.0853. 
 
31. N-(tert-butyl)-2-hydroxy-2-(4-hydroxy-3-methoxyphenyl)acetamide 
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1H NMR (500 MHz, CDCl3): δ 6.82-6.92 (m, 3 H, Aryl), 5.70 (br s, 1 H, -OH), 4.83 (d, 1 
H, J = 3.1 Hz, Ha), 3.88 (s, 3 H, OMe), 3.73 (d, 1 H, J = 3.4 Hz, -OH), 1.32 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): 178.3, 138.7, 136.1, 132.8, 126.9, 121.2, 115.7, 80.7, 62.7, 
35.4. 
 
HRMS (EIMS, M+): calcd for C13H19NO4 253.1314, found 253.1329. 
 
32. N-(2-(tert-butylamino)-1-(4-hydroxy-3-methoxyphenyl)-2-oxoethyl)-N-(4-
nitrophenyl)acrylamide 
 
1H NMR (500 MHz, CDCl3): δ 8.05 (d, 2 H, J = 8.3 Hz, Aryl), 7.10-7.60 (m, 2 H, Aryl 
and vinyl overlap), 6.30-6.81 (m, 4 H, Aryl and vinyl overlap), 6.08 (s, 1 H, Ha), 5.70-
5.90 (m 1 H, vinyl), 5.56 (s, 2 H, vinyl), 4.01 (br s, 1 H, -OH), 3.64 (s, 3 H, OMe), 1.12 
(s, 9H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 168.7, 165.2, 146.9, 146.5, 146.1, 145.4, 132.1, 129.3, 
128.2, 125.5, 123.7, 114.5, 112.3, 64.6, 55.9, 51.8, 28.6. 
 
HRMS (EIMS, M+):  
 
33. N-(4-nitrophenyl)acrylamide 
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1H NMR (500 MHz, CDCl3): δ 8.09 (d, 2 H, J = 9.2 Hz, Aryl), 7.73 (d, 2 H, J = 9.2 Hz, 
Aryl), 6.37 (dd, 1 H, J1 = 16.8 Hz, J2 = 1.2 Hz, vinyl), 6.28 (dd, 1 H, J1 = 17.1 Hz, J2 = 
10.1 Hz, vinyl), 5.70 (dd, 1 H, J1 = 10.1 Hz, J2 = 1.2 Hz, vinyl), 4.70 (s, 1 H, -NH). 
 
13C NMR (125 MHz, CDCl3): δ 164.7, 146.9, 145.7, 131.6, 130.4, 124.7, 119.6. 
 
HRMS (EIMS, M+): calcd for C9H8N2O3 192.0535, found 192.0546. 
 
34. (E)-N-benzylidene-P,P-diphenylphosphinic amide 
 
1H NMR (500 MHz, CDCl3): δ 9.32 (d, 1 H, J = 32.0 Hz, Ha), 7.91-8.41 (m, 5 H, Ph), 
7.41-7.58 (m, 10 H, Ph). 
 
13C NMR (125 MHz, CDCl3): δ 173.6, 135.8, 135.6, 133.6, 132.4, 131.7, 131.5, 130.1, 
128.8, 128.5, 128.4. 
 
HRMS (EIMS, M+): calcd for C19H16NOP 305.0970, found 305.0983. 
 
35. N-(2-methylene-3-oxo-1-phenylbutyl)-P,P-diphenylphosphinic amide 
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1H NMR (500 MHz, CDCl3): δ 7.80-7.92 (m, 4 H, Ph), 7.14-7.49 (m, 12 H, Ph and –NH 
overlap), 6.16 (s, 1 H, Ha), 6.09 (s, 1 H, Hb), 5.05 (t, 1 H, J = 10.7 Hz, Hc), 4.42 (dd, 1 H, 
J1 = 11.0 Hz, J2 = 8.6, -NH), 2.22 (s, 3 H, -Me). 
 
13C NMR (125 MHz, CDCl3): δ 199.3, 148.7, 141.4, 133.2, 132.2, 132.1, 131.9, 128.3, 
128.2, 126.9, 126.3, 57.0, 26.6. 
 
HRMS (EIMS, M+): calcd for C23H22NO2P 375.1388, found 375.1394. 
 
36. 3-(amino(phenyl)methyl)but-3-en-2-one 
 
1H NMR (500 MHz, CDCl3): δ 7.26-7.38 (m, 5 H, Ph), 6.40 (s, 1 H, Ha), 6.27 (s, 1 H, 
Hb), 5.40 (br d, 1 H, J = 4.3 Hz, Hc), 3.73 (d, 2 H, J = 11.3 Hz, -NH2), 2.26 (s, 3 H, -Me). 
 
13C NMR (125 MHz, CDCl3): δ 197.8, 143.9, 134.8, 128.8, 127.3, 126.7, 125.9 54.3, 
25.9. 
 
HRMS (EIMS, M+): calcd for C11H13NO 175.0997, found 175.1015. 
 
37. 4-((tert-butyldimethylsilyl)oxy)-3-methoxybenzaldehyde 
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1H NMR (500 MHz, CDCl3): δ 9.84 (s, 1 H, -CHO), 7.33-7.42 (m, 2 H, aryl), 6.93-6.99 
(m, 2 H, aryl), 3.9 (s, 3 H, OMe), 1.0 (s, 9 H, t-Bu), 0.4 (s, 6 H, Me and Me overlap). 
 
13C NMR (125 MHz, CDCl3): δ 190.9, 151.6, 151.3, 130.9, 126.2, 120.7, 110.1, 55.4, 
25.6, -4.6. 
 
HRMS (EIMS, M+): calcd for C14H23O3Si 267.1416, found 267.1420. 
 
38. 2-(tert-butylamino)-1-(4-((tert-butyldimethylsilyl)oxy)-3-methoxyphenyl)-2-
oxoethyl ethyl fumarate 
 
1H NMR (500 MHz, CDCl3): δ 6.80-6.98 (m, 5 H, -CH=CH- and aryl overlap), 5.97 (s, 1 
H, Ha), 5.68 (bs, 1 H, -NH), 4.26 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 3.80 (s, 3 H, OMe), 
1.34 (s, 9 H, -NHt-Bu), 1.31 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 0.97 (s, 9 H, -Sit-Bu), 0.15 
(s, 6 H, Me and Me overlap). 
 
13C NMR (125 MHz, CDCl3): δ 166.9, 164.7, 163.6, 151.2, 146.0, 137.4, 134.9, 132.6, 
128.5, 120.9, 120.4, 111.7, 76.2, 61.5, 55.5, 51.7, 29.6, 28.6, 25.7, 18.4, 14.1, -4.6. 
 
HRMS (M+, EIMS): calcd for C14H23NaO3Si 516.2394, found 516.2413. 
 
39. (E)-1-(benzylamino)-3,3-dimethyl-1-oxobutan-2-yl 4-oxo-4-(p-tolyl)but-2-enoate 
t-Bu
O
O
O
NH
( )-301
O
Me
Ha
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1H NMR (500 MHz, CDCl3): δ 7.88 (d, 1 H, J = 15.6 Hz, -CH=CH-), 7.79 (d, 1 H, J = 
8.3 Hz, Aryl), 7.14-7.27 (m, 7 H, Aryl and Ph overlap), 6.86 (d, 1 H, J = 15.6 Hz, -
CH=CH-), 5.20 (s, 1 H, -NH), 4.97 (s, 1 H, Ha), 4.40 (ddd, 2 H, J1 = 35.1 Hz, J2 = 15.0 
Hz, J3 = 5.8 Hz, -NCH2Ph), 2.37 (s, 3 H, -Me), 1.05 (s, 9 H, t-Bu). 
 
13C NMR (125 MHz, CDCl3): δ 188.4, 167.9, 164.5, 144.9, 137.8, 137.3, 133.6, 130.8, 
129.4, 128.8, 128.4, 127.5, 127.2, 81.6, 42.9, 34.1, 26.1, 21.5. 
 
HRMS (EIMS, M+): C24H27NO4 393.1940, found 393.1955. 
 
40. 2-(Cyclohexylamino)-1-(2-nitrophenyl)-2-oxoethyl ethyl fumarate 
 
1H NMR (500 MHz, CDCl3): δ 8.0 (dd, 1 H, J1 = 8.2 Hz, J2 = 1.2 Hz, Hb), 7.80 (dd, 1 H, 
J1 = 7.6 Hz, J2 = 1.2 Hz, Aryl), 7.67 (dt, 1 H, J1 = 7.6 Hz, J2 = 1.2 Hz, Aryl), 7.52 (dt, 1 
H, J1 = 7.6 Hz, J2 = 1.2 Hz, Aryl), 6.92 (dd, 2 H, J1 = 17.4 Hz, J2 = 15.9 Hz, -CH=CH-), 
6.67 (s, 1 H, Ha), 6.34 (d, 1 H, J = 7.9 Hz, -NH), 4.22-4.29 (m, 2 H, -OCH2CH3), 3.70-
3.79 (m, 1 H, Hc), 1.88-1.98 (m, 1 H, Cy), 1.53-1.83 (m, 4 H, Cy), 1.31 (t, 3 H, J = 7.3 
Hz, -OCH2CH3), 1.02-1.27 (m, 5 H, Cy). 
 
13C NMR (125 MHz, CDCl3): δ 165.2, 164.4, 163.6, 148.0, 135.5, 133.8, 131.8, 130.2, 
129.8, 129.7, 124.8, 71.4, 61.5, 48.6, 32.6, 32.5, 25.3, 24.5, 14.0. 
 
HRMS (EIMS, M+): calcd for C20H24N2O7 404.1584, found 404.1597. 
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41. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(1H-indol-3-yl)-2-oxoethyl)amino)-4-
oxobut-2-enoate 
 
1H NMR (400 MHz, CDCl3): δ 7.28-7.36 (m, 2 H, Aryl), 7.18-7.25 (m, 4 H, Aryl and –
CH=CH- overlap), 7.08-7.17 (m, 3 H, Aryl), 6.74-6.95 (m, 3 H, Aryl and –CH=CH- 
overlap), 5.96 (s, 1 H, Ha), 5.56 (br s, 1 H, -NH), 4.84 (d, 1 H, J = 17.8 Hz, -NCH2Ph), 
4.62 (d, 1 H, J = 17.8 Hz, -NCH2Ph), 4.16 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 1.33 (s, 9 H, 
t-Bu), 1.24 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 168.9, 167.2, 164.9, 136.9, 136.3, 129.2, 128.8, 127.9, 
127.7, 127.1, 122.9, 121.8, 120.1, 118.9, 112.8, 111.6, 71.9, 61.8, 60.7, 28.7, 14.1. 
 
HRMS (EIMS, M+): calcd for C27H31N3O4 461.2315, found 461.2327. 
 
42. Ethyl 2-((2'S,3S,4'R)-1'-benzyl-2'-(tert-butylcarbamoyl)-5'-oxospiro[indole-3,3'-
pyrrolidin]-4'-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 8.02 (s, 1 H, Hd), 7.49 (d, 1 H, J = 7.9 Hz, Aryl), 7.26-
7.36 (m, 6 H, Aryl), 7.14 (t, 1 H, J = 7.6 Hz, Aryl), 7.02 (d, 1 H, J = 7.3 Hz, Aryl), 5.27 
(br s, 1 H, -NH), 5.09 (d, 1 H, J = 14.3 Hz, -NCH2Ph), 4.09 (dd, 1 H, J1 = 9.5 Hz, J2 = 4.9 
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Hz, Hb), 4.06 (d, 1 H, J = 14.7 Hz, -NCH2Ph), 3.93 (dq, 2 H, J1 = 7.3 Hz, J2 = 1.2 Hz, -
OCH2CH3), 3.90 (s, 1 H, Ha), 2.64 (dd, 1 H, J1 = 16.8 Hz, J2 = 4.9 Hz, Hc), 1.74 (dd, 1 H, 
J1 = 17.1 Hz, J2 = 9.5 Hz, Hc), 1.31 (s, 9 H, t-Bu), 1.08 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 173.9, 172.6, 170.7, 166.8, 155.0, 137.6, 135.2, 129.4, 
129.1, 128.9, 128.6, 128.3, 126.8, 121.9, 64.3, 62.8, 60.7, 52.3, 46.8, 41.2, 30.9, 28.5, 
13.9. 
 
HRMS (EIMS, M+): calcd for C27H31N3O4 461.2315, found 461.2329. 
 
43. Ethyl 2-((1R,3aS,5aS,10bS)-3-benzyl-5-(tert-butyl)-2,4-dioxo-1,2,3,3a,4,5,5a,6-
octahydropyrrolo[3',2':3,4]pyrrolo[2,3-b]indol-1-yl)acetate 
 
1H NMR (500 MHz, CDCl3): δ 7.20-7.38 (m, 5 H, Ph), 6.98-7.09 (m, 1 H, Aryl), 6.63-
6.74 (m, 2 H, Aryl), 6.58 (d, 1 H, J = 7.9 Hz, Aryl), 5.81 (s, 1 H, Hd), 5.24 (d, 1 H, J = 
14.1 Hz, -NCH2Ph), 4.48 (d, 1 H, J = 14.1 Hz, -NCH2Ph), 3.76-3.96 (m, 2 H, -
OCH2CH3), 3.74 (s, 1 H, Ha), 3.24 (dd, 1 H, J1 = 11.6 Hz, J2 = 3.7 Hz, Hb), 3.11 (dd, 1 H, 
J1 = 18.3 Hz, J2 = 4.3 Hz, Hc), 2.70 (dd, 1 H, J1 = 18.3 Hz, J2 = 11.6 Hz, Hc), 1.50 (s, 9 H, 
t-Bu), 0.98 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (125 MHz, CDCl3): δ 172.3, 172.1, 171.0, 149.4, 135.8, 129.3, 128.9, 128.6, 
127.7, 126.7, 124.2, 119.9, 110.9, 83.2, 66.0, 60.7, 55.1, 52.6, 47.1, 45.2, 31.8, 28.1, 13.9. 
 
HRMS (EIMS, M+): calcd for C27H31N3O4 461.2315, found 461.2321. 
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44. (E)-Ethyl 4-(benzyl(2-(tert-butylamino)-1-(1-methyl-1H-indol-3-yl)-2-
oxoethyl)amino)-4-oxobut-2-enoate 
 
1H NMR (500 MHz, CDCl3): δ 6.80-7.48 (m, 10 H, Aryl and –CH=CH- overlap), 6.64 
(d, 1 H, J = 15.6 Hz, -CH=CH-), 6.46 (s, 1 H, Hb), 6.10 (s, 1 H, Ha), 5.72 (t, 1 H, J = 4.8 
Hz, -NH), 4.72 (dd, 2 H, J1 = 44.9 Hz, J2 = 17.4 Hz, -NCH2Ph), 4.10-4.19 (m, 2 H, -
OCH2CH3), 3.85 (s, 3 H, -Me), 1.34 (s, 9 H, t-Bu), 1.23 (t, 3 H, J = 7.3 Hz, -OCH2CH3). 
 
13C NMR (100 MHz, CDCl3): δ 168.9, 167.2, 164.9, 136.9, 136.3, 129.2, 128.8, 127.9, 
127.7, 127.1, 122.9, 121.8, 120.1, 118.9, 112.8, 111.6, 71.9, 61.8, 60.7, 34.9, 28.7, 14.1. 
 
HRMS (EIMS, M+): calcd for C28H33N3O4 475.2471, found 475.2483. 
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CHAPTER 4 
 
Rapid Entry into Anomeric Substituted D-Galactofuranosides: Effect of 
Lewis Acids under Microwave Irradiation using Modified 
Fischer/Lubineau Conditions 
 
4. Introduction 
 The cyclic hemiacetal forms of monosaccharides having five-membered ring or 
the tetrahydrofuran skeleton are commonly known as furanoses.  Glycosides are 
molecules in which a sugar group or monosaccharide is linked to a non-sugar group 
either by nitrogen, oxygen, sulfur or halogen (Figure 26).  Glycosides having furanose 
form are called furanosides.  The furanosides were known to adopt a puckered 
conformation for many years.  However, Beevers and Cochran in 1947 had utilized X-ray 
study to show that the D-fructofuranose residue in sucrose sodium bromide dehydrate 
adopts an envelope conformation.192 
 
 
Figure 26. Furanosides. 
 
Furanosides have been found in many natural products, especially in nucleic 
acids.  However, there is remarkable contrast in biodistribution among various furanose-
containing glycoconjugates.  For example, D-galactofuranosides (D-Galf, 358a, 
hexafuranoside, Figure 27), have been found in many microorganisms such as pathogenic 
bacteria, fungi, and protozoan parasites, and are highly immunogenic.193  D-Galf is 
essential for the survival of various pathogenic bacteria e.g. anaerobic bacteria 
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Bacteoride fragilis,193c, 194 however it is absent in higher eukaryotes e.g. in mammalian 
cells.193a  Consequently, in recent years, the scientific community has realized that D-Galf 
can be utilized to study various biological systems to develop potential new 
therapeutics.195  On the other hand, structurally analogous pentafuranoside L-
arabinofuranose (L-Araf, 358b, Figure 27) is present in soil fungi, bacteria, and plants.196  
The D-Galf and L-Araf have been found to be very essential components of the glycocalix 
of these pathogens for their cell survival and morphology.  For example, internal D-Galf 
units are present in the cell wall of arabinogalactan.  The Mycobacterium tuberculosis 
and Mycobacterium leprae contain internal D-Galf units in their cell wall composed of L-
Araf.  The lipopolysaccharide of Klebsiella pneumoniae, and lipophospoglycan of 
Leishmania also contain internal D-Galf units.  In addition, the lipopeptidophosphoglycan 
(LPPG) and O-linked oligosaccharides of Trypanosoma cruzi have been found to contain 
terminal nonreducing residues of D-Galf units. 
 
O
OH
HO
HO
HO
H OR
358a
O
OH
HO
HO
H OR
358b
 
Figure 27. D-Galactofuranoside and L-Arabinofuranoside. 
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Figure 28. D-Galf containing naturally occurring oligosaccharides. 
 
The mycobacterium species possess a cell wall that is composed of ~30 D-Galf 
residues and this impermeable cell wall protects them against environment.197  In recent 
years, scientist have reported that mycobacterium species causing disease in particular 
tuberculosis is associated with the increasing occurrence of AIDS in many developing 
countries.  Other examples include the zwitterionic polysaccharide PS A1 (359), isolated 
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from anaerobic bacteria Bacteroride fragilis 9434, is known to modulate immune system 
by eliciting T-cell response via the MHC II pathway;198a-d the glycosphingolipid 
Agelagalastatin (360) which was isolated from Western Pacific marine sponge Agelas 
sp., have been shown to inhibit human cancer cell growth with very high GI50 values in 
vivo;198e-f the UDP-D-Galf (361) which is a biosynthetic glycosyl donor, presumably use 
the enzyme galactofuranosyl tranferase to incorporate it into cell-surface 
carbohydrates;198g-h the GPI membrane anchor (362)198i-l and the toxin 363 isolated from 
Helminthosporium sp. (Figure 28).  Moreover, glycofuranosides are becoming important 
as surfactants, liquid crystals and building blocks for glycofuranosyl donors in 
oligosaccharide synthesis.199  In addition, glycofuranosides have been utilized to 
synthesize lignin and their monomeric derivatives those are water-soluble as well 
biodegradable.200 
 
4.1. Synthetic Routes and Challenges 
Although, most pyranosides are commercially available, corresponding 
hexofuranosides are typically synthesized from the pyranosides due to their commercial 
inavailability.  Over the past decade, there have been significant advancements in 
glycosylation methodology using protected carbohydrates.  To this extent, there are few 
literatures that described chemical synthesis of O-glycosides from completely 
unprotected carbohydrates in a single step.  Single-step synthesis of O-glycosides from 
completely unprotected carbohydrates is quite challenging due to potential a) self-
condensation of unprotected sugars, b) anomerizations and, c) ring-chain tautomerisation 
of unprotected sugars during reaction time-course.201  In order to synthesize of 
hexofuranosides from completely unprotected glycosyl donors directly: (a) the glycosyl 
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acceptor must be trapped faster to prevent any undesired coupling with glycosyl donors 
having unprotected hydroxyl groups, (b) the over equilibrium between starting materials, 
intermediates and products must be controlled effectively and should be toward product 
side, (c) the α/β-anomeric ratio of products must be good to excellent. 
In 1893, Fischer developed the method of glycosylation of lower alcohols with 
unprotected carbohydrates e.g. 364 using protic acids (Scheme 85).202  Because the 
reaction is carried out under thermodynamic control, generally it is conducted with a 
large excess of glycosyl acceptor alcohol (ROH) to drive the equilibrium to glycoside 
366.  Consequently, this method is useful for the synthesis of glycosides of lower 
alcohols such as methyl, benzyl or allylic alcohol.  Typically, the reaction requires high 
temperature, long reaction time and leads to a mixture of the anomeric mixture of 
furanosides and pyranosides.  Thus the reaction is practically useful since it provides the 
thermodynamically stable axial glycoside of pyranosides as the major product. 
 
 
Scheme 85. The Fischer glycosylation of unprotected sugars. 
 
In an advancement, Fischer and Lubineau established that when pyranosides are 
subjected to glycosylation using FeCl3 as a Lewis acid and methanol as an acceptor under 
refluxing conditions, the reaction provided the kinetically favored methyl furanoside 367 
as major product as a mixtures α and β anomers (Scheme 86).203  The reaction provides 
minor amount of the thermodynamically favored methyl pyranoside 368, also as a 
mixtures of α and β anomers.  However, the reaction takes about 28 h to complete which 
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is inconvenient for practical purposes.  In addition, it is cumbersome to separate the α/β 
anomers of furaosides from the α/β anomers of pyranosides if the crystallization method 
does not work. 
 
 
Scheme 86. The Fischer-Lubineau glycosylation using FeCl3 as catalyst. 
 
 In 1986, Gedge,204a Westaway204a and Majetich204b reported the use of microwave 
(μwave) in chemical reactions for the first time and since then, interest within the 
scientific community in this extraordinary synthetic tool has increased exponentially.  To 
date, microwave irradiation has been successfully applied in enzymatic reaction, despite 
the fact that enzymes are sensitive to heat.205 
 In recent years, although μwave technology has become a powerful and 
alternative tool over the traditional heating process in organic synthesis, this technology 
has not been employed widely in carbohydrate synthesis probably due to the fact that 
carbohydrates have been known to be very sensitive to heat.  According to 
Abramovitch206 and Loupy243a, if in a reaction the ‘polarity is increased from the ground 
state toward the transition state’, μwave irradiation can influence them.  Furthermore, 
Westway and co-workers validated that ‘microwave heating is less destructive than 
thermal heating’.207  These hypothesis have encouraged scientific community toward the 
use of μwave in carbohydrate synthesis.  Microwave irradiation has been successfully 
employed to perform protection/deprotection,208 SN2 reaction,209 and enzyme-catalyzed 
glycosylation.210a  Most recently, it has also been utilized to perform glycosylation of 
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oxazolidine donors.210b  Current μwave technology offers precise control of temperature 
and pressure in capped vial; even temperature range up to -78 oC can reached.  With the 
recent advancement, scale-up of products can be easily performed via dedicated 
continuous flow microwave.  Whatsmore is the fact that reports have emerged describing 
‘microwave effects’ on reaction outcomes are far different and unexpected than what was 
originally designed.106 
 To this extent, the chemical synthesis of glycofuranosides remains important yet 
challenging as α/β mixtures of both furanosides and pyranosides are not easily isolatable, 
the lengthy reaction time course.  Furthermore, most reaction protocol suffers from an 
inability to achieve conditions necessary to obtain the kinetically favored furanoside in 
good yields and high anomeric excess.  Although, a few literature reports are available on 
the use of microwave in glycosylation of the hexopyranoses to synthesize 
hexopyranosides,211 to date, there is no report on the use of microwave irradiation in 
synthesis of hexafuranosides synthesis from the hexopyranoses.  Thus, we speculated that 
it would be quite interesting to study the effect of microwave on hexofuranosides 
synthesis especially that of D-galactofuranosides. 
 
4.2. Results and Discussions 
 As a part of our research interest in synthesizing zwitterionic polysaccharide PS 
A1 and our developmental program in sustainable chemistry, we needed to synthesize 
allyl D-galactofuranoside building blocks.  Since the original Fischer/Lubineau method is 
quite lengthy, we decided to employ μwaves in the Fischer/Lubineau glycosylation 
method and carry out the reaction in two stages under the same temperature.  Since the 
spectroscopic data of methyl-D-galactofuranosides and methyl-D-galactopyranosides are 
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ample in literature, methanol was chosen as the acceptor alcohol for the convenience of 
comparing NMR data and as a measure for our success. 
Table 25.  Optimization of the microwave-assisted synthesis of D-galactofuranoside.a 
O
OH
HO
OH
OH
OH
Anh. FeCl3 , Anh. MeOH
wave, 300 W, temp, time
O
OH
HO
HO
HO
H OMe O
OH
HO
OH
OH
OMe
+
367 368364  
Entry Stage 1 Stage 2 % yieldb/α:βc % yieldb
(overall) Temp 
(oC) 
Time 
(min) 
Temp 
(oC) 
Time 
(min) 
D-Galf 
(367) 
D-Galp 
(368) 
1 60 5 70 5 25/1:2 5/1.5:1 30 
2 60 10 70 5 35/1:3 10/2:1 45 
3 60 20 70 15 60/1:5 15/3.1 75 
4 60 30 70 25 70/1:7 17/5:1 87 
5 60 30 70 35 75/1:8 20/5.5:1 95 
a CEM Discover Microwave, microwave power was set to 300 W. b Isolated. c 
Determined from 1H NMR sample of unpurified reaction mixture; chemical shift of 
anomers were compared to literature values. 
 
Thus, when D-galactopyranoside in methanol was subjected to μwave irradiation 
in the presence of Lewis acid catalyst FeCl3 for 5 min at stage 1 (μwave was equilibrated 
to 300 W, 60 oC, 4 bar) and 5 min at stage 2 (μwave was equilibrated to 300 W, 70 oC, 5 
bar), the overall conversion was 35%.  The consumption of starting material was 
monitored by thin layer chromatography and 1H NMR spectroscopy.  Further 
optimization of time course of the two stages, the reaction after 65 min provided 75% 
yield of the desired D-Galf with good α/β selectivity (Table 25).  It has been observed that 
continuing the reaction longer than 70 min or increasing the temperatures of the stage 1 
and 2, leads to lower yield of D-Galf or decomposition of starting material.  D-Galf 
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anomers were separated from D-Galp anomers by column chromatography on a silica gel 
column using a 20:1 CH2Cl2-MeOH mixture and their structural assignments were based 
on the 1H and 13C NMR spectroscopy and on previously reported data.203 It is quite 
significant that we have been able to reduce the reaction time from 28 h to 65 min and 
also improved the yield of D-galactofuranosides over the original method. 
Next, we were interested to study the effect of other Lewis acids and catalysts on 
D-Galf/D-Galp ratio (Table 26).  A thorough literature search revealed that carbohydrate 
and their derivatives are well known to form complexes with metal ions.212  Furthermore, 
experimental studies showed that the Fischer glycosylation of methanol in presence of 
strong acids may be affected by the presence of metal cations, in particular those from 
second row of the periodic table and thus can influence the α/β selectivity as well as the 
D-Galf/D-Galp ratio.213  Table 26 shows the effect of different Lewis acids and catalyst on 
yield of D-Galf/D-Galp and their α/β selectivity.  It has been observed that Lewis acids in 
which the central atom is in +I, +III or +IV oxidation state provided excellent overall 
yield.  However, Cu(I), Cu(II) and Zn(II) did not provide any product.  On the other 
hand, AgF and FeCl3 gave the best yield of D-Galf, whereas the rest of the Lewis acids 
employed gave D-Galp as the major product.  It can be seen from Table 26 that the 
oxidation state of central atom of the Lewis acids does not control the ratio of D-Galf/D-
Galp, but the nature of the central atom seemed to affect the α/β ratios. 
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Table 26.  Effect of Lewis acids/catalysts on μwave-assisted D-Galf synthesis.a 
 
Entry Catalyst Central Metal Atom 
Oxidation State 
% yieldb/α:βc % yieldc
(overall) 367 368 
1 AgF I 75/1:6 21/5.5:1 96 
2 AlCl3 III 15/1:7 80/5:1 95 
3 BF3.OEt2 III 25/1:5 63/5:1 88 
4 CuI I 0/- 0/- 0 
5 CuSO4 II 0/- 0/- 0 
6 FeCl3 III 75/1:8 20/5:1 95 
7 InCl3 III 23/1:7 74/5:1 97 
8 Sc(OTf)3 III 25/1:7 70/5:1 95 
9 TiCl4 IV 15/1:4 75/4.5:1 90 
10 Ti(Oi-Pr)4 IV 16/1:4 73/4.5:1 89 
11 Yb(OTf)3 III 20/1:7 72/5:1 92 
12 ZnCl2 II 0/- 0/- 0 
13 TMSOTf - 0/- 0/- 0 
13 Amberlyst 15 - 15/1:5 75/9:1 90 
a CEM Discover Microwave, microwave power was set to 300 W. b Isolated. c 
Determined from 1H NMR of unpurified reaction mixture; chemical shift of anomers 
were compared to literature values. 
 
In general, metal cations are known to co-ordinate with ligands via their O-atoms.  
A majority of these metal-ligand complexes, however, are formed via co-ordination with 
negatively charged O-atoms of an anion such as carboxylate or enolate.  Neutral O-atom 
of the crown compounds and cryptates co-ordinate surrounding the metal cation via six or 
more O-atoms.214  Angyal and co-workers have studied the complexation of metal cations 
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in detail using various alkaline-earth metal cations.  They have postulated that 
polyhydroxy cyclohexane/tetrahydropyran rings in which the hydroxyl groups having 
axial-equatorial-axial orientation, are capable to form complexes with alkaline-earth 
metal ions.  On the other hand, polyhydroxy cylcopentane or tetrahydrofuran rings having 
consecutive cis hydroxyl groups, can form complexes (Figure 29).215  In addition, it was 
their observation that the radii of metal ions affect the extent of complexion and shifts the 
equilibrium in favor of α-anomers.  Although, there is no literature precedence on the use 
of Lewis acids in furanoside synthesis under µwave irradiation, our results are in good 
agreement with Angyal’s theory.  Thus, we rationalized that the size, coordination 
number and outer orbital electron configuration of the central atom of the Lewis acids are 
responsible for the observed α/β ratio and yield of products.  However, the mode of 
complexion might be somewhat different than Angyal’s proposal. 
 
 
Figure 29. Co-ordination of alkaline-earth metal ions with D-allopyranose, D-
 
ethodology to other alcohols, we decided to use allyl 
alcohol and 2-phenylethanol in the modified Fischer-Lubineau method of furanoside 
synthesis.  Both 1-allyl-D-galactofuranoside 370 and 2-phenylethyl-D-galactofuranoside 
371 were obtained in good yield and α/β selectivities (Scheme 87).  Thin layer 
chromatography showed that the allyl D-galactofuranosides were well separated from 
allopyranosides, 3-O-methyl-D-gulopyranose and D-allofuranosides. 
In order to extend this m
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allyl D-galactopyranosides and we have been able separate the anomers of 1-allyl-D-
galactofuranosides via column chromatography on a silica gel column using 20:1 mixture 
of CH2Cl2-MeOH as the eluent.  The structure of the major product, 1-allyl-α-D-
galactofuranoside, was confirmed by 1H, 13C, GQFCOSY, GHMQC and GNOE 
spectroscopy, and unequivocally confirmed by X-ray crystal structure analysis (Figure 
30). 
 
Scheme 87. Synthesis of 1-allyl- and 2-phenylethyl-D-galactofurnosides. 
 
 
Figure 30. X-ray crystal structure of 1-allyl-α-D-galactofuranoside 370a. 
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In addition, 1-allyl-β-D-galactofuranoside (370b) was synthesized separately 
(Scheme 88) via Schmidt glycosylation216 and the chemical shift of the anomeric carbon 
was used to determinine the α/β ratio from 1H NMR of unpurified reaction mixture after 
work-up.  The chemical shift of anomeric carbons of 1-allyl-D-galactopyranosides was 
compared with reported values and used to determine the α/β ratio.  The α/β ratios were 
determined from 1H and 13C NMR of crude reaction mixture.  Furthermore, 1-allyl-
2,3,4,6-tetracetate- α-D-galactofuranoside (377c) was also synthesized and compared 
with literature values.  To the best of our knowledge, this is the first X-ray crystal 
structure of unprotected D-galactofuranoside with an allyl group at the anomeric position. 
 
 
Scheme 88. Synthesis of 1-allyl β-D-galactofuranoside. 
 
 A general mechanism for the formation of 1-alkyl-D-galactofuranoside and -
galactopyranoside is shown in Scheme 89.  It is well known that the unprotected 
galactose 364 is in equilibrium with the open chain form 378.  The oxygen of the 
aldehyde group at C-1 and the hydroxyl group at C-4 coordinate with Lewis form a 7-
membered transition state 379 which permits conformation changes that forms 
intermediate 380.  The hydroxyl group at C-4 then attacks the activated carbonyl carbon 
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to form the 5-membered ring intermediate 381a or 381b.  On the other hand, attack of the 
hydroxyl group at C-5 onto the electrophilic carbonyl carbon form a 6-membered ring 
intermediate 384.  It is well known that 5-membered ring formation is faster than a 6-
membered ring.217  Thus, the D-galactofuranoside intermediate 381 is the kinetically 
controlled product and D-galactopyranoside intermediate 384 is the thermodynamically 
controlled product.  The intermediates 381 and 383, then collapse to form the 
oxocarbenium intermediate 382 and 384 respectively.  Nucleophilic attack by solvent or 
alcohol onto the anomeric carbon results in the formation of final products having α-
anomers as the major isomer probably due to the co-ordination of Lewis acids with the 
1,2,3-hydroxyl groups as noted by Angyal. 
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Scheme 89.  Proposed mechanism of D-galactofurnoside synthesis under microwave 
irradiation. 
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4.3.  Materials and Methods 
 All Reagents were purchased from Aldrich unless otherwise noted.  Anhydrous 
ferric chloride was purchased from Alfa Aesar.  Anhydrous methanol was purchased 
from EMD chemicals (DriSolv).  Palladium chloride was purchased from STREM 
chemicals.  Indium chloride, copper iodide and copper sulfate were purchased from Alfa 
Aesar.  TMSOTf was purchased from Acros organics.  Allyl alcohol was distilled prior to 
use.  Except as otherwise indicated, reactions were carried out under argon.  Microwave 
reactions were conducted using a capped vial on CEM Discover System.  All reactions 
were monitored by thin layer chromatography using 0.25 mm Dynamic Adsorbents 
L.L.C. precoated silica gel (particle size 0.03-0.07 mm, catalog no. 84111).  Column 
chromatography was performed using Whatman Purasil 60 Ǻ (230-400 mesh ASTM) 
silica gel.  Yields refer to chromatographically and spectroscopically pure compounds, 
except as otherwise noted.  Diastereomeric ratios were determined from 1H NMR spectra 
of non-purified reaction mixtures.  Proton and carbon-13 NMR spectra were recorded on 
Varian Mercury 400, Varian Unity 500 and Varian 500 Direct Drive System 
spectrometers.  The residual CDCl3 singlet at δ 7.26 ppm and δ 77 ppm were used as the 
standard for 1H NMR and 13C NMR spectra respectively.  Mass spectra were recorded on 
Micromass GCT at 70 eV. 
4.3.1 General method for silicone oil-bath-mediated D-galactofuranoside 
synthesis: 
 A 25 mL RB flask was oven dried, capped and cooled under Argon.  To 
the flask D-galactopyranose (0.2 g, 1.1 mmol) was added followed by FeCl3 (0.18 g, 1.1 
mmol).  To the mixture, anhydrous methanol (6.2 mL) was added slowly and the mixture 
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was refluxed at 60 oC for 24 h followed by 70 oC for 4 h.  The flask was then allowed to 
reach room temperature, then saturated NaHCO3 (5 mL) was added and stirred for 5 min.  
The reaction mixture was then filtered through neutral celite and the filtrate was dried on 
rotavap to afford a yellow slurry.  The slurry was then extracted with a mixture of hot 
ethyl acetate/ethanol mixture (2:1).  The extract was then filtered through celite and dried 
over rotavap.  The extraction process was repeated again.  The filtrate was concentrated 
under vacuum and purified by gradient column chromatography using silica gel as the 
stationary phase and mixture of methanol and dichloromethane (1:15 to 1:5) as the 
mobile phase. 
4.3.2. General method for microwave-assisted D-galactofuranoside synthesis: 
 A 10 mL CEM Discover microwave vial was oven dried, capped and 
cooled under Argon.  To the vial D-galactopyranose (0.05 g, 0.28 mmol) was added 
followed by FeCl3 (0.045 g, 0.28 mmol).  To the mixture, anhydrous methanol (2.5 mL) 
was added slowly and then the cap was quickly replaced with a new cap.  The vial was 
capped according to manufacturer’s instructions and placed in the single-mode 
microwave cavity.  Then the microwave was run at two stages: (a) 30 min at 60 oC, 10 
Bar and 300 W (b) 35 min, 70 oC, 10 Bar and 300 W.  After allowing the vial to cool to 
room temperature, saturated NaHCO3 (3 mL) was added and stirred for 5 min.  The 
reaction mixture was then filtered through neutral celite and the filtrate was dried on 
rotavap to afford a yellow slurry.  The slurry was then extracted with a mixture of hot 
ethyl acetate/ethanol mixture (2:1).  The extract was then filtered through celite and dried 
over rotavap.  The extraction process was repeated again.  The filtrate was concentrated 
under vacuum and purified by gradient column chromatography using silica gel as the 
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stationary phase and mixture of methanol and dichloromethane (1:15 to 1:5) as the 
mobile phase. 
4.3.3 Synthesis of 1-allyl-β-D-galactofuranoside from anomeric mixture of 1-
allyl-D-galactofuranoside: 
 Anomeric mixture of 1-allyl-D-galactofuranoside (369) (0.39 g, 1.77 mmol) was 
taken in a dry RB flask equipped with magnetic stir bar.  To the flask pyridine (5.34 mL, 
68.75 mmol) was added at 0 oC under Argon and the solution was stirred for 5 min.  
Next, benzoyl chloride (2.65 mL, 15.55 mmol) was added dropwise to the stirring 
solution.  The resulting mixture was allowed to reach room temperature slowly and 
monitored by thin layer chromatography (TLC).  After 5 h, TLC showed complete 
consumption of 369 and the reaction was solidified.  Dichloromethane (5 mL) was added 
to the flask to dissolve the solid.  Next, toluene (50 mL) was added to the flask and the 
mixture was concentrated on rotavap.  The crude product was purified via gradient 
column chromatography using silica gel as the stationary phase and mixture of ethyl 
acetate/hexane (1:20 to 1:3) as the mobile phase to afford 1-allyl-2,3,5,6-tetrabenzoyl-D-
galactofuranoside (374)(1.11 g, 99%) as a white solid. 
 1.11 g (1.75 mmol) of 374 was taken in an oven dried RB flask equipped with 
magnetic stir bar under Argon.  To the flask, anhydrous methanol (8.8 mL) was added 
followed by anhydrous dichloromethane (14 mL).  To the stirred solution under Argon, 
palladium chloride (39 mg, 0.22 mmol) was added at room temperature.  The resulting 
solution was stirred at room temperature for 12 h, after which TLC showed complete 
consumption of starting material.  The solvent was removed on rotavap and the crude 
product was purified via gradient column chromatography using silica gel as the 
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stationary phase and a mixture of ethyl acetate/hexane (1:5 to 1:1) as the mobile phase to 
obtain 0.96 g (92%) of the hemiacetal 375 as a white solid. 
 Hemiacetal 375 (0.29 g, 0.48 mmol) was taken in an oven dried RB flask under 
Argon and dissolved in anhydrous dichloromethane (1.5 mL).  After cooling the solution 
to 0 oC, DBU (37 µL, 0.25 mmol) was via syringe.  To mixture, CCl3CN (0.48 mL, 4.8 
mmol) was added dropwise at 0 oC and the resulting solution was stirred for 1-2 h at 0 oC.  
After TLC showed completion of reaction, the solvent was removed under reduced 
pressure on rotavap.  The crude product was purified via silica gel column 
chromatography using a 1:6 mixture of ethyl acetate/hexane as the eluent to afford 0.34 g 
(95%) of the trichloroacetamidate 376 (α:β = 1:10) as colorless oil. 
 The donor 376 (0.18 g, 0.24 mmol) was taken in an oven dried RB flask and 
magnetic stir bar was placed inside.  To the flask 45 mg 4 Å MS (oven dried 24 h 
followed by heat gun dried under high vacuum) was added followed by the acceptor allyl 
alcohol (14 µL, 0.25 mmol) and the solution was stirred at room temperature for 30 min.  
After cooling to -20 oC (ice-NaCl mixture), TMSOTf (0.5 µL) was added and the 
resulting mixture was stirred at -20 oC for 1 h.  Next, the reaction was allowed to reach 0 
oC slowly and quenched with Et3N (10 µL).  The solution was filtered and concentrated 
on rotavap.  The crude product was purified via silica gel column chromatography using 
a 1: 4 mixture of ethyl acetate/hexane to afford 0.14 g (90%) of 1-allyl-2,3,5,6-
tetrabenzoyl-β-D-galactofuranoside (377) as a white solid. 
 To a RB flask containing 0.11 g (0.18 mmol) of 377, a 5:1 mixture of 
methanol/THF (11.3 mL) was added and the solution was cooled to 0 oC.  Next, 3 N 
NaOH (0.74 mL) was added to the flask and reaction was allowed to reach room 
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temperature slowly over 1 h and stirred for additional 4 h.  The reaction mixture was then 
concentrated on rotavap and the crude product was purified via gradient silica gel column 
chromatography using a mixture of dichloromethane/methanol (20:1 to 6:1) as the eluent 
to afford 38 mg (99%) of the target compound 1-allyl-β-D-galactofuranoside (370b). 
4.4. Experimental Data 
1. 1-Allyl-α-D-galactofuranoside 
O
HO
HO
HO
H
370a
OHO
Hc
Hc
Hb Ha
Ha
 
1H NMR (400 MHz, CD3OD): δ 5.86 (dddd, 1 H, J = 17.4, 10.4, 6.2, 5.2 Hz, Hb), 5.19-
5.28 (m, 1 H, Ha), 5.04-5.12 (m, 1 H, Ha), 4.81 (d, 1 H, J = 4.9 Hz, H-1), 4.15-4.25 (m, 1 
H, H-3), 3.95-4.05 (m, 2 H, H-4 and Hc overlap), 3.84-3.90 (m, 1 H, H-2), 3.60-3.66 (m, 
1 H, Hc), 3.50-3.58 (m, 2 H, H-6 and H-5 overlap), 3.41-3.50 (m, 1 H, H-6). 
 
13C NMR (100 MHz, CD3OD): δ 135.7, 117.5, 101.8, 83.5, 78.8, 76.2, 74.5, 69.7, 64.0. 
 
HRMS (EIMS, M+ + Na): calcd for C9H16NaO6 243.0845, observed 243.0847. 
 
2. 1-Allyl-2,3,4,6-tetrabenzoyl-α-D-galactofuranoside 
O
BzO
BzO
BzO
H
OBzO
Hc
Hc
Hb Ha
Ha
377a  
1H NMR (400 MHz, CDCl3): δ 7.91-8.7 (m, 8 H, Aryl), 7.31-7.59 (m, 12 H, Aryl), 6.25 
(t, 1 H, J = 6.5 Hz, H-3), 5.71-5.88 (m, 2 H, Hb and H-2 overlap), 5.47-5.55 (m, 2 H), 
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5.18-5.25 (m, 1 H, Ha), 5.08-5.15 (m, 1 H, Ha), 4.79 (dd, 1 H, J = 12.2, 4.1 Hz, Hc), 4.69 
(dd, 1 H, J = 11.8, 5.7 Hz, Hc), 4.61 (t, 1 H, J = 5.7 Hz, H-4), 4.36 (dd, 1 H, J = 13.8, 5.7 
Hz, H-6), 4.04 (dd, 1 H, J = 13.0, 5.7 Hz, H-6). 
 
13C NMR (100 MHz, CDCl3): δ 165.9, 165.7, 165.5, 133.5, 133.4, 133.3, 133.1, 132.9, 
130.0, 129.9, 129.8, 129.7, 129.6, 129.0, 128.9, 128.4, 128.3, 128.2, 117.3, 99.5, 78.6, 
77.5, 74.6, 71.7, 69.1, 62.9. 
 
HRMS (EIMS, M+ + Na): calcd for C37H32NaO10 659.1893, observed 659.1895. 
 
3. 1-Trichloroacetamidate-2,3,4,6-tetrabenzoyl-β-D-galactofuranoside 
O
OBz
BzO
BzO
BzO
H O
HN CCl3
376 ( anomer  
1H NMR (500 MHz, CDCl3): δ 8.53 (s, 1 H, =NH), 8.02-8.16 (dd, 4 H, J = 18.0, 7.6 Hz, 
Aryl), 7.86-7.99 (dd, 4 H, J = 21.4, 7.6 Hz, Aryl), 7.20-7.65 (m, 12 H, Aryl), 6.71 (s, 1 H, 
H-1), 6.15-6.21 (m, 1 H, H-2), 5.80 (d, 1 H, J = 4.0 Hz), 5.78 (s, 1 H), 4.86-4.91 (m, 1 
H), 4.75-4.83 (m, 2 H). 
 
13C NMR (125 MHz, CDCl3): δ 165.9, 165.7, 165.4, 165.1, 160.2, 133.6, 133.5, 133.3, 
133.0, 130.0, 129.9, 129.8, 129.6, 129.4, 129.2, 128.7, 128.4, 128.3, 128.2, 102.8, 84.5, 
80.7, 76.9, 69.9, 63.3. 
 
HRMS (EIMS, M+ + Na): calcd for C36H28Cl3NNaO10 760.0676, observed 760.0679. 
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4. 1-Allyl-2,3,4,6-tetrabenzoyl-β-D-galactofuranoside 
 
1H NMR (500 MHz, CDCl3): δ 8.01-8.11 (m, 4 H, Aryl), 7.96-8.01 (m, 2 H, Aryl), 7.89-
7.94 (m, 2 H, aryl), 7.49-8.0 (m, 4 H, Aryl), 7.22-7.45 (m, 8 H, Aryl), 6.05-6.11 (m, 1 H, 
H-4), 5.95 (dddd, 1 H, J = 17.4, 10.4, 6.2, 5.2 Hz, Hb), 5.65 (d, 1 H, J = 5.2 Hz, H-2), 
5.52 (d, 1 H, J = 0.9 Hz, H-3), 5.32-5.39 (m, 2 H, H-1 and Ha overlap), 5.19-5.25 (m, 1 
H, Ha), 4.73-4.81 (m, 2 H, Hc), 4.69 (dd, 1 H, J = 5.2, 3.4 Hz, H-5), 4.26-4.33 (m, 1 H, H-
6), 4.13 (dd, 1 H, J = 13.1, 6.1 Hz, H-6). 
 
13C NMR (125 MHz, CDCl3): δ 166.1, 165.7, 165.6, 165.4, 133.6, 133.5, 133.3, 133.2, 
133.1, 129.9, 129.8, 129.7, 129.6, 129.5, 129.0, 128.9, 128.4, 128.3, 117.6, 104.9, 82.2, 
81.3, 77.6, 70.3, 68.0, 63.5. 
 
HRMS (EIMS, M+ + Na): calcd for C37H32NaO10 659.1893, observed 659.1897. 
 
5. 1-Allyl-β-D-galactofuranoside 
O
OH
HO
HO
HO
H O
370b
Ha
HaH
b
Hc
Hc
 
1H NMR (400 MHz, CD3OD): δ 5.88 (dddd, 1 H, J = 17.4, 10.4, 6.2, 5.2 Hz, Hb), 5.28 
(qd, 1 H, J = 17.0, 1.6 Hz, Ha), 5.11-5.14 (qd, 1 H, J = 10.5, 1.6 Hz, Ha), 4.89 (d, 1 H, J = 
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2.0 Hz, H-1), 4.16-4.23 (m, 1 H, H-3), 3.98-4.03 (m, 1 H, H-6), 3.95-3.98 (m, 3 H, H-2 
and Hc overlap), 3.93 (dd, 1 H, J = 6.5, 3.2 Hz, H-6), 3.68-3.74 (m, 1 H, H-5), 3.62 (br s, 
-OH), 3.60 (d, 1 H, J = 1.3 Hz, H-4). 
 
13C NMR (100 MHz, CD3OD): δ 135.9 (Cb), 117.1 (Ca), 108.7 (H-1), 84.3 (C-6), 83.4 
(C-2), 78.8 (Cc), 72.4 (C-5), 69.4 (C-3), 64.5 (C-4). 
 
HRMS (EIMS, M+ + Na): calcd for C9H16NaO6 243.0845, observed 243.0848. 
 
6. 1-Phenylethyl-α-D-galactofuranoside 
 
1H NMR (500 MHz, CDCl3): δ 7.23-7.29 (m, 2 H, Ph), 7.15-7.21 (m, 3 H, Ph), 4.90 (d, 1 
H, J = 3.4 Hz, H-1), 3.66-4.6 (m, 7 H, H-2, H-3, H-4, H-5, H-6 and -OCH2CH2Ph 
overlap), 3.40-3.46 (m, 1 H, -OCH2CH2Ph), 2.88 (t, 2 H, J = 6.7 Hz, -OCH2CH2Ph). 
 
13C NMR (125 MHz, acetone-d6): δ 140.1, 129.8, 129.0, 126.9, 99.9, 85.6, 83.8, 78.9, 
76.1, 71.4, 62.5. 36.7. 
 
13C NMR (125 MHz, CD3OD): δ 140.3, 130.1, 129.3, 127.2, 100.2, 84.2, 83.3, 78.7, 76.6, 
72.2, 71.5, 62.8. 36.9. 
 
HRMS (EIMS, M+ + Na): calcd for C14H20NaO6 307.1158, observed 307.1163. 
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7. Allyl-2,3,4,6-tetraacetate-α-D-galactofuranoside 
 
1H NMR (400 MHz, CDCl3): δ 5.86 (dddd, 1 H, J = 17.4, 10.4, 6.2, 5.2 Hz, Hb), 5.58 (t, 1 
H, J = 7.3 Hz, H-2), 5.11-5.30 (m, 4 H), 5.02 (dd, 1 H, J = 8.1, 4.9 Hz), 4.30 (dd, 1 H, J = 
12.2, 4.9 Hz), 4.18-4.25 (m, 1 H), 4.05-4.16 (m, 2 H), 3.86-3.96 (m, 2 H), 2.09 (s, 3 H, -
OCOCH3), 2.08 (s, 3 H, -OCOCH3), 2.05 (s, 3 H, -OCOCH3), 2.02 (s, 3 H, -OCOCH3). 
 
13C NMR (100 MHz, CD3OD): δ 170.3, 169.9, 169.7, 133.6, 117.1, 98.6, 77.7, 76.3, 73.5, 
70.5, 68.5, 62.2, 20.8, 20.7, 20.6, 20.5. 
 
HRMS (EIMS, M+ + Na): calcd for C17H24NaO10 411.1267, observed 411.1265. 
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CHAPTER 5 
 
p-N,N-Dimethylamino Benzyl (PDMAB) Group as an Ammonia 
Equivalent and Novel Functional Handle in Organic Synthesis 
 
5. Introduction 
 The art of organic synthesis relies on novel strategies for protection and 
deprotection of functional groups.218  Protecting groups (PGs) have been found to be very 
crucial handles for the synthesis of wide range of oligosaccharides219, peptides220, 
polyketides221 and complex natural products222 possessing significant biological 
activities.  Although, there are some recent reports on protection group free complex 
molecule synthesis223, the protection-deprotection strategy still remains a significant 
mainstay of organic synthesis.  There are several criteria for a PG to be employed in a 
synthetic strategy: (a) facile access of the PG; (b) the PG can be installed easily in good-
to-high yield; (c) the PG should not have another potential reactive functionality that 
might participate in other reaction during installation/removal; (d) the PG should not be 
affected by other synthetic transformations i.e. should be compatible with other 
functionalities; (e) removal of the PG should form a by-product that can easily be 
separated; and (f) the PG can be deprotected easily under mild conditions at a desired 
stage of synthetic strategy.  Furthermore, incorporating PGs, having orthogonal reactivity 
with other common PGs, are valuable synthetic blocks that can offer flexibility to design 
strategies for the synthesis of complex architectures. 
 Among many protecting groups in organic synthesis, the benzyl as well as 
modified benzyl ethers have been frequently used.224  They are most commonly 
 284
employed to protect hydroxyl groups in carbohydrate or polyhydroxy compounds.  The 
robust nature along with their unique cleavage mechanism makes them compatible with 
many other common PGs.  Benzyl ethers are commonly cleaved by oxidation in presence 
of DDQ,225 CAN,226 DDQ-Mn(OAc)3,227 or by hydrogenolysis, Lewis acids228 and 
others.229  However, tuning of electronic property of the phenyl group of the benzyl ether 
has generated a range of arylmethyl PGs having alter reactivity e.g. para-methoxybenzyl 
(PMB, 388). dimethoxybenzyl (DMB, 389), napthylmethyl (NAP, 390),230 para-
bromobenzyl (PBB, 391)231, and many others (Figure 31). 
 
 
Figure 31.  Benzyl protecting groups employed in carbohydrate synthesis. 
 
 Although the use of para-hydroxy benzyl (PHB) group has not seen much success 
due to its relatively unstable nature under very mild conditions,232 recently, Jobron and 
Hindsgaul have reported that protected-PHB ethers para-acetoxybenzyl (PAB, 393) and 
para-(tert-butyldimethylsilyl)-oxybenzyl (394) are promising in the art of carbohydrate 
synthesis.  They have shown that these groups (393, 394) can be cleaved under mild 
conditions.224b  Unlike the electron withdrawing acetate esters and silyl ethers, the 
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protected-PHB ethers exert less electronic influence on glycosyl donors.233  More 
recently, Dudley et al reported the use of para-siletanylbenzyl (PSB, 395) in 
carbohydrate synthesis.234 
 Every protection-deprotection strategy has its own limitations.  For example, 
DDQ is commonly used for the removal of PMB and DMB groups under nearly neutral 
conditions.  However, DDQ is an expensive reagent and chromatographic removal of the 
by-product, HDDQ can be a cumbersome process.  Although, several catalytic systems 
have been developed235 to recycle HDDQ into DDQ, they are not typically compatible 
with other functionalities present in carbohydrates or other molecules.  Moreover, Lewis 
acids (e.g. BF3.OEt2, Me2BBr) and DDQ mediated unmasking of PMB group suffers 
from the drawback of using stoichiometirc amounts.  Despite recent advancements, there 
is no single PG in a particular series that can be regarded as the best.  As a result there are 
continuous efforts among the scientific community to develop new protecting groups that 
will not only be cleavable under mild/neutral conditions and orthogonal to other 
commonly used protecting groups but also a close fit to the hypothetical best PG. 
From the preceding discussion, it can be seen that over the last decade, several 
new PGs have been developed primarily for their application in carbohydrate synthesis.  
Ironically, most of these new PGs have not found any application in other areas of 
synthetic chemistry. 
 Peptides are an important class of compounds and there are reports that 
polypeptides which contain unnatural peptides can have increased bioavailability, 
resistance to degradation and improved bioactivity.  Among many reactions, the U-4CCR 
has the capability to generate unnatural peptides from simple starting materials.  
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However, to mimic any natural peptide, the U-4CCR must incorporate ammonia as the 
amine component.  There are only few literature precedents where ammonia has been 
used in the U-4CCR.236  The potential problem of using ammonia in U-4CCR is the 
formation of undesired side products (Scheme 90).237a 
 
 
Scheme 90.  Ammonia in U-4CCR generates side products 398 and 399. 
 
In order to solve this problem, less nucleophilic solvents e.g. trifluoroethanol have 
been employed or the side products are selectively hydrolyzed using mild acids e.g. 
pyridinium p-toluenesulfonate (PPTS).237b  Furthermore, chiral primary amines bearing 
auxiliaries have also been utilized as the amine component, since the auxilaries can be 
cleaved after post-Ugi condensation.238  To date, 1-amino glycopyranoses, 
ferrocenylmethylamine have been used successfully for this purpose and employed in the 
synthesis of chiral amino acids.  However, the synthesis of these chiral auxiliaries 
requires multistep syntheses, rendering it costly and time consuming.239 
 Thus, in recent years, there is a continuous effort among the scientific community 
to develop new types of ammonia equivalents for enantioselective synthesis of 
unsaturated amino acids,240 Ugi reaction,241 reductive amination,242 palladium-catalyzed 
amination,243 intramolecular hydroamination,244 amino carbonylation,245 synthesis of 
primary amine,246 and aza-Michael addition (Figure 32).247 
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Figure 32.  Examples of ammonia equivalents employed in organic synthesis. 
 
As a part our ongoing research program in developing new methods and strategies 
for sustainable chemistry, we were interested to develop a new reaction that would be 
useful in synthetic chemistry especially in MCCR and carbohydrate chemistry.  From our 
established methodology, we envisioned that microwaves could possibly alter reactivity 
of para-substituted benzyl groups. 
 
5.1. p-N,N-Dimethylamino Benzyl (PDMAB) Group as an Ammonia (NH3) 
Equivalent in MCCR 
 During our small molecule synthesis, we observed that when para-hydroxy 
benzylamine was used in the U-4CCR and the resulting acyclic product was irradiated 
under microwave, the reaction provided an appreciable amount of para-hydroxy benzyl 
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alcohol (14, Chapter 2, Scheme 38) along with the desired DKP product (chapter 2, 
Scheme 28).  We anticipated that the use of a stronger electron donating group on the 
phenyl ring of the benzyl group might provide this product (14) in increased yield and 
would help us to study the effect on electron donating groups on benzyl group under 
µwave irradiation.  Thus we decided to use p-N,N-dimethyl benzylamine (PDMAB-NH2, 
414), trimethylacetaldehyde 4d, fumaric acid monoethyl ester 2a and tert-butyl 
isocyanide 3c in the Ugi 4CCR and isolated the acyclic product 415 in excellent yield.  
When 415 was irradiated under microwave at 300 W, 200 oC, 18 bar for 20 min in water, 
the reaction did not provide the expected 2-azaspiro[4.5]decane-3,8-dienone 416.  
Instead, compound 417 was obtained which lacks the p-N,N-dimethylbenzyl (PDMAB) 
group (Scheme 91). 
 
 
Scheme 91. PDMAB group is labile under microwave irradiation. 
 
 The identity of the deprotected product 417 was established by 1H, 13C, DEPT, 
mass spectroscopy and unequivocally confirmed by X-ray structure analysis (Figure 33).  
From Scheme 91, it is quite clear that p-N,N-dimethylbenzyl (PDMAB) amine can act as 
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ammonia equivalent in the U-4CCR and can be removed under microwave irradiation in 
water without any additives.  It must be noted that the acyclic compound 415 is stable on 
bench-top for several months.  Next, we decided to study the substrate scope of this 
reaction and a series of acyclic Ugi product has been synthesized using various 
aldehydes, acids and isocyanides and will be subjected to µwave irradiation(Table 27). 
Table 27.  Scope of PDMAB group as ammonia (NH3) equivalent in U-4CCR.a 
 
Entry R1 R2 R4 Compd/ 
% yield 
1 t-butyl (1c) Ethylacrolein (2a) t-butyl (3c) 415 (98)/417(98) 
2 p-methoxyphenyl (1) Ethelnene (2f) Cyclohexyl (3d) 418a(96)/419a(n.db) 
3 Piperonyl (1) Cyclopropyl (2) 2,6-dimethylphenyl (3b) 418b(95)/419b(n.d) 
4 o-nitophenyl (1) Cyclopropyl (2) Isopropyl (3f) 418c(93)/419c(n.d) 
5 Piperonyl (1)  p-methoxyphenyl (2) 2,6-dimethylphenyl (3b) 418d(94)/419d(n.d) 
6 Isopropyl (1)  p-bromophenyl (2) 2,6-dimethylphenyl (3b) 418e(92)/419e(n.d) 
7 Naphthalene (1) m-bromophenyl (2) Cyclohexyl (3d) 418f(95)/419f(n.d) 
a CEM Discover Microwave. b Reaction will be performed. 
 
 A proposed mechanism for the formation of PDMAB deprotected product 419 is 
shown in Scheme 92.  Microwave irradiation influences the lone pair on the nitrogen of 
the N,N-dimethyl group, allowing to fall down, break the benzylic carbon-nitrogen bond 
that results in the formation of the deprotected intermediate 420 and aza-quinone methide 
intermediate 421.  Nucelophilic attack by water onto the electrophilic methide carbon 
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forms the intermediate 422.  Protonation-deprotonation provides the final products 419 
and the PDMAB alcohol 424. 
 
Scheme 92.  Proposed mechanism for the formation of PDMAB deprotected product 419. 
 
 
Scheme 93. PMB group is not labile under microwave irradiation. 
 
 To determine the applicability of the PDMAB group in carbohydrate chemistry, 
we decided to revisit our earlier finding and elected to use para-methoxy benzyl (PMB) 
amine as a coupling partner in the Ugi reaction having same coupling partners (Scheme 
93).  Thus, when the acyclic Ugi product 66 was irarradiated under microwave using 
previous conditions, thin layer chromatography showed that there was no reaction.  This 
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further confirmed that the PMB group was stable and not labile in the presence of 
microwave irradiation. 
 
Figure 33. X-ray crystal structure of PDMAB deproteced product (±)-417. 
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5.2. PDMAB as a Novel, Alternative Protecting Group in Carbohydrate 
Synthesis 
 
 With this result in hand (Scheme 92), we then decided to synthesize p-N,N-
dimethylaminobenzyl (PDMAB) alcohol 424a from p-N,N-dimethylamino benzaldehyde 
425a.  PDMAB alchol was then converted to the corresponding methanesulfonate 426.  
However, compound 426 is quite unstable and converts into a dimeric species 427 
(Scheme 94).  Hence, we decided to prepare 426 as the semi-stable compound. 
 
O
R2N
OH
R2N
OMs
Me2N
MeOH, 0 oC
NaBH4, 30 min
CH2Cl2,Et3N
0 oC, MsCl, 1 h
Me2N NMe2
R = Me, 425a
R = Ph, 425b
R = Me, 424a
R = Ph, 424b
426
427
99%
424a
 
Scheme 94. Synthesis of PDMAB methanesulfonate. 
 
 In order to install the PDMAB group on carbohydrate alcohols, compound 430 
was synthesized from commercially available 428 via benzylidene acetal formation 
followed by chemoselective benzyl protection of the 3-hydroxyl group.248  Treatment of 
430 with NaH in anhydrous THF at 0 oC followed by addition of freshly prepared 426 in 
THF, did not provide the desired product 431, probably due to dimerization of 426 
(Scheme 95). 
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Scheme 95. Initial attempt to install PDMAB group at C-2. 
 
 A probable mechanism for the formation of dimmer 427 is shown in Scheme 96.  
Since OMs is a very good leaving group and 426 is a nucleophilic moiety, electron-
donation from them p-N,N-dimethyl group promotes the formation of aza-quinone 
methide intermediate 421.  Nucleophilic attack onto the methide carbon by 426 forms the 
intermediate 432.  The mesylate ion then attacks the sulfur atom of the intermediate 432 
forming mesyl anhydride, formaldehyde as by product and provides the dimmer 427.249 
 
 
Scheme 96. Proposed mechanism for the formation dimer 427. 
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Thus, we speculated that the corresponding tosylate derivative might be more 
stable and easy to handle.  Accordingly, the tosylate derivative 433 was synthesized from 
PDMAB alcohol 424a using tosyl chloride (TsCl) and NaH in THF at 0 oC and 
immediately transferred into the flask containing 434.  Gratifyingly, the reaction provided 
60% yield of the desired product.  With 431 in hand, we then subjected it to previously 
established microwave irradiation conditions in a 10:1 mixture of methanol and 
dichloromethane and the reaction afforded 430 in albeit low yield (Scheme 97).  Further 
adjustment of microwave irradiation conditions and use of methanol as solvent provided 
the desired product in good yield. 
 
 
Scheme 97. Installation and removal of PDMAB group under microwave irradiation. 
 
With this result in hand, we next decided to examine the installation of PDMAB 
group at different positions of D-glucose. We have been successful at illustrating that the 
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PDMAB group can be easily installed on carbohydrates and selectively removed in the 
presence of benzyl as well as the PMB group (Figure 34).250 
 
 
Figure 34. PDMAB is removable in presence of PMB under microwave irradiation. 
 
5.3. p-(N,N-Dimethylamino)-Benzyl Thiol (PDMAB-SH) as a Novel 
Functional Handle to Install Thiol Group in Carbohydrate Synthesis 
 
 Glycobiology251 has been rapidly developing in the combined areas of 
carbohydrate chemistry and biochemistry as a means to study the synthesis and biological 
properties of natural polysaccharides.252  In recent years, glycobiology has utilized well-
defined carbohydrates and derivatives to study various biological systems.  These studies 
have shown that carbohydrates interact with proteins in a specific manner and they play 
crucial roles in cell proliferation, communication, death, and adhesion.  Furthermore, 
carbohydrates have been implicated to be involved in many infectious diseases as well as 
cancer.253 
 However, for a detail understanding of these specific interactions, well-defined 
carbohydrate ligands are essential for the development of new therapeutic drugs.  Toward 
this extent, thioglycosides in which sulfur replaces oxygen of normal glycosidic bond, 
have become the typical glycosyl donors in the synthesis of thio-oligoaccharides.  In 
addition, protein-thio-oligoaccharide binding studies indicate that S-linked 
oligosaccharides are more flexible and have more conformational isomers than their 
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counterpart natural O-linked.254  Furthermore, the S-atom of the S-linked oligosaccharides 
can form hydrogen bonds with ligands and thus provide additional advantages over C-
linked oligosaccharides.255 
 
 
Figure 35. Examples of bioactive thioglycosides. 
 
 To date, 5-thio-D-mannose (439a, isolated from the marine sponge Clathia 
pyramida), thiolactomycin (439b, isolated from Norcardia  sp.), salacinol (439c, isolated 
from Indian anti-diabetes herb Salacia reticulata) and the plant metabolite sinigrin 
(439d) are the only known natural thioglycosides (Figure 35).256  Although, natural thio-
glycosides are rare, thioaldoses are known to inhibit glycosidases.257  D-glucose 
transportation across membranes and release of insulin are known to be affected by 5-
thio-D-glucose.258  5-Thio-L-fucose has shown strong inhibition of bovine α-L-
fucosidase.259  The 1,5-dithio-D-xylopyranoses have been found to be essential 
components of orally active antithrombotic glycoside theraputics.260a  Auranolin was 
marketed as Ridaura for the treatment of Rheumatoid arthritis (Figure 35).260b  Several 
other synthetic thiophycosides have shown promising biological activities.260c  Moreover, 
recent study showed that S-linked glycosides are not being easily degraded by chemical 
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and enzymatic hydrolysis compared to their O-linked counter parts.255b, 261  Experimental 
evidence suggests that thio-glycosides have potential as therapeutics to treat cancer and 
other infectious diseases.262  In addition, thio-glycosides have also been employed to 
introduce fatty alkyl chains on sugars for the preparation of non-ionic surfactant and 
liquid crystals.  Conversion of glyconolactones into S-alkyl-1-thiopentitols, has provided 
important molecular properties e.g. amphiphilic and mesophasic.263 
 Thus, efficient synthetic methods for synthesizing thio-glycosides are necessary 
since these structures can serve as acceptors in the synthesis of bioactive thio-
oligosaccharides.  In 1961, Schwartz et al. and Adley et al. independently synthesized 
thioglycosides for the first time.264  Thereafter, the chemistry of thioglycosides was 
advanced by many groups e.g. Whistler et al.265, Al-Masoudi-Hughes,266  Hashimoto-
Yusua,267 and others.268 
 
 
Scheme 98. Representative synthetic method to install thiol group on carbohydrates. 
 
 There are few synthetic methods available to install a thiol (-SH) group on 
carbohydrates.269  Existing methods require external additives to install a sulfur-bearing 
group followed by a chemical deprotection.  In addition, these reaction suffers from low 
yields and removal of the by-products remains problematic.270  For example, to install a 
thiol group at the 6-position, the most common method is the nucleophilic displacement 
of 6-iodo/6-tosyl group by a thioacetate group, followed by base-catalyzed removal of the 
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acetate group (Scheme 98) which is not compatible if benzoyl or chloroacetyl groups are 
present in the same carbohydrate.  With the success of PDMAB group as new functional 
handle and protecting group under neutral conditions, we envisioned that the PDMAB 
alcohol 424a can be converted into the corresponding thiol 446 and used as a masked 
thiol (Scheme 99).  Moreover, we speculated that the PDMAB thiol can also be removed 
under microwave irradiation employing previously established conditions. 
 
Scheme 99.  Synthesis of PDMAB-SH. 
 
 PDMAB thiol 446 was synthesized following a literature procedure on similar 
substrate.271  Treatment of 424 with a aqueous HCl solution of thiourea, refluxing the 
solution at 70 oC, followed by basification and refluxing provides 70% of the desired 
product 446 along with the 20% of the dimerized side-product 447 (Scheme 99).  It has 
been observed that storage of compound 446 as a concentrated solution, in particular 
nonpolar solvents, leads to reversible formation of the dimeric species 447.  It is quite 
noteworthy that 446 forms a different dimer compared to 424 (Scheme 94 and Scheme 
99)  This may be due to the fact that –SH is bad leaving group compared to –OH and 
sulfur is more nucleophilic than oxygen.  Hence, the thiol group of remaining 446 can 
attack the methide carbon of the aza-quinone methide intermediate and deprotonation 
provides dimeric coumpound 447 (Scheme 100). 
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Scheme 100. Proposed mechanism for the formation of dimer 447. 
 
 
Scheme 101. Installation of PDMAB-SH on C-6 of galactoside. 
 
 We speculated that the dimer 447 might not interfere with the installation of 
PDMAB-S group on carbohydrates and decided to use the crude reaction immediately 
without purification.  D-Galactose 364 was converted to the corresponding1,2,3,4-
diisopropylidine derivative 448 in presence of anhydrous CuSO4 in dry acetone and 
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concentrated sulfuric acid.309  Mesylation of 448 using MsCl in presence of Et3N afforded 
quantitative yield of 449.  Initial attempts to perform a SN2 displacement on 449 using 
NaH, DMF and 446 at room temperature did not provide any of the desired product.  
After a thorough literature search, we decided to use DMSO a primary solvent and DMF 
as the co-solvent (helps to prevent solidification of solution) in the displacement reaction 
and the reaction provided excellent yield of the desired product 450 (Scheme 101)  
Microwave irradiation of 450 in water forms 451 with concurrent loss of PDMAB-S and 
isopropylidine groups.  Since it is known that compound of the type 451 are susceptible 
to undergo dimerization, we decided not to isolate 451 and treat with benzoyl chloride to 
afford the corresponding benzoyl derivative 452. 
 
 
Scheme 102. Stability of PDMAB-S group under acidic conditions. 
 
 Next, we examined the stability of the PDMAB-S group under acidic conditions.  
It has been observed that the PDMAB-S group is quite stable under acidic conditions.  
Treatment of 450 with trifluoroacetic acid (TFA) for 4 h did not provide the expected 
product; only starting material was recovered (Scheme 102).  In order to remove the 
isopropylidine groups and simultaneously protect by acetate group, 450 was treated with 
acetic anhydride and concentrated sulfuric acid at -20 oC.  Even, under this condition, the 
 301
PDMAB-S was quite stable the expected product 453 was obtained in about 50% yield 
(Scheme 102). 
 Then, we examined the installation of PDMAB-S group on the C-3 position of 
galactoside.  Thus, compound 455 was synthesized from 429 by treating with acetic 
anhydride in presence of Et3N at room temperature.  Compound 455 was converted to the 
triflate 456 by treating with triflic anhydride and pyridine at -20 oC.  The triflate 456 was 
used directly after work for the SN2 displacement in presence of 426 and NaH in 
DMSO/DMF.  Gratifyingly, the reaction provided expected product 457 was obtained in 
60% yield along with 30% of the unexpected product 458 (Scheme 103)  Identity of 
compound 457 and 458 was confirmed by 1H, 13C NMR as well as HRMS.  It is known 
that neighbouring group participation of ester functionalities in the triflate-activated 
carbohydrates, where 5- or 6-membered acyloxonium intermediates may form during 
thiolation and also solvent plays important roles.310  We think that compound 458 is 
forming via a 5-membered ring intermediate, however, the detailed mechanism is not 
known at this point in time. 
 
 
Scheme 103. Installation of PDMAB-S group at C-3 of D-glucoside. 
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 Next, we focused on installing PDMAB-S group at the anomeric carbon.  Thus, 
the glycosyl bromide 461 was synthesized from D-glucose 459 via peracetylation 
followed by bromination using 45% HBr in AcOH.  Initial attempt to install 446 under 
phase transfer conditions did not provide the desired product 462.  However, when 
HgBr2-Hg(CN)2 catalyst was employed, 462 was obtained in low yield (Scheme 104). 
 
O
AcO
AcO
AcO
AcO
OAc
O
HO
HO
HO
HO
OH
O
AcO
AcO
AcO
AcO
Br
O
AcO
AcO
AcO
AcO
SPDMAB
459
CH2Cl2, Ac2O
DMAP, Pyr
0 oC-rt, 24 h
99%
CH2Cl2, 0 oC
45% HBr, 4 h
95%
cond B 10%Condition A: 446, benzene/water
NaOH, Bu4NI, rt
Condition B: 446, CH2Cl2, drierite
Hg(CN)2, HgBr2, 0 oC-rt
460 461
462  
Scheme 104.  Installation of PDMAB-S group at the C-1 of glucoside. 
 
5.4. Application of p-(N,N-Dimethylamino)-Benzyl Thiol (PDMAB-SH) 
Toward the Synthesis of β-Thio Carbonyl Building Blocks 
 β-Thio aldehydes are very important synthetic building blocks because the sulfur 
functionality can be readily removed by oxidative or reductive means, or converted into 
other useful functional groups e.g. sulfoxides or disulfides.  Thus, they are the part of 
active research interest of many chemists.274  We examined the possibility of of using 
PDMAB-SH to synthesize β-thio aldehydes in conjunction of microwave irradiation.  
 303
Thus, we elected to use cinnamaldehyde 463, the thio-Michael reaction and the reaction 
provided good of the desired sulfa-Michael addition (SMA) product 464 (Scheme 105). 
 
Scheme 105. Sulfa-Michael addition toward β-thio aldehyde synthesis. 
 
 Following these studies, we have synthesized a few other sulfa-Michael products 
as shown in Scheme 106.  These thio-Michael/sulfa-Michael products can be irradiated 
under microwave in future to obtain β-thio/β-sulfa carbonyl building blocks.  In addition, 
employing a chiral catalyst in the sulfa-Michael addition can lead to an asymmetric 
synthesis of these β-thio/ β-sulfa ketones. 
 
Scheme 106. Examples of additional SMA products. 
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5.5. Studies Toward the Synthesis of p-(N,N-Dimethylamino)-Benzyl Selenol 
(PDMAB-SeH) as Novel Functional Handle to Install Selenol on 
Carbohydrates. 
 
 In contrary to recent developments in glycobiology and of interest in thio-
oligosaccharide, there are very few literature reports available on seleno-glycosides or 
seleno-oligosaccharides.  This could be due to the rare occurrence of seleno-containing 
natural carbohydrates.  However, in 1977, Zingaro and coworkers275 strongly suggested 
the presence of naturally-containing seleno-glycosides in Astragalus racemosus.  
Although, nearly 20 years earlier, scientists had suggested that selenium is essential for 
mammalian organisms.276  In 1974, Zingaro and co-workers discovered the presence of 
selenium in the enzyme glutathione peroxidase.277a  Recent studies indicate that selenium 
plays essential roles to prevent inflammatory, cardiovascular, neurological, cancer, 
infectious diseases as well as in aging.277  Furthermore, seleno-sugars metabolites have 
been found in rats (Figure 36).277 
 
 
Figure 36.  Metabolites and bioactive seleno-glycosides. 
 
 We speculated that p-(N,N-dimethylamino)benzyl selenol 473 (PDMAB-SeH) can 
synthesized using selenourea under similar conditions to that of PDMAB-SH (Scheme 
107).  However, when we attempted the reaction, only the dimeric species 474 was 
obtained as the major product as confirmed by 1H, 13C NMR and HRMS.  Although, we 
 305
had isolated a fraction from the crude reaction mixture and 1H NMR was quite 
satisfactory to that of 473, the HRMS did not match with our expected exact mass.  It 
could be due to the very unstable nature of compound 473 under the HRMS measurement 
conditions.  Formation of 474 takes place via similar mechanism as shown earlier except 
the equilibrium lies completely toward the dimer. 
 
 
Scheme 107. Effort toward the synthesis of 473. 
 
The mechanism of formation for the dimer 474 is presumed to follow the same 
pathway as that for PDMAB-SH (Scheme 108).  It must be noted that PDMAB-SeH and 
PDMAB-SH forms dimeric species containing their hetero atoms incorporated within the 
benzylic carbons; whereas PDMAB-OH forms dimeric compound without incorporating 
O-atom within the benzylic carbons (Scheme 94). 
 
 
Scheme 108. Proposed mechanism for the formation of 474. 
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5.6. Materials and Methods 
 All Reagents were purchased from Aldrich unless otherwise noted.  p-N,N-
dimethylamino benzaldehyde was purchased from Alfa Aesar.  Anhydrous methanol, 
tetrahydrofuran, acetone and dichloromethane were purchased from Alfa Aesar.  
Anhydrous methanol was purchased from EMD chemicals (DriSolv).  p-Toluene sulfonic 
acid was purchased from Acros organics.  Thiourea  and selenourea were purchased from 
Alfa Aesar.  Except as otherwise indicated, reactions were carried out under Argon.  
Microwave reactions were conducted using a capped vial on CEM Discover System.  All 
reactions were monitored by thin layer chromatography using 0.25 mm Dynamic 
Adsorbents, L.L.C. precoated silica gel (particle size 0.03-0.07 mm, catalog no. 84111).  
Column chromatography was performed using Whatman Purasil 60 Ǻ (230-400 mesh 
ASTM) silica gel.  Yields refer to chromatographically and spectroscopically pure 
compounds, except as otherwise noted.  Diastereomeric ratios were determined from 1H 
NMR spectra of non-purified reaction mixtures.  Proton and carbon-13 NMR spectra 
were recorded on Varian Mercury 400, Varian Unity 500 and Varian 500 Direct Drive 
System spectrometers.  The residual CDCl3 singlet at δ 7.26 ppm and δ 77 ppm were used 
as the standard for 1H NMR and 13C NMR spectra respectively.  Mass spectra were 
recorded on Micromass GCT at 70 eV. 
5.6.1. General method for PDMAB deprotection from acyclic Ugi product: 
 To a 10 mL vial (CEM Discover System) equipped with magnetic stirring 
bar, 50 mg of acyclic Ugi starting material was taken and 2.5 mL of distilled water was 
added to it.  The vial was capped properly and placed in the microwave.  Then 
microwave was run for 20-25 min at 200 oC, 18 Bar and 300 W.  After cooling the vial at 
 307
room temperature, ethyl acetate was added and shaken thoroughly.  The organic layer 
was separated and the aqueous layer was extracted with ethyl acetate (2 × 2 mL).  The 
organic layers were combined, dried over Na2SO4 and filtered.  The filtrate was dried 
under vacuum and purified by gradient silica gel column chromatography using a mixture 
of ethyl acetate and hexane (1:5 to 1:2) as the eluent. 
5.6.2. General method for the installation of PDMAB group starting from 
PDMAB alcohol: 
 To a oven dried RB flask equipped with magnetic stir bar, p-N,N-dimethylamino 
benzaldehyde (2 g, 13.4 mmol), was taken.  Anhydrous methanol (52 mL) was added to 
the flask and stirred at 0 oC for 15 min.  To the stirring solution, NaBH4 (0.83 g, 21.94 
mmol) was added slowly in portion.  The resulting mixture was stirred for 30 min at 0 oC 
and the reaction was quenched with water (40 mL) slowly.  The mixture was then 
extracted with dichloromethane (2 × 30 mL) and the organic layer was washed with brine 
(2 × 20 mL).  The organic layers were combined and dried over Na2SO4 and concentrated 
under vacuum on rotavap.  The alcohol 424a was sufficiently pure (>98%), stored under 
Argon and used without further purification. 
 A solution of 424a (53.6 mg, 0.354 mmol) in anhydrous THF (1.5 mL) was added 
dropwise to a RB flask containing NaH (60% mineral oil) (14 mg, 0.354 mmol) in 1 
anhydrous THF (1 mL) at 0oC while stirring.  After 1 h, TLC showed complete 
consumption of starting material and formation of 433 (confirmed by 1H NMR), and the 
reaction mixture was kept at 0oC for immediate addition in the next step. 
 NaH (60% in mineral oil) (28 mg, 0.708 mmol) was taken in a oven dried RB 
flask equipped with magnetic stir bar under Argon.  To the flask, 1 ml anhydrous THF 
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was added and the solution was cooled to 0oC.  The alcohol 430 (100 mg, 0.354 mmol) in 
1.5 ml anhydrous THF was added dropwise to the stirring solution at 0 oC.  After stirring 
20 min, freshly prepared PDMAB (para- dimethyl amino benzyl) tosylate (433) was 
added dropwise to the reaction mixture at 0 oC.  The reaction mixture was then allowed to 
warm to room temperature slowly and stirred overnight.  The reaction was quenched with 
water (0.5 mL) and diluted with ethyl acetate (50 mL).  The reaction mixture was then 
washed with brine (2 x 25 mL), water (2 x 25 mL), and dried over anhydrous Na2SO4.  
The organic layer was concentrated under vacuum on rotavap and the residue was 
purified by gradient silica gel column chromatography using a mixture of ethyl acetate 
and hexane (1:4 to 1:2) as the eluent. 
5.6.3. General method for the installation of PDMAB thio group at C-6 
starting from PDMAB thiol: 
 Thiourea (0.94 g, 12.3 mmol) was dissolved in a mixture of water (1.3 mL) and 
12 N HCl (2.5 mL).  To stirring mixture, alcohol 424a (1.85 g. 12.3 mmol) was added 
and the clear solution was stirred at room temperature for 1 h followed 3 h at 70 oC.  The 
reaction mixture was then cooled to room temperature and solution of NaOH (2.02 g) in 
water (4.9 mL) was added.  A light green precipitate of isothiourea formed which was 
heated to 80 oC for 30 min.  The precipitate was dissolved and an oily organic layer was 
formed.  The reaction mixture was transferred to a separatory funnel and extracted with 
diethyl ether (2 × 20 mL).  The aqueous layer was titrated with 12 N HCl to pH 12 and 
extracted with diethyl ether (2 × 20 mL).  The organic layers were combined, dried over 
Na2SO4 and concentrated under vacuum on rotavap.  For spectroscopic characterization, 
the small amount of the crude product (40 mg) was purified via preparative TLC using a 
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1:10 mixture of ethyl acetate and hexane as the eluent to obtain the pure thiol 446.  The 
crude product contains ~20% of the dimeric compound 447 and used without further 
purification for subsequent experimentations. 
 D-Galactose (4 g, 22 mmol) and anhydrous CuSO4 (8 g, 50 mmol) were taken in a 
oven dried RB flask equipped with magnetic stir bar under Argon.  Anhydrous acetone 
(100 mL) was added to the flask and stirred for 10 min and then concentrated H2SO4 (0.5 
mL) was added to the mixture.  The resulting solution was stirred at room temperature for 
40 h.  The reaction was then filtered and the residue was washed with acetone (2 × 10 
mL).  The filtrate was then treated NaHCO3 (25 mL) and concentrated under reduced 
pressure on rotavap.  The residue was extracted with CHCl3 (4× 40 mL) and the 
combined CHCl3 extracts were dried over Na2SO4 and concentrated under reduced 
pressure on rotavap.  The crude product was purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent to 
afford 448. 
 To an oven dried RB flask 448 (2.23 g, 0.86 mmol) was taken and dissolved in 
dichloroemethane (3.5 mL).  Triethylamine (0.14 mL, 1.03 mmol) was added dropwise to 
the stirring solution at -5 oC.  To the resulting mixture, methanesulfonyl chloride (0.09 
mL, 1.12 mmol) was added dropwise.  The reaction mixture was then slowly warmed to 
25 oC and stirred for 4 h until TLC showed complete consumption of starting material.  
The reaction was then diluted with dichloromethane (3 mL) at 0 oC and treated with 
saturated NaHCO3 (5 mL).  The organic layer was separated, washed with brine (2 × 10 
mL) and dried over Na2SO4.  After concentrating the organic layer on rotavap, the syrup 
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was purified via silica gel column chromatography using a 1:2 mixture of ethyl acetate 
and hexane as the eluent to afford 449. 
 The thiol 446 (0.19 g, 1.15 mmol) was taken in an oven dried RB flask equipped 
with magnetic stir bar under Argon.  Anhydrous DMSO was added to the flask and the 
solution was cooled to 0 oC.  NaH (60% in mineral oil, 0.082 g, 1.23 mmol) was added to 
the solution and the ice-bath was removed.  After stirring at room temperature for 30 min, 
the reaction mixture was cooled to 0 oC and a solution of the mesylate 449 in anhydrous 
DMSO was added dropwise.  Next, anhydrous DMF (2 mL) was added to the reaction 
mixture to prevent solidification at 0 oC.  The reaction mixture was stirred at 0 oC for 30 
min, then slowly warmed to room temperature and heated to 80-100 oC until TLC 
showed complete consumption of the mesylate 449.  The reaction was quenched with 
slow addition of water (1 mL) at 0 oC and further diluted with water (50 mL).  The 
solution was extracted with ethyl acetate (2 × 20 mL) and the organic layer was 
separated.  The aqueous layer was washed with ethyl acetate (2 × 10 mL).  The organic 
layers were combined, dried over Na2SO4 and concentrated under reduced pressure on 
rotavap.  The crude syrup was purified via gradient silica gel column chromatography 
using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent to afford 0.306 g of the 
pure 450. 
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5.7. Experimental Data 
1. (E)-ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)(4-
(dimethylamino)benzyl)amino)-4-oxobut-2-enoate 
N
OHN
t-Bu
Me2N
CO2Et
O
( )-415
Ha
Hb
 
1H NMR (500 MHz, CDCl3): δ 7.33 (d, 1 H, J = 15.4 Hz, -CH=CH-), 7.03 (d, 2H, J = 8.9 
Hz, aryl), 6.75 (d, 1 H, J = 15.4 Hz, -CH=CH-), 6.44 (bs, 1 H, -NH), 461 (dd, 2 H, J = 
37.3, 17.3 Hz, -CH2Ar), 4.22 (bs, 1 H, Ha), 4.17 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 2.44 
(septet, 1 H, J = 6.5 Hz, Hb), 1.27 (s, 9 H, t-Bu), 1.25 (t, 3 H, J = 7.3 Hz, -OCH2CH3), 
0.93 (d, 2 H, J = 6.5 Hz, i-Pr), 0.75 (d, 3 H, J = 6.5 Hz, i-Pr) 
 
13C NMR (125 MHz, CDCl3): δ 168.9, 166.6, 165.4, 149.9, 134.4, 131.4, 127.9, 112.5, 
60.9, 51.1, 40,5, 28.5, 27.2, 19.6, 19.0, 14.0 
 
HRMS (EIMS, M+): calcd for C24H37N3O4 431.2784, found 431.2787. 
 
2. (E)-ethyl 4-((1-(tert-butylamino)-3-methyl-1-oxobutan-2-yl)amino)-4-oxobut-2-
enoate 
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1H NMR (500 MHz, CDCl3): δ 7.39 (d, 1 H, J = 8.6 Hz, -NH), 7.03 (d, 1 H, J =15.2 Hz, -
CH=CH-), 6.81 (d, 1 H, J = 15.2 Hz, -CH=CH-), 4.23 (q, 2 H, J = 7.3 Hz, -OCH2CH3), 
4.20 (dd, 1 H, J = 9.1, 4.6 Hz, Ha), 2.03 (m, Hb), 1.32 (s, 9 H, t-Bu), 1.29 (t, 3 H, J = 7.3 
Hz, -OCH2CH3), 0.95 (d, 3 H, J = 6.5 Hz, i-Pr), 0.93 (d, 3 H, J = 6.5 Hz, i-Pr) 
 
13C NMR (125 MHz, CDCl3): δ 170.1, 165.4, 163.7, 136.2, 130.6, 61.1, 59.5, 51.7, 31.4, 
29.7, 28.6, 19.1, 18.4, 14.1 
 
HRMS (EIMS, M+): calcd for C15H26N2O4 298.1893, found 298.1889. 
 
3. p-N,N-Dimethylaminobenzyl (PDMAB) alcohol 
 
1H NMR (500 MHz, CDCl3): δ 7.26 (d, 2 H, J = 8.3 Hz, aryl), 6.75 (d, 2 H, J = 8.9 Hz, 
aryl), 5.57 (d, 1 H, J = 2.7 Hz, -CH2Ar), 2.98 (s, 6 H, -NMe2), 1.88 (bs, 1 H, OH) 
 
13C NMR (125 MHz, CDCl3): δ 150.3, 128.9, 128.5, 112.6, 65.2, 40.6 
 
HRMS: EIMS (M+): calcd for C9H13NO 151.0997, found 151.0995 
 
4. p-N,N-Diphenylaminobenzyl (PDPAB) alcohol 
 It was synthesized from p-N,N-Diphenylamino benzaldehyde following similar 
procedure as described for PDMAB alcohol. 
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1H NMR (500 MHz, CDCl3): δ 7.26-7.32 (m, 6 H, aryl), 7.11-7.17 (m, 6 H, aryl), 7.03-
7.09 (m, 2 H, aryl), 4.63 (d, 1 H, J = 2.8 Hz, -CH2Ar), 2.85 (bs, 1 H, OH) 
 
13C NMR (125 MHz, CDCl3): δ147.6, 147.2, 134.9, 129.1, 128.2, 124.0, 123.9, 122.6, 
64.6,  
 
HRMS (EIMS, M+): calcd for C19H17NO 275.1310, found 275.1310. 
 
5. 4,4'-methylenebis(N,N-dimethylaniline) 
 
1H NMR (400 MHz, CDCl3) δ: 7.14-7.08 (m, 4H), 6.76-6.71 (m, 4H), 3.86 (d, 2H, J = 
4.4 Hz), 2.95 (s, 6H), 2.94 (s, 6H). 
 
13C NMR (100 MHz, CDCl3) δ: 149.3, 130.6, 129.7, 113.3, 41.2, 40.2. 
 
HRMS (EIMS, M+): calcd for C17H22N2 254.1783, found 254.1786. 
 
6. Methyl 4-6-O-benzylidine- α-D-glucopyranoside 
 
 To a oven dried RB flask equipped with magnetic stir bar under Argon, methyl-α-
D-glucopyranoside (1.0 g, 5.15 mmol) was taken and dissolved in anhydrous DMF (20 
mL).  To the stirring solution, α,α-dimethoxy benzaldehyde (0.95 mL, 6.18 mmol) was 
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added followed by catalytic amount of p-tosyl sulfonic acid at room tempertaure.  The 
resulting solution was stirred at room temperature for 1 h and on rotavap (virtually dried 
apparatus) for 6 h at 45-50 oC.  Then the reaction mixture was quenched with saturated 
NaHCO3 (2 mL) and diluted with water (100 mL).  The solution was extracted with ethyl 
acetate (3 × 20 mL) and the organic layers were combined, dried over Na2SO4.  The 
organic layer was concentrated under reduced pressure on rotavap and purified via 
gradient silica gel column chromatography using a mixture of ethyl acetate/hexane (1:4 to 
2:1) as the eluent to afford 1.16 g of pure methyl 4-6-O-benzylidine-α-D-glucopyranoside 
(429). 
1H NMR (300 MHz, CDCl3): δ 7.44-7.50 (m, 2 H, Ph), 7.30-7.36 (m, 3 H), 5.49 (s, 1 H, -
CHPh), 4.72 (d, 1 H, J = 4.0 Hz, H-1), 4.24 (dd, 1 H, J = 9.8, 4.4 Hz, H-4), 3.89 (t, 1 H, J 
= 9.2 Hz, H-2), 3.76 (dt, 1 H, J = 15.0, 4.6 Hz, H-6), 3.69 (t, 1 H, J = 10.1 Hz, H-3), 3.57 
(dd, 1 H, J = 9.2, 3.7 Hz, H-6), 3.44 (t, 1 H, J = 9.2 Hz, H-5), 3.40 (s, 3 H, OMe), 3.0 (bs, 
2 H, 2-OH, 3-OH). 
 
13C NMR (75 MHz, CDCl3): δ 162.6, 137.1, 129.1, 128.2, 126.3, 101.8, 99.8, 80.9, 72.7, 
71.3, 68.9, 62.3, 55.4, 36.4, 31.4. 
 
HRMS (EIMS, M+): calcd for C14H18O6 282.1103, found 282.1101. 
 
7. Methyl 3-O-benzyl-4-6-O-benzylidine- α-D-glucopyranoside 
 
 Methyl 4-6-O-benzylidine-α-D-glucopyranoside (429) was dissolved in benzene 
and 40% KOH was added to the flask.  Next, benzyl chloride was added slowly at room 
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temperature and the resulting mixture was refluxed for 10 min.  After TLC showed 
complete consumption of starting material, the reaction was extracted with ethyl acetate.  
The organic layers were combined, dried over Na2SO4 and concentrated  under reduced 
pressure on rotavap.  The residue was purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent. 
1H NMR (400 MHz, C6D6): δ: 7.60 (d, 2H, J = 7.3 Hz, aryl), 7.38 (d, 2H, J = 7.3 Hz, 
aryl), 7.17 (dd, 2H, J = 7.3, 7.3 Hz, aryl), 7.13-7.08 (m, 3H, aryl), 7.04 (d, 1H, J = 7.3 
Hz, aryl), 5.27 (s, 1H, benzylidene H), 4.94 (d, 1H, J = 11.4 Hz, -Bn), 4.78 (d, 1H, J = 
11.4 Hz, -Bn), 4.44 (d, 1H, J = 4.1 Hz, H1), 4.06 (dd, 1H, J = 10.5, 4.9 Hz, H6), 3.74 (dd, 
1H, J = 9.7, 8.9 Hz, H3), 3.72 (ddd, 1H, J = 10.5, 9.7, 4.9 Hz, H5), 3.66 (dd, 1H, J = 9.7, 
4.1 Hz, H2), 3.42 (dd, 1H, J = 10.5, 8.9 Hz, H4), 3.39 (dd, 1H, J = 10.5, 9.7 Hz, H6’),  
2.84 (s, 3H, -OMe). 
 
13C NMR (125 MHz, C6D6): δ 139.6, 138.5, 129.0, 128.5, 128.3, 128.1, 127.9, 127.6, 
126.6, 101.6, 100.5, 82.2, 79.5, 74.8, 73.2, 69.1, 62.9, 54.9. 
 
IR (neat): 3519, 2954, 2921, 2851, 1737, 1464, 1367, 1330, 1283, 1213, 1174, 1142, 
1078, 1032, 993, 968, 749, 736, 695, 672, 657, 621. 
 
HRMS (EIMS, M+): calcd for C21H24O6 372.1573, found 372.1574. 
 
8. Methyl 2-O-p-N,N-dimethylaminobenzyl-3-O-benzyl-4-6-O-benzylidine-α-D-
glucopyranoside 
O
BnO
PDMABO
O
OMe
OPh
431  
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1H NMR (400 MHz, C6D6): δ: 7.63 (d, 2H, J = 6.5 Hz, aryl), 7.45 (d, 2H, J = 7.3 Hz, 
aryl), 7.33 (d, 2H, J = 8.9 Hz, aryl), 7.22-7.06 (m, 6H, aryl), 6.58 (d, 2H, J = 8.9 Hz, 
aryl), 5.36 (s, 1H, benzylidene H), 5.02 (d, 1H, J = 11.4 Hz, -PDMAB), 4.92 (d, 1H, J = 
11.4 Hz, -PDMAB), 4.76 (d, 1H, J = 11.3 Hz, -Bn), 4.62 (d, 1H, J = 11.3 Hz, -Bn), 4.63 
(d, 1H, J = 3.2 Hz, H1), 4.27 (dd, 1H, J = 9.7, 8.9 Hz, H3), 4.14 (dd, 1H, J = 9.7, 4.9 Hz, 
H6), 3.92 (ddd, 1H, J = 10.5, 9.7, 4.9 Hz, H5), 3.67 (dd, 1H, J = 8.9, 3.2 Hz, H2), 3.55 (dd, 
1H, J = 9.7, 9.7 Hz, H4), 3.49 (dd, 1H, J = 10.5, 9.7 Hz, H6’),  3.07 (s, 3H, -OMe), 2.48 
(s, 6H, -NMe2 on PDMAB). 
 
13C NMR (125 MHz, C6D6): δ 150.6, 139.9, 138.6, 129.7, 128.9, 128.3, 128.1, 127.9, 
127.4, 126.7, 112.7, 101.7, 99.8, 82.9, 79.6, 78.8, 75.2, 73.5, 69.4, 62.8, 55.1, 40.2. 
 
HRMS: ESIMS (M+H)+ calcd for C30H36NO6 506.2543, found 506.2519. 
 
[α]23D -51.6o (c, 0.19, CHCl3) 
 
IR (neat): 3064, 3033, 2923, 2855, 1733, 1708, 1672, 1614, 1523, 1454, 1369, 1352, 
1213, 1175, 1086, 1054, 1030, 995, 918, 807, 747, 698, 677, 657, 626, 614. 
 
9. p-N,N-Dimethylaminobenzyl thiol 
 
1H NMR (500 MHz, CDCl3): δ 7.20 (d, 2 H, J = 8.9 Hz, Aryl), 6.71 (d, 2 H, J = 8.6 Hz, 
Aryl), 3.17 (d, 2 H, J = 7.0 Hz, -CH2Ar), 2.95 (s, 6 H, -NMe2). 
13C NMR (125 MHz, CDCl3): δ 149.7, 128.9, 128.7, 112.8, 40.7, 28.5. 
HRMS: EIMS (M+) calcd for C9H13NS 167.0769, found 167.0775. 
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10. 4,4'-(Thiobis(methylene))bis(N,N-dimethylaniline) 
 
1H NMR (500 MHz, CDCl3): δ 7.18 (d, 2 H, J = 8.6 Hz, Aryl), 7.16 (d, 2 H, J = 8.6 Hz, 
Aryl), 6.71 (t from d and d overlap, J = 8.6 Hz, 4 H, Aryl), 3.63 (s, 2 H, -CH2Ar), 3.57 (s, 
2 H, -CH2Ar), 2.95 (s, 12 H, 2 × –NMe2). 
13C NMR (125 MHz, CDCl3): δ 149.9, 149.5, 130.2, 129.7, 129.4, 126.2, 124.9, 112.7, 
112.5, 53.4, 43.1, 40.7, 40.6, 34.9. 
HRMS: EIMS (M+) calcd for C18H24N2S 300.1660, found 300.1661. 
 
11. 1,2:3,4-Diisopropylidine-α-D-galactopyranoside 
 
1H NMR (300 MHz, CDCl3): δ 5.54 (d, 1 H, J = 5.5 Hz, H-1), 4.59 (dd, 1 H, J = 7.9, 2.4 
Hz, H-2), 4.31 (dd, 1 H, J = 5.5, 2.5 Hz, H-3), 4.25 (dd, 1 H, J = 7.9, 1.8 Hz, H-4), 3.66-
3.88 (m, 3 H, H-5 and H-6 overlap), 2.34 (bs, 1 H, 6-OH), 1.51 (s, 3H, Me), 1.43 (s, 3 H, 
Me), 1.31 (s, 6 H, Me and Me overlap). 
13C NMR (75 MHz, CDCl3): δ 109.4, 108.6, 96.2, 71.5, 70.7, 70.5, 68.1, 62.2, 25.9, 25.8, 
24.9, 24.2 
 
HRMS: EIMS (M+) calcd for C12H20O6 260.1260, found 260.1255. 
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12. 1,2:3,4-Di-O-isopropylidine-6-methanesulfonyl-α-D-galactopyranoside 
 
1H NMR (400 MHz, CDCl3): δ 5.48 (d, 1 H, J = 4.9 Hz, H-1), 4.58 (dd, 1 H, J = 7.4, 2.4 
Hz, H-2), 4.27-4.33 (m, 3 H, H-5 and H-6 overlap), 4.19 (dd, 1 H, J = 8.1, 1.6 Hz, H-3), 
4.05 (m, 1 H, H-4), 3.03 (s, 3 H, Me), 1.48 (s, 3 H, Me), 1.37 (s, 3 H, Me), 1.28 (s, 6 H, 
Me and Me overlap). 
 
13C NMR (100 MHz, CDCl3): δ 109.6, 108.8, 96.0, 70.4, 70.1, 68.9, 66.2, 37.7, 25.8, 
25.7, 24.7, 24.2. 
 
HRMS: EIMS (M+) calcd for C13H22O8S 338.1035, found 338.1029. 
 
13. 1,2:3,4-Di-O-isopropylidine-6-p-N,N-dimethylaminobenzyl-thio-α-D-
galactopyranoside 
 
1H NMR (500 MHz, CDCl3): δ 7.19 (d, 2 H, J = 8.5 Hz, aryl), 6.68 (d, 2 H, J = 8.5 Hz, 
aryl), 5.54 (d, 1 H, J = 4.9 Hz, H-1), 4.61 (dd, 1 H, J = 7.9, 2.1 Hz, H-2), 4.33 (dd, 1 H, J 
= 7.9, 1.8 Hz, H-3), 4.30 (dd, 1 H, J = 4.9, 2.4 Hz, H-4), 3.87 (dt, 1 H, J = 7.0, 1.8 Hz, H-
 319
5), 3.71 (s, 2 H, -CH2Ar), 2.92 (s, 6 H, NMe2), 2,68 (d, 2 H, J = 7.0 Hz, H-6), 1.53 (s, 3 
H, Me), 1.45 (s, 3 H, Me), 1.35 (s, 3 H, Me), 1.33 (s, 3 H, Me) 
 
13C NMR (125 MHz, CDCl3): δ 149.5, 129.8, 129.6, 125.9, 112.7, 109.1, 108.4, 96.6, 
71.5, 70.8, 70.5, 67.5, 40.6, 36.1, 30.6, 26.1, 25.9, 24.8, 24.4 
 
HRMS: EIMS (M+) calcd for C21H31NO5S 409.1935, found 409.1930 
 
14. 1,2,3,4-tetraacetate-6-p-N,N-dimethylaminobenzyl-thio-α-D-galactopyranoside 
 
 Compound 453 (0.01 g, 0.02 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and Ac2O (2 mL) was added to the flask at -
20 oC.  To the stirring solution, 2 drops of concentrated H2SO4 was added via a syringe.  
After stirring the solution at -20 oC for 2 h, it was allowed to reach room temperature 
slowly and stirred for 24 h.  The reaction mixture was then quenched with saturated 
NaHCO3 (10 mL) and extracted with CH2Cl2 (2 × 10 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The 
residue was purified via preparative TLC using a 1:3 mixture of ethyl acetate/hexane as 
the eluent. 
1H NMR (500 MHz, CDCl3): δ 7.14 (d, 2 H, J = 8.5 Hz, aryl), 6.69 (d, 2 H, J = 8.3 Hz, 
aryl), 6.35 (d, 1 H, J = 1.2 Hz, H-1), 5.51-5.54 (m, 1 H, H-2), 5.26-5.29 (m, 1 H, H-3), 
4.04 (m, 1 H, H-4), 3.86-3.88 (m, 1 H, H-5), 3.64 (d, 2 H, J = 2.8 Hz, -CH2Ar), 2.94 (s, 6 
H, NMe2), 2.58 (dd, 1 H, J = 13.7, 6.7 Hz, H-6), 2.41 (dd, 1 H, J = 13.7, 7.3 Hz, H-6), 
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2.15 (s, 3 H, -COCH3), 2.09 (s, 3 H, -COCH3), 2.01 (s, 3 H, -COCH3), 2.00 (s, 3 H, -
COCH3) 
 
HRMS (M+, EIMS): calcd for C23H31NO9S 497.1720, found 497.1710 
 
15. 1,2,3,4-tetraacetate-6-thioacetate-α-D-galactopyranoside 
 
1H NMR (500 MHz, CDCl3): δ 6.86 (d, 1 H, J = 4.3 Hz, H-1), 5.47 (t, 1 H, J = 4.3 Hz, H-
2), 5.39 (dd, 1 H, J = 6.4, 3.7 Hz, H-3), 4.26 (dd, 1 H, J = 11.6, 6.1 Hz, H-6), 4.15 (dd, 1 
H, J = 11.6, 6.1 Hz, H-6), 3.76 (t, 1 H, J = 4.6 Hz, H-4), 2.92-2.95 (m, 1 H, H-5), 2.13 (s, 
6 H, -COCH3 and -COCH3 overlap), 2.10 (s, 3 H, -COCH3), 2.09 (s, 3 H, -COCH3), 2.08 
(s, 3 H, -COCH3) 
 
HRMS: EIMS (M+ + Na) calcd for C16H22O10NaS 429.0831, found 429.0831 
 
16. Methyl 2-O-acetyl-4-6-O-benzylidine-α-D-glucopyranoside 
 
 To a solution of methyl 4,6-O-benzylidine-α-D-glucopyranoside (0.128 g, 0.45 
mmol) in anhydrous dichloromethane (1.3 mL) in a oven dried RB flask under under 
Argon, Ac2O (0.068 mL, 0.63 mmol) was added slowly.  After stirring the solution for 30 
min at room temperature, Et3N (0.41 mL, 4.05 mmol) was added dropwise.  The resulting 
mixture was stirred at room temperature for 24 h and quenched with methanol (5 equiv.) 
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after TLC showed completion of the reaction.  The reaction mixture was then 
concentrated under reduced pressure on rotavap.  The residue was dissolved in ethyl 
acetate (10 mL) and washed with saturated NaHCO3 (2 × 10 mL), brine (2 × 10 mL) 
respectively.  The organic layers were combined and dried over Na2SO4.  The crude 
product was purified via gradient column chromatography using silica gel as the 
stationary phase and a mixture of ethyl acetate/hexane (1:5 to 1:1) as the eluent to afford 
the major product as a white solid 
1H NMR (500 MHz, CDCl3): δ 7.47-7.52 (m, 2 H, Ph), 7.34-7.43 (m, 3 H, Ph), 5.55 (s, 1 
H, -CHPh), 4.95 (d, 1 H, J = 3.7 Hz, H-1), 4.80 (dd, 1 H, J = 9.8, 3.7 Hz, H-4), 4.29 (dd, 
1 H, J = 10.1, 4.6 Hz, H-2), 4.17 (t, 1 H, J = 9.5 Hz, H-3), 3.84 (dt, 1 H, J = 10.1, 4.6 Hz, 
H-6), 3.55 (t, 1 H, J = 9.5 Hz, H-5), 3.44 (s, 3 H, OMe), 2.59 (bs, 1 H, 3-OH), 2.15 (s, 3 
H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.7, 136.9, 129.3, 128.3, 126.3, 102.0, 97.5, 81.3, 73.5, 
68.6, 55.4, 20.9. 
HRMS: EIMS (M+) calcd for C16H20O7 324.1209, found 324.1211 
 
17. Methyl 3-O-acetyl-4-6-O-benzylidine-α-D-glucopyranoside 
O
AcO
HO
O
OMe
OPh
 
1H NMR (500 MHz, CDCl3): δ 7.42-7.47 (m, 2 H, Ph), 7.33-7.38 (m, 3 H, Ph), 5.49 (s, 1 
H, -CHPh), 5.33 (t, 1 H, J = 9.8 Hz, H-3), 4.81 (d, 1 H, J = 3.7 Hz, H-1), 4.31 (dd, 1 H, J 
= 4.6 Hz, H-4)3.87 (dt, 1 H, J = 10.1, 4.7 Hz, H-6), 3.75 (t, 1 H, J = 10.4 Hz, H-2), 3.66 
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(dt, 1 H, J = 10.4, 3.8 Hz, H-6), 3.58 (t, 1 H, J = 9.5 Hz, H-5), 3.47 (s, 3 H, OMe), 2.22 
(bs. 1 H, 2-OH), 2.12 (s, 3 H, -COCH3),  
 
13C NMR (125 MHz, CDCl3): δ 171.1, 136.9, 129.1, 128.2, 126.2, 101.5, 100.1, 78.6, 
72.3, 71.9, 68.9, 62.7, 55.6, 21.1 
 
HRMS: EIMS (M+) calcd for C16H20O7 324.1209, found 324.1211 
 
18. Methyl 2,3-di-O-acetyl-4-6-O-benzylidine-α-D-glucopyranoside 
 
1H NMR (500 MHz, CDCl3): δ 7.42-7.47 (m, 2 H, Ph), 7.33-7.38 (m, 3 H, Ph), 5.58 (t, 1 
H, J = 9.8 Hz, H-2), 5.55 (s, 1 H, -CHPh), 4.89-4.96 (m, 2 H, H-1 and H-3 overlap), 4.33 
(dd, 1 H, J = 10.1, 4.9 Hz, H-4), 3.93 (dt, 1 H, J = 9.8, 4.6 Hz, H-6), 3.77 (t, 1 H, J = 10.4 
Hz, H-6), 3.67 (t, 1 H, J = 9.8 Hz, H-5), 3.41 (s, 3 H, OMe), 2.09 (s, 3 H, -COCH3), 2.05 
(s, 3 H, -COCH3) 
13C NMR (125 MHz, CDCl3): δ 170.4, 169.8, 136.9, 129.1, 128.2, 126.1, 101.5, 97.6, 
79.2, 71.6, 68.9, 68.8, 62.3, 55.3, 20.8, 20.7. 
 
HRMS: EIMS (M+) calcd for C18H22O8 366.1315, found 366.1312 
 
19. Methyl 2-O-acetyl-3-p-N,N-dimethylaminobenzyl-thio-4-6-O-benzylidine-α-D-
glucopyranoside 
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 Methyl 2-O-acetyl-4-6-O-benzylidine-α-D-glucopyranoside (455) (0.087 g, 0.268 
mmol) was dissolved in anhydrous dichloromethane (6.5 mL) and cooled to -40 oC (dry 
ice in m-xylene).  To the stirring solution under Argon, anhydrous pyridine (0.129 mL, 
1.6 mmol) was added followed by Tf2O (0.18 mL, 1.07 mmol) dropwise.  The reaction 
was then monitored via TLC.  After 2 h, TLC showed complete consumption of the 
starting material and the reaction was quenched with 1 N HCl (5 mL).  The reaction 
mixture was then washed with saturated NaHCO3 (10 mL) and water (10 mL) 
respectively.  The organic layers were combined, dried over Na2SO4 and concentrated 
under reduced pressure on rotavap to obtain the 3-O-triflate 456.  Due to the sensitivity 
toward heat and instability of 456, it was used directly into the preceding step. 
 To a oven dried RB flask equipped with magnetic stir bar under Argon, 446 
(0.073 g, 0.438 mmol) was dissolved in anhydrous DMSO (1.4 mL).  To the flask, NaH 
(60% in mineral oil, 0.027 g, 0.57 mmol) was added and the mixture was stirred at room 
temperature for 10 min.  The flask was then cooled to -5 oC and a solution of 456 (0.125 
g, 0.274 mmol) in anhydrous DMSO (2 mL) was added slowly.  After stirring the 
solution at 0 oC for 1 hr, anhydrous DMF (1 mL) was added to prevent further 
solidification of reaction mixture.  The reaction was stirred for additional 1 h at 0 oC and 
then slowly warmed to room temperature.  After TLC showed complete consumption of 
starting material, the reaction was quenched with saturated NaHCO3 (5 mL), washed with 
brine (2 × 10 mL).  The organic layers were combined, dried over Na2SO4 and 
concentrated under reduced pressure on rotavap.  The residue was purified via gradient 
silica gel column chromatography using a mixture of ethyl acetate/hexane (1:5 to 1:1) as 
the eluent. 
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1H NMR (500 MHz, CDCl3): δ 7.43-7.48 (m, 2 H, Ph), 7.32-7.39 (m, 3 H, Ph), 7.22 (d, 2 
H, J = 7.7 Hz, aryl), 6.68 (d, 2 H, J = 8.5 Hz, aryl), 5.60 (s, 1 H, -CHPh), 5.33 (t, 1 H, J = 
2.8 Hz, H-2), 4.56 (d, 1 H, J = 1.1 Hz, H-1), 4.24-4.34 (m, 2 H), 4.17 (dd, 1 H, J = 9.2, 
3.2 Hz, H-3), 3.85 (dd, 1 H, J = 13.1 Hz, H-6), 3.76 (t, 1 H, J = 11.9 Hz), 3.27 (s, 3 H, 
OMe), 3.23 (dd, 1 H, J = 2.8, 0.7 Hz, H-4), 2.90-2.96 (m, 7 H, H-5 and NMe2 overlap), 
2.11 (s, 3 H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.9, 149.9, 137.3, 129.8, 129.1, 128.3, 126.2, 124.8, 
112.7, 102.0, 101.6, 74.5, 69.9, 69.3, 58.9, 55.3, 45.8, 40.6, 36.9, 21.3. 
 
HRMS: EIMS (M+) calcd for C25H31NO6S 473.1872, found 473.1869 
 
20. 
 
1H NMR (500 MHz, CDCl3): δ 7.48-7.53 (m, 2 H, Ph), 7.34-7.40 (m, 3 H, Ph), 5.58 (s, 1 
H, -CHPh), 4.89 (d, 1 H, J = 2.7 Hz, H-1), 4.24 (dd, 1 H, J = 10.1, 4.9 Hz), 4.09 (dt, 1 H, 
J = 9.2, 5.2 Hz), 3.96 (dd, 1 H, J = 9.2, 1.2 Hz), 3.69 (t, 1 H, J = 10.4 Hz), 3.53 (d, 1 H, J 
= 4.3 Hz), 3.50 (dd, 1 H, J = 4.6, 3.1 Hz), 3.47 (s, 3 H, OMe). 
 
13C NMR (125 MHz, CDCl3): δ 137.1, 129.2, 128.3, 126.3, 102.8, 95.3, 77.9, 68.9, 60.0, 
55.9, 53.1, 50.7 
 
HRMS: EIMS (M+ + Na) calcd for C14H16NaO5 287.0895, found 287.0895 
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21. 3-((4-(dimethylamino)benzyl)thio)-3-phenylpropanal 
 
 To an oven dried 10 mL CEM microwave vial, aldehyde (0.16 g, 1.21 mmol) was 
dissolved in 2.5 mL EtOH.  To the vial, 0.01 g of K3PO4 was added followed by the thiol 
(0.18 g, 1.06 mmol).  The vial was capped according to the manufacturer instruction and 
placed into microwave cavity.  Microwave was equilibrated to 100 oC for 15 min and 
TLC showed complete consumption of starting material.  The solution was concentrated 
under reduced pressure on rotavap and the residue was purified via gradient silica gel 
column chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 9.58 (br t, 1 H, -CHO), 7.32-7.39 (m, 3 H, Ph), 7.24-7.31 
(m, 2 H, Ph), 7.09 (d, 2 H, J = 8.6 Hz, Aryl), 6.68 (d, 2 H, J = 8.6 Hz, Aryl), 4.19 (t, 1 H, 
J = 7.6 Hz, Ha), 3.52 (d, 1 H, J = 13.4 Hz, Hd), 3.42 (d, 1 H, J = 13.4 Hz, Hd), 2.95 (s, 6 
H, -NMe2), 2.86-2.94 (m, 2 H, Hb). 
 
13C NMR (125 MHz, CDCl3): δ 199.7, 149.7, 141.2, 129.7, 128.7, 127.9, 127.5, 124.9, 
112.6, 49.5, 42.6, 40.6, 35.1. 
 
HRMS: EIMS (M+) calcd for C18H21NOS 299.1344, found 299.1342. 
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22. Methyl 3-((4-(dimethylamino)benzyl)thio)propanoate 
 
1H NMR (500 MHz, CDCl3): δ 7.18 (d, 2 H, J = 8.6 Hz, Aryl), 6.69 (d, 2 H, J = 8.6 Hz, 
Aryl), 3.68 (s, 3 H, -OMe), 3.67 (s, 2 H, -CH2Ar), 2.94 (s, 6 H, -NMe2), 2.65-2.72 (m, 2 
H, -SCH2CH2CO2Me), 2.52-2.60 (m, 2 H, -SCH2CH2CO2Me). 
 
13C NMR (125 MHz, CDCl3): δ 172.5, 129.6, 112.7, 51.7, 40.7, 35.7, 34.4, 26.0. 
 
HRMS: EIMS (M+) calcd for C13H19NO2S 253.1136, found 253.1342. 
 
24. 3-((4-(Dimethylamino)benzyl)thio)cyclohexanone 
 
1H NMR (500 MHz, CDCl3): δ 7.17 (d, 2 H, J = 8.6 Hz, Aryl), 6.68 (d, 2 H, J = 8.3 Hz, 
Aryl), 3.72 (d, 1 H, J = 13.4 Hz, Ha), 3.68 (d, 1 H, J = 13.4 Hz, Ha), 2.94 (s, 6 H, -NMe2), 
2.89-2.96 (m, 1 H, Cy), 2.67 (dd, 1 H, J = 14.3, 4.6 Hz, Hb), 2.28-2.42 (m, 3 H, Cy), 
2.03-2.15 (m, 2 H, Cy), 1.61-1.77 (m, 2 H, Cy). 
 
13C NMR (125 MHz, CDCl3): δ 208.9, 149.5, 129.5, 125.6, 112.7, 47.9, 41.7, 40.9, 40.6, 
34.4, 31.3, 24.2. 
 
HRMS: EIMS (M+) calcd for C15H21NOS 263.1344, found 263.1349. 
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25. 4,4'-(Selenobis(methylene))bis(N,N-dimethylaniline) 
 
1H NMR (400 MHz, CDCl3): δ 7.21 (t from d and d overlap, 4 H, J = 8.1 Hz, Aryl), 6.74 
(d, 2 H, J = 8.1 Hz, Aryl), 6.72 (d, 2 H, J = 8.1 Hz, Aryl), 3.94 (s, 2 H, -CH2Ar), 3.74 (s, 
2 H, -CH2Ar), 2.98 (s, 12 H, 2 × -NMe2) 
 
13C NMR (100 MHz, CDCl3): δ 149.6, 149.2, 129.7, 129.6, 126.5, 126.5, 112.6, 112.3, 
40.6, 40.5, 32.8, 27.1. 
 
HRMS: EIMS (M+) calcd for C18H24N2Se 348.1105, found 348.1111 
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CHAPTER 6 
 
Synthetic Study Toward Neutral Glycosylation 
 
6. Introduction 
In recent years, a significant amount of biological studies involving naturally 
occurring products such as membranes, cell walls, and antibiotics as well as the 
mechanisms of these substances, made clear the biological significance of the glycons of 
glycoconjugates (e.g., glycoproteins, glycolipids) in molecular recognition for the 
exchange of biological information.278  The O-glycosylation method, which is a crucial 
synthetic methodology to attach carbohydrate to other carbohydrate moieties or other 
molecules (aglycon), is continuously becoming more and more important.  Several 
synthetic methodologies have been developed in the last decade for this purpose, 
however many of these requires costly, and toxic reagents.278  Toward this end, there are 
few literature reports available that describe glycosylation under nearly neutral or mild 
conditions.  For example, glycosylation using promoter LiClO4,279 LiOTf,280 and 
others.281  Jensen and co-workers have reported an inter- and intramolecular 
glycosylation using DISAL (dinitro salisylate derivatives) donors under neutral 
conditions and .282  Recently, microwave irradiation has become an alternative choice to 
perform glycosylation.281, 283 
Phenols are known to undergo glycosylation with glycosyl halides under mild 
basic conditions via phenoxide ions.284  Following this observation, we embarked on 
devising a strategy for neutral glycosylation encompassing the ability of PDMAB group 
to form alkoxide ion under µwave irradiation. 
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6.1. A microwave-influenced neutral glycosylation via alkoxide 
 We envisioned that installation of PDMAB group at the anomeric position on 
carbohydrates followed by subsequent microwave irradiation in the presence of a suitable 
electrophile might enable us to perform alkoxide-based neutral glycosylation.  Thus 
compound 375 was synthesized from 374 following a previous procedure (Chapter 4, 
Scheme 88).  Glycosylation of 375 in the presence of PDMAB-OH using promoter 
TMSOTf provided 70% of the desired product 475.  With 475 in hand, we decided to 
subject it to microwave irradiation in THF in presence of allyl bromide.  Gratifyingly, the 
reaction afforded 60% desired product 373 as a 1:10 mixture of α and β anomers (Scheme 
109).  The 1H and 13C NMR spectra of the product were in excellent agreement with our 
previously obtained product 373. 
 
 
Scheme 109.  Microwave-influenced neutral glycosylation via alkoxide 
 
 Following this result, our lab was encouraged to apply the methodology using 
other glycosides.  To date, we have been successful in showing that the methodology can 
provide utility to perform glycosylation to synthesize monosaccharides as well as 
disaccharides as shown in scheme 134.285 
 A proposed mechanism for the alkoxide-based neutral glycosylation is shown in 
scheme 135.  As shown previously (Scheme 97, 101), microwave irradiation promotes 
the formation alkoxide 480 via the formation of the well known aza-quinone methide 
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421.  Intermediate 480 might be in equilibrium with 481 and 482; in the presence of 
suitable electrophiles, they undergo SN2 or SN2/ displacement reactions to afford the final 
product 483. 
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Scheme 110.  Application of alkoxide-based neutral glycosylation. 
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Scheme 111.  Proposed mechanism of the alkoxide-based neutral glycosylation. 
 
6.2. Approach Toward an Entirely Neutral Glycosylation via Oxocarbenium 
Ion 
 Recently, Rychnovski and co-workers reported a clever method of synthesizing α-
acetoxy ethers via DIBALH reduction and in situ acetylation of esters (Scheme 112).  In 
presence of DIBALH, the ester 484 forms aluminate 485 that was trapped by acetic 
anhydride to obtain α-acetoxy ethers 486 as synthetically useful intermediates.286 
 
 
Scheme 112.  Rychnovsky’s method of preparing α-acetoxy ethers 
 
 Based on Rychnovsky’s method, our hypothesis was that a carbohydrate moiety 
487 having an ester group at the anomeric carbon that contains a masked PDMAB group 
which could be revealed upon DIBALH reduction and in situ trapping with Ac2O would 
provide 489 (Scheme 113).  Since the α-acetoxy group is an activated leaving group, we 
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speculated that microwave irradiation would promote the formation of the aza-quinone 
methide intermediate 490 that would then be eliminated via electron donation from the 
ring oxygen to form the oxocarbenium intermediate 491.  In presence of a suitable 
acceptor, the donor 491 would be glycosylated to afford 492. 
 
 
Scheme 113.  Working hypothesis toward neutral glycosylation via oxocarbonium ion. 
 
 With this working hypothesis in mind, we attempted to synthesize the ester 495 
via a Mitsunobu reaction287 of the hemiacetal 494 with p-(N,N-dimethylamino)benzoic 
acid (495, PDMABA).  However, the reaction provided moderate yield and we chose to 
use EDCI (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), DMAP.  The EDCI 
method provided quantitative yield of the desired product 495 (Scheme 114). 
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Scheme 114.  Synthesis of the PDMABA ester 496. 
 
 When the ester 496 was subjected to Rychnovsky’s conditions, the expected 
product 497 was not obtained (Scheme 115).  Instead, a mixture of the hemiacetal 494, 
acetate 498 and 499 were obtained.  Running the reaction repeatedly under extremely dry 
solvents, reagents as well as air and moisture free schlenk line, did not provide the 
desired product  
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Scheme 115.  Attempted synthesis of α-acetoxy ether 497. 
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 We reasoned that the intermediate of the type 488 is not stable due to the presence 
of very strong electron-donating N,N-dimethyl amino group.  Also, we speculated that the 
furanoside ring might not permit the formation of stable oxocarbenium intermediate.  
Thus, we decided to synthesize the glucoside ester 501 from commercially available 
hemicaetal 500 via EDCI coupling in excellent yield.  Unfortunately, when prior 
conditions of reduction and trapping were employed, the expected product 502 was not 
obtained again.  Instead, the hemiacetal 500, acetates 503 and 499 were obtained 
(Scheme 116). 
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Scheme 116.  Attempted synthesis of the ester 502. 
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Scheme 117. Attempted synthesis of ester 506. 
 
 Next, we decided to use p-methoxy benzoic acid 504 (PMBA) in the EDCI 
coupling reaction with 500.  The PMBA ester 505 was obtained in excellent yield.  
Unfortunately, again, when prior conditions were employed, the desired product 506 was 
not obtained.  Instead, the hemiacetal 500, acetates 507 and 508 were obtained (Scheme 
117) 
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Scheme 118. Synthesis α-acetoxy ether 510 of the benzoic ester 509. 
 
 We then synthesized the benzoic ester 509 from the hemiacetal 500 in excellent 
yield.  Gratifyingly, the ester 509 provided the desired product 510 under Rychnovsky’s 
conditions (Scheme 118).  However, 510 was inseparable from the acetate 503 and due to 
sensitivity of the α-acetoxy ether 510, we decided to use it as a mixture for the next step.  
When the ester was irradiated under microwave using methanol as solvent, to our 
surprise, the α-methoxy ether 512 was obtained as a 1:3 mixture of diastereomers which 
was separated from the acetate via preparative TLC (Scheme 119). 
 
 337
 
Scheme 119. Formation of α-methoxy ether from α-acetoxy ether under µwave 
irradiation. 
 
 
Scheme 120. Proposed mechanism for the formation of α-methoxy ether 512. 
 
 A proposed mechanism for the formation of α-methoxy ether 512 is depicted in 
Scheme 120.  Under microwave irradiation, the lone pair of electrons on the exocyclic 
anomeric oxygen eliminates the acetate group to form the intermediate 513.  Methanol 
then attacks the electrophilic benzylic carbon to form the intermediate 514.  
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Alternatively, methanol can attack the α-carbon and eliminate the acetate group via an 
SN2 pathway to form the intermediate 514.  Deprotonation of the intermediate 514 
provides the final product 512. 
 
O
OBn
O
N
O
Al(i-Bu)2
O
OBn
O
N
OH
+
O
OBn
O
N
O
Al(i-Bu)2
O
OBn
N
O
+
O
OBn
O
N
O
Al(i-Bu)2
O
OBn
O
N
DIBALH
O
OBn
OAc
Ac2O
O
OBn
OHH
515 424
515 425
515 516
517
518
519
520
Ac2O, Pyr., DMAP
N
OAc 499
OAc
 
Scheme 121. Proposed mechanism for the formation of acetate side-products. 
 
 A proposed a mechanism that counts for the formation of acetates and hemiacetal 
from the α-acetoxy ethers is shown in Scheme 121.  Electron donation from the N,N-
dimethylamino group (or OMe) from the aluminate 515 under microwave irradiation 
allows the formation of intermediate 516.  Further electron donation from ring oxygen 
forms the aldehyde 425 and oxocarbenium intermediate 517.  Alternatively, electron 
donation from the ring oxygen can eliminate the O-aluminate can form the aldehyde 425 
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and 517.  This might possibly take place when there is no electron-donating moiety 
present on the phenyl ring.  Reduction by DIBALH converts the aldehyde 425 into 
corresponding alcohol 424 which can explain the requirement of additional DIBALH 
during the reaction.  Alternatively, electron donation from the N, N-dimethyl group (or 
OMe) allows the formation of alkoxide 518 and the alcohol 424 might form via hydride 
reduction.  The alkoxide then may undergo protonation to provide the hemiacetal 520 or 
attack Ac2O to provide the acetate 519.  The oxocarbenium ion intermediate then 
undergoes glycosylation with the acetate ion to afford 519.  In the presence of Ac2O, 
pyridine and DMAP, the alcohol 424 forms the acetate 499 (or 507 and 511) 
 
O
BnO
OBn O
BnO
BnO
OAc
O O
OAc
486
O O
510
SPh
521
CH2Cl2, -78 oC
BF3.OEt2, PhSH, 1 h
wave, MeOH
300 W, 180 oC
18 bar, 20 min
O
BnO
OBn O
BnO
BnO
OMe
512
92%
dr > 10:1
95%
dr = 1.3:1
 
Scheme 122. Comparison of our method with Rychnovsky’s method. 
 
 It is quite noteworthy that we were able to create a new carbon-hetero atom bond 
without any external additives from the α-acetoxy ether 510 under entirely neutral 
conditions utilizing microwave irradiation.  On the other hand, Rychnovsky and co-
workers have utilized costly additives to obtain similar results as shown in Scheme 122. 
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 We speculated that with some fine tuning of the electronic property of the 
PDMAB group, we would be able to achieve our initial goal.  Thus, the aldehyde 524 
was synthesized from the commercially available p-nitrodiphenylamine 522 via 
methylation using NaH and MeI followed by formylation via Vilsmeyer-Hack reaction 
using POCl3.288  The aldehyde was then converted into the corresponding p-(N-methyl-p-
nitophenylamino)benzyl alcohol 525 (PMNPAB) using NaBH4 and then to the dimethoxy 
PMNPAB using p-TsOH in methanol; all with excellent yields (Scheme 123). 
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Scheme 123.  Synthesis of PMNPAB alcohol 525 and PMNPAB α,α-dimethoxy ether 
526 from amine 522. 
 
 Next, we decided to examine the stability of the PMNPAB group under common 
oxidative removal conditions normally used for the PMB group.  Thus, we synthesized 
the 4,6-bezylidine acetal 527 from 428 and 526 in presence of p-TsOH in excellent yield 
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(Scheme 124).  The C-2 and C-3 hydroxyl groups were then protected with PMB groups 
in the presence of NaH and p-methoxybenzyl chloride to obtain 528.  When compound 
528 was treated with DDQ in a mixture of CH2Cl2/water for 2 h at 0 oC, gratifyingly the 
PMNPAB group remained intact, whereas the PMB groups were removed.  Thus, we 
were able to conclude that the PMNPAB group is orthogonal to the PMB under DDQ 
removal conditions. 
 
 
Scheme 124.  PMNPAB group is orthogonal to PMB group under DDQ removal 
conditions. 
 
 In order to investigate the effect of microwave irradiation on this newly developed 
PMNPAB group of the originally discovered PDMAB group, we installed the PMNPAB 
group via Ag2O mediated glycozylation with the glycosyl bromide donor 461 to obtain 
529.  Gratifyingly, microwave irradiation of 529 in a 10:1 mixture of methanol/water was 
able to remove the PMNPAB group to afford the hemicaetal 530 and by-product 531 
(Scheme 125).. 
 
 342
 
Scheme 125. PMNPAB group is cleavable under microwave irradiation. 
 
 Next, we decided to synthesize a few more derivatives of PDMAB to test them 
using Rychnovsy’s conditions to obtain α-acetoxy ethers like 502.  Thus, commercially 
available 3-fluoro-4-nitro benzoic acid (532) was esterified to obtain 533 which was 
reduced by Fe(0)/NH4Cl in a 4:1 mixture of ethanol/water to afford the aniline derivative 
534 in quantitative yield.  Methylation of 534 with 0.99 equivalent of MeI in presence of 
NaH in dry DMF provided 30% of the dimethylated aniline derivative 535 and 70% of 
the mono-methylated aniline derivative 539.  Lithium aluminum hydride (LAH) 
reduction of the ester 535 provided corresponding alcohol 536 in excellent yield.  The 
alcohol 536 was then converted to the HCl salt of the chloride 537 by refluxing with 
SOCl2 in chloroform.  Saponification of 535 in the presence of 2.5 M LiOH in a mixture 
of THF/water can provide the acid 538 (Scheme 127). 
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Scheme 126. Synthesis of fluoro-derivatives of PDMAB. 
 
 The mono-methylated aniline derivative 539 can be converted into the 
corresponding N-methyl-N-trifluromethane derivative 540 by treating with 
trifluoromethane iodide (CF3I) and NaH at -78 oC.  LAH reduction of 540 followed by 
halogenation can provide the salt 543.  Saponification of 540 and 539 by 2.5 N LiOH in a 
mixture of THF/water can provide corresponding acids 541 and 544 respectively.  The 
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alcohols (539, 542, 545) and the corresponding chloride salts (537, 543, 546) can be used 
to test their feasibility as protecting groups in carbohydrate, peptide and amino acid 
synthesis.  The acids 538, 541 and 544 can be used to synthesize esters 547, 548 and 549 
respectively and will be subjected to Rychnovsky’s conditions to examine the feasibility 
of obtaining α-acetoxy ethers 550, 551, 552 respectively.  In a similar fashion, compound 
524 and 525 can be converted into the corresponding acid that can be used to synthesize 
ester 553 and will be subjected to Rychnovsky’s conditions to examine the feasibility of 
obtaining α-acetoxy ether 554. 
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Scheme 127. Proposed synthetic route for new α-acetoxy ethers having para-substituents 
with varying electronic nature. 
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6.3. Materials and Methods 
 All Reagents were purchased from Aldrich unless otherwise noted.  EDCI was 
purchased from Alfa Aesar.  Anhydrous methanol, tetrahydrofuran, acetone and 
dichloromethane were purchased from Alfa Aesar.  Anhydrous methanol was purchased 
from EMD chemicals (DriSolv).  p-Toluene sulfonic acid was purchased from Acros 
organics.  Except as otherwise indicated, reactions were carried out under Argon.  
Microwave reactions were conducted using a capped vial on CEM Discover System.  All 
reactions were monitored by thin layer chromatography using 0.25 mm Dynamic 
Adsorbents, L.L.C. precoated silica gel (particle size 0.03-0.07 mm, catalog no. 84111).  
Column chromatography was performed using Whatman Purasil 60 Ǻ (230-400 mesh 
ASTM) silica gel.  Yields refer to chromatographically and spectroscopically pure 
compounds, except as otherwise noted.  Diastereomeric ratios were determined from 1H 
NMR spectra of non-purified reaction mixtures.  Proton and carbon-13 NMR spectra 
were recorded on Varian Mercury 400, Varian Unity 500 and Varian 500 Direct Drive 
System spectrometers.  The residual CDCl3 singlet at δ 7.26 ppm and δ 77 ppm were used 
as the standard for 1H NMR and 13C NMR spectra respectively.  Mass spectra were 
recorded on Micromass GCT at 70 eV. 
 
6.3.1. DDQ-mediated deprotection of PMB group in presence of PMNPAB 
group: 
 To a RB flask equipped with magnetic stir bar, compound 528 (0.071 g, 0.106 
mmol) was taken and dissolved in CH2Cl2 (2.2 mL).  To the solution, water (0.22 mL) 
was added and the solution was cooled to 0 oC.  DDQ (0.051 g, 0.226 mmol) was added 
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in portion and the solution was stirred for 2 h at 0 oC.  Next, the solution was slowly 
warmed to room temperature and the solution was concentrated under reduced pressure 
on rotavap.  The residue was purified via gradient silica gel column chromatography 
using a mixture of ethyl acetate/hexane (1:2 to 3:1) as the eluent. 
 
6.4. Experimental Data 
1. 1-Bromo-2,3,4,6-tetraacetate-α-D-glucopyranoside 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, 
1,2,3,4,6-pentacaetate-D-glucopyranose (4.31 g, 11.04 mmol) was taken and dissolved in 
anhydrous CH2Cl2 (25 mL).  The solution was then cooled to 0 oC and 45% HBr in 
glacial acetic acid (16 mL) was added dropwise.  The flask was then covered with 
aluminum foil and resulting mixture was stirred at 0 oC until TLC showed (2 h) complete 
consumption of starting material.  The reaction was then quenched with saturated 
NaHCO3 (20 mL), washed with brine (20 mL) and extracted with CH2Cl2 (2 ×20 mL).  
The organic layers were combined, dried over Na2SO4 and concentrated under reduced 
pressure on rotavap.  The residue sufficiently pure and was used directly without further 
purification. 
1H NMR (500 MHz, CDCl3): δ 6.60 (d, 1 H, J = 4.0 Hz, H-1), 5.54 (t, 1 H, J = 9.8 Hz, H-
3), 5.15 (t, 1 H, J = 9.8 Hz, H-2), 4.82 (dd, 1 H, J = 10.1, 4.0 Hz, H-5), 4.25-4.35 (m, 2 
H, H-4 and H-6 overlap), 4.94-4.14 (m, 1 H, H-6), 2.09 (s, 3 H, -COCH3), 2.08 (s, 3 H, -
COCH3), 2.04 (s, 3 H, -COCH3), 2.02 (s, 3 H, -COCH3) 
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13C NMR (125 MHz, CDCl3): δ 170.5, 169.8, 169.7, 169.4, 86.6, 86.4, 72.1, 70.7, 70.4, 
70.1, 70.0, 67.3, 66.9, 60.9, 20.7, 20.6, 20.5, 20.4. 
 
HRMS (EIMS, M+): calcd for C14H19BrO9 410.0212, found 410.0216 
 
2.  
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, NaH 
(60% in mineral oil) was added followed by anhydrous DMF (4 mL).  After stirring the 
solution for 10 min at room temperature, a solution of allyl-α-D-galactofuranoside (0.645 
g, 2.93 mmol) in anhydrous DMF (5.6 mL) was added dropwise at 0 oC.  The reaction 
mixture was slowly warmed to room temperature and stirred for 15 min.  Next benzyl 
chloride (3.14 mL, 27 mmol) was added slowly and the reaction was allowed to stir for 6 
h at room temperature.  The reaction was then cooled to 0 oC and quenched with 
methanol (6 mL).  After diluting the reaction mixture with water (50 mL), it was 
extracted with dichloromethane (3 × 20 mL).  The organic layer was dried over Na2SO4 
and concentrated under reduced pressure on rotavap.  The residue was purified via 
gradient silica gel column chromatography using a mixture of ethyl acetate/hexane (1:20 
to 1:10) as the eluent. 
 Allyl 2,3,4,6-tetrabenzyl-α-D-galactofuranoside (0.847 g, 1.46 mmol) was taken 
in an oven dried RB flask equipped with magnetic stir bar under Argon.  To the flask, 
anhydrous CH2Cl2 (13.5 mL) and methanol (7.3 mL) were added respectively.  After 
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dissolving the starting material, PdCl2 (0.03 g, 0.17 mmol) was added and the reaction 
mixture was stirred at room temperature for 4-6 h.  The reaction mixture was then 
concentrated under reduced pressure on rotavap.  The residue was purified via gradient 
silica gel column chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as 
the eluent. 
 The hemiacetal (0.42 g, 0.78 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and dissolved in anhydrous CH2Cl2 (2 mL).  
After cooling the flask to 0 oC, EDCI (2.25 g, 14.49 mmol) followed by DMAP (0.036 g, 
0.295 mmol) and p-N,N-dimethylbenzoic acid (0.25 g, 1.51 mmol) was added to the 
mixture and allowed to warm to room temperature slowly over a period of 30 min.  After 
stirring 16 h at room temperature, the solution was diluted with water (30 mL) and the 
organic layer was separated, dried over Na2SO4 and concentrated under reduced pressure 
on rotavap.  The residue was purified via gradient silica gel column chromatography 
using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 7.90 (d, 2 H, J = 8.6 Hz, aryl), 7.09-7.48 (m, 20 H, Ph), 
6.53 (d, 2 H, 8.6 Hz, aryl), 4.40-4.81 (m, 10 H), 4.23-4.34 (m, 1 H), 4.09-4.21 (m, 1 H), 
3.56-3.90 (m, 3 H), 3.03 (s, 6 H, NMe2) 
 
13C NMR (125 MHz, CDCl3): δ 165.7, 153.5, 138.6, 138.2, 138.1, 137.4, 131.8, 128.4, 
128.3, 128.2, 128.1, 127.8, 127.7, 127.5, 127.3, 116.6, 110.7, 100.0, 93.7, 87.2, 83.9, 
81.7, 80.3, 78.4, 73.3, 70.4, 40.0. 
 
HRMS (EIMS, M+): cacld for C43H45NO7 687.3196, found 687.3199. 
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3. 
O
BnO
BnO
BnO
BnO
501 ( anomer)
O
O
NMe2
 
 Starting from commercially available 2,3,4,6-tertabenzyl-D-glucopyranose, 501 
was synthesized via EDCI coupling as described for 496. 
1H NMR (500 MHz, CDCl3): δ 8.01 (d, 2 H, J = 8.9 Hz, aryl), 7.20-7.41 (m, 20 H, Ph), 
7.16 (m, 2 H, aryl), 6.9 (d, 1 H, J = 6.7 Hz), 5.88 (d, 1 H, J = 6.1 Hz, H-1), 4.93 (d, 1 H, -
CH2Ph), 4.85 (d, 3 H, J = 11.0 Hz, -CH2Ph), 4.77 (d, 1 H, J = 11.0 Hz, -CH2Ph), 4.64 (d, 
1 H, J = 12.2 Hz, -CH2Ph), 4.57 (d, 1 H, J = 11.0 Hz, -CH2Ph), 4.49 (d, 1 H, J = 12.2, -
CH2Ph), 3.75-3.86 (m, 5 H), 3.64-3.70 (m, 1 H), 3.10 (s , 6 H, NMe2) 
 
13C NMR (125 MHz, CDCl3): δ 164.6, 138.5, 138.1, 137.9, 132.0, 128.4, 128.3, 128.1, 
128.0, 127.9, 127.8, 127.7, 127.6, 113.2, 113.1, 94.5, 84.9, 81.0, 75.7, 75.5, 74.9, 73.5, 
68.1, 41.5 
 
HRMS (EIMS, M+): cacld for C43H45NO7 687.3196, found 687.3192. 
 
4. 
O
BnO
OBn
BnO
BnO
503 ( anomer)
OAc
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1H NMR (500 MHz, CDCl3): δ 7.24-7.37 (m, 18 H, Ph), 7.12-7.17 (m, 2 H, Ph), 5.61 (d, 
1 H, J = 7.9 Hz, H-1), 4.43-5.02 (m, 8 H, -CH2Ph), 3.95 (t, 1 H, J = 9.2 Hz), 3.53-3.78 
(m, 5 H), 2.06 (s, 3 H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 169.3, 138.6, 138.4, 138.1, 137.9, 137.8, 137.7, 137.6, 
128.5, 128.4, 128.3, 128.3, 128.1, 127.9, 127.8, 127.8, 127.8, 127.7, 127.7, 127.6, 94.0, 
84.8, 81.0, 77.2, 75.7, 75.0, 73.5, 68.1, 21.1 
 
HRMS (EIMS, M+): cacld for C36H38O7 582.2618, found 582.2620. 
 
5. 
 
1H NMR (500 MHz, CDCl3): δ 8.04-8.12 (m, 2 H, aryl), 7.18-7.44 (m, 20 H, Ph), 6.92-
6.71 (m, 2 H, aryl), 6.64 (d, 1 H, J = 3.7 Hz, H-1), 5.92 (m, 1 H), 4.78-5.07 (m, 6 H), 
4.56-4.72 (m, 2 H), 4.49-4.55 (m, 1 H), 4.12 (t, 1 H, J = 9.5 Hz), 4.0-4.04 (m, 1 H), 3.90 
(s, 3 H, OMe), 3.79-3.88 (m, 1 H0, 3.68-3.73 (m, 1 H). 
 
13C NMR (125 MHz, CDCl3): δ 164.5, 163.8, 138.5, 138.1, 137.9, 132.0, 128.4, 128.3, 
128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 121.6, 113.7, 94.5, 84.9, 80.9, 75.6, 75.0, 74.9, 
73.5, 68.1, 55.4. 
 
HRMS (EIMS, M+): cacld for C42H42O8 674.2880, found 674.2883. 
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6. 
 
1H NMR (500 MHz, CDCl3): δ 8.07-8.17 (m, 2 H, aryl), 7.59-7.66 (m, 1 H, aryl), 7.45-
7.54 (m, 2 H, aryl), 7.17-7.43 (m, 20 H, Ph), 6.66 (d, 1 H, J = 3.7 Hz, H-1), 4.49-5.07 (m, 
8 H, -CH2Ph), 4.12 (t, 1 H, J = 9.2 Hz), 3.77-3.92 (m, 5 H), 3.62-3.74 (m, 1 H) 
 
13C NMR (125 MHz, CDCl3): δ 164.9, 138.5, 138.1, 137.9, 132.0, 128.4, 128.3, 128.1, 
128.0, 127.9, 127.8, 127.7, 127.6, 94.7, 84.9, 81.8, 78.9, 75.7, 75.4, 73.5, 73.0, 68.0,  
 
HRMS (EIMS, M+): cacld for C41H40O7 644.2774, found 644.2771. 
 
7. 
 
 The benzoic ester 505 (0.044 g, 0.067 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon (via Schlenk line) and anhydrous CH2Cl2 
(0.34 mL) was added to the flask.  After cooling the solution to -78 oC, 1.0 M DIBAL-H 
in cyclohexane (0.08 mL, 0.08 mmol) was added dropwise.  The solution was then stirred 
for 2-4 h until TLC showed complete consumption of starting material.  Next, pyridine 
(0.016 mL, 0.197 mmol) was added followed by Ac2O (0.025 mL, 0.26 mmol) and the 
resulting mixture stirred at -78 oC for 12 h, then slowly warmed to -20 oC.  The reaction 
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was then quenched with saturated Rochelle’s salt solution (0.4 mL), stirred for 30 min 
and allowed to reach room temperature.  The solution was then extracted with CH2Cl2 (3 
× 5 mL).  The organic layers were combined, dried over Na2SO4 and concentrated under 
pressure on rotavap.  The residue was rapidly purified via gradient column 
chromatography using pre-neutralized (by 0.1% NEt3) silica gel as the stationary phase 
and a mixture of ethyl acetate/hexane (1:5 to 1:1) as the eluent.  The desired product 510 
and the undesired side product 503 had similar Rf values and seemed difficult to separate.  
Due to the sensitivity and stability of 510, further purification was not attempted and used 
directly in the next step. 
1H NMR (500 MHz, CDCl3): δ 7.14-7.49 (m, 25 H, Ph), 6.89 (s, 1 H, -CH(OAc)Ph), 5.58 
(d, 1 H, J = 3.7 Hz, H-1), 4.41-5.05 (m, 8 H, -CH2Ph), 3.93-4.02 (m, 1 H), 3.51-3.83 (m, 
5 H), 2.16 (s, 3 H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 169.7, 169.6, 139.1, 138.9, 138.6, 138.4, 138.2, 128.7, 
128.6, 128.6, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 96.4, 95.4, 85.1, 81.9, 81.3, 
79.5, 77.5, 75.9, 75.7, 75.3, 73.8, 73.1, 68.3 
 
HRMS (EIMS, M+): cacld for C43H44O8 688.3036, found 688.3033. 
 
8. 
 
 To a 10 mL CEM Discover microwave vial equipped with magnetic stir bar under 
Argon, 510 (0.01 mg, 0.015 mmol) was taken and anhydrous methanol (1.5 mL) was 
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added.  The perforated septum was replaced with new septum quickly, capped according 
to the manufacturer direction and placed into microwave reaction cavity.  The microwave 
was equilibrated to 190 oC, 18 bar for 25 min.  TLC of the reaction indicated the 
formation of new product.  The solution was transferred to a 25 mL RB flask and 
concentrated under reduced pressure on rotavap.  The residue was quickly purified via 
preparative silica gel chromatography using a 1:10 mixture of ethyl acetate and hexane as 
the eluent. 
1H NMR (500 MHz, CDCl3): δ 7.15-7.52 (m, 25 H, Ph), 5.57 (s, 1 H, -CH(OMe)Ph), 
5.40 (d, 1 H, J = 3.7 Hz, H-1), 4.98-5.07 (m, 1 H, -CH2Ph), 4.78-4.89 (m, 3 H, -CH2Ph), 
4.53-4.62 (m, 1 H), 4.38-4.52 (m, 3 H, -CH2Ph), 4.08 (t, 1 H, J = 9.8 Hz), 3.53-3.73 (m, 5 
H), 3.48 (s, 3 H, OMe) 
 
13C NMR (125 MHz, CDCl3): δ 139.1, 138.9, 138.6, 138.4, 138.2, 128.7, 128.6, 128.6, 
128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 103.1, 93.8, 82.0, 79.9, 77.7, 75.6, 73.5, 
73.0, 71.0, 68.4 
 
HRMS (M++ Na, EIMS): calcd for C42H44NaO7 683.2985, found 683.2983 
 
9. N-methyl-4-nitro-N-phenylaniline 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, p-
nitrodiphenylamine (0.5 g, 2.35 mmol) was taken and dissolved in anhydrous DMF (4.5 
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mL) at room temperature.  To the solution, NaH (60% in mineral oil, 0.21 g, 4.7 mmol) 
was added in protion.  After stirring 15 min at room temperature, the solution was cooled 
to 0 oC and methyl iodide (0.51 mL, 3.53 mmol) was added dropwise.  The resulting 
solution was stirred for 2-4 h at 0 oC and then quenched with cold water.  The reaction 
mixture was then diluted with water (50 mL) and extracted with ethyl acetate (4 × 20 
mL).  The organic layers were combined, dried over Na2SO4 and concentrated under 
reduced pressure on rotavap.  The crude product was spectroscopically pure enough and 
used in the preceding step without further purification. 
1H NMR (500 MHz, CDCl3): δ 7.96-8.11 (m, 3 H, aryl), 7.45 (t, 2 H, J = 7.6 Hz, aryl), 
7.27-7.34 (m, 1 H, aryl), 7.18-7.25 (m, 2 H, aryl), 6.61-6.71 (m, 2 H, aryl), 3.4 (s, 3 H, 
NMe) 
 
13C NMR (125 MHz, CDCl3): δ 162.5, 153.7, 146.3, 138.1, 130.2, 126.8, 126.7, 125.7, 
112.4, 40.5. 
 
HRMS (EIMS, M+): cacld for C13H12N2O2 228.0899, found 228.0895. 
 
10. p-(methyl(4-nitrophenyl)amino)benzaldehyde 
N
O2N
Me
CHO
524  
 Anhydrous DMF (1.11 mL, 14.3 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and cooled to 0 oC.  To the cooled solution, 
POCl3 (1.3 mL, 14.3 mmol) was added dropwise (caution: generates heat!!).  After a 
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while, the reaction mixture solidifies and the ice-bath was removed, warmed with a heat 
gun.  The flask was cooled to 0 oC again.  The process was repeated 3/4 times over 1 h 
and then the reaction mixture turns into brick color.  Then, a solution of 523 (1.09 g, 4.77 
mmol) in anhydrous DMF (3 mL) was added slowly via syringe at 0 oC.  The resulting 
solution was then heated to 95 oC and allowed to stir for 4 h after which TLC showed 
complete consumption of starting material.  The reaction mixture was then cooled to 
room temperature and poured into ice-water, neutralized with NaOH pellets.  The 
solution was extracted with CH2Cl2 (2× 20 mL).  The organic layers were combined, 
washed with saturated NaHCO3 (20 mL), brine (20 mL) and dried over Na2SO4.  The 
organic layer was then concentrated under reduced pressure on rotavap and the residue 
was purified via gradient silica gel column chromatography using a mixture of ethyl 
acetate/hexane (1:1:5 to 1:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 9.94 (s, 1 H, -CHO), 8.14 (d, 2 H, J = 9.2 Hz, aryl), 7.88 
(d, 2 H, J = 8.5 Hz, aryl), 7.28 (d, 2 H, J = 8.5 Hz, aryl), 7.04 (d, 2 H, J = 9.2 Hz, aryl), 
3.49 (s, 3 H, NMe) 
 
13C NMR (125 MHz, CDCl3): δ 190.5, 152.6, 151.9, 140.9, 132.0, 131.5, 125.6, 122.6, 
117.7, 40.3 
 
HRMS (EIMS, M+): cacld for C14H12N2O3 256.0848, found 256.0851. 
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11. p-(methyl-N-(4-nitrophenyl)amino)benzyl alcohol 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, aldehyde 
524 (0.437 g, 1.71 mmol) was dissolved in anhydrous methanol (6.7 mL).  The solution 
was cooled to 0 oC and NaBH4 (0.105 g, 2.77 mmol) was added in portion.  The reaction 
mixture was then stirred for 40 min at 0 oC and quenched with water (0.5 mL).  After 
dilution with water (10 mL), the solution was extracted with CH2Cl2 (2 × 20 mL).  The 
organic layers were combined, dried over Na2SO4.  The crude residue was purified 
rapidly via gradient silica gel (neutralized with 0.1% NEt3) column chromatography 
using a 1:3 mixture of ethyl acetate/hexane as the eluent. 
1H NMR (500 MHz, CDCl3): δ 8.04 (d, 2 H, J = 9.2 Hz, aryl), 7.46 (d, 2 H, J = 8.5 Hz, 
aryl), 7.25 (d, 2 H, J = 8.5 Hz, aryl), 6.64 (d, 2 H, J = 9.5 Hz, aryl), 4.74 (s, 2 H, -
CH2Ar), 3.40 (s, 3 H, NMe), 1.90 (bs, 1 H, OH) 
 
13C NMR (125 MHz, CDCl3): δ 153.7, 145.7, 139.4, 138.2, 128.8, 126.7, 125.8, 112.5, 
64.7, 40.5. 
 
HRMS (EIMS, M+): cacld for C14H14N2O3 258.1004, found 258.1008. 
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13. p-N-methyl-N-(4-nitrophenyl) α,α-dimethoxybenzaldehyde 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, the 
aldehyde 524 (0.3 g, 1.17 mmol) was taken and dissolved in anhydrous methanol (10 
mL).  The solution was cooled to 0 oC and catalytic p-TsOH was (0.019 g, 0.1 mmol) was 
added.  The resulting solution was slowly warmed to room temperature and stirred for 4 
h.  The reaction mixture was then concentrated and used directly in the next step. 
1H NMR (500 MHz, CDCl3): δ 8.04 (d, 2 H, J = 9.2 Hz, aryl), 7.46 (d, 2 H, J = 8.5 Hz, 
aryl), 7.25 (d, 2 H, J = 8.5 Hz, aryl), 6.64 (d, 2 H, J = 9.5 Hz, aryl), 5.42 (s, 2 H, -
CH2Ar), 3.40 (s, 3 H, NMe), 3.38 (s, 6 H, OMe and OMe overlap) 
 
13C NMR (125 MHz, CDCl3): δ 153.9, 146.7, 138.6, 136.9, 128.8, 126.5, 125.9, 112.9, 
103.0, 53.2, 40.7 
 
HRMS (EIMS, M+): cacld for C16H18N2O4 302.1267, found 302.1269. 
 
14. 
O
HO
HO
O
O
N
Me
O2N
OMe527  
 Methyl-α-D-glucopyranoside (0.145 g, 0.75 mmol) was taken in an oven dried RB 
flask equipped with magnetic stir bar under Argon.  To the flask, anhydrous DMF (6 mL) 
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was added followed by 526 (0.271 g, 0.90 mmol).  After adding catalytic amount of p-
TsOH (0.013 g, 0.07 mmol), the reaction mixture was heated to 50 oC on a rotavap (bump 
trap adapter and reservoir was pre-dried in oven) under reduced for 4 h.  Next, the 
reaction mixture was concentrated and purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:1 to 4:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 8.06 (d, 2 H, J = 9.5 Hz, aryl), 7.58 (d, 2 H, J = 8.2 Hz, 
aryl), 7.24 (d, 2 H, J = 8.5 Hz, aryl), 6.69 (d, 2 H, J = 9.2 Hz, aryl), 5.58 (s, 1 H, -CHAr), 
4.82 (d, 1 H, J = 4.0 Hz, H-1), 4.32 (dd, 1 H, J = 9.8, 4.3 Hz, H-4), 3.96 (t, 1 H, J = 9.2 
Hz, H-6), 3.83 (dt, 1 H, J = 10.4, 4.9 Hz, H-3), 3.77 (t, 1 H, J = 10.1 Hz, H-6), 3.65 (dd, 1 
H, J = 9.2, 4.0 Hz, H-2), 3.53 (t, 1 H, J = 9.5 Hz, H-5), 3.48 (s, 3 H, OMe), 3.39 (s, 3 H, 
NMe). 
 
13C NMR (125 MHz, CDCl3): δ 153.5, 147.2, 138.5, 135.4, 128.3, 126.3, 125.7, 112.9, 
101.3, 99.7, 80.9, 73.0, 71.9, 68.9, 62.3, 55.7, 40.4. 
 
HRMS (M++ Na, EIMS): calcd for C21H24NaN2O8 455.1430, found 455.1424 
 
15. 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, 
compound 527 (0.103 g, 0.24 mmol) was taken and dissolved in anhydrous DMF (2 mL).  
After cooling the solution to 0 oC, NaH (60% in mineral oil, 0.04 g, 0.72 mmol) was 
added in portion; the reaction was slowly warmed to room temperature and stirred for 15 
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min.  Then, the reaction the mixture cooled to 0 oC again and p-methoxybenzyl chloride 
(0.12 mL, 0.84 mmol) was added dropwise followed by catalytic amount of 
tetrabutylammonium bromide (TBAI, 0.008 g, 0.022 mmol).  The resulting mixture was 
stirred at room temperature for 6 h.  The reaction was quenched by slow addition of 
methanol (5 mL) at 0 oC.  The reaction mixture was then diluted with water (50 mL) and 
extracted with CH2Cl2 (3 × 20 mL).  The organic layers were combined, washed with 
brine (30 mL).  After drying on Na2SO4, the organic layer was concentrated under 
reduced pressure on rotavap.  The residue was purified via gradient silica gel (neutralized 
with 0.1% NEt3) column chromatography using a mixture of ethyl acetate/hexane (1:4 to 
2:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 8.03-8.10 (d, 2 H, J = 9.5 Hz, aryl), 7.56 (d, 2 H, J =9.5 
Hz, aryl), 7.21-7.36 (m, 6 H, aryl), 6.87 (d, 2 H, J = 8.8 Hz, aryl), 6.85 (d, 2 H, J = 8.5 
Hz, aryl), 6.70 (d, 2 H, J = 9.5 Hz, aryl), 5.57 (s, 1 H, -CHAr), 4.81 (q, 2 H, J = 11.0 Hz, 
aryl), 4.79 (d, 1 H, J = 11.6 Hz, Bn), 4.63 (d, 1 H, J = 11.6 Hz, Bn), 4.54 (d, 1 H, J = 3.7 
Hz, H-1), 4.27 (dd, 1 H, J = 10.1, 4.9 Hz, H-4), 4.01 (t, 1 H, J = 9.2 Hz, H-6), 3.81 (s, 3 
H, OMe), 3.79 (s, 3 H, OMe), 3.72 (t, 1 H, J = 10.4 Hz, H-6), 3.59 (t, 1 H, J = 9.5 Hz, H-
3), 3.53 (dd, 1 H, J = 9.2, 3.7 Hz, H-2), 3.41 (s, 3 H, OMe), 3.40 (s, 3 H, NMe) 
 
13C NMR (125 MHz, CDCl3): δ 159.4, 159.2, 153.6, 146.9, 138.4, 135.8, 131.6, 130.9, 
130.2, 129.7, 129.6, 127.9, 126.2, 125.7, 125.6, 122.5, 117.7, 113.8, 113.7, 112.8, 100.5, 
99.3, 82.0, 78.8, 78.2, 75.0, 73.4, 69.1, 62.2, 55.2, 40.4 
 
HRMS (M++ Na, EIMS): calcd for C37H40N2NaO10 695.2581, found 695.2583. 
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16. 
 
 1-Bromo-2,3,4,6-tertaacetate-α-D-glucopyranoside (461) (0.085 g) was taken in 
an oven dried RB flask equipped with magnetic stir bar under Argon.  To the flask, 4 Å 
MS (oven dried 24 h followed by heat gun dried under high vacuum) was added followed 
by anhydrous diethyl ether (3 mL).  The mixture was then stirred for 30 min at room 
temperature and then Ag2O was added.  The resulting solution was stirred at room 
temperature for 24 h.  Next, the reaction mixture was concentrated under reduced 
pressure on rotavap.  The residue was purified via gradient silica gel (neutralized with 
0.1% NEt3) column chromatography using a mixture of ethyl acetate/hexane (1:2 to 2:1) 
as the eluent. 
1H NMR (500 MHz, CDCl3): δ 8.03-8.11 (m, 2 H, aryl), 7.33-7.42 (m, 2 H, aryl), 7.16-
7.24 (m, 2 H, aryl), 6.64-6.74 (m, 2 H, aryl), 5.22 (t, 1 H, J = 9.5 Hz, H-2), 5.06-5.17 (m, 
2 H), 4.92 (d, 1 H, J = 12.2 Hz, -CH2Ar), 4.52-4.68 (m, 2 H), 4.29 (dd, 1 H, J = 12.5, 4.9 
Hz, H-6), 4.16-4.24 (m, 2 H), 3.40 (s, 3 H, -NMe), 2.11 (s, 3 H, -COCH3), 2.04 (s, 3 H, -
COCH3), 2.03 (s, 3 H, -COCH3), 2.01 (s, 3 H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.6, 170.3, 169.4, 169.3, 153.6, 146.1, 135.2, 130.1, 
129.4, 126.5, 125.8, 112.7, 99.6, 72.7, 71.9, 71.3, 70.1, 68.4, 61.9, 60.4, 40.5, 20.7, 20.6, 
20.5, 20.4. 
 
HRMS (M++ Na, EIMS): calcd for C28H32NaN2O12 611.1853, found 611.1842 
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17. 
 
1H NMR (500 MHz, CDCl3): δ 8.06 (d, 2 H, J = 9.2 Hz, aryl), 7.43 (d, 2 H, J = 8.2 Hz, 
aryl), 7.21 (d, 2 H, J = 8.2 Hz, aryl), 6.68 (d, 2 H, J = 9.2 Hz, aryl), 4.48 (s, 2 H, -
CH2OMe), 3.45 (s, 3 H, OMe), 3.39 (s, 3 H, NMe) 
 
13C NMR (125 MHz, CDCl3): δ 153.7, 145.8, 136.9, 129.5, 126.6, 125.8, 112.5, 74.1, 
58.4, 40.5 
 
HRMS (M++ Na, EIMS): calcd for C15H16N2NaO3 295.1059, found 295.1063 
 
18. 
 
 3-Fluro-4-nitrobenzoic acid (2.0 g, 10.8 mmol) was taken in an oven dried RB 
flask and dissolved in anhydrous methanol (34.8 mL) under Argon.  To the stirring 
solution concentrated H2SO4 (0.35 mL) and the reaction was refluxed for 24 h.  The 
reaction mixture was then cooled to room temperature and small amount of solid K2CO3 
(0.03 g) was added.  The solution was then concentrated under reduced pressure on 
rotavap to afford a yellow residue.  The residue was dissolved on CH2Cl2 (20 mL) and 
washed with saturated NaHCO3 (17 mL).  The organic layer was separated and the 
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aqueous layer was extracted with ethyl acetate (3 × 20 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap to 
afford a yellow solid.  The crude product was sufficiently pure and used directly in the 
next step without further purification. 
1H NMR (500 MHz, CDCl3): δ 8.06-8.11 (m, 1 H, aryl), 7.90-7.97 (m, 2 H, aryl), 3.97 (s, 
3 H, -CO2Me) 
 
13C NMR (125 MHz, CDCl3): δ 163.9, 156.1, 153.9, 136.6, 126.1, 125.4, 119.7 (JC-F = 
88.5 Hz), 53.1 
 
HRMS (EIMS, M+): calcd for C8H6FNO4 199.0281, found 199.0285. 
 
19. 
 
 Methyl 3-fluoro-4-nitrobenzoate (2.27 g, 11.4 mmol) was taken in a 250 mL RB 
flask equipped with magnetic stir bar.  To the flask, Fe (40 mesh) powder (9.72 g, 170.99 
mmol) and solid NH4Cl (0.613 g, 11.46 mmol) were added.  Ethanol (100 mL) and water 
(33 mL) were added.  The resulting mixture was refluxed at 80 oC for 18 h and after 
cooling to room temperature, filtered through celite.  The filtrate was dried over Na2SO4 
and concentrated under reduced pressure on rotavap.  The yellow residue was sufficiently 
pure and used in the next step without further purification. 
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1H NMR (500 MHz, CDCl3): δ 7.6-7.71 (m, 2 H, aryl), 6.74 (t, 1 H, J = 8.5 Hz, aryl), 
4.15 (bs, 2 H, -NH2), 3.86 (s, 3 H, -CO2Me). 
 
13C NMR (125 MHz, CDCl3): δ 166.4, 151.2, 149.3, 139.3, 126.9, 120.0, 116.6, 115.2, 
51.9 
 
HRMS (M+, EIMS): calcd for C8H8FNO2 169.0539, found 169.0542. 
 
20. 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, the 
amine 534 (0.632 g, 3.74 mmol) was taken and dissolved in anhydrous DMF (8 mL).  
The solution was then cooled to 0 oC and NaH (60% in mineral oil, 0.15 g, 3.74 mmol) 
was added in portion.  After stirring the solution at room temperature for 20 min, it was 
cooled to 0 oC again.  To the cooled reaction mixture, MeI (0.53 mL, 3.74 mmol) was 
added dropwise over 15 min.  The resulting mixture was then allowed to reach room 
temperature slowly and stirred additional 18 h.  The reaction was quenched by the 
addition of methanol (5 mL) at 0 oC and then diluted with water (80 mL).  The solution 
was then extracted with ethyl acetate (3 × 20 mL).  The aqueous layer was further 
extracted with CH2Cl2 (2 × 20 mL).  The organic layers were dried over Na2SO4 and 
combined.  Concentration of the organic layer under reduced pressure on rotavap, 
afforded a mixture of mono-methylated, di-methylated and unreacted starting material.  
 364
Purification of the crude residue via gradient silica gel column chromatography using a 
mixture of ethyl acetate/hexane (1:40 to 1:10) as the eluent afforded the mono-methylated 
compound as the major and the di-methylated compound as the mior product. 
1H NMR (500 MHz, CDCl3): δ 7.71 (dd, 1 H, J = 8.5, 2.1 Hz, aryl), 7.64 (dd, 1 H, J = 
14.7, 2.1 Hz, aryl), 6.78 (t, 1 H, J = 8.9 Hz, aryl), 3.87 (s, 3 H, -CO2Me), 2.98 (s, 6 H, 
NMe2) 
 
13C NMR (125 MHz, CDCl3): δ 166.3, 153.8, 151.8, 144.13,  126.4, 120.7, 117.5, 116.1, 
51.9, 42.2 
 
HRMS (M+, EIMS): calcd for C10H12FNO2 198.0930, found 198.0928 
 
21. 
 
 Methyl 3-fluoro-4-p-(N,N-dimethylamino)benzoate (0.907 g, 4.6 mmol) was 
taken in an oven dried RB flask equipped with magnetic stir bar under Argon.  To the 
flask, anhydrous diethyl ether (10 mL) was added and the stirred solution was cooled to 0 
oC.  Next, LiAlH4 (0.174 g, 4.6 mmol) was added slowly in portion.  The reaction was 
then monitored via TLC.  When TLC showed the completion of the reaction, the reaction 
was quenched with methanol (3 mL).  The reaction was then diluted with water (10 mL) 
and extracted with diethyl ether (3 × 20 mL).  The organic layers were combined, dried 
over Na2SO4 and concentrated under reduced pressure on rotavap.  The yellow residue 
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was rapidly purified via gradient silica gel (pre-neutralized with 0.1% NEt3) column 
chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 6.95-7.02 (m, 2 H, aryl), 6.84 (t, 1 H, J = 8.5 Hz, aryl), 
4.53 (s, 2 H, -CH2Ar), 2.80 (s, 6 H, NMe2), 2.70 (bs, 1 H, OH). 
13C NMR (125 MHz, CDCl3): δ 155.9, 153.9, 139.8, 134.5, 122.7, 118.1, 115.0, 64.0, 
42.8. 
 
HRMS (M+, EIMS): calcd for C9H12FNO 170.0981, found 170.0983. 
 
22. 
 
 The alcohol 536 (0.958 g, 5.66 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon.  To the flask, anhydrous CHCl3 (24 mL) 
was added and the stirred solution was cooled to 0 oC.  Next, SOCl2 (0.79 mL, 6.59 
mmol) was added dropwise to the cooled solution over 15 min.  The reaction mixture was 
then slowly warmed to room temperature, stirred for 10 min and then refluxed for 1 h.  
The solution was then concentrated under reduced pressure on rotavap.  For 
spectroscopic data, 100 mg of the crude salt was treated with saturated NaHCO3 (10 mL) 
and extracted with CH2Cl2 (2 × 10 mL).  The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure on rotavap. 
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1H NMR (500 MHz, CDCl3): δ 6.96-7.06 (m, 2 H, aryl), 6.83-6.90 (m, 1 H, aryl), 4.36 (s, 
2 H, -CH2Cl), 2.94 (s, 6 H, NMe2). 
 
13C NMR (125 MHz, CDCl3): δ 155.9, 154.0, 140.2, 131.3, 123.7, 117.9, 115.7, 57.9, 
42.8 
 
HRMS (M+, EIMS): calcd for C9H11ClFN 187.0564, found 187.0569. 
 
23. 
 
1H NMR (500 MHz, CDCl3): δ 7.71-7.79 (m, 1 H, aryl), 7.61 (dd, 1 H, J = 2.5, 1.8 Hz, 
aryl), 6.62 (t, 1 H, J = 8.6 Hz, aryl), 4.44 (bs, 1 H, -NH), 3.86 (s, 3 H, CO2Me), 2.92 (s, 3 
H, -NHMe). 
 
13C NMR (125 MHz, CDCl3): δ 166.6, 151.2, 149.3, 141.8, 127.3, 117.9, 115.2, 109.7, 
51.7, 29.7 
 
HRMS (M+, EIMS): calcd for C9H10FNO2 184.0774, found 184.0777 
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CHAPTER 7 
 
Synthetic Study Toward The Total Synthesis Of The Repeating 
Tetrasaccharide Unit Of The Zwitterionic Polysaccharide PS A1 
 
7. Introduction 
Zwitterionic polysachharides (ZPSs) (Figure 37) are characterized by the presence 
of positive and negative charges on adjacent monosaccharides.  Although, the majority of 
polysaccharides in pathogenic bacteria commonly have either negatively charged groups 
or no charged groups at all; the capsular polysaccharides PS A1 (359) and PS A2 (555) 
from Bacterorides fragilis 9343, Sp 1 (556) from strepcoccus pneumoniae are the few 
naturally occurring ZPSs. 
 
 
Figure 37. Naturally occurring zwitterionic polysaccharides. 
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PS A1 which was isolated from pathogenic gram-negative anaerobic bacteria 
Bacterorides fragilis by fermentation, is a clear example of zwitterionic 
characharacter.198  It has size of 100-120 kDa which correlates to 100-120 repeating 
units.  PS A1 is composed of a repeating tetrsaccharide unit with antigenic carboxylate of 
pyruvate ketal spanning C4-C6 in the D-galactopyranosyl mopiety, 2-acetamido-4-amino-
L-fucose moiety, 2-acetamido-D-galactopyranosyl moiety in the polymer backbone and 
antigenic galactofuranosyl moiety in the side chain.  The ZPS PS A1 has the following 
sequence: [→3)-β-D-Galp-(1→3)-α-D-Sugp-(1→4)[β-D-Galf-(1→3)]-α-D-GalpNAc-
(1→] (where Sug = 2-acetamido-4-amino-2,4,6-trideoxygalactose).289  Spectroscopic data 
(e.g. NMR, CD) have indicated that the average solution structure of ZPS-PS A1 is 
composed of helical conformation with repeating units per turn and a pitchof 20 Å.290  
The zwitterionic charges which are exposed toward the outer-surface of the polymer 
favor interaction with other molecules.  In contrast to majority of pathogenic 
polysaccharides, they are known to have the ability to modulate the cellular immune 
system by eliciting an MHC-II T-cell response.291  This discovery was noted when 
studies were conducted for abscess formation.198b  The underlying cellular mechanism for 
abscess formation requires T-cell activation.291a  Conversely, abscess formation can be 
prevented by prophylactic subcutaneous injection of purified ZPS-PS A1 alone.  
Experimental Studies have proven that the unusual immunologic property of PS A1 is 
likely to be caused by its zwitterionic character.  Neutralization of either the positively 
charged amino groups or the negatively charged carboxyl groups show strongly reduced 
biological activity as compared to the unmodified polysaccharide.292  It is noteworthy that 
isolation of PS A1 from Bacterorides fragilis is cumbersome and only milligram 
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quantities can be obtained.  Recently, we have shown that chemically modified PS A1 
with a cancer antigen (Tn-PS A1) can elicit MHC-II mediated immune response that 
specifically targets the conjugated antigen.293 
 
7.1. Retrosynthetic Analysis of ZPS PS A1 
 Our retrosynthetic analysis indicates that the ZPS PS A1 the protected repeating 
unit of the tetrasaccharide can be assembled via three separate ways: (a) convergent, (b) 
linear approach, (c) divergent approach, from protected monosaccharides 559-565 
following the sequence of glycosylation events depicted in Figure 38-40. 
 
Figure 38. Convergent approach for the repeating tetrasaccharide unit of ZPS PS A1. 
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Figure 39. Linear approach for the repeating tetrasaccharide unit of ZPS PS A1. 
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7.2.  Forward Synthesis of the Tetrasaccharide Unit via Linear Approach 
 Our group has previously studied the assembly of disaccharide units 557 and 
558294 (retrosynthetic analysis-I, Figure 38) employing the Kahne295 as well as the 
Schmidt216 glycosylation methods.  Unfortunately, the desired tetrasaccharide unit 359 
was not obtained.  In lieu of these initial attempts, we decided to pursue the lineas 
approach (Figure 39). 
7.2.1.  Synthesis of the D-galactofuranoside unit 559 
 In order to synthesize 2,3,5,6-tetrabenzoyl-D-galactofuranosyl hemiacetal (374), 
D-galactopyanose was converted to 1-allyl-α-D-galactofuranoside (568) in presence of 
DMPU, allyl bromide and NaH at 0 oC.296  Benzoylation of 568 using benzoyl chloride in 
pyridine, followed by deallylation in the presence of palladium chloride provided the 
hemiacetal 374 in excellent yield.  For SAR studies; bezylation, acetylation and 
pivoylation of 568 were also carried out following the same procedure.294  The 1-allyl-
2,3,5,6-tetrabenzyl- and 1-allyl-2,3,4,6-tetraacetyl -α-D-galactofuranoside were converted 
into the corresponding hemiacetals 494 and 569 respectively (Scheme 128). 
 
Scheme 128. Synthesis of D-galactofuranosyl hemiacetals. 
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Scheme 129. Oxidative cleavage of 568 and oxime formation. 
 
 With the 1-allyl-α-D-galactofuranoside (568) in hand, we carried out a preliminary 
study to convert it into the corresponding 1-allyl-4-carboxaldehyde-α-D-galactofuranoside 
via NaIO4-mediated selective oxidative cleavage of terminal diols consisting of a primary 
alcohol group.297  When 568 was treated with 1.13 equivalents of NaIO4 in a 1:1 mixture 
of ethanol/water, the reaction was completed within 15 min; on the other hand, use of less 
than 1 equivalent of NaIO4 rendered the reaction incomplete.  We also tested variation of 
ethanol/water in the reaction, however the use of less than 3 equivalents of ethanol led to 
partial solubility of 568.  Finally, we decided to test the feasibility of running the reaction 
under near physiological conditions.  Thus, 568 was dissolved in a 1:1 mixture of ethanol 
and 0.15 M NaCl and a 0.15 M solution of NaIO4 in NaCl was added.  After stirring the 
reaction at room temperature for 10 min in the dark, the TLC showed complete 
conversion and the hydrated aldehyde 571 was obtained in excellent yield.  In order to 
attach the Tn conjugate to the odxidized D-galactofuranoside motif of ZPS PS A1,293 a 
model reaction was carried out using the hydrated aldehyde 571. Thus, O-benzyl 
hydroxyl amine was allowed to react with 571 immediately and the expected oxime 572 
was obtained in good yield as a 7:1 mixture of E/Z diastereomers.  The identity of 
compound 572 was confirmed the 1H NMR and HRMS (Scheme 129). 
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7.2.2.  Synthesis of the 2-acetamido-D-galactopyranoside unit 560 
 Next, we focused on synthesizing the 2-acetamido-D-galactopyranosyl 
hydrochloride (D-galactosamine hydrochloride) unit 560.  In the presence of acetic 
anhydride (Ac2O) and pyridine, 2-amino-D-galactopyranose was converted into the 
corresponding peracetylated compound 574 that was thio-glycosylated in the presence of 
BF3.OEt2 and thio-phenol to obtain 575 as a 1:10 mixture of α/β anomers.  Due to 
neighbouring group participation by the 2-acetamido group, the β anomer was obtained 
as the major product.298  Purified β anomer of 575 was deacetylated under Zemplin 
conditions299 to afford triol 576 in quantitative yield.  The triol was converted into the 
corresponding benzylidine acetal 560 by treating with α,α-dimethoxy benzaldehyde and 
p-TsOH at 50 oC on rotavap (Scheme 130). 
 
 
Scheme 130. Synthesis of the 2-acetamido-D-galactopyranoside unit 560. 
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7.2.3.  Synthesis of the 2-acetamido-4-amino-L-fucose unit 561 
 2-Acetamido-D-glucopyranosyl hydrochloride (D-glucosamine hydrochloride) 577 
was converted into the corresponding peracetylated compound 578 via diazo transfer300 
followed by acetylation (Scheme 131).  Thio-glycosylation of 578 with thio-phenol 
provided excellent yield of 579 as a 1:12 mixture of α/β anomers.  Deprotection of the 
acetyl groups by NaOMe followed by tosylation of the 6-OH afforded the tosylate 580 in 
good yield.  Reductive elimination in the presence of NaI, HMPA and sodium cyano 
borohydride (NaCNBH3)301 provided 1-phenylthio-6-deoxy-3,4-dihydroxy-2-acetamido-
D-gluccopyranoside 581.  Protection of the diol with PMB followed by epoxidation in 
presence of m-CPBA302 provided the desired sulfoxide derivative 582 in excellent yield. 
 
 
Scheme 131. Synthesis of the sulfoxide 582. 
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With 582 in hand our plan was to perform the 2nd glycosylation and then remove 
the PMB groups for the 3rd glycosylation (Figure 38).  Next, our plan was to install the 
mesyl (Ms) group on the 4-OH and perfom a SN2 transformation using NaN3 to the 
corresponding azido derivative. 
 
7.2.4.  Synthesis of the 4,6-Pyruvate Acetal-2,3-Dibenzoyl-D-
Galactopyranoside Unit 564 
 Peracetylation of D-galactopyranose using Ac2O, pyridine, and DMAP followed 
by glycosylation in the presence of thio-phenol and boron trifluoride dietherate afforded 
the tetraaceate 583 in 92% yield.  Deacetylation of 583 using NaOMe followed by 
benzylidene acetal formation using p-methoxyphenyl α,α-dimethoxy benzaldehyde 
provided 585 in good yield.  Benzoylation in the presence of benzoyl chloride followed 
by deprotection of benzylidine acetal in the presence of DDQ afforded the diol 587 in 
excellent yield.  Treatment of 587 with methyl pyruvate in the presence of BF3.OEt2 in 
CH3CN provided the desired pyruvate acetal 588 in good yield (Scheme 132).303 
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Scheme 132. Synthesis of pyruvate acetal unit 564. 
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Scheme 133. Effort toward the synthesis of 3-OPMB protected pyruvate acetal 592. 
 
 Next, we examined the synthesis of 3-OPMB protected pyruvate acetal 592 that 
could used to elongate the repeating tetraaccharide unit of ZPS PS A1 (Scheme 133).  
Thus, 1-phenylthio-β-D-galactopyranoside (584) was converted to 3-p-methoxybenzyl-1-
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phenylthio-β-D-galactopyranoside 589 via stannylation followed by heating with p-
methoxybenzyl chloride in the presence of CsF in DMF for 4 days.  Benzylidine acetal 
formation of 589 followed by benzoylation afforded 590 in 75% yield.340  Due to the 
presence of PMB group at the 3-position and sensitivity of PMB group towards acids, 
deprotection of the benzylidine acetal was carried out at 0 oC in presence of p-TsOH to 
obtain 591 in excellent yield.  Next, we examined different conditions to install the 
methyl pyruvate group at the 4,6-positions (Table 28).304  However, none of the 
conditions provided the desired pyruvate acetal 592, either removal of the PMB group or 
no reaction was observed.  We speculated that because of the low reactivity of methyl 
pyruvate, the acetal formation is not giving the desired product.  Thus, we decided to 
synthesize methyl-2,2-bis(phenylthio)propanoate and subjected to the pyruvate acetal 
formation.  Again, the desired product was not obtained, only removal of the PMB group 
was observed. 
 
Table 28. Conditions for the synthesis of 592. 
Entry Conditions % Yield (592)
1 Methyl pyruvate, CH3CN, BF3.OEt2, rt, 4 Å MS 0 
2 Methyl pyruvate, CH3CN, p-TsOH, rt, 4 Å MS 0 
3 Methyl pyruvate, DMF, p-TsOH, rt, 4 Å MS 0 
4 Methyl pyruvate, DMF, CSA, rt, 4 Å MS 0 
5 Methyl pyruvate, DMF, p-TsOH, 60-80 oC, 4 Å MS 0 
6 1, 1’-Dithiophenyl Methyl pyruvate, DMF, p-TsOH, 60-80 oC 0 
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Scheme 134. Proposed synthesis of 3-OAllyl and 3-OPMB pyruvate acetals. 
 
 We speculated that a 3-OAllyl protected pyruvate acetal 596 could also be used to 
obtain the 3-OPMB protected pyruvate acetal 592.  Thus, stannylation using dibutyl tin 
oxide followed by heating in the presence of CsF and allyl bromide in DMF for 4 days 
afforded corresponding 1-phenylthio-3-allyl-β-D-galactopyranoside (593) in 40% yield.304  
Benzylidine acetal formation of 593 followed by benzoylation could be used to provide 
594.  Deprotection of the benzylidine acetal followed by treatment with methyl pyruvate 
and BF3.OEt2 could be used to provide the desired pyruvate acetal 596.  Deallylation of 
596 using PdCl2 followed by protection of the 3-OH with PMB group could also provide 
the other desired pyruvate acetal 592 (Scheme 134). 
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7.2.5.  Assembly of the Monosaccharide Units via Linear Approach 
 With the monosaccharide units in hand, we moved forward to assemble them via 
a sequential glycosylation strategy.  Thus, 2,3,5,6-tetrabenzoyl-D-galactofuranosyl 
hemiacetal (374) was converted to the corresponding trichloroacetamidate donor 376 
following a previously described methods (Scheme 88, Chapter 4).  The donor 376 and 
acceptor 576 were dissolved in anhydrous CH2Cl2, stirred at -20 oC for 30 min in the 
presence of 4 Å MS (freshly dried by heat-gun under high-vacuum) followed by the 
addition of the activator TMSOTf305 which provided the desired disaccharide 598 in 75% 
yield.  Neighbouring group participation from the benzoyl group promotes formation of β 
configuration at the newly formed glycosidic bond.  Chemoselective bezylidine acetal 
ring opening using triethylsilane (Et3SiH) and triflic acid (TfOH) combination306 afforded 
compound 557 in 92% yield.  Next, the sulfoxide donor 582, acceptor 557, di-tert-butyl-
4-methyl-pyridine (DTBMP) were dissolved in anhydrous CH2Cl2, stirred at -78 oC for 
30 min in presence of 4 Å MS (freshly dried by heat-gun under high-vacuum) and then 
the activator triflic anhydride (Tf2O) was added.295  The reaction was then slowly warmed 
to -20 oC over 1 h and quenced.  Gradient column chromatography using silica gel as the 
stationary phase and ethyl acetate/hexane (1:4 to 1:1) as mobile phase provided the 
desired product 599 in 30% yield (Scheme 135).  Steric hindrance exerted by the 
furanosyl motif307 of the acceptor 557 might be responsible for the observed low yield.  
Furthermore, the presence of electron withdrawing azido group at C2 disfavors the build 
up of any positive charge on C1, making the donor 582 somewhat disarmed and less 
reactive.308  In addition, the 4-OH group of pyranoses are less reactive.309  The 
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trisaccharide was inseparable from some impurity that was thought to be the aglycon 
transfer product 606 via the pathway shown in Scheme 136.310 
 
Scheme 135. Assembly of the monosaccharide units. 
 
Attempts to further purify compound 599 via silica gel column chromatography 
led to decomposition.  Thus, we decided to move forward and DDQ removal of PMB 
groups from 509 provided the diol compound 600 in 85% yield.  Pre-activation of the 
donor 600 by N-iodo-succinimide (NIS) and TMSOTf in anhydrous CH2Cl2 in the 
presence of 4 Å MS (freshly dried by heat-gun under high-vacuum) followed by addition 
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of the acceptor 588311 did not provide the desired tetrasaccharide 601 (Scheme 135).  It is 
suspected that since the acceptor also contains a thiophenyl group at the anomeric 
position and the presence of N-acetyl group at C-2 favors formation of positive charge at 
C1, making the acceptor more reactive than donor 588 which is disarmed and less 
reactive due to the presence of benzoyl group at C2, which leads to unkown side reaction 
(Scheme 136).308 
 
 
Scheme 136. Possible mechanism for the aglycon transfer pathway. 
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7.3. Synthetic Study via Divergent Approach 
 Being unsuccessful in the construction of the tetrasaccharide unit via the linear 
approach, we elected to examine the alternative divergent approach.  We speculated that 
the initial construction of of the disaccharide 565 would be more feasible as it could 
avoid the steric hindrance of furanosyl moiety and would enable us to set the required α 
stereochemistry at C-1 of the 3,4-di-p-methoxybenzyl,-2-azido-6-deoxy fucose motif.  
Thus the trichloro acetamidate donor 609 was synthesized from compound 581.  
Protection of the 3,4-dihydroxyl groups by PMB group afforded the corresponding di-
PMB product 606 which was treated with NIS in a 1:6 mixture of CH3CN and water to 
obtain the hemiacetal 608.  The trichloroacetamidate 609 was obtained by treating 608 
with DBU and trichloroacetonitrile at 0 oC for 2-4 h (Scheme 137).  Compound 609 was 
purified via gradient silica gel column (neutralized with 1% Et3N) chromatography using 
ethyl acetate/hexane (1:4 to 1:1) mixture as the eluent.  It is important to note that 609 is 
quite unstable (probably due to the presence of electron withdrawing azido group at C-2) 
and spontaneously converts into corresponding hemiacetal 608 at room temperature.  
Thus it was used directly after purification. 
 
 
Scheme 137. Synthesis of di-PMB protected trichloroacetamidate 609. 
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Scheme 138. Synthesis of 3-Oallyl protected acceptor 614. 
 
 Next, we focused on the synthesis of 3-Oallyl protected 2-azido 4,6-benzylidine-
D-galactopyranoside.  Thus, 2-amino-D-galactopyranose was converted to the 
corresponding 2-azido,1-3,4,6-tetraacetyl-D-galactopyranoside 610 via diazo transfer 
using imidazoyl-1-sulfonyl hydrochloride in the presence of K2CO3, CuSO4.5H2O300 
followed by per-acetylation as described earlier (Scheme 131).  Glycosylation of 610 
with thio-phenol provided 611 as a 7:1 mixture of α/β anomers.  Deprotection of the 
acetyl groups using NaOMe followed by benzylidine acetal formation in presence of α,α-
dimethoxy benzaldehyde and camphor sulfonic acid (CSA) in CH3CN afforded 613 in 
good yield.  Allylation of 613 using allylbromide and NaH in DMF provided the 3-
OAllyl product 614 (Scheme 138).  As described earlier, chemoselective benzylidine 
acetal ring opening by Et3SiH/TfOH306 afforded the desired acceptor 614 in excellent 
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yield.  Compound 614 observed to be not so stable for an extended period of time when 
stored at 0 oC.  Thus it was prepared as required. 
 With the donor 609 and acceptor 614 in hand, we examined the coupling 
employing Schmidt’s conditions.  The donor 609 and acceptor 614 were dissolved in 
anhydrous CH2Cl2 in presence of 4 Å MS (freshly dried by heat-gun under high-vacuum) 
for 1 h at 0 oC and then the activator TMSOTf was added.  However, the expected 
disaccharide 615 was not obtained even after use of 0.3-0.5 equiv. of the activator 
TMSOTf (Scheme 139).  Probably, the 4-OH of the acceptor is unreactive and requires a 
longer reaction time.  Moreover, the PMB groups of the donor 609 might render some 
steric hindrance during glycosylation.  Furthermore, the presence of azido group at C2 
disfavors the build up of any positive charge at C1, making it somewhat disarmed and 
less reactive.308 
 
 
Scheme 139. Coupling of donor 609 and acceptor 614. 
 
 Hence, we revised our synthetic strategy and decided to replace PMB with acetate 
groups.  Thus, acetylation of 581 followed by the steps described previously (Scheme 
141) afforded the desired trichloroacetamidate 618 in excellent yield (Scheme 140). 
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Scheme 140. Synthesis of di-acetate protected trichloroacetamidate 618. 
 
 With 618 in hand, we performed the glycosylation with the acceptor 614 as 
described for 615.  Gratifyingly, the desired disaccharide 619 was obtained in 30% yield 
along with the aglycon transfer product 616 (Scheme 141).  Unreacted 614 was recovered 
via gradient silica gel column chromatography.  It is noteworthy to mention that, the 
coupling provides exclusively α-product which was confirmed by 1H and 13C NMR.  Our 
result is also in good aggrement with literature precedence on similar couplings.310e, 312  
The indentity of compound 619 was further confirmed by 1H-1H GDQFCOSY, GHMQC 
and GHMBC. 
 
 
Scheme 141. Synthesis of disaccharide 619. 
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Scheme 142. Synthesis of trichloroacetamidate 621 of the pyruvate acetal 588. 
 
 Next, we decided to couple disaccharide 619 with the trichloroacetamidate of the 
benzoyl protected pyruvate acetal 588.  Thus, 588 was converted to the corresponding 
hemiacetal 620 which was converted to trichloroacetamidate 621 following the procedure 
as described earlier (Scheme 142). 
 
 
Scheme 143. Synthesis of trisaccharide 623. 
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 With 621 in hand, we carried out the glycosylation with the acceptor 622 
following the procedure described for 619.  The desired trisaccharide 623 was obtained in 
good yield along with the aglycon transfer310 product 588 which was inseparable.  Thus, 
we decided to use 623 without further purification.  The idenity of compound 623 was 
confirmed by 1H, 13C, 1H-1HGDQFCOSY.  Lower yield could be due to the presence of 
benzoyl group at C2 which makes the donor 621 somewhat disarmed and less reactive.  
Furthermore, the pyruvate acetal locks the ring in a specific conformation that might also 
disfavor the formation of planner oxocarbonium ion due to torsional strain.313  Next, 623 
was subjected to deallylation in presence of PdCl2,296 after 4 h TLC showed 50% 
conversion.  However, after 12 h, unfortunately decomposition of the starting material 
was observed (Scheme 143). 
 A probable mechanism for the formation of aglycon transfer product 588 and side 
products is shown in scheme 145.310d  Activation of the donor 621 by TMSOTf forms 
2,2,2-trichloro-N-trimethylsilylacetamide (625)and the benzoxonium ion 626.  The 
thiophenol group at anomeric position of the acceptor 622 then attack on the C1 of 626 
and forms the β-thioplycoside 588 via sulfonium intermediate as shown in Scheme 160.  
The reactive intermediate 628 can either be trapped be a nucleophile or will decompose.  
Thus either 625 or the 3-OH (more reactive than 4-OH) of the acceptor 622 can serve as 
nucleophile and provide the trichloroacetamide derivative 629 or the polymerization 
product 630 respectively (Scheme 144). 
 
 
 
 388
O
O
BzO
OBz
OMeO2C
Me
621
O
NH
CCl3
TMS OTf
O
O
BzO
O
OMeO2C
Me
OPhO
N
H
CCl3
O
O
BzO
O
OMeO2C
Me
O
Ph
OTf
O
N3
O
OBn
AllylO O
N3
SPh
OH
OH
CH3
O N3
O
OBn
AllylO
O
628
N3
OHHO
H3C
TMS
O
O
BzO
OBz
OMeO2C
Me
588
SPh
622
O N3
O
OBn
AllylO
O
629
N3
OH
HO
H3C
N
H
O
CCl3
626
627
OTf
625
O
N3
O
OBn
AllylO
O
N3
OH
HO
H3C
O
N3
O
BnO
OAllylO
N3
O
HO
H3C
630
SPh
622
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7.4. Future Direction 
 Since we have observed aglycon transfer during the synthesis of 619 (Scheme 
141), the future strategy would be to prevent this side reaction.  Gildersleeve and co-
workers have shown that use of 2,6-dimethylphenylthio group at the anomeric position of 
the acceptor 614 was effective to prevent aglycon transfer during TMSOTf-mediated 
glycosylation.310  Thus, the 2,6-dimethylphenylthio group protected accetor 632 can be 
synthesized following the procedure outlined in Scheme 138. 
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Scheme 145. Future direction toward the synthesis of repeating tetrasachharide unit of 
ZPS PS A1. 
 Coupling of the acetate (or cloroacetate) protectecd donor 631 with 2,6-
dimethylphenylthio protected acceptor 632 via Schmidt glycosylation can provide the 
disachharide 633.  Deprotection of the acetyl groups in presence of NaOMe can provide 
 390
the diol 634.  Schmidt glycosylation with the donor 621 in presence of TMSOTf can 
afford the trisachharide 635.  Mesylation of 635 followed by deallylation, protection with 
levulinic group, reduction of the azido group (by Adam’s catalyst) and finally SN2 
displacement of OMs group by azide can provide the trisachharide 636.  Removal of the 
levulinic group by thiourea followed by Schmidt glycosylation with the donor 376, 
debenzylation in presence of Pd/C and global deprotection of benzoyl groups as well as 
the ester group can provide the desired tetrasachharide 637. 
 Alternatively, the chloroacetyl protected disachharide 633 can be subjected to 
deallylation followed by Schmidt glycosylation with donor 376 to obtain trisachharide 
638.  The chloroacetyl group can deprotected by thiourea and the acceptor can be 
subjected to Schmidt glycosylation with the donor 621 to access the tetrasachharide 639.  
Mesylation of 638 followed by SN2 displacement by NaN3, debenzylation and global 
deprotection can provide the tetrasachharide 637. 
 In case, the deallylation in presence of PdCl2 fails, the iridium based catalyst 
[Ir(COD)(PMePh2)]PF6 in presence of H2 in THF followed by treatment with HgCl2 and 
HgO in acetone/H2O can be employed.  Then the steps described above can be followed. 
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7.5. Materials and Methods 
 All Reagents were purchased from Aldrich unless otherwise noted.  Anhydrous 
methanol, tetrahydrofuran, acetone and dichloromethane were purchased from Alfa 
Aesar.  Anhydrous methanol was purchased from EMD chemicals (DriSolv).  p-Toluene 
sulfonic acid and TMSOTf were purchased from Acros organics.  Thiophenol, Allyl 
bromide, methyl pyruvate, DMPU and NIS were purchased from Alfa Aesar.  Palladium 
chloride was purchased from Stream Chemicals.  Except as otherwise indicated, reactions 
were carried out under Argon.  All reactions were monitored by thin layer 
chromatography using 0.25 mm Dynamic Adsorbents, L.L.C. precoated silica gel 
(particle size 0.03-0.07 mm, catalog no. 84111).  Column chromatography was performed 
using Whatman Purasil 60 Ǻ (230-400 mesh ASTM) silica gel.  Yields refer to 
chromatographically and spectroscopically pure compounds, except as otherwise noted.  
Diastereomeric ratios were determined from 1H NMR spectra of non-purified reaction 
mixtures.  Proton and carbon-13 NMR spectra were recorded on Varian Mercury 400, 
Varian Unity 500 and Varian 500 Direct Drive System spectrometers.  The residual 
CDCl3 singlet at δ 7.26 ppm and δ 77 ppm were used as the standard for 1H NMR and 13C 
NMR spectra respectively.  Mass spectra were recorded on Micromass GCT at 70 eV. 
 
7.5. Experimental Data 
1. 
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 To an oven dried RB flask equipped with magnetic stir bar under Argon, 
compound 598 (0.145 g, 0.148 mmol) was taken and 4 Å MS (0.042 g, oven dried for 24 
h followed by heat gun under high vacuum) was added to the flask.  After adding 
anhydrous CH2Cl2 (2 mL), the flask was stirred for 1 h at room temperature and then 
cooled to -78 oC.  To the stirred solution, Et3SiH (8 µL, 0.488 mmol) was added followed 
by TfOH (4 µL, 0.444 mmol).  The resulting solution was stirred at -78 oC for 1 h and 
then neutralized by the addition of Et3N (0.3 mL) followed by methanol (0.5 mL).  The 
mixture was then diluted with CH2Cl2 (10 mL) and washed with saturated NaHCO3 (10 
mL).  The aqueous layer was washed with CH2Cl2 (5 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The 
crude residue was purified via gradient silica gel (neutralized with 0.1% Et3N) column 
chromatography using a mixture of ethyl acetate/hexane (1:3 to 1:1) as the eluent to 
afford 0.134 g (92%) of 557 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 8.06-8.12 (m, 2 H, aryl), 7.95-8.03 (m, 4 H, aryl), 7.48-
7.60 (m, 6 H, aryl), 7.27-7.45 (m, 14 H, aryl), 7.20-7.26 (m, 2 H, aryl), 5.96 (m, 1 H), 
5.91 (d, 1 H, J = 7.3 Hz, H-1), 5.68 (dd,1 H, J = 5.6, 1.8 Hz), 5.38-5.45 (m, 3 H), 4.81 
(dd, 1 H, J = 5.8, 3.7 Hz), 4.75 (dd, 1 H, J = 11.9, 4.6 Hz), 4.68 (dd, 1 H, J = 11.9, 6.7 
Hz), 4.51 (s, 2 H), 4.47 (dd, 1 H, J = 10.4, 3.1 Hz), 4.16 (d, 1 H, J = 2.7 Hz), 3.62-3.77 
(m, 4 H), 2.7 (bs, 1 H, 4-OH), 1.99 (s, 3 H, -NHCOCH3) 
 
13C NMR (125 MHz, CDCl3): δ 171.4, 166.1, 165.8, 165.7, 165.6, 137.9, 133.6, 133.5, 
133.4, 133.3, 133.2, 131.9, 129.9, 129.9, 129.8, 129.4, 129.3, 128.9, 128.7, 128.5, 128.4, 
128.4, 128.3, 127.7, 127.5, 107.7, 85.0, 82.9, 81.1, 77.8, 77.1, 73.6, 70.1, 69.9, 69.6, 63.1, 
52.6, 46.6, 23.6. 
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HRMS (EIMS, M+ +Na): cald for C55H50NNaO14S 1003.2850, found 1003.2854. 
 
2. 1-Phenylthio-2-N-acetyl-4,6-benzylidene-β-D-galactopyranoside 
 
 To an oven dried RB flask equipped with magnetic stir under Argon, Na (0.07 g, 
3.04 mmol, washed with dry hexane) was taken and cooled to 0 oC.  Anhydrous methanol 
(39 mL) was then added at oC; the solution was stirred for 1-2 h until all Na completely 
dissolved and the solution was kept at 0 oC.  1-Phenylthio-2-N-acetyl-3,4,6-triacetate-β-
D-galactopyranose (575) (3.38 g, 7.70 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and dissolved in anhydrous methanol (10 
mL).  The flask was then cooled to 0 oC and freshly prepared NaOMe (39 mL, 0.08 M) 
was added slowly via a syringe.  The resulting solution was then slowly warmed to room 
temperature and stirred for 12 h.  The reaction mixture was then neutralized to pH 6 with 
Amberlite 120 and then filtered.  The filtrate was dried over Na2SO4 and concentrated 
under reduced pressure on rotavap to afford 2.47 g (99%) of triol 576 as a colorless oil. 
 The triol 576 (2.47 g, 7.89 mmol) was dissolved in anhydrous DMF (29 mL) 
under Argon.  To the solution, catalytic amount of p-TsOH was added the resulting 
mixture was heated to 50 oC on rotavap under reduced pressure for 6 h.  The reaction 
mixture was then cooled to room temperature and diluted with water (200 mL).  The 
solution was then then extracted with ethyl acetate (3 × 20 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The 
residue was purified via gradient silica gel column chromatography using a mixture of 
 394
ethyl acetate/hexane (1:3 to 3:1) as the eluent to afford 2.53 g (80%)of 560 as a white 
solid. 
1H NMR (500 MHz, CDCl3): δ 7.57-7.64 (m, 2 H, Ph), 7.40-7.49 (m, 3 H, Ph), 7.31-7.37 
(m, 3 H, Ph), 7.22-7.28 (m, 3 H, Ph), 5.5 (s, 1 H, -CHPh), 4.84-4.89 (m, 1 H), 4.34 (d, 1 
H, J = 12.5 Hz, H-6), 4.15-4.20 (m, 1 H), 4.01 (d, 1 H, J = 12.5 Hz, H-6), 3.81-3.86 (m, 2 
H), 3.53 (s, 1 H), 2.35 (bs, 1 H, 3-OH), 2.0 (s, 3 H, -NHCOCH3) 
 
HRMS (EIMS, M+): cald for C21H23NO5S 401.1297, found 401.1291. 
 
3. 
 
 D-Galactosamine hydrochloride (3 g, 13.91 mmol) was taken in an oven dried RB 
flask equipped with magnetic stir bar under Argon.  Anhydrous CH2Cl2 (50 mL) was then 
added to the flask and cooled to 0 oC.  To the solution, pyridine (16.87 mL, 208.65 mmol) 
was added dropwise via syringe followed Ac2O (13.15 mL, 139.10 mmol) and DMAP 
(0.15 g, 1.23 mmol).  The resulting mixture was then slowly warmed to room temperature 
and stirred for 18 h.  The reaction was then quenched with with saturated NaHCO3 (100 
mL) at 0 oC.  The solution was then extracted with CH2Cl2 (2 × 30 mL).  The organic 
layers were combined, dried over Na2SO4 and concentrated under reduced pressure on 
rotavap.  The residue was diluted with toluene (100 mL) and further concentrated under 
reduced pressure on rotavap to remove remaining AcOH and pyridine.  The residue was 
then purified via gradient silica gel column chromatography using a mixture of ethyl 
acetate/hexane (1:4 to 1:1) as the eluent to afford 5.85 g (99%) of 574 as a white solid. 
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 4 Å MS was dried in oven for 24 h followed by heat gun under high vacuum and 
then transferred to an oven dried RB flask equipped with magnetic stir bar under Argon.  
To the flask, 574 (3.55 g, 9.13 mmol) was added and dissolved in anhydrous CH2Cl2 (40 
mL).  The solution was then cooled to 0 oC and PhSH (2.82 mL, 27.38 mmol) was added 
followed by BF3.OEt2 (4.59 mL, 36.50 mmol).  The resulting mixture was stirred at 0 oC 
for 4 h, then slowly warmed to room temperature and stirred for 4 h.  TLC showed that 
reaction was incomplete and thus the reaction mixture was refluxed for 24 h in a silicone-
based oil-bath.  After cooling reaction to room temperature, the reaction was quenched 
with saturated NaHCO3 to pH 7 and extracted with CH2Cl2 (3 × 20 mL).  The organic 
layers were combined, washed with brine (50 mL) and dried over Na2SO4.  After 
concentrating the organic layer under reduced pressure on rotavap, the residue was 
purified via gradient silica gel column chromatography using a mixture of ethyl 
acetate/hexane (1:5 to 5:1) as the eluent to afford 3.48 g (95%) of 575 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 7.46-7.51 (m, 2 H, Ph), 7.24-7.31 (m , 3 H, Ph), 6.0 (d, 1 
H, J = 9.2 Hz, H-1), 5.36 (d, 1 H, J = 3.4 Hz), 5.21 (dd, 1 H, J = 10.7, 3.4 Hz), 4.94 (d, 1 
H, J = 10.4 Hz), 4.19 (dd, 1 H, J = 19.8, 10.1 Hz), 4.14 (dd, 1 H, J = 11.0, 7.0 Hz, H-6), 
4.08 (dd, 1 H, J = 11.1, 5.8 Hz, H-6), 3.94 (t, 1 H, J = 6.7 Hz), 2.10 (s, 3 H, -COCH3), 2.0 
(s, 3 H, -COCH3), 1.96 (s, 3 H, -COCH3), 1.95 (s, 3 H, -COCH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.4, 170.3, 170.2, 133.1, 131.8, 128.8, 127.7, 86.9, 
74.3, 71.0, 66.9, 61.9, 49.6, 23.3, 20.6 
 
HRMS (EIMS, M+): cald for C20H25NO8S 439.1301, found 439.1298. 
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4. 
 
 D-Glucosamine hydrochloride (3 g, 13.92 mmol) was taken in an oven dried RB 
flask equipped with magnetic stir bar under Argon and anhydrous methanol (75 mL) was 
added.  To the solution, K2CO3 (4.65 g, 33.63 mmol) and CuSO4.5H2O (0.06 g, 0.27 
mmol) and imidazole-1-sulfonyl azide (3.51 g, 16.68 mmol) were added respectively.  
The resulting mixture was stirred at room temperature for 18 h and then diluted with 
MeOH (25 mL).  The solution was then filtered, the filtrate was dried over Na2SO4 and 
concentrated under reduced pressure on rotavap. 
 To the peracetylated residue was dissolved in anhydrous CH2Cl2 (25 mL) and 
Ac2O (10.5 mL, 111 mmol), pyridine (17 mL, 210.19 mmol) were added followed by 
catalytic amount of DMAP (0.17 g, 1.39 mmol) at 0 oC.  The resulting mixture was then 
slowly warmed to room temperature and stirred for 18 h.  The reaction was then cooled to 
0 oC and quenched with saturated NaHCO3 to pH 7.  The solution was then extracted 
with CH2Cl2 (3 × 20 mL) and the aqueous layer was washed with additional CH2Cl2 (20 
mL).  The organic layers were combined, dried over Na2SO4 and concentrated under 
reduced pressure on rotavap.  The residue was diluted with toluene (100 mL) and further 
concentrated under reduced pressure on rotavap to remove remaining AcOH and 
pyridine.  The syrup was then purified via gradient silica gel column chromatography 
using a mixture of ethyl acetate/hexane (1:6 to 1:1) as the eluent to obtain 4.16 g (80%) 
of 578 a white solid. 
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 2-azido-1,3,4,6-tetraacetate-D-glucopyranoside (3.0 g, 8.04 mmol) was taken in 
an oven dried RB flask equipped with magnetic stir bar under Argon.  4 Å MS (0.1 g, 
oven dried for 24 h followed by heat gun dried under high vacuum) was added to the 
flask.  The mixture was stirred in anhydrous CH2Cl2 for 30 min at room temperature.  
After cooling to 0 oC, PhSH (1.66 mL, 16.07 mmol) and BF3.OEt2 (3.03 mL, 24.12 
mmol) were added respectively.  The resulting mixture was slowly warmed to room 
temperature over 2 h and then stirred for 18 h.  The reaction was then quenched with 
saturated NaHCO3 to pH 7 and extracted with CH2Cl2 (3 × 20 mL).  The aqueous layer 
was washed with additional CH2Cl2 (20 mL).  The organic layer were combined, dried 
over Na2SO4 and concentrated under reduced pressure on rotavap.  The residue was 
purified via gradient silica gel column chromatography using a mixture of ethyl 
acetate/hexane (1:6 to 1:1) as the eluent to afford 575 as a white solid. 
1H NMR (400 MHz, CDCl3): δ 7.45-7.53 (m, 2 H, Ph), 7.27-7.38 (m, 3 H, Ph), 5.62 (d, 1 
H, J = 4.9 Hz, H-1), 5.32 (t, 1 H, J = 9.3 Hz, H-3), 5.03 (t, 1 H, J = 10.5 Hz, H-4), 4.54-
4.64 (m, 1 H), 4.28 (dd, 1 H, J = 17.0, 4.9 Hz), 4.06 (dd, 1 H, J = 10.5, 5.7 Hz), 4.01 (dd, 
1 H, J = 2.5, 1.6 Hz), 2.09 (s, 3 H, –COCH3), 2.04 (s, 3 H, –COCH3), 2.01 (s, 3 H, –
COCH3) 
 
HRMS (EIMS, M+): cald for C20H25NO8S 439.1301, found 439.1298. 
 
5. 
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 1-Phenylthio-2-azido-3,4,6-triacetate-D-glucopyranoside (2.8 g, 7.38 mmol) was 
taken in an oven dired RB flask equipped with magnetic stir bar under Argon, dissolved 
in anhydrous MeOH (8 mL) and cooled to 0 oC.  To the flask, freshly prepared NaOMe 
solution (0.067 g in 37 mL anhydrous MeOH) at 0 oC was added dropwise.  The resulting 
solution was then slowly warmed to room temperature and stirred for 18 h.  The raction 
was then neutralized with amberlite IR-120 to pH 6 and filtered.  The filtrate was dried 
over Na2SO4 and concentrated under reduced pressure on rotavap.  The triol was used 
directly without further purification. 
 1-Phenylthio-2-azido-D-glucopyranoside (1.2 g, 4.04 mmol) was taken in an oven 
dried RB flask equipped with magnetic stir bar under Argon and dissolved in anhydrous 
CH2Cl2 (30 mL).  Pyrdine (1.31 mL, 16.16 mmol) was added and the solution was cooled 
0 oC.  Next, TsCl (0.79 g, 4.12 mmol) was added dropwise via syringe.  The resulting 
mixture was then slowly warmed to room temperature and stirred for 6 h.  The reaction 
was quenched with 1 N HCl (5 mL), the organic layer was washed with brine (2 × 20 
mL).  The organic layers were combined and dried over Na2SO4.  After concentrating the 
organic layer under reduced pressure on rotavap, the residue was purified via gradient 
silica gel column chromatography using a mixture of ethyl acetate/hexane (1:3 to 2:1) as 
the eluent. 
 1-Phenylthio-2-azido-6-O-tosylate-D-glucopyranoside (1.0 g, 2.22 mmol) was 
taken in an oven dried RB flask equipped with magnetic stir bar under Argon and 
dissolved in HMPA (40 mL).  To the solution, NaI (0.49 g, 3.32 mmol) and NaCNBH3 
(1.67 g, 26.59 mmol) were added respectively.  The resulting solution was then heated to 
70 oC for 18 h.  The reaction was then cooled to 0 oC and diluted with water (20 mL).  
 399
The solution was then extracted with diethyl ether (3 × 20 mL) and the organic layers 
were separated.  The aqueous layer was further washed with diethyl ether (20 mL).  The 
organic layers were combined, washed with brine and dried over Na2SO4.  The organic 
layer was concentrated under reduced pressure on rotavap and purified via gradient silica 
gel column chromatography using a mixture of ethyl acetate/hexane (1:5 to 1:1) as the 
eluent. 
1H NMR (500 MHz, CDCl3): δ 7.47-7.57 (m, 2 H, Ph), 7.27-7.37 (m, 3 H, Ph), 5.54 (d, 1 
H, J = 5.6 Hz, H-1), 4.19-4.30 (m, 1 H), 3.84 (dd, 1 H, J = 10.8, 5.6 Hz), 3.76 (t, 1 H, J = 
9.4 Hz), 3.28 (dt, 1 H, J = 10.0, 2.4 Hz), 2.71 (bs, 1 H, OH), 2.38 (bs, 1 H, OH), 1.32 (d, 
3 H, J = 6.4 Hz, CH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.7, 170.1, 170.0, 134.4, 132.4, 129.5, 128.3, 86.7, 72, 
2, 68.9, 68.7, 62, 1, 61.8, 21.0, 20.9, 20.8 
 
HRMS (EIMS, M+ + Na): cald for C12H15N3NaO3S 304.0732, found 304.0729. 
 
6. 
 
 1-Phenylthio-2-azido-6-deoxy-D-glucopyranoside (0.072 g, 0.26 mmol) was 
taken in an oven dried RB flask equipped with magnetic stir bar under Agron and 
dissolved in anhydrous DMF (1.5 mL).  After cooling the solution to 0 oC, NaH (0.04 g, 
0.78 mmol, 60% in mineral oil) was added in portion, then the mixture was allowed to 
warm to room temperature and stirred for 15 min.  The reaction was again cooled to 0 oC 
and PMBCl (0.12 mL, 0.89 mmol) was added followed by catalytic amount of TBAI.  
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The resulting mixture was then slowly warmed to room temperature, stirred for 4 h and 
heated to 60 oC until TLC showed complete consumption of starting material.  After 
cooling the flask to 0 oC, the reaction was quenched with methanol (5 mL) and diluted 
with water (50 mL).  The solution was then extracted with CH2Cl2 (3 × 20 mL), the 
organic layers were combinbed, dried over Na2SO4.  The organic layer was concentrated 
under reduced pressure on rotavap and purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:20 to 1:6) as the eluent. 
 The di-PMB protected compound (0.042 g, 0.081 mmol) was taken in an oven 
dried RB flask equipped with magnetic stir bar under Argon and dissolved in anhydrous 
CH2Cl2 (3.2 mL).  After cooling the solution to -78 oC, m-CPBA (0.019 g, 0.11 mmol) 
was added in portion and stirred for 1 h.  The reaction was then quenched with saturated 
NaHCO3 (5 mL) and extracted with CH2Cl2 (2 × 10 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The 
residue was purified via gradient silica gel column chromatography using a mixture of 
ethyl acetate/hexane (1:5 to 1:1) as the eluent. 
1H NMR (500 MHz, CDCl3): δ 7.68-7.76 (m, 2 H, aryl), 7.48-7.57 (m, 3 H, aryl), 7.29 (d, 
2 H, J = 8.6 Hz, -CH2PMP), 7.21 (d, 2 H, J = 8.6 Hz, -CH2PMP), 6.9 (d, 2 H, J = 8.6 Hz, 
aryl), 6.87 (d, 2 H, J = 8.6 Hz, aryl), 4.79 (d, 1 H, J = 10.7 Hz, -CH2PMP), 4.72 (d, 1 H, J 
= 10.7 Hz, -CH2PMP), 4.69 (d, 2 H, J = 10.7 Hz, -CH2PMP), 4.55 (d, 1 H, J = 4.9 Hz, H-
1), 4.50 (d, 1 H, J = 10.7 Hz, -CH2PMP), 4.19 (dd, 1 H, J = 7.6, 4.9 Hz), 4.14 (dd, 1 H, J 
= 7.6, 4.9 Hz), 3.87 (q, 1 H, J = 6.1 Hz, H-5), 3.81 (s, 6 H, OMe, OMe), 3.18 (dd, 1 H, J 
= 8.5, 6.7 Hz, H-2), 1.02 (d, 3 H, J = 6.4 Hz, -CH3) 
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13C NMR (125 MHz, CDCl3): δ 159.5, 159.4, 141.6, 131.5, 129.8, 129.6, 129.5, 129.4, 
128.9, 125.5, 113.9, 113.8, 94.3, 81.3, 79.1, 74.2, 73.9, 73.1, 61.2, 55.3, 17.7 
 
HRMS (EIMS, M+): cald for C28H31N3O6S 537.1934, found 537.1938. 
 
7. 1-Phenylthio-2,3,4,6-tetraacetate-β-D-galactopyranoside 
 
 It was synthesized following the procedure described for compound 575. 
1H NMR (500 MHz, CDCl3): δ 7.47-7.53 (m, 2 H, Ph), 7.28-7.33 (m, 3, Ph), 5.4 (d, 1 H, 
J = 3.4, 0.6 Hz), 5.22 (t, 1 H, J = 10.1 Hz), 5.04 (dd, 1 H, J = 9.8, 3.4 Hz), 4.71 (d, 1 H, J 
= 10.1 Hz, H-1), 4.17 (dd, 1 H, J = 11.6, 7.0 Hz, H-6), 4.10 (dd, 1 H, J = 11.3, 6.1 Hz, H-
6), 3.93 (t, 1 H, J = 7.0 Hz), 2.10 (s, 3 H, Me), 2.08 (s, 3 H, Me), 2.02 (s, 3 H, Me), 1.96 
(s, 3 H, Me). 
 
13C NMR (125 MHz, CDCl3): δ 170.3, 170.1, 169.9, 169.3, 132.5, 132.4, 128.8, 128.1, 
86.5, 74.3, 71.9, 67.2, 67.1, 61.6, 20.8, 20.6, 20.5, 20.4 
 
HRMS (EIMS, M+): cald for C20H24O9S 440.1141, found 440.1138. 
 
8. 
 
 It was synthesized from compound 583 by treating with NaOMe solution as 
described previously for compound 575. 
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1H NMR (500 MHz, CD3OD): δ 7.44-7.52 (m, 2 H, Ph), 7.12-7.25 (m, 3 H, Ph), 4.51 (d, 
1 H, J = 9.8 Hz, H-1), 3.82 (dd, 1 H, J = 3.4, 0.6 Hz), 3.68 (dd, 1 H, J = 11.6, 7.0 Hz, H-
6), 3.63 (dd, 1 H, J = 11.3, 5.2 Hz, H-6), 3.53 (t, 1 H, J = 9.5 Hz), 3.48 (m, 1 H), 3.42 
(dd, 1 H, J = 9.2, 3.4 Hz) 
 
13C NMR (125 MHz, CD3OD): δ 164.1, 160.1, 156.0, 118.3, 108.6, 104.3, 99.0, 98.4, 
90.6. 
 
HRMS (EIMS, M+): cald for C12H16O5S 272.0718, found 272.0722. 
 
9. 
 
 It was synthesized from compound 584 following the procedure described 
previously for compound 560. 
1H NMR (500 MHz, CDCl3): δ 7.69 (d, 2 H, J = 6.7 Hz, aryl), 7.27-7.37 (m, 5 H, Ph), 
6.88 (d, 2 H, J = 6.7 Hz, aryl), 5.46 (s, 1 H, -CHPMP), 4.5 (q, 1 H, J = 4.9 Hz), 4.36 (dd, 
1 H, J = 12.5, 1.2 Hz), 4.19 (d, 1 H, J = 1.6 Hz, H-1), 4.01 (dd, 1 H, J = 12.5, 1.5 Hz), 
3.82 (s, 3 H, Ome), 3.64-3.72 (m, 2 H), 3.53 (d, 1 H, J = 0.9 Hz), 2.6 (bs, 2 H, 2-OH, 3-
OH),  
 
13C NMR (125 MHz, CDCl3): δ 160.6, 133.9, 132.7, 131.0, 130.4, 129.4, 129.2, 128.4, 
128.1, 113.8, 101.5, 87.2, 75.6, 74.0, 70.3, 69.5, 69.1, 55.6. 
 
HRMS (EIMS, M+ + Na): cald for C20H22NaO6S 413.1035, found 413.1036. 
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11. 
 
 Compound 585 (1.4 g, 3.59 mmol) was taken in oven dried RB flask equipped 
with magnetic stir bar under Argon and dissolved in anhydrous CH2Cl2 (10 mL).  After 
cooling the solution to 0 oC, pyridine (1.45 mL, 17.95 mmol) and Benzoyl (Bz) chloride 
(3.35 mL, 17.95 mmol) were added followed by catalytic amount of DMAP.  The 
resulting solution was slowly warmed to room temperature and stirred for 18 h.  The 
reaction was cooled to 0 oC and quenched with saturated NaHCO3 (10 mL).  The solution 
was then extracted with CH2Cl2 (3 × 20 mL), washed with brine (50 mL) and combined 
organic layer was dried over Na2SO4.  After concentrating the organic layer under 
reduced pressure on rotavap, the residue was purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:5 to 1:1) as the eluent. 
 Compound 586 (2.5 g, 4.18 mmol) was taken in an oven dried RB flask equipped 
with magnetic stir bar and dissolved in CH2Cl2 (30 mL).  Water (3 mL) was added and 
the solution was then cooled to 0 oC.  To the solution, DDQ (1.42 g, 6.26 mmol) was 
added in portion, the resulting mixture was slowly warmed to room temperature and 
stirred for 18 h.  The reaction was then diluted with CH2Cl2 (20 mL) and washed with 
saturated NaHCO3 (30 mL).  The organic layer was separated and the aqueous layer was 
washed additional CH2Cl2 (2 × 20 mL).  The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure on rotavap.  The residue was purified 
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via gradient silica gel column chromatography using a mixture of ethyl acetate/hexane 
(1:4 to 2:1) as the eluent to afford 587 as a white solid. 
 1-Phenylthio-2,3-di-O-benzoyl-β-D-galactopyranoside (0.118 g, 0.246 mmol) was 
taken in an oven dried RB flask and dissolved in anhyrous CH3CN.  To the solution, 
methyl pyruvate (51 µL, 0.492 mmol) was added followed by BF3.OEt2 (62 µL, 0.492 
mmol) at room temperature.  The resulting mixture was stirred for 48 h at room 
temperature.  The reaction was then cooled to 0 oC and quenched with saturated NaHCO3 
(5 mL).  The solution was then extracted with CH2Cl2 (2 × 10 mL) and the aqueous layer 
was further extracted with additional CH2Cl2 (10 mL).  The organic layers were 
combined, dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The 
residue was purified via gradient silica gel column chromatography using a mixture of 
ethyl acetate/hexane (1:4 ro 1:1) as the eluent to obtain 588 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 7.93-8.30 (m, 4 H, Bz), 7.29-7.64 (m, 11 H, Aryl), 5.77 
(t, 1 H, J = 10.1 Hz, H-2), 5.29 (s, 1 H), 5.22 (dd, 1 H, J = 9.8, 3.4 Hz), 4.92 (d, 1 H, J = 
10.1 Hz, H-1), 4.57 (d, 1 H, J = 3.4 Hz), 4.20 (dd, J = 12.8, 1.2 Hz, H-6), 4.03 (dd, 1 H, J 
= 12.8, 1.2 Hz, H-6), 3.64 (s, 3H, CO2Me), 1.54 (s, 3 H, Me). 
13C NMR (125 MHz, CDCl3): δ 170.4, 166.4, 165.3, 133.9, 133.5, 133.4, 131.8, 130.1, 
130.0, 129.9, 129.5, 129.0, 128.6, 128.6, 128.5, 98.9 (C-1), 85.9, 74.2, 69.4, 69.3, 67.2, 
52.7, 25.8. 
 
HRMS (EIMS, M+ + Na): cald for C30H28NaO9S 587.1352, found 587.1349. 
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12. 
 
 1-Phenylthio-β-D-galactopyranoside (0.05 g, 0.184 mmol) was taken in an oven 
dried RB flask equipped with magnetic stir bar under Argon and dissolved in anhydrous 
MeOH (2 mL).  To the solution, Bu2SnO (0.046 g, 0.184 mmol) was added and the 
resulting mixture was refluxed for 2-3 h (until a clear solution appears).  The reaction 
mixture was then concentrated under reduced pressure on rotavap (rotavap bump trap and 
reservoir was oven dried ).  The residue was dissolved in anhydrous DMF (2 mL) under 
Argon and PMBCl (27 µL, 0.189 mmol) was added followed by CsF (0.029 g, 0.19 
mmol).  The resulting mixture was heated to 50 oC for 4 days.  The reaction was then 
diluted with toluene and concentrated under reduced pressure on rotavap.  The residue 
was purified via gradient silica gel column chromatography using a mixture of 
MeOH/CH2Cl2 (1:60 to 1:10) as the eluent. 
 
1H NMR (500 MHz, CD3OD): δ 7.49 (d, 2 H, J = 7.0 Hz, aryl), 7.13-7.33 (m, 5 H, aryl), 
6.82 (d, 2 H, J = 8 Hz, aryl), 4.63 (d, 1 H, J = 11.3 Hz, -CH2PMP), 4.56 (d, 1 H, J = 11. 6 
Hz, -CH2PMP), 4.53 (d, 1 H, J = 9.8 Hz, H-1), 3.98 (d, 1 H, J = 2.7 Hz), 3.72 (s, 3 H, 
OMe), 3.61-3-74 (m, 3 H), 3.44 (t, 1 H, J = 6.4 Hz), 3.33 (dd, 1 H, J = 9.2, 3.4 Hz),  
 
13C NMR (125 MHz, CD3OD): δ 160.6, 135.7, 132.2, 131.6, 130.6, 129.7, 127.9, 124.6, 
90.1, 83.2, 80.3, 72.4, 70.1, 67.4, 62.5, 55.6. 
 
HRMS (EIMS, M+ + Na): cald for C20H24NaO6S 415.1191, found 415.1195. 
 
 
 406
13. 
 
 Compound 589 (0.217 g, 0.553 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and dissolved in anhydrous DMF (5 mL) 
and α,α-diemthoxy benzaldehyde (0.168 mL, 1.11 mmol) was added followed by 
catalytic amount of p-TsOH.  The resulting mixture was heated to 50 oC under reduced 
pressure on rotavap (bump trap and reversoir was dried in oven) for 6 h.  The reaction 
was diluted with toluene (20 mL) and concentrated under reduced pressure on rotavap.  
The residue was purified via silica gel column chromatography using a mixture of ethyl 
acetate/hexane (1:4 to 2:1) as the eluent to afford 1-Phenylthio-3-p-methoxylbenzyl-4,6-
benzylidine-β-D-galactopyranoside. 
 
1H NMR (500 MHz, CDCl3): δ 7.70 (d, 2 H, J = 7.3 Hz, aryl), 7.19-7.48 (m, 10 H, aryl), 
6.84 (d, 2 H, J = 8.5 Hz, aryl), 5.54 (s, 1 H, -CHPh), 4.66 (dd, 2 H, J = 24.7, 12.4 Hz, -
CH2Ph), 4.53 (d, 1 H, J = 9.5 Hz), 4.35 (d, 1 H, J = 12.2 Hz, H-6), 4.17 (d, 1 H, J = 3.1 
Hz), 3.98 (d, 1 H, J = 12.2 Hz, H-6), 3.94 (t, 1 H, J = 9.5 Hz), 3.80 (s, 3 H, OMe), 3.50 
(dd, 1 H, J = 9.2, 3.1 Hz), 3.44 (s, 1 H), 2.54 (s, 1 H) 
 
13C NMR (125 MHz, CDCl3): δ 159.3, 137.8, 133.7, 130.7, 129.9, 129.5, 128.9, 128.8, 
128.0, 126.5, 113.8, 101.1, 86.9, 79.8, 73.2, 71.1, 70.0, 69.3, 67.1, 55.2. 
 
HRMS (EIMS, M+ + Na): cald for C27H28NaO6S 503.1504, found 503.1501. 
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14. 
 
 1-Phenylthio-3-p-methoxybenzyl-4,6-benzylidine-β-D-galactopyranoside (0.124 
g, 0.258 mmol) was taken in an oven dried RB flask equipped with magnetic stir bar 
under Argon and dissolved in anhydrous CH2Cl2 (3 mL).  After cooling the solution to 0 
oC, pyridine (0.3 mL, 1.29 mmol) was added followed by benzoyl chloride (0.11 mL, 
0.774 mmol).  The resulting mixture was then slowly warmed to room temperature and 
stirred for 6 h.  The reaction was diluted with toluene (20 mL) and concentrated under 
reduced pressure on rotavap.  The residue was was purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent to 
afford 590 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 8.01-8.09 (m, 2 H, aryl), 7.57-7.67 (m, 3 H, aryl), 7.43-
7.53 (m, 4 H, aryl), 7.34-7.42 (m, 3 H, aryl), 7.2-7.33 (m, 3 H, aryl), 7.12 (d, 2 H, J = 8.6 
Hz, aryl), 6.68 (d, 2 H, J = 8.6 Hz, aryl), 5.56 (t, 1 H, J = 9.8 Hz), 5.51 (s, 1 H, -CHPh), 
4.82 (d, 1 H, J = 9.8 Hz, H-1), 4.58 (d, 1 H, J = 12.5 Hz, -CH2Ph), 4.50 (d, 1 H, J = 12.2 
Hz, -CH2Ph), 4.39 (dd, 1 H, J = 12.5, 1.2 Hz, H-6), 4.24 (d, 1 H, J = 3.1 Hz), 4.04 (dd, 1 
H, J = 12.2, 1.2 Hz, H-6), 3.77 (dd, 1 H, J = 9.8, 3.36 Hz), 3.74 (s, 3 H, OMe), 3.50 (s, 1 
H) 
 
13C NMR (125 MHz, CDCl3): δ 164.9, 159.2, 137.6, 133.6, 132.9, 131.6, 130.2, 129.8, 
129.7, 129.3, 128.9, 128.7, 128.3, 128.1, 126.6, 113.6, 101.2, 85.4, 77.7, 73.2, 70.6, 70.1, 
69.2, 69.0, 55.1. 
 
HRMS (EIMS, M+ + Na): calcd for C34H32NaO7S 607.1766, found 607.1769. 
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15. 
 
 Compound 590 (0.22 g, 0.377 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and dissolved in anhydrous methanol (11 
mL).  Catalytic amount of p-TsOH (0.006 g, 0.03 mmol) was added and the solution was 
stirred at room temperature for 5 days.  The reaction mixture was then concentrated under 
reduced pressure on rotavap and purified via gradient silica gel column chromatography 
using a mixture of ethyl acetate/hexane (1:2 to 4:1) as the eluent to afford 591 as a white 
solid. 
1H NMR (500 MHz, CDCl3): δ 7.98-8.04 (m, 2 H, aryl), 7.58-7.64 (m, 1 H, aryl), 7.4-7.5 
(m, 4 H. Aryl), 7.22-7.29 (m, 3 H, aryl), 7.02-7.09 (m, 2 H, aryl), 6.63-6.69 (m, 2 H, 
aryl), 5.47 (t, 1 H, J = 9.8 Hz, H-2), 4.77 (d, 1 H, J = 10.1 Hz, H-1), 4.58 (d, 1 H, J = 12 
Hz), 4.44 (d, 1 H, J = 12 Hz), 4.12 (dd, 1 H, J = 3.4, 0.9 Hz), 4.06 (dd, 1 H, J = 11.9, 7.0 
Hz, H-6), 3.84 (dd, 1 H, J = 11.6, 4.6 Hz, H-6), 3.72 (s, 3 H, OMe), 3.66 (dd, 1 H, J = 
9.2, 3.4 Hz), 3.61 (m, 1 H), 2.3 (bs, 2 H, 4-OH, 6-OH) 
 
13C NMR (125 MHz, CDCl3): δ 165.3, 159, 4, 133.1, 133.0, 132.2, 129.9, 129.6, 128.9, 
128.8, 128.4, 127.7, 113.8, 86.5, 78.7, 78.4, 71.1, 69.6, 66.8, 62.5, 55.2. 
 
HRMS (EIMS, M+ + Na): calcd for C34H32NaO7S 607.1766, found 607.1769. 
 
 
 
 
 
 
 
 
 409
16. 
 
 To an oven dried RB flask equipped with magnetic stir bar under Argon, the 
donor 376 (0.055 g, 0.074 mmol) and acceptor 576 (0.029 g, 0.074 mmol) were taken.  
To the flask, 4 Å MS (0.02 g, freshly dried by heat-gun under high-vacuum) was added 
followed by anhydrous CH2Cl2 (3 mL) and the flask was cooled to -20 oC for 30 min.  
Next, the activator TMSOTf (12 µL, 0.067 mmol) was added and the reaction was stiired 
at -20 oC for 1.5 h.  The reaction mixture was then slowly warmed to -10 oC and 
quenched by the addition of solid NaHCO3 (0.02 g).  The solution was then filtered 
through a celite pad and the filtrate was concentrated under reduced pressure on rotavap.  
The residue was purified via gradient silica gel column chromatography using a mixture 
of ethyl acetate/hexane (1:4 to 1:1) as the eluent to afford disaccharide 598 in 75% yield. 
1H NMR (500 MHz, CDCl3): δ 8.03-8.11 (m, 2 H, aryl), 7.95-8.02 (m, 2 H, aryl), 7.77-
7.87 (m, 4 H, aryl), 7.62-7.69 (m, 2 H, aryl), 7.45-7.58 (m, 4 H, aryl), 7.15-7.44 (m, 16 H, 
aryl), 6.0 (m, 1 H), 5.74 (d, 1 H, J = 7.0 Hz), 5.64 (d, 1 H, J = 5.8 Hz), 5.59 (d, 1 H, J = 
10.1 Hz), 5.48 (s, 1 H, -CHPh), 5.38 (s, 1 H), 5.34 (d, 1 H, J = 1.2 Hz), 4.81 (dd, 1 H, J = 
10.4, 3.4 Hz), 4.77 (dd, 1 H, J = 11.9, 4.6 Hz), 4.80 (dd, 1 H, J = 5.5, 3.4 Hz), 4.68 (dd, 1 
H, J = 11.6, 6.4 Hz), 4.33 (d, 1 H, J = 3.1 Hz), 4.30 (d, 1 H, J = 12.5 Hz), 3.85 (d, 1 H, J 
= 12.5 Hz), 3.47-3.57 (m, 2 H), 2.05 (s, 3 H, -NHCOCH3) 
 
 410
13C NMR (125 MHz, CDCl3): δ 171.9, 166.4, 165.9, 165,8, 162,8, 138.3, 133.7, 133.7, 
133.6, 133.4, 132.2, 130.2, 130.0, 129.9, 129.7, 129.6, 129.1, 129.0, 128.9, 128.9, 128.8, 
128.7, 128.7, 128.6, 128.3, 127.9, 126.5, 107.8, 100.8, 83.5, 82.9, 81.2, 77.4, 76.3, 75.6, 
70.3, 70.0, 69.6, 63.6, 52.6, 36.7, 23.9. 
 
HRMS (EIMS, M+ + Na): calcd for C55H48NNaO14S 1001.2693, found 1001.2695. 
 
17. 
 
1H NMR (500 MHz, CDCl3): δ 7.48-7.53 (m, 2 H, aryl), 7.22-7.39 (m , 7 H, aryl), 6.80-
6.96 (m, 2 H, aryl), 5.51 (d, 1 H, J = 5.5 Hz, H-1), 4.77-4.92 (m, 4 H, -CH2PMP), 4.50-
4.66 (m, 1 H), 4.25-4.33 (m, 1 H, H-5), 3.88-3.93 (m, 1 H), 3.83 (s, 6 H, OMe, OMe), 
3.78 (dd, 1 H, J = 9.6, 8.9 Hz), 3.32 (t, 1 H, J = 9.5 Hz), 1.27 (d, 3 H, J = 6.4 Hz, -CH3) 
 
13C NMR (125 MHz, CDCl3): δ 159.5, 159.4, 133.8, 133.5, 132.0, 130.0, 129.9, 129.5, 
129.1, 129.0, 127.6, 113.9, 87.0, 83.9, 81.4, 75.4, 75.0, 68.5, 64.4, 55.3, 55.2, 17.7. 
 
HRMS (EIMS, M+ + Na): calcd for C28H31N3NaO5S 544.1882, found 544.1881. 
18. 
 
 Starting from D-galactosamine hydrochloride, compound 612 was synthesized 
following the procedure described for compound 581. 
 411
1H NMR (500 MHz, CDCl3): δ 7.47-7.52 (m, 2 H, Ph), 7.17-7.26 (m, 3 H, Ph), 5.6 (d, 1 
H, J = 5.5 Hz, H-1), 4.39-4.47 (m, 1 H), 4.25 (t, 1 H, J = 6.4 Hz), 4.02 (dd, 1 H, J = 11.0, 
5.2 Hz), 3.86-3.90 (m, 1 H), 3.60-3.74 (m, 2 H, H-6) 
 
13C NMR (125 MHz, CDCl3): δ 133.7, 133.0, 129.9, 128.6, 88.1, 80.7, 75.2, 69.7, 64.5, 
62.6. 
 
HRMS (EIMS, M+ + Na): calcd for C12H15N3NaO4S 320.0681, found 320.0683. 
 
19. 
 
 Compound 612 (0.5 g, 1.68 mmol) was taken in an oven dried RB flask equipped 
with magnetic stir bar under Argon and 4 Å MS (freshly dried by heat gun under high 
vacuum).  To the flask, anhydrous CH3CN (15 mL) was added and the solution was 
cooled to 0 oC.  α,α-Dimethoxy benzaldehyde (0.51 mL, 3.36 mmol) was added followed 
by catalytic amount of CSA (0.008 g, 0.34 mmol).  The resulting solution was slowly 
warmed to room temperature and stirred for 24 h.  The reaction mixture was then 
concentrated under reduced pressure on rotavap and the residue was purified via gradient 
silica gel column chromatography using a mixture of ethyl acetate/hexane (1:4 to 2:1) as 
the eluent to afford 1-phenylthio-2-azido-4,6-benzylidine-α-D-galactopyranoside (613) as 
a white solid. 
 Compound 613 (0.2 g, 0.52 mmol) was taken in an oven dried RB flask equipped 
with magnetic stir bar under Argon and dissolved in anhydrous DMF (10 mL).  After 
cooling the solution to 0 oC, NaH (0.032g, 0.78 mmol, 60% in mineral oil) was added in 
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portion.  The reaction mixture was then slowly warmed to room temperature and stirred 
for 15 min.  Freshly distilled allyl bromide (0.07 mL, 0.78 mmol) was added at 0 oC, then 
the solution was slowly warmed to room temperature and stirred for 6 h.  The reaction 
was then quenched by addition of methanol (2 mL) at 0 oC and then diluted with water 
(10 mL).  The solution was then extracted with CH2Cl2 (3 × 20 mL) and the aqueous 
layer was further extracted with CH2Cl2 (10 mL).  The organic layers were combined, 
dried over Na2SO4 and concentrated under reduced pressure on rotavap.  The residue was 
purified via sgradient silica gel (neutralized with 0.1% NEt3) column chromatography 
using a mixture of ethyl acetate/hexane (1:4 to 1:1) as the eluent to afford 614 as a white 
solid.  Compound 614 found to be sensitive to column chromatography and also under 
decomposition when stored at 0 oC for over 3 months. 
1H NMR (500 MHz, CDCl3): δ 7.49-7.58 (m, 4 H, Ph), 7.25-7.43 (m, 6 H, Ph), 6.03 (ddd, 
1 H, J = 12.8, 8.0, 4.4 Hz -CH2–CH=CH2), 5.79 (d, 1 H, J = 5.5 Hz, H-1), 5.61 (s, 1 H, -
CHPh), 5.41 (m, 1 H, -CH2–CH=CH2), 5.28 (m, 1 H, -CH2–CH=CH2), 4.47 (dd, 1 H, J = 
10.5, 5.5 Hz), 4.40 (d, 1 H, J = 3.5 Hz), 4.20-4.31 (m, 3 H), 4.19 (s, 1 H), 4.08-4.15 (m, 1 
H), 3.82 (dd, 1 H, J = 10.5, 3.5 Hz, H-2) 
 
13C NMR (125 MHz, CDCl3): δ 137.7, 134.5, 134.0, 131.3, 129.4, 129.3, 128.5, 127.6, 
126.5, 118.1, 101.319, 87.8, 76.3, 73.1, 70.6, 69.6, 64.1, 59.5. 
 
HRMS (EIMS, M+ + Na): calcd for C22H23N3NaO4S 448.1307, found 448.1303. 
20. 
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 Compound 615 was obtained via cemoselective ring opening of benzylidine acetal 
in presence of TfOH as described previously for compound 557. 
1H NMR (500 MHz, CDCl3): δ 7.49-7.59 (m, 3 H, Ph), 7.20-7.41 (m, 12 H, Ph), 6.0 (ddd, 
1 H, J = 16.8,11.3, 5.8 Hz, -CH2–CH=CH2), 5.62 (d, 1 H , J = 5.4 Hz, H-1), 5.39 (d, 1 H, 
J = 7.4 Hz, -CH2–CH=CH2), 5.29 (d, 1 H, J = 10.4 Hz, -CH2–CH=CH2), 4.50-4.62 (m, 3 
H), 4.27 (m, 2 H), 4.20 (m, 2 H), 3.81 (dd, 1 H, J = 10.1, 5.2 Hz), 3.74 (dd, 1 H, J = 10.1, 
5.8 Hz), 3.68 (dd, 1 H, J = 10.4, 3.1 Hz, H-2), 2.72 (bs, 1 H, OH) 
 
13C NMR (125 MHz, CDCl3): δ 137.8, 133.7, 133.2, 132.4, 132.3, 128.9, 128.4, 127.7, 
127.6, 118.4, 87.4, 77.5, 73.6, 70.8, 69.7, 69.5, 66.7, 59.4. 
 
HRMS (EIMS, M+ + Na): calcd for C22H25N3NaO4S 450.1463, found 450.1467. 
 
21. 1-Phenylthio-2-azido-3,4-di-O-acetate-6-deoxy-α-D-glucopyranpside 
 
 1-Phenylthio-2-azido-6-deoxy-α-D-glucopyranpside (0.39 g, 1.39 mmol) was 
taken in an oven dried RB flask equipped with magnetic stir bar under Argon and 
dissolved in CH2Cl2 (10 mL).  After cooling the solution to 0 oC, pyridine (0.71 mL, 6.93 
mmol), Ac2O (0.71 mL, 6.93 mmol) and DMAP (0.003 g, 0.024 mmol) were added 
respectively.  The resulting mixture was warmed slowly to room temperature and stirred 
for 18 h.  The reaction was neutralized by slow addition of saturated NaHCO3 (10 mL) at 
0 oC.  The solution was then extracted with CH2Cl2 (2 × 10 mL) and aqueous layer was 
further washed with CH2Cl2 (10 mL).  The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure on rotavap.  The residue was purified 
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via gradient silica gel column chromatography using a mixture of ethyl acetate/hexane 
(1:5 to 1:2) as the eluent to afford 616 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 7.42-7.48 (m, 2 H, Ph), 7.22-7.31 (m, 3 H, Ph), 5.52 (d, 1 
H, J = 5.7 Hz, H-1), 5.26 (dd, 1 H, J = 10.5, 8.9 Hz, H-3), 4.76 (t, 1 H, J = 9.7 Hz, H-4), 
4.32-4.45 (m, 1 H, H-5), 4.0 (dd, 1 H, J = 10.5, 5.6 Hz, H-2), 2.05 (s, 3 H, -COCH3), 2.02 
(s, 3 H, -COCH3), 1.15 (d, 3 H, J = 6.1 Hz, CH3) 
 
13C NMR (125 MHz, CDCl3): δ 169.8, 169.6, 132.9, 131.9, 128.9, 127.7, 86.4, 73.7, 71.8, 
66.5, 61.8, 20.5, 16.9. 
 
HRMS (EIMS, M+ + Na): calcd for C16H19N3NaO5S 365.1045, found 365.1048. 
 
22. 2-Azido-3,4-di-O-acetate-6-deoxy-α-D-glucopyranose 
 
 Compound 616 (0.44 g, 1.20 mmol) was taken in a RB flask equipped with 
magnetic stir bar and dissolved in CH3CN (17 mL) and then water (4.2 mL) was added.  
The solution was then cooled to 0 oC and NIS (0.46 g, 2.05 mmol) was added in one 
portion.  The solution was then stirred at 0 oC until TLC showed complete conversion (1-
2 h).  The reaction was then quenched by addition of saturated Na2S2O3 (15 mL) solution 
at 0 oC.  The solution was extracted with CH2Cl2 (3 × 20 mL) and the aqueous layer was 
further washed with CH2Cl2 (10 mL).  The organic layers were combined, dried over 
Na2SO4 and concentrated under reduced pressure on rotavap.  The residue was purified 
via gradient silica gel column chromatography using a mixture of ethyl acetate/hexane 
(1:5 to 1:1) as the eluent to afford 617 as a colorless syrup. 
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1H NMR (500 MHz, CDCl3): δ 5.46 (t, 1 H, J = 9.8 Hz, H-3), 5.31 (d, 1 H, J = 3.4 Hz, H-
1), 4.96 (t, 1 H, J = 9.8 Hz, H-4), 4.75 (dt, 1 H, J = 9.5, 2.4 Hz), 4.15 (m, 1 H), 3.65 (bs, 1 
H, OH), 3.38 (dd, 1 H, J = 10.4, 3.4 Hz, H-2), 2.07 (s, 3 H, -COCH3), 2.04 (s, 3 H, -
COCH3), 1.16 (d, 3 H, J = 6.1 Hz, CH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.3, 170.2, 91.9, 73.9, 72.6, 70.4, 65.3, 20.7, 20.6, 
17.3. 
 
HRMS (EIMS, M+ + Na): calcd for C10H15N3NaO6 296.0859, found 296.0861. 
 
23. 1-Trichloroacetamidate-2-azido-3,4-di-O-acetate-6-deoxy-α-D-glucopyranoside 
 
 Compound 617 (0.026 g, 0.01 mmol) was taken in an oven dried RB flask 
equipped with magnetic stir bar under Argon and dissolved in anhydrous CH2Cl2 (3 mL).  
After cooling the solution to 0 oC, CCl3CN (0.048 mL, 0.48 mmol) and DBU (0.022 mL, 
0.14 mmol) were added respectively.  The reaction was monitored via TLC and after 4 h 
the reaction mixture was concentrated under reduced pressure on rotavap.  The residue 
was purified via gradient silica gel column (neutralized with 0.1% NEt3) chromatography 
using a mixture of ethyl acetate/hexane (1:5 to 1:1) as the eluent (after certain interval 
0.1% NEt3) to afford 618 as a colorless syrup. 
1H NMR (500 MHz, CDCl3): δ 8.79 (s, 1 H, NH), 6.51 (d, 1 H, J = 3. 7 Hz, H-1), 5.48 (t, 
1 H, J = 10.1 Hz, H-3), 4.87 (t, 1 H, J = 9.8 Hz, H-4), 4.11 (q, 1 H, J = 6.11 Hz, H-5), 
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3.72 (dd, 1 H, J = 10.7, 3.7 Hz, H-2), 2.11 (s, 3 H, -COCH3), 2.06 (s, 3 H, -COCH3), 1.21 
(d, 3 H, J = 6.1 Hz, CH3) 
 
13C NMR (125 MHz, CDCl3): δ 169.9, 169.8, 160.7, 94.2, 73.3, 70.5, 68.2, 60.9, 20.7, 
20.6, 17.3. 
 
HRMS (EIMS, M+ + Na): calcd for C12H15Cl3N4NaO6 438.9955, found 438.9952. 
 
24. 
 
 The donor 618 (0.023 g, 0.054 mmol) and acceptor 615 (0.026 g, 0.065 mmol) 
was taken in an oven dried RB flask equipped with magnetic stir bar under Argon and 4 
Å MS (0.12 g, freshly dried by heat gun under high vacuum after overnight over-drying 
at 140 oC).  To the flask, anhydrous CH2Cl2 (4.2 mL) was added and the solution was 
stirred for 30 min at -20 oC.  Next, TMSOTf (13 µL, 0.071 mmol) was added and the 
resulting mixture was monitored via TLC.  After 15 min, the reaction was quenched solid 
NaHCO3 (0.02 g) and filtered through a Buchner funnel.  The filtrate was concentrated 
under reduced pressure and the residue was purified via gradient silica gel column 
chromatography using a mixture of ethyl acetate/hexane (1:6 to 1:2) as the eluent to 
afford 620 as white solid. 
1H NMR (500 MHz, CDCl3): δ 7.44-7.51 (m, 2 H, aryl), 7.29-7.41 (m, 8 H, aryl), 5.95 
(ddd, 1 H, J = 16.8,11.3, 5.8 Hz, -CH2–CH=CH2), 5.62 (d, 1 H, J = 5.5 Hz, H-1), 5.33-
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5.43 (m, 2 H, -CH2–CH=CH2 overlap), 5.23-5.31 (m, 1 H, -CH2–CH=CH2), 4.91 (d, 1 H, 
J = 3.7 Hz, H-1′), 4.73 (t, 1 H, J = 9.8 Hz, 4.56 (d, 1 H, J = 11.9 Hz, -CH2Ph), 4.48 (d, 1 
H, J = 11.9 Hz, -CH2Ph), 4.43 (dd, 1 H, J = 9.2, 5.5 Hz), 4.36 (dd, 1 H, J = 10.4, 6.4 Hz), 
4.22-4.31 (m, 2 H), 4.11 (dd, 1 H, J = 12.4, 5.4 Hz), 3.85 (t, 1 H, J = 9.4 Hz), 3.63 (dd, 1 
H, J = 10.8, 2.9 Hz), 3.45 (dd, 1 H, J = 9.3, 5.7 Hz, H-2′), 3.25 (dd, 1 H, J = 10.7, 3.7 Hz, 
H-2), 2.07 (s, 3 H, -COCH3), 2.06 (s, 3 H, -COCH3), 1.12 (d, 1 H, J = 6.1 Hz, -CH3) 
 
13C NMR (125 MHz, CDCl3): δ 170.4, 170.1, 137.5, 134.0, 132.4, 129.3, 128.8, 128.5, 
128.9, 127.9, 118.2, 98.1, 87.8, 74.2, 73.8, 72.8, 71.5, 70.8, 69.9, 66.7, 65.8, 62.0, 59.8, 
20.9, 17.9. 
 
HRMS (EIMS, M+ + Na): calcd for C32H38N6NaO9S 705.2319, found 705.2321. 
 
25. 2,3-di-O-Benzoyl-4,6-pyruvate acetal-D-galactopyranose 
 
 Compound 621 was obtained from 588 following the procedure as described for 
the synthesis of compound 617. 
1H NMR (500 MHz, CDCl3): δ 7.96-8.49 (m, 4 H, aryl), 7.48-7.55 (m, 2 H, aryl), 7.33-
7.42 (m, 4 H, aryl), 5.61-5,73 (m, 2 H), 4.50-4.61 (m, 1 H), 4.02 (s, 1 H), 3.63 (s, 3 H, 
OMe), 3.41-3.49 (m, 1 H), 1.61 (s, 3 H, Me) 
 
13C NMR (125 MHz, CDCl3): δ 170.2, 166.2, 165.9, 133.3, 133.1, 129.8, 129.7, 128.4, 
128.3, 98.7, 91.3, 69.8, 69.1, 68.8, 68.7, 65.3, 61.4, 52.4, 25.7. 
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HRMS (EIMS, M+ + Na): calcd for C24H24NaO10 495.1267, found 495.1269. 
 
26. 
 
 Compound 622 was obtained from compound 621 following the procedure as 
described for the synthesis of compound 618. 
1H NMR (500 MHz, CDCl3): δ 8.59 (s, 1 H, NH), 8.03 (d, 2 H, J = 7.3 Hz, aryl), 7.98 (d, 
2 H, J = 7.3 Hz, aryl), 7.48-7.57 (m, 2 H, aryl), 7.41 (t, 2 H, J = 7.6 Hz, aryl), 7.37 (t, 2 
H, J = 7.6 Hz, aryl), 6.83 (d, 1 H, J = 3.4 Hz, H-1), 6.01 (dd, 1 H, J = 10.7, 3.7 Hz, H-2), 
5.71 (dd, 1 H, J = 10.7, 3.7 Hz, H-3), 4.73 (d, 1 H, J = 3.4 Hz, H-4), 4.14 (d, 1 H, J = 
11.9 Hz, H-6), 4.05 (d, 1 H, J = 11.9 Hz, H-6), 4.04 (s, 1 H), 3.68 (s, 3 H, OMe), 1.63 (s, 
3 H, Me) 
 
13C NMR (125 MHz, CDCl3): δ 169.9, 166.2, 165.6, 160.6, 133.4, 133.3, 129.8, 129.8, 
129.5, 128.9, 128.4, 128.4, 98.8, 94.5, 90.9, 69.2, 69.1, 67.1, 64.9, 64.1, 52.5, 25.6. 
 
HRMS (EIMS, M+ + Na): calcd for C26H24Cl3NNaO10 638.0363, found 638.0367. 
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27. 
 
 To an oven dried RB flask (A) equipped with magnetic stir bar under Argon, Na 
(0.115 g, 0.138 mmol, washed with dry hexane) was taken and the flask was cooled to 0 
oC.  Anhydrous methanol (5 mL) was added to the flask slowly and stirred until all Na 
was completely dissolved (1-2 h).  The solution was kept at 0 oC for immediate use.  In a 
separate oven dried flask (B) equipped with magnetic stir bar under Argon, compound 
620 (0.026 g, 0.039 mmol) was taken and dissolved in anhydrous methanol (5 mL).  
After cooling the solution (flask B) to 0 oC, freshly prepared NaOMe (flask A) was added 
slowly.  The resulting mixture was warmed slowly to room temperature and stirred until 
TLC showed complete conversion (2-4 h).  The reaction was then neutralized by slow 
addition of amberlite IR-120 (H+ resin) to pH 6.  The solution was then filter via Buchner 
funnel.  The filtrate was concentrated under reduced pressure on rotavap and purified via 
gradient silica gel column chromatography using a mixture of ethyl acetate/hexane (1:5 to 
1:1) as the eluent to afford 623 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 7.45-7.53 (m, 2 H, aryl), 7.21-7.41 (m, 8 H, aryl), 5.97 
(ddd, 1 H, J = 16.8,11.3, 5.8 Hz, -CH2–CH=CH2), 5.62 (d, 1 H, J = 5.5 Hz, H-1), 5.38 
(dd, 1 H, J = 17.4, 1.50 Hz, -CH2–CH=CH2), 5.27 (dd, 1 H, J = 10.7, 1.50 Hz, -CH2–
CH=CH2), 4.91 (d, 1 H, J = 3.7 Hz, H-1′), 4.54 (dd, 2 H, J = 17.4 , 11.4 Hz, -CH2Ph), 
4.45 (dd, 1 H, J = 8.6, 5.8 Hz), 4.28-4.35 (m, 1 H, H-6), 4.26 (d, 1 H, J = 2.7 Hz), 4.20 
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(dd, 1 H, J =10.7, 5.5 Hz), 4.17 (dd, 1 H, J = 9.5, 6.4 Hz), 4.06-4.13 (m, 1 H), 3.98 (t, 1 
H, J = 9.5 Hz), 3.88 (t, 1 H, J = 8.9 Hz), 3.64 (dd, 1 H, J = 10.7, 2.8 Hz), 3.50 (dd, 1 H, J 
= 9.5, 6.1 Hz), 3.19 (t, 1 H, J = 9.2 Hz), 3.12 (dd, 1 H, J = 10.7, 3.9 Hz), 2.88 (bs, 1 H, 3-
OH), 2.48 (bs, 1 H, 4-OH), 1.26 (d, 1 H, J = 6.1 Hz, -CH3) 
 
13C NMR (125 MHz, CDCl3): δ 137.4, 133.8, 132.5, 128.9, 128.5, 128.1, 128.0, 127.7, 
117.9, 98.3, 87.6, 77.1, 76.6, 73.5, 72.0, 71.5, 70.9, 69.8, 67.6, 66.8, 63.7, 59.9. 
 
HRMS (EIMS, M+ + Na): calcd for C28H34N6NaO7S 621.2107, found 621.2105. 
 
28. 
 
 To an oven dried flask the donor 622 (0.013 g, 0.02 mmol) was taken under 
Agron.  Freshly dried (overnight in oven at 140 oC followed by heat gun under high 
vacuum) 4 Å MS (0.011 g) was added to the flask and connected to under high vacuum 
for 1 h under Argon.  The flask was then quickly capped and anhydrous CH2Cl2 (1.5 mL) 
was added.  After cooling the solution to -20 oC, a solution of the acceptor 623 (0.01 g, 
0.017 mmol) in anhydrous CH2Cl2 was slowly via syringe followed by TMSOTf (4 µL, 
0.018 mmol).  The resulting solution was stirred for 20 min at -20 oC and then quenched 
by addition of solid NaHCO3 (0.01 g) and filtered via Buchner funnel.  The filtrate was 
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concentrated under reduced pressure on rotavap and purified via preparative TLC using a 
1:2 mixture of ethyl acetate/hexane as the eluent to afford 623 as a white solid. 
1H NMR (500 MHz, CDCl3): δ 7.96-8.08 (m, 4 H, aryl), 7.18-7.59 (m, 14 H, aryl), 5.97 
(ddd, 1 H, J = 16.8,11.3, 5.8 Hz, -CH2–CH=CH2), 5.81 (t, 1 H, J = 9.8 Hz, H-3′′), 5.57 (d, 
1 H, J = 5.5 Hz, H-1), 5.45 (dd, 1 H, J = 10.4, 3.7 Hz), 5.31-5.41 (m, 2 H), 5.21-5.30 (m, 
2 H), 4.88 (d, 1 H, J = 7.9 Hz, H-1′′), 4.56 (d, 1 H, J = 3.4 Hz), 4.41 (s, 2H, -CH2Ph), 
4.27-4.34 (m, 1 H, H-6), 4.03-4.22 (m, 10 H), 3.80 (dd, 1 H, J = 10.4, 8.5 Hz), 3.76 (s, 1 
H), 3.60-3.73 (m, 9 H), 3.42 (dd, 1 H, J = 9.2, 6.1 Hz), 3.31 (t, 1 H, J = 9.5 Hz), 3.01 (dd, 
1 H, J = 10.4, 3.7 Hz), 2.36 (t, 1 H, J = 7.6 Hz), 1.61 (s, 3 H, Me), 1.28 (d, 1 H, J = 6.1 
Hz, -CH3) 
 
13C NMR (125 MHz, CDCl3): δ 169.9, 166.1, 165.3, 137.2, 133.7, 133.5, 133.3, 133.2, 
132.9, 129.9, 129.7, 129.0, 128.6, 128.5, 128.4, 128.3, 128.0, 118.1, 101.8, 98.8, 98.4, 
87.8, 82.3, 80.5, 73.4, 72.5, 71.6, 71.1, 69.7, 68.7, 67.6, 66.8, 66.0, 64.7, 62.5, 59.8, 52.4, 
29.7, 25.5, 18.1, 14.1. 
 
HRMS (EIMS, M+ + Na): calcd for C52H56N6NaO16S 1075.3371, found 1075.3375. 
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NMR Spectra of Chapter 3 
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 682
13C NMR ((2R,4aR,6S,7R,8R,8aR)-7-hydroxy-6-methoxy-2-
phenylhexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate) 
 
 
 
 
 683
DEPT NMR ((2R,4aR,6S,7R,8R,8aR)-7-hydroxy-6-methoxy-2-
phenylhexahydropyrano[3,2-d][1,3]dioxin-8-yl acetate) 
 
 
 
 
 684
1H NMR ((2R,4aR,6S,7R,8S,8aR)-6-methoxy-2-phenylhexahydropyrano[3,2-
d][1,3]dioxine-7,8-diyl diacetate) 
 
 
 
 
 685
13C NMR ((2R,4aR,6S,7R,8S,8aR)-6-methoxy-2-phenylhexahydropyrano[3,2-
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NMR Spectra of Chapter 6 
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APPENDIX VII 
 
X-ray Crystallographic Data 
 
1. Major diastereomer of diketopiperazine (±)-12 
 
      Table 1.  Crystal data and structure refinement for BANT.  
   
   
      Identification code               bant  
   
      Empirical formula                 C27 H34 N2 O5  
   
      Formula weight                    466.56  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Triclinic,  P-1  
   
      Unit cell dimensions              a = 9.3537(3) A   alpha = 62.0420(10) 
deg.  
                                        b = 12.2519(4) A    beta = 82.9170(10) 
deg.  
                                        c = 12.3436(4) A   gamma = 88.012(2) 
deg.  
   
      Volume                            1239.52(7) A^3  
   
      Z, Calculated density             2,  1.250 Mg/m^3  
   
      Absorption coefficient            0.086 mm^-1  
   
      F(000)                            500  
   
      Crystal size                      0.40 x 0.29 x 0.19 mm  
   
      Theta range for data collection   1.88 to 30.73 deg.  
   
      Limiting indices                  -13<=h<=13, -15<=k<=17, 0<=l<=17  
   
      Reflections collected / unique    38899 / 7644 [R(int) = 0.0292]  
   
      Completeness to theta = 28.30     99.7 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9838 and 0.9664  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    7644 / 0 / 317  
   
      Goodness-of-fit on F^2            1.093  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0410, wR2 = 0.1114  
   
      R indices (all data)              R1 = 0.0503, wR2 = 0.1163  
   
      Largest diff. peak and hole       0.444 and -0.251 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for BANT.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          O(1)         8557(1)       9338(1)        -49(1)       16(1)  
          O(2)         6560(1)       7862(1)       4456(1)       18(1)  
          N(1)         7265(1)       9525(1)       2621(1)       13(1)  
          C(1)         8319(1)      10059(1)       1480(1)       13(1)  
          C(2)         8585(1)       9086(1)       1036(1)       13(1)  
          N(2)         8858(1)       7943(1)       1934(1)       13(1)  
          C(3)         8668(1)       7642(1)       3251(1)       13(1)  
          C(4)         7419(1)       8359(1)       3501(1)       13(1)  
          C(5)         6053(1)      10238(1)       2747(1)       14(1)  
          C(6)         6169(1)      10946(1)       3353(1)       19(1)  
          C(7)         5033(1)      11720(1)       3340(1)       27(1)  
          C(8)         3844(1)      11780(1)       2759(1)       28(1)  
          C(9)         3721(1)      11030(1)       2210(1)       23(1)  
          C(10)        4816(1)      10225(1)       2218(1)       16(1)  
          C(11)        7441(1)      10864(1)       4020(1)       27(1)  
          C(12)        4657(1)       9338(1)       1709(1)       21(1)  
          C(13)        7849(1)      11272(1)        469(1)       14(1)  
          C(14)        8091(1)      12342(1)        721(1)       16(1)  
          O(3)         9081(1)      12429(1)       1219(1)       21(1)  
          O(4)         7097(1)      13198(1)        272(1)       25(1)  
          C(15)        7255(2)      14324(1)        382(1)       38(1)  
          C(16)        8206(2)      15258(1)       -722(1)       50(1)  
          C(17)        8842(1)       6887(1)       1656(1)       16(1)  
          C(18)        7418(1)       6180(1)       2148(1)       15(1)  
          C(19)        6210(1)       6631(1)       1527(1)       17(1)  
          C(20)        4876(1)       6033(1)       2019(1)       19(1)  
          C(21)        4726(1)       4957(1)       3156(1)       17(1)  
          C(22)        5918(1)       4487(1)       3785(1)       19(1)  
          C(23)        7252(1)       5098(1)       3274(1)       18(1)  
          O(5)         3388(1)       4411(1)       3594(1)       23(1)  
          C(24)       10078(1)       7662(1)       3809(1)       17(1)  
          C(25)        9689(1)       7197(1)       5205(1)       21(1)  
          C(26)       11142(1)       6774(1)       3603(1)       23(1)  
          C(27)       10827(1)       8932(1)       3246(1)       21(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for BANT.  
           _____________________________________________________________  
   
            O(1)-C(2)                     1.2294(10)  
            O(2)-C(4)                     1.2385(10)  
            N(1)-C(4)                     1.3456(11)  
            N(1)-C(5)                     1.4451(12)  
            N(1)-C(1)                     1.4903(11)  
            C(1)-C(13)                    1.5198(12)  
            C(1)-C(2)                     1.5302(12)  
            C(2)-N(2)                     1.3581(11)  
            N(2)-C(3)                     1.4763(11)  
            N(2)-C(17)                    1.4874(11)  
            C(3)-C(4)                     1.5255(13)  
            C(3)-C(24)                    1.5676(13)  
            C(5)-C(6)                     1.3987(12)  
            C(5)-C(10)                    1.4011(13)  
            C(6)-C(7)                     1.3956(15)  
            C(6)-C(11)                    1.5035(15)  
            C(7)-C(8)                     1.3781(18)  
            C(8)-C(9)                     1.3874(16)  
            C(9)-C(10)                    1.3948(14)  
            C(10)-C(12)                   1.5074(13)  
            C(13)-C(14)                   1.5127(12)  
            C(14)-O(3)                    1.2069(12)  
            C(14)-O(4)                    1.3362(12)  
            O(4)-C(15)                    1.4610(13)  
            C(15)-C(16)                   1.506(2)  
            C(17)-C(18)                   1.5100(12)  
            C(18)-C(19)                   1.3939(13)  
            C(18)-C(23)                   1.3953(12)  
            C(19)-C(20)                   1.3863(13)  
            C(20)-C(21)                   1.3985(13)  
            C(21)-O(5)                    1.3629(11)  
            C(21)-C(22)                   1.3880(14)  
            C(22)-C(23)                   1.3939(13)  
            C(24)-C(27)                   1.5292(13)  
            C(24)-C(26)                   1.5366(14)  
            C(24)-C(25)                   1.5379(13)  
   
            C(4)-N(1)-C(5)              120.56(7)  
            C(4)-N(1)-C(1)              119.42(7)  
            C(5)-N(1)-C(1)              119.96(7)  
            N(1)-C(1)-C(13)             113.33(7)  
            N(1)-C(1)-C(2)              108.15(7)  
            C(13)-C(1)-C(2)             111.69(7)  
            O(1)-C(2)-N(2)              123.68(8)  
            O(1)-C(2)-C(1)              121.87(8)  
            N(2)-C(2)-C(1)              114.44(7)  
            C(2)-N(2)-C(3)              121.45(7)  
            C(2)-N(2)-C(17)             118.29(7)  
            C(3)-N(2)-C(17)             116.87(7)  
            N(2)-C(3)-C(4)              109.99(7)  
            N(2)-C(3)-C(24)             115.87(7)  
            C(4)-C(3)-C(24)             115.48(7)  
            O(2)-C(4)-N(1)              122.13(8)  
            O(2)-C(4)-C(3)              120.70(8)  
            N(1)-C(4)-C(3)              117.11(7)  
            C(6)-C(5)-C(10)             122.33(9)  
            C(6)-C(5)-N(1)              119.26(8)  
            C(10)-C(5)-N(1)             118.37(8)  
            C(7)-C(6)-C(5)              117.31(10)  
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            C(7)-C(6)-C(11)             120.73(9)  
            C(5)-C(6)-C(11)             121.94(9)  
            C(8)-C(7)-C(6)              121.32(10)  
            C(7)-C(8)-C(9)              120.47(10)  
            C(8)-C(9)-C(10)             120.31(10)  
            C(9)-C(10)-C(5)             118.03(9)  
            C(9)-C(10)-C(12)            121.13(9)  
            C(5)-C(10)-C(12)            120.81(8)  
            C(14)-C(13)-C(1)            111.72(7)  
            O(3)-C(14)-O(4)             124.74(9)  
            O(3)-C(14)-C(13)            124.35(9)  
            O(4)-C(14)-C(13)            110.85(8)  
            C(14)-O(4)-C(15)            116.69(9)  
            O(4)-C(15)-C(16)            110.09(11)  
            N(2)-C(17)-C(18)            111.33(7)  
            C(19)-C(18)-C(23)           118.09(8)  
            C(19)-C(18)-C(17)           120.85(8)  
            C(23)-C(18)-C(17)           120.95(8)  
            C(20)-C(19)-C(18)           121.11(8)  
            C(19)-C(20)-C(21)           120.02(9)  
            O(5)-C(21)-C(22)            122.83(8)  
            O(5)-C(21)-C(20)            117.39(9)  
            C(22)-C(21)-C(20)           119.78(9)  
            C(21)-C(22)-C(23)           119.43(8)  
            C(22)-C(23)-C(18)           121.56(9)  
            C(27)-C(24)-C(26)           108.12(8)  
            C(27)-C(24)-C(25)           108.61(8)  
            C(26)-C(24)-C(25)           109.17(8)  
            C(27)-C(24)-C(3)            114.55(8)  
            C(26)-C(24)-C(3)            108.12(8)  
            C(25)-C(24)-C(3)            108.18(7)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for BANT.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     18(1)      18(1)      13(1)      -7(1)       0(1)      -1(1)  
    O(2)     18(1)      16(1)      14(1)      -4(1)       4(1)      -2(1)  
    N(1)     13(1)      13(1)      12(1)      -5(1)       1(1)       0(1)  
    C(1)     12(1)      12(1)      11(1)      -4(1)       1(1)      -2(1)  
    C(2)     10(1)      13(1)      15(1)      -6(1)       1(1)      -2(1)  
    N(2)     14(1)      12(1)      13(1)      -6(1)       0(1)      -1(1)  
    C(3)     13(1)      13(1)      12(1)      -4(1)       0(1)      -1(1)  
    C(4)     13(1)      14(1)      13(1)      -6(1)      -1(1)      -2(1)  
    C(5)     16(1)      12(1)      13(1)      -5(1)       2(1)       1(1)  
    C(6)     26(1)      16(1)      15(1)      -8(1)       4(1)      -4(1)  
    C(7)     36(1)      19(1)      26(1)     -14(1)       9(1)      -1(1)  
    C(8)     26(1)      18(1)      32(1)      -8(1)       9(1)       6(1)  
    C(9)     17(1)      19(1)      24(1)      -4(1)       3(1)       2(1)  
    C(10)    15(1)      15(1)      15(1)      -5(1)       2(1)      -1(1)  
    C(11)    38(1)      27(1)      19(1)     -14(1)      -3(1)      -7(1)  
    C(12)    17(1)      24(1)      23(1)     -12(1)      -2(1)      -3(1)  
    C(13)    15(1)      12(1)      12(1)      -4(1)      -1(1)      -1(1)  
    C(14)    20(1)      12(1)      13(1)      -4(1)       1(1)       0(1)  
    O(3)     23(1)      19(1)      23(1)     -10(1)      -5(1)      -2(1)  
    O(4)     32(1)      18(1)      30(1)     -13(1)     -13(1)      10(1)  
    C(15)    54(1)      23(1)      50(1)     -24(1)     -23(1)      16(1)  
    C(16)    85(1)      16(1)      47(1)     -10(1)     -31(1)       1(1)  
    C(17)    16(1)      13(1)      19(1)      -8(1)       2(1)      -1(1)  
    C(18)    16(1)      11(1)      16(1)      -7(1)       0(1)      -1(1)  
    C(19)    22(1)      13(1)      14(1)      -3(1)      -3(1)      -2(1)  
    C(20)    18(1)      16(1)      19(1)      -4(1)      -6(1)      -1(1)  
    C(21)    16(1)      13(1)      18(1)      -6(1)      -1(1)      -2(1)  
    C(22)    21(1)      12(1)      17(1)      -2(1)      -3(1)      -2(1)  
    C(23)    18(1)      13(1)      21(1)      -4(1)      -5(1)       1(1)  
    O(5)     17(1)      17(1)      26(1)      -2(1)      -2(1)      -4(1)  
    C(24)    14(1)      17(1)      15(1)      -3(1)      -2(1)      -1(1)  
    C(25)    19(1)      23(1)      15(1)      -4(1)      -4(1)      -1(1)  
    C(26)    16(1)      25(1)      24(1)      -8(1)      -3(1)       5(1)  
    C(27)    17(1)      20(1)      20(1)      -3(1)      -5(1)      -5(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for BANT.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         9249         10222          1708          15  
          H(3)         8323          6759          3702          16  
          H(7)         5082         12216          3739          32  
          H(8)         3102         12337          2735          34  
          H(9)         2888         11066          1826          28  
          H(11A)       7548         10004          4639          32  
          H(11B)       7288         11384          4430          32  
          H(11C)       8315         11150          3426          32  
          H(12A)       3773          9510          1311          25  
          H(12B)       4606          8488          2384          25  
          H(12C)       5489          9438          1101          25  
          H(13A)       8397         11434          -333          17  
          H(13B)       6813         11204           408          17  
          H(15A)       7684         14124          1145          46  
          H(15B)       6296         14674           437          46  
          H(16A)       9176         14932          -739          59  
          H(16B)       8256         16027          -667          59  
          H(16C)       7805         15421         -1480          59  
          H(17A)       9628          6323          2032          19  
          H(17B)       9019          7200           751          19  
          H(19)        6303          7360           754          21  
          H(20)        4064          6354          1584          23  
          H(22)        5825          3756          4556          22  
          H(23)        8068          4769          3703          22  
          H(105)       3431(18)      3697(16)      4287(16)      43(4)  
          H(25A)      10565          7161          5580          25  
          H(25B)       9238          6370          5583          25  
          H(25C)       9015          7763          5342          25  
          H(26A)      11418          7081          2714          28  
          H(26B)      10683          5951          3960          28  
          H(26C)      12003          6723          4002          28  
          H(27A)      11705          8863          3631          25  
          H(27B)      10177          9508          3391          25  
          H(27C)      11080          9241          2355          25  
         ________________________________________________________________  
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         Table 6.  Torsion angles [deg] for BANT.  
         ________________________________________________________________  
   
          C(4)-N(1)-C(1)-C(13)                                168.55(7)  
          C(5)-N(1)-C(1)-C(13)                                 -8.55(11)  
          C(4)-N(1)-C(1)-C(2)                                  44.15(10)  
          C(5)-N(1)-C(1)-C(2)                                -132.95(8)  
          N(1)-C(1)-C(2)-O(1)                                 132.48(8)  
          C(13)-C(1)-C(2)-O(1)                                  7.10(12)  
          N(1)-C(1)-C(2)-N(2)                                 -47.92(10)  
          C(13)-C(1)-C(2)-N(2)                               -173.29(7)  
          O(1)-C(2)-N(2)-C(3)                                -170.84(8)  
          C(1)-C(2)-N(2)-C(3)                                   9.57(11)  
          O(1)-C(2)-N(2)-C(17)                                -12.29(13)  
          C(1)-C(2)-N(2)-C(17)                                168.12(7)  
          C(2)-N(2)-C(3)-C(4)                                  33.36(11)  
          C(17)-N(2)-C(3)-C(4)                               -125.48(8)  
          C(2)-N(2)-C(3)-C(24)                                -99.89(10)  
          C(17)-N(2)-C(3)-C(24)                               101.27(9)  
          C(5)-N(1)-C(4)-O(2)                                  -1.56(13)  
          C(1)-N(1)-C(4)-O(2)                                -178.64(8)  
          C(5)-N(1)-C(4)-C(3)                                 175.71(7)  
          C(1)-N(1)-C(4)-C(3)                                  -1.37(11)  
          N(2)-C(3)-C(4)-O(2)                                 139.48(8)  
          C(24)-C(3)-C(4)-O(2)                                -87.08(10)  
          N(2)-C(3)-C(4)-N(1)                                 -37.83(10)  
          C(24)-C(3)-C(4)-N(1)                                 95.61(9)  
          C(4)-N(1)-C(5)-C(6)                                  88.99(10)  
          C(1)-N(1)-C(5)-C(6)                                 -93.94(10)  
          C(4)-N(1)-C(5)-C(10)                                -93.16(10)  
          C(1)-N(1)-C(5)-C(10)                                 83.91(10)  
          C(10)-C(5)-C(6)-C(7)                                 -4.41(13)  
          N(1)-C(5)-C(6)-C(7)                                 173.35(8)  
          C(10)-C(5)-C(6)-C(11)                               174.17(9)  
          N(1)-C(5)-C(6)-C(11)                                 -8.07(13)  
          C(5)-C(6)-C(7)-C(8)                                   0.33(14)  
          C(11)-C(6)-C(7)-C(8)                               -178.27(9)  
          C(6)-C(7)-C(8)-C(9)                                   2.45(16)  
          C(7)-C(8)-C(9)-C(10)                                 -1.25(15)  
          C(8)-C(9)-C(10)-C(5)                                 -2.64(14)  
          C(8)-C(9)-C(10)-C(12)                               175.52(9)  
          C(6)-C(5)-C(10)-C(9)                                  5.56(13)  
          N(1)-C(5)-C(10)-C(9)                               -172.22(8)  
          C(6)-C(5)-C(10)-C(12)                              -172.60(8)  
          N(1)-C(5)-C(10)-C(12)                                 9.62(12)  
          N(1)-C(1)-C(13)-C(14)                                77.71(9)  
          C(2)-C(1)-C(13)-C(14)                              -159.83(7)  
          C(1)-C(13)-C(14)-O(3)                                34.26(12)  
          C(1)-C(13)-C(14)-O(4)                              -148.35(8)  
          O(3)-C(14)-O(4)-C(15)                                 1.17(15)  
          C(13)-C(14)-O(4)-C(15)                             -176.21(9)  
          C(14)-O(4)-C(15)-C(16)                               88.01(13)  
          C(2)-N(2)-C(17)-C(18)                               -98.12(9)  
          C(3)-N(2)-C(17)-C(18)                                61.41(10)  
          N(2)-C(17)-C(18)-C(19)                               77.96(10)  
          N(2)-C(17)-C(18)-C(23)                              -98.15(10)  
          C(23)-C(18)-C(19)-C(20)                               0.89(14)  
          C(17)-C(18)-C(19)-C(20)                            -175.33(8)  
          C(18)-C(19)-C(20)-C(21)                              -0.14(15)  
          C(19)-C(20)-C(21)-O(5)                              179.89(9)  
          C(19)-C(20)-C(21)-C(22)                              -0.40(15)  
          O(5)-C(21)-C(22)-C(23)                              179.85(9)  
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          C(20)-C(21)-C(22)-C(23)                               0.17(14)  
          C(21)-C(22)-C(23)-C(18)                               0.62(15)  
          C(19)-C(18)-C(23)-C(22)                              -1.14(14)  
          C(17)-C(18)-C(23)-C(22)                             175.08(9)  
          N(2)-C(3)-C(24)-C(27)                                64.56(11)  
          C(4)-C(3)-C(24)-C(27)                               -66.12(10)  
          N(2)-C(3)-C(24)-C(26)                               -56.05(10)  
          C(4)-C(3)-C(24)-C(26)                               173.27(7)  
          N(2)-C(3)-C(24)-C(25)                              -174.15(8)  
          C(4)-C(3)-C(24)-C(25)                                55.16(10)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
  
 
 
 
 Table 7.  Hydrogen bonds for BANT [A and deg.].  
 ____________________________________________________________________________  
   
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O5-H105        0.896    1.810   170.91    2.699    O2 [ -x+1, -y+1, -z+1 ] 
   
 
 
2. 4-hydroxybenzyl alcohol (14) from µwave reaction 
 
      Table 1.  Crystal data and structure refinement for xava.  
   
   
      Identification code               xava  
   
      Empirical formula                 C7 H8 O2  
   
      Formula weight                    124.13  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Orthorhombic,  Pna21  
   
      Unit cell dimensions              a = 9.3503(4) A   alpha = 90 deg.  
                                        b = 11.0090(5) A    beta = 90 deg.  
                                        c = 5.8847(3) A   gamma = 90 deg.  
   
      Volume                            605.76(5) A^3  
   
      Z, Calculated density             4,  1.361 Mg/m^3  
   
      Absorption coefficient            0.099 mm^-1  
   
      F(000)                            264  
   
      Crystal size                      0.10 x 0.09 x 0.09 mm  
   
      Theta range for data collection   2.86 to 28.31 deg.  
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      Limiting indices                  0<=h<=12, 0<=k<=14, -7<=l<=7  
   
      Reflections collected / unique    10949 / 1512 [R(int) = 0.0696]  
   
      Completeness to theta = 28.30     100.0 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9911 and 0.9901  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    1512 / 1 / 90  
   
      Goodness-of-fit on F^2            1.049  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0395, wR2 = 0.0733  
   
      R indices (all data)              R1 = 0.0532, wR2 = 0.0776  
   
      Absolute structure parameter      -0.9(13)  
   
      Largest diff. peak and hole       0.166 and -0.165 e.A^-3  
  
 
 
         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for xava.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          O(1)         1607(1)        222(1)       6648(2)       18(1)  
          C(1)         2542(2)        709(1)       5100(3)       15(1)  
          C(2)         2791(2)        198(2)       2991(3)       15(1)  
          C(3)         3784(2)        731(1)       1531(3)       15(1)  
          C(4)         4517(2)       1779(1)       2142(3)       15(1)  
          C(5)         4240(2)       2283(2)       4273(3)       17(1)  
          C(6)         3263(2)       1764(2)       5750(3)       16(1)  
          C(7)         5562(2)       2368(1)        556(3)       16(1)  
          O(2)         4958(1)       3494(1)       -261(2)       18(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for xava.  
           _____________________________________________________________  
   
            O(1)-C(1)                     1.3716(19)  
            C(1)-C(2)                     1.382(2)  
            C(1)-C(6)                     1.397(2)  
            C(2)-C(3)                     1.394(2)  
            C(3)-C(4)                     1.390(2)  
            C(4)-C(5)                     1.395(2)  
            C(4)-C(7)                     1.499(2)  
            C(5)-C(6)                     1.384(2)  
            C(7)-O(2)                     1.4449(19)  
   
            O(1)-C(1)-C(2)              123.03(14)  
            O(1)-C(1)-C(6)              116.79(15)  
            C(2)-C(1)-C(6)              120.18(15)  
            C(1)-C(2)-C(3)              119.64(15)  
            C(4)-C(3)-C(2)              121.23(16)  
            C(3)-C(4)-C(5)              118.11(16)  
            C(3)-C(4)-C(7)              121.33(16)  
            C(5)-C(4)-C(7)              120.56(15)  
            C(6)-C(5)-C(4)              121.49(15)  
            C(5)-C(6)-C(1)              119.34(17)  
            O(2)-C(7)-C(4)              108.88(12)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
             
  
 
 
    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for xava.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     22(1)      16(1)      17(1)      -3(1)       4(1)      -6(1)  
    C(1)     14(1)      13(1)      17(1)       3(1)       1(1)       1(1)  
    C(2)     15(1)      13(1)      16(1)       1(1)      -3(1)       0(1)  
    C(3)     16(1)      15(1)      13(1)      -1(1)       0(1)       4(1)  
    C(4)     15(1)      15(1)      15(1)       1(1)      -2(1)       4(1)  
    C(5)     17(1)      14(1)      20(1)      -1(1)      -3(1)       0(1)  
    C(6)     18(1)      17(1)      15(1)      -3(1)      -1(1)       0(1)  
    C(7)     15(1)      14(1)      20(1)       3(1)       2(1)       3(1)  
    O(2)     19(1)      14(1)      20(1)       2(1)       5(1)       3(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for xava.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(01)        1170(20)      -364(16)      6050(40)      26(6)  
          H(2)         2288          -512          2538          17  
          H(3)         3963           370            93          17  
          H(5)         4733          2998          4721          20  
          H(6)         3084          2122          7191          20  
          H(7A)        6472          2530          1361          20  
          H(7B)        5764          1821          -739          20  
          H(02)        5560(20)      3849(17)     -1170(40)      37(7)  
         ________________________________________________________________  
  
 
 
 Table 6.  Hydrogen bonds for xava [A and deg.].  
 ____________________________________________________________________________  
   
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O1-H01         0.842    1.812   173.27    2.649    O2 [ -x+1/2, y-1/2, z+1/2 ] 
 
 O2-H02         0.869    1.911   169.99    2.772    O1 [ x+1/2, -y+1/2, z-1 ] 
   
 
 
3. 2-azaspiro[4.5]deca-6,9-diene-3,8-dione (±)-16 
 
      Table 1.  Crystal data and structure refinement for BTRA.  
   
   
      Identification code               btra  
   
      Empirical formula                 C22 H32 N2 O5  
   
      Formula weight                    404.50  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Triclinic,  P-1  
   
      Unit cell dimensions              a = 9.9541(4) A   alpha = 89.230(2) 
deg.  
                                        b = 12.8285(5) A    beta = 82.115(2) 
deg.  
                                        c = 18.2464(7) A   gamma = 78.410(2) 
deg.  
   
      Volume                            2260.67(15) A^3  
   
      Z, Calculated density             4,  1.188 Mg/m^3  
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      Absorption coefficient            0.084 mm^-1  
   
      F(000)                            872  
   
      Crystal size                      0.16 x 0.16 x 0.04 mm  
   
      Theta range for data collection   1.96 to 28.37 deg.  
   
      Limiting indices                  -13<=h<=13, -17<=k<=17, 0<=l<=24  
   
      Reflections collected / unique    59289 / 11216 [R(int) = 0.0897]  
   
      Completeness to theta = 28.30     99.3 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9966 and 0.9867  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    11216 / 0 / 553  
   
      Goodness-of-fit on F^2            1.032  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0723, wR2 = 0.1522  
   
      R indices (all data)              R1 = 0.1504, wR2 = 0.1791  
   
      Largest diff. peak and hole       0.347 and -0.346 e.A^-3  
  
 
 
         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for BTRA.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          N(1)         2489(2)       3262(1)       -388(1)       24(1)  
          C(1)         2595(2)       3863(2)        190(1)       25(1)  
          C(2)         4031(2)       3514(2)        406(1)       26(1)  
          C(3)         4497(2)       2364(2)         76(1)       27(1)  
          C(4)         3779(2)       2496(2)       -635(1)       28(1)  
          O(1)         1690(2)       4584(1)        495(1)       30(1)  
          C(5)         4085(3)       3660(2)       1221(1)       29(1)  
          C(6)         4006(3)       4810(2)       1420(2)       33(1)  
          O(2)         4498(2)       5435(2)       1034(1)       50(1)  
          O(3)         3349(2)       5041(1)       2105(1)       39(1)  
          C(7)         3338(3)       6104(2)       2382(2)       47(1)  
          C(8)         2401(4)       6233(2)       3103(2)       65(1)  
          C(9)         3917(3)       1595(2)        583(1)       28(1)  
          C(10)        4690(3)        814(2)        918(2)       32(1)  
          C(11)        6193(3)        643(2)        800(2)       38(1)  
          C(12)        6813(3)       1304(2)        253(2)       41(1)  
          C(13)        6039(3)       2078(2)        -87(2)       37(1)  
          O(4)         6915(2)        -33(2)       1152(1)       52(1)  
          C(14)        1318(3)       3514(2)       -806(1)       26(1)  
          C(15)         827(3)       2524(2)      -1041(1)       33(1)  
          C(16)         409(3)       1883(2)       -367(2)       38(1)  
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          C(17)        -400(3)       2889(2)      -1467(2)       53(1)  
          C(18)        1724(3)       4175(2)      -1474(1)       36(1)  
          O(5)         2649(2)       3789(2)      -1963(1)       75(1)  
          N(2)          990(2)       5173(2)      -1462(1)       29(1)  
          C(19)        1091(3)       5952(2)      -2062(2)       38(1)  
          C(20)          96(3)       6969(2)      -1795(2)       44(1)  
          C(21)        2547(3)       6137(4)      -2218(3)      111(2)  
          C(22)         635(4)       5535(3)      -2744(2)       79(1)  
          N(3)         7549(2)      -1045(2)       4019(1)       29(1)  
          C(23)        7588(3)        -59(2)       4248(1)       28(1)  
          C(24)        8975(2)        187(2)       3953(1)       28(1)  
          C(25)        9502(2)       -615(2)       3296(1)       27(1)  
          C(26)        8872(3)      -1576(2)       3600(1)       32(1)  
          O(6)         6635(2)        552(1)       4629(1)       32(1)  
          C(27)        8952(3)       1352(2)       3785(1)       30(1)  
          C(28)        8784(3)       2026(2)       4466(2)       37(1)  
          O(7)         9059(2)       1715(2)       5063(1)       53(1)  
          O(8)         8305(2)       3038(2)       4308(1)       54(1)  
          C(29)        8220(5)       3800(3)       4897(2)       90(2)  
          C(30)        9099(7)       4413(7)       4892(4)       75(2)  
          C(30')       7559(11)      4779(5)       4679(4)       97(4)  
          C(31)        8874(3)       -199(2)       2618(1)       27(1)  
          C(32)        9596(3)         32(2)       1994(1)       29(1)  
          C(33)       11117(3)       -126(2)       1911(1)       31(1)  
          C(34)       11779(3)       -608(2)       2536(1)       30(1)  
          C(35)       11049(3)       -854(2)       3158(1)       30(1)  
          O(9)        11781(2)        136(2)       1351(1)       46(1)  
          C(36)        6446(3)      -1594(2)       4336(1)       34(1)  
          C(37)        6133(3)      -2379(2)       3790(2)       42(1)  
          C(38)        5648(3)      -1809(2)       3108(2)       48(1)  
          C(39)        5027(3)      -2947(3)       4170(2)       61(1)  
          C(40)        6862(3)      -2134(2)       5049(2)       41(1)  
          O(10)        7914(2)      -2836(2)       5015(1)       64(1)  
          N(4)         6013(2)      -1783(2)       5664(1)       36(1)  
          C(41)        6110(3)      -2211(2)       6417(2)       45(1)  
          C(42)        4973(3)      -1546(3)       6934(2)       54(1)  
          C(43)        7513(3)      -2144(4)       6642(2)       86(1)  
          C(44)        5905(4)      -3355(3)       6416(2)       78(1)  
         ________________________________________________________________  
  
 
 
           Table 3.  Bond lengths [A] and angles [deg] for BTRA.  
           _____________________________________________________________  
   
            N(1)-C(1)                     1.343(3)  
            N(1)-C(14)                    1.460(3)  
            N(1)-C(4)                     1.471(3)  
            C(1)-O(1)                     1.233(3)  
            C(1)-C(2)                     1.514(3)  
            C(2)-C(5)                     1.510(3)  
            C(2)-C(3)                     1.558(3)  
            C(3)-C(9)                     1.490(3)  
            C(3)-C(13)                    1.493(3)  
            C(3)-C(4)                     1.557(3)  
            C(5)-C(6)                     1.508(3)  
            C(6)-O(2)                     1.195(3)  
            C(6)-O(3)                     1.336(3)  
            O(3)-C(7)                     1.458(3)  
            C(7)-C(8)                     1.494(4)  
            C(9)-C(10)                    1.331(3)  
            C(10)-C(11)                   1.454(4)  
            C(11)-O(4)                    1.241(3)  
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            C(11)-C(12)                   1.456(4)  
            C(12)-C(13)                   1.332(3)  
            C(14)-C(18)                   1.530(3)  
            C(14)-C(15)                   1.535(4)  
            C(15)-C(16)                   1.527(4)  
            C(15)-C(17)                   1.529(3)  
            C(18)-O(5)                    1.221(3)  
            C(18)-N(2)                    1.340(3)  
            N(2)-C(19)                    1.479(3)  
            C(19)-C(21)                   1.504(4)  
            C(19)-C(20)                   1.512(4)  
            C(19)-C(22)                   1.521(4)  
            N(3)-C(23)                    1.346(3)  
            N(3)-C(26)                    1.469(3)  
            N(3)-C(36)                    1.471(3)  
            C(23)-O(6)                    1.238(3)  
            C(23)-C(24)                   1.504(3)  
            C(24)-C(27)                   1.518(3)  
            C(24)-C(25)                   1.554(3)  
            C(25)-C(35)                   1.494(3)  
            C(25)-C(31)                   1.506(3)  
            C(25)-C(26)                   1.556(3)  
            C(27)-C(28)                   1.494(4)  
            C(28)-O(7)                    1.202(3)  
            C(28)-O(8)                    1.332(3)  
            O(8)-C(29)                    1.445(4)  
            C(29)-C(30)                   1.289(7)  
            C(29)-C(30')                  1.377(7)  
            C(31)-C(32)                   1.324(3)  
            C(32)-C(33)                   1.474(3)  
            C(33)-O(9)                    1.221(3)  
            C(33)-C(34)                   1.462(3)  
            C(34)-C(35)                   1.331(3)  
            C(36)-C(37)                   1.530(4)  
            C(36)-C(40)                   1.534(3)  
            C(37)-C(38)                   1.523(4)  
            C(37)-C(39)                   1.524(4)  
            C(40)-O(10)                   1.231(3)  
            C(40)-N(4)                    1.333(4)  
            N(4)-C(41)                    1.481(3)  
            C(41)-C(42)                   1.497(4)  
            C(41)-C(44)                   1.521(4)  
            C(41)-C(43)                   1.528(4)  
   
            C(1)-N(1)-C(14)             121.83(19)  
            C(1)-N(1)-C(4)              112.6(2)  
            C(14)-N(1)-C(4)             124.40(19)  
            O(1)-C(1)-N(1)              126.5(2)  
            O(1)-C(1)-C(2)              125.1(2)  
            N(1)-C(1)-C(2)              108.5(2)  
            C(5)-C(2)-C(1)              113.6(2)  
            C(5)-C(2)-C(3)              117.43(19)  
            C(1)-C(2)-C(3)              102.84(19)  
            C(9)-C(3)-C(13)             112.3(2)  
            C(9)-C(3)-C(4)              110.2(2)  
            C(13)-C(3)-C(4)             112.9(2)  
            C(9)-C(3)-C(2)              110.4(2)  
            C(13)-C(3)-C(2)             110.3(2)  
            C(4)-C(3)-C(2)              100.12(17)  
            N(1)-C(4)-C(3)              102.19(18)  
            C(6)-C(5)-C(2)              111.70(19)  
            O(2)-C(6)-O(3)              123.5(2)  
            O(2)-C(6)-C(5)              125.4(3)  
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            O(3)-C(6)-C(5)              111.1(2)  
            C(6)-O(3)-C(7)              115.6(2)  
            O(3)-C(7)-C(8)              106.1(2)  
            C(10)-C(9)-C(3)             123.7(2)  
            C(9)-C(10)-C(11)            121.4(2)  
            O(4)-C(11)-C(10)            121.6(3)  
            O(4)-C(11)-C(12)            121.5(2)  
            C(10)-C(11)-C(12)           116.9(2)  
            C(13)-C(12)-C(11)           121.5(2)  
            C(12)-C(13)-C(3)            123.5(2)  
            N(1)-C(14)-C(18)            108.2(2)  
            N(1)-C(14)-C(15)            113.15(18)  
            C(18)-C(14)-C(15)           111.6(2)  
            C(16)-C(15)-C(17)           110.4(2)  
            C(16)-C(15)-C(14)           110.8(2)  
            C(17)-C(15)-C(14)           108.3(2)  
            O(5)-C(18)-N(2)             125.1(2)  
            O(5)-C(18)-C(14)            120.6(2)  
            N(2)-C(18)-C(14)            114.4(2)  
            C(18)-N(2)-C(19)            125.6(2)  
            N(2)-C(19)-C(21)            110.0(2)  
            N(2)-C(19)-C(20)            106.7(2)  
            C(21)-C(19)-C(20)           110.5(3)  
            N(2)-C(19)-C(22)            108.8(2)  
            C(21)-C(19)-C(22)           111.5(3)  
            C(20)-C(19)-C(22)           109.2(2)  
            C(23)-N(3)-C(26)            112.2(2)  
            C(23)-N(3)-C(36)            121.3(2)  
            C(26)-N(3)-C(36)            124.5(2)  
            O(6)-C(23)-N(3)             125.8(2)  
            O(6)-C(23)-C(24)            125.5(2)  
            N(3)-C(23)-C(24)            108.7(2)  
            C(23)-C(24)-C(27)           114.6(2)  
            C(23)-C(24)-C(25)           103.1(2)  
            C(27)-C(24)-C(25)           116.60(19)  
            C(35)-C(25)-C(31)           112.2(2)  
            C(35)-C(25)-C(24)           110.5(2)  
            C(31)-C(25)-C(24)           110.40(18)  
            C(35)-C(25)-C(26)           113.55(19)  
            C(31)-C(25)-C(26)           109.4(2)  
            C(24)-C(25)-C(26)           100.18(18)  
            N(3)-C(26)-C(25)            102.05(19)  
            C(28)-C(27)-C(24)           113.0(2)  
            O(7)-C(28)-O(8)             124.8(3)  
            O(7)-C(28)-C(27)            125.8(3)  
            O(8)-C(28)-C(27)            109.4(2)  
            C(28)-O(8)-C(29)            115.6(3)  
            C(30)-C(29)-C(30')           74.2(6)  
            C(30)-C(29)-O(8)            121.9(4)  
            C(30')-C(29)-O(8)           108.4(5)  
            C(32)-C(31)-C(25)           124.2(2)  
            C(31)-C(32)-C(33)           121.2(2)  
            O(9)-C(33)-C(34)            122.3(2)  
            O(9)-C(33)-C(32)            121.4(2)  
            C(34)-C(33)-C(32)           116.4(2)  
            C(35)-C(34)-C(33)           122.1(2)  
            C(34)-C(35)-C(25)           123.5(2)  
            N(3)-C(36)-C(37)            112.7(2)  
            N(3)-C(36)-C(40)            108.0(2)  
            C(37)-C(36)-C(40)           112.2(2)  
            C(38)-C(37)-C(39)           110.0(3)  
            C(38)-C(37)-C(36)           110.9(2)  
            C(39)-C(37)-C(36)           109.5(2)  
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            O(10)-C(40)-N(4)            125.8(3)  
            O(10)-C(40)-C(36)           119.3(3)  
            N(4)-C(40)-C(36)            114.9(2)  
            C(40)-N(4)-C(41)            126.3(2)  
            N(4)-C(41)-C(42)            107.5(2)  
            N(4)-C(41)-C(44)            108.5(3)  
            C(42)-C(41)-C(44)           109.7(3)  
            N(4)-C(41)-C(43)            109.8(2)  
            C(42)-C(41)-C(43)           109.9(3)  
            C(44)-C(41)-C(43)           111.4(3)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
             
 
 
    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for BTRA.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    N(1)     26(1)      20(1)      25(1)       2(1)      -1(1)      -3(1)  
    C(1)     28(1)      20(1)      25(1)       6(1)       1(1)      -7(1)  
    C(2)     23(1)      25(1)      30(1)       2(1)       2(1)      -8(1)  
    C(3)     22(1)      23(1)      35(1)       2(1)      -2(1)      -5(1)  
    C(4)     27(1)      21(1)      32(1)      -2(1)       4(1)      -2(1)  
    O(1)     33(1)      24(1)      29(1)      -2(1)       0(1)      -1(1)  
    C(5)     30(1)      27(1)      34(1)       3(1)      -4(1)     -11(1)  
    C(6)     34(2)      34(2)      35(2)       0(1)     -13(1)     -10(1)  
    O(2)     64(1)      38(1)      53(1)       0(1)       1(1)     -29(1)  
    O(3)     58(1)      31(1)      30(1)      -2(1)     -15(1)      -9(1)  
    C(7)     78(2)      26(1)      42(2)      -6(1)     -31(2)      -7(1)  
    C(8)    118(3)      38(2)      36(2)      -5(1)     -25(2)       5(2)  
    C(9)     22(1)      29(1)      35(1)       1(1)      -4(1)      -7(1)  
    C(10)    31(2)      24(1)      44(2)       5(1)      -9(1)      -9(1)  
    C(11)    30(2)      25(1)      61(2)      -2(1)     -14(1)      -3(1)  
    C(12)    20(1)      33(2)      67(2)      -3(1)      -4(1)      -3(1)  
    C(13)    24(1)      38(2)      48(2)      -2(1)       4(1)      -9(1)  
    O(4)     38(1)      38(1)      82(2)       5(1)     -25(1)      -3(1)  
    C(14)    29(1)      27(1)      19(1)       2(1)      -2(1)       2(1)  
    C(15)    35(2)      32(1)      31(1)      -2(1)     -11(1)       2(1)  
    C(16)    38(2)      37(2)      43(2)      -3(1)      -6(1)     -15(1)  
    C(17)    60(2)      43(2)      58(2)     -11(2)     -35(2)       0(2)  
    C(18)    35(2)      39(2)      28(1)       9(1)       1(1)       6(1)  
    O(5)     80(2)      66(2)      46(1)      28(1)      31(1)      34(1)  
    N(2)     26(1)      31(1)      28(1)       8(1)      -1(1)      -3(1)  
    C(19)    33(2)      39(2)      39(2)      21(1)      -1(1)      -3(1)  
    C(20)    57(2)      35(2)      41(2)      14(1)      -6(1)     -10(1)  
    C(21)    39(2)     123(4)     168(5)     110(4)      -5(2)     -19(2)  
    C(22)   143(4)      52(2)      27(2)      13(2)     -13(2)      12(2)  
    N(3)     25(1)      32(1)      29(1)       6(1)       0(1)     -10(1)  
    C(23)    28(1)      37(2)      21(1)      10(1)      -6(1)      -9(1)  
    C(24)    28(1)      34(1)      24(1)       6(1)      -4(1)      -9(1)  
    C(25)    22(1)      33(1)      26(1)       6(1)      -3(1)      -6(1)  
    C(26)    29(1)      37(2)      31(1)       9(1)      -1(1)      -8(1)  
    O(6)     29(1)      41(1)      27(1)       2(1)      -2(1)      -9(1)  
    C(27)    31(1)      36(1)      25(1)       6(1)      -4(1)     -10(1)  
    C(28)    41(2)      44(2)      31(2)       7(1)      -2(1)     -26(1)  
    O(7)     69(2)      68(1)      33(1)       9(1)     -19(1)     -34(1)  
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    O(8)     96(2)      35(1)      30(1)      -4(1)       9(1)     -27(1)  
    C(29)   168(5)      57(2)      50(2)     -23(2)      26(3)     -62(3)  
    C(30)    47(5)     101(6)      76(5)     -48(5)       8(4)     -23(4)  
    C(30')  195(10)     20(3)      48(4)       1(3)      35(5)      10(4)  
    C(31)    22(1)      30(1)      31(1)       4(1)      -6(1)      -5(1)  
    C(32)    30(1)      31(1)      27(1)       4(1)      -8(1)      -8(1)  
    C(33)    32(2)      32(1)      29(1)      -3(1)       1(1)     -12(1)  
    C(34)    22(1)      31(1)      37(2)       2(1)      -6(1)      -7(1)  
    C(35)    29(1)      29(1)      34(1)       7(1)      -9(1)      -6(1)  
    O(9)     36(1)      68(1)      35(1)      11(1)       5(1)     -20(1)  
    C(36)    30(2)      40(2)      33(2)      10(1)       0(1)     -15(1)  
    C(37)    37(2)      40(2)      50(2)       2(1)       2(1)     -16(1)  
    C(38)    49(2)      57(2)      43(2)     -10(2)      -4(2)     -22(2)  
    C(39)    60(2)      65(2)      67(2)       3(2)      -2(2)     -39(2)  
    C(40)    32(2)      47(2)      47(2)      20(1)      -5(1)     -14(1)  
    O(10)    43(1)      70(2)      66(2)      40(1)      11(1)       5(1)  
    N(4)     28(1)      48(1)      34(1)      17(1)      -5(1)     -12(1)  
    C(41)    31(2)      65(2)      40(2)      24(2)      -7(1)     -12(1)  
    C(42)    52(2)      78(2)      36(2)      21(2)     -12(2)     -18(2)  
    C(43)    43(2)     161(4)      59(2)      43(3)     -24(2)     -26(2)  
    C(44)   102(3)      64(2)      56(2)      31(2)      18(2)     -14(2)  
    _______________________________________________________________________  
  
 
 
         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for BTRA.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(2)         4636          3964           128          31  
          H(4A)        4351          2783         -1046          33  
          H(4B)        3589          1812          -795          33  
          H(5A)        3304          3403          1512          35  
          H(5B)        4957          3226          1352          35  
          H(7A)        2988          6650          2029          57  
          H(7B)        4283          6174          2456          57  
          H(8A)        1463          6188          3018          78  
          H(8B)        2386          6927          3324          78  
          H(8C)        2739          5668          3438          78  
          H(9)         2939          1666           673          34  
          H(10)        4250           358          1240          39  
          H(12)        7793          1181           136          49  
          H(13)        6492          2470          -454          44  
          H(14)         531          3967          -482          32  
          H(15)        1596          2067         -1373          40  
          H(16A)       -344          2327           -38          46  
          H(16B)       1206          1653          -101          46  
          H(16C)         97          1257          -529          46  
          H(17A)      -1134          3377         -1155          63  
          H(17B)       -755          2269         -1603          63  
          H(17C)       -100          3254         -1916          63  
          H(1N2)        250(30)      5320(20)     -1156(15)      44(9)  
          H(20A)       -846          6834         -1694          53  
          H(20B)        132          7512         -2176          53  
          H(20C)        359          7222         -1341          53  
          H(21A)       2796          6430         -1774         133  
          H(21B)       2609          6641         -2624         133  
          H(21C)       3184          5461         -2359         133  
          H(22A)       1230          4845         -2895          94  
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          H(22B)        708          6041         -3148          94  
          H(22C)       -328          5450         -2629          94  
          H(24)        9595           -19          4341          34  
          H(26A)       8725         -2025          3193          39  
          H(26B)       9469         -2019          3925          39  
          H(27A)       9826          1414          3472          36  
          H(27B)       8180          1624          3500          36  
          H(29A)       7291          4266          4933         108  
          H(29B)       8246          3395          5362         108  
          H(30A)       9167          4782          4419          90  
          H(30B)      10008          3987          4957          90  
          H(30C)       8791          4937          5297          90  
          H(30D)       7453          5300          5082         117  
          H(30E)       6645          4729          4559         117  
          H(30F)       8111          5007          4242         117  
          H(31)        7897           -97          2639          33  
          H(32)        9124           306          1592          34  
          H(34)       12760          -750          2497          36  
          H(35)       11537         -1200          3535          36  
          H(36)        5584         -1043          4473          40  
          H(37)        6997         -2920          3633          50  
          H(38A)       5426         -2323          2774          58  
          H(38B)       6385         -1479          2852          58  
          H(38C)       4822         -1258          3257          58  
          H(39A)       4176         -2424          4327          73  
          H(39B)       5354         -3323          4603          73  
          H(39C)       4839         -3460          3823          73  
          H(1N4)       5190(30)     -1300(20)      5619(15)      49(9)  
          H(42A)       5094          -806          6922          65  
          H(42B)       5005         -1816          7438          65  
          H(42C)       4077         -1581          6781          65  
          H(43A)       8247         -2639          6335         103  
          H(43B)       7524         -2334          7163         103  
          H(43C)       7670         -1417          6571         103  
          H(44A)       5000         -3372          6269          93  
          H(44B)       5950         -3646          6913          93  
          H(44C)       6635         -3782          6065          93  
         ________________________________________________________________  
 
 
 
         Table 6.  Torsion angles [deg] for BTRA.  
         ________________________________________________________________  
   
          C(14)-N(1)-C(1)-O(1)                                  9.9(3)  
          C(4)-N(1)-C(1)-O(1)                                 177.9(2)  
          C(14)-N(1)-C(1)-C(2)                               -169.56(19)  
          C(4)-N(1)-C(1)-C(2)                                  -1.6(2)  
          O(1)-C(1)-C(2)-C(5)                                  30.9(3)  
          N(1)-C(1)-C(2)-C(5)                                -149.60(19)  
          O(1)-C(1)-C(2)-C(3)                                 158.9(2)  
          N(1)-C(1)-C(2)-C(3)                                 -21.6(2)  
          C(5)-C(2)-C(3)-C(9)                                  43.5(3)  
          C(1)-C(2)-C(3)-C(9)                                 -82.0(2)  
          C(5)-C(2)-C(3)-C(13)                                -81.2(3)  
          C(1)-C(2)-C(3)-C(13)                                153.3(2)  
          C(5)-C(2)-C(3)-C(4)                                 159.6(2)  
          C(1)-C(2)-C(3)-C(4)                                  34.1(2)  
          C(1)-N(1)-C(4)-C(3)                                  24.0(2)  
          C(14)-N(1)-C(4)-C(3)                               -168.31(19)  
          C(9)-C(3)-C(4)-N(1)                                  81.5(2)  
          C(13)-C(3)-C(4)-N(1)                               -151.98(19)  
          C(2)-C(3)-C(4)-N(1)                                 -34.8(2)  
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          C(1)-C(2)-C(5)-C(6)                                 -76.2(3)  
          C(3)-C(2)-C(5)-C(6)                                 163.8(2)  
          C(2)-C(5)-C(6)-O(2)                                 -34.9(4)  
          C(2)-C(5)-C(6)-O(3)                                 147.4(2)  
          O(2)-C(6)-O(3)-C(7)                                  -3.8(4)  
          C(5)-C(6)-O(3)-C(7)                                 174.0(2)  
          C(6)-O(3)-C(7)-C(8)                                 172.6(2)  
          C(13)-C(3)-C(9)-C(10)                                 7.1(4)  
          C(4)-C(3)-C(9)-C(10)                                133.9(2)  
          C(2)-C(3)-C(9)-C(10)                               -116.4(3)  
          C(3)-C(9)-C(10)-C(11)                                -0.9(4)  
          C(9)-C(10)-C(11)-O(4)                               174.6(3)  
          C(9)-C(10)-C(11)-C(12)                               -5.1(4)  
          O(4)-C(11)-C(12)-C(13)                             -175.3(3)  
          C(10)-C(11)-C(12)-C(13)                               4.4(4)  
          C(11)-C(12)-C(13)-C(3)                                2.4(4)  
          C(9)-C(3)-C(13)-C(12)                                -7.9(4)  
          C(4)-C(3)-C(13)-C(12)                              -133.2(3)  
          C(2)-C(3)-C(13)-C(12)                               115.7(3)  
          C(1)-N(1)-C(14)-C(18)                                94.5(2)  
          C(4)-N(1)-C(14)-C(18)                               -72.1(3)  
          C(1)-N(1)-C(14)-C(15)                              -141.3(2)  
          C(4)-N(1)-C(14)-C(15)                                52.2(3)  
          N(1)-C(14)-C(15)-C(16)                               58.4(3)  
          C(18)-C(14)-C(15)-C(16)                            -179.3(2)  
          N(1)-C(14)-C(15)-C(17)                              179.6(2)  
          C(18)-C(14)-C(15)-C(17)                             -58.0(3)  
          N(1)-C(14)-C(18)-O(5)                                65.1(3)  
          C(15)-C(14)-C(18)-O(5)                              -60.0(4)  
          N(1)-C(14)-C(18)-N(2)                              -114.8(2)  
          C(15)-C(14)-C(18)-N(2)                              120.0(3)  
          O(5)-C(18)-N(2)-C(19)                                 5.2(5)  
          C(14)-C(18)-N(2)-C(19)                             -174.9(2)  
          C(18)-N(2)-C(19)-C(21)                              -58.9(4)  
          C(18)-N(2)-C(19)-C(20)                             -178.8(3)  
          C(18)-N(2)-C(19)-C(22)                               63.6(3)  
          C(26)-N(3)-C(23)-O(6)                              -177.7(2)  
          C(36)-N(3)-C(23)-O(6)                               -13.3(4)  
          C(26)-N(3)-C(23)-C(24)                                3.2(3)  
          C(36)-N(3)-C(23)-C(24)                              167.64(19)  
          O(6)-C(23)-C(24)-C(27)                              -31.0(3)  
          N(3)-C(23)-C(24)-C(27)                              148.1(2)  
          O(6)-C(23)-C(24)-C(25)                             -158.8(2)  
          N(3)-C(23)-C(24)-C(25)                               20.3(2)  
          C(23)-C(24)-C(25)-C(35)                            -153.66(18)  
          C(27)-C(24)-C(25)-C(35)                              79.9(3)  
          C(23)-C(24)-C(25)-C(31)                              81.7(2)  
          C(27)-C(24)-C(25)-C(31)                             -44.8(3)  
          C(23)-C(24)-C(25)-C(26)                             -33.6(2)  
          C(27)-C(24)-C(25)-C(26)                            -160.1(2)  
          C(23)-N(3)-C(26)-C(25)                              -25.2(2)  
          C(36)-N(3)-C(26)-C(25)                              170.9(2)  
          C(35)-C(25)-C(26)-N(3)                              152.8(2)  
          C(31)-C(25)-C(26)-N(3)                              -81.0(2)  
          C(24)-C(25)-C(26)-N(3)                               35.0(2)  
          C(23)-C(24)-C(27)-C(28)                              74.1(3)  
          C(25)-C(24)-C(27)-C(28)                            -165.4(2)  
          C(24)-C(27)-C(28)-O(7)                               22.4(4)  
          C(24)-C(27)-C(28)-O(8)                             -158.9(2)  
          O(7)-C(28)-O(8)-C(29)                                 4.6(4)  
          C(27)-C(28)-O(8)-C(29)                             -174.1(3)  
          C(28)-O(8)-C(29)-C(30)                              104.6(6)  
          C(28)-O(8)-C(29)-C(30')                            -172.9(5)  
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          C(35)-C(25)-C(31)-C(32)                              -6.5(3)  
          C(24)-C(25)-C(31)-C(32)                             117.2(3)  
          C(26)-C(25)-C(31)-C(32)                            -133.5(3)  
          C(25)-C(31)-C(32)-C(33)                               1.3(4)  
          C(31)-C(32)-C(33)-O(9)                             -176.3(3)  
          C(31)-C(32)-C(33)-C(34)                               3.5(4)  
          O(9)-C(33)-C(34)-C(35)                              177.2(3)  
          C(32)-C(33)-C(34)-C(35)                              -2.5(4)  
          C(33)-C(34)-C(35)-C(25)                              -3.3(4)  
          C(31)-C(25)-C(35)-C(34)                               7.5(3)  
          C(24)-C(25)-C(35)-C(34)                            -116.1(3)  
          C(26)-C(25)-C(35)-C(34)                             132.2(3)  
          C(23)-N(3)-C(36)-C(37)                              151.0(2)  
          C(26)-N(3)-C(36)-C(37)                              -46.4(3)  
          C(23)-N(3)-C(36)-C(40)                              -84.4(3)  
          C(26)-N(3)-C(36)-C(40)                               78.1(3)  
          N(3)-C(36)-C(37)-C(38)                              -60.8(3)  
          C(40)-C(36)-C(37)-C(38)                             176.9(2)  
          N(3)-C(36)-C(37)-C(39)                              177.6(2)  
          C(40)-C(36)-C(37)-C(39)                              55.4(3)  
          N(3)-C(36)-C(40)-O(10)                              -62.6(3)  
          C(37)-C(36)-C(40)-O(10)                              62.3(3)  
          N(3)-C(36)-C(40)-N(4)                               117.5(3)  
          C(37)-C(36)-C(40)-N(4)                             -117.6(3)  
          O(10)-C(40)-N(4)-C(41)                               -4.4(5)  
          C(36)-C(40)-N(4)-C(41)                              175.4(2)  
          C(40)-N(4)-C(41)-C(42)                              178.0(3)  
          C(40)-N(4)-C(41)-C(44)                              -63.4(4)  
          C(40)-N(4)-C(41)-C(43)                               58.5(4)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
  
 
 
 Table 7.  Hydrogen bonds for BTRA [A and deg.].  
 ____________________________________________________________________________  
   
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N2-H1N2        0.853    2.113   168.19    2.953    O1 [ -x, -y+1, -z ] 
 
 N4-H1N4        0.933    1.986   166.63    2.902    O6 [ -x+1, -y, -z+1 ] 
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4. Compound (±)-251 
 
      Table 1.  Crystal data and structure refinement for DAMI.  
   
   
      Identification code               dami  
   
      Empirical formula                 C32 H39 N2 O5  
   
      Formula weight                    531.65  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Triclinic,  P-1  
   
      Unit cell dimensions              a = 10.138(3) A   alpha = 79.039(9) 
deg.  
                                        b = 11.923(4) A    beta = 68.399(9) 
deg.  
                                        c = 13.076(4) A   gamma = 68.566(10) 
deg.  
   
      Volume                            1365.1(7) A^3  
   
      Z, Calculated density             2,  1.293 Mg/m^3  
   
      Absorption coefficient            0.087 mm^-1  
   
      F(000)                            570  
   
      Crystal size                      0.40 x 0.20 x 0.06 mm  
   
      Theta range for data collection   1.68 to 28.46 deg.  
   
      Limiting indices                  -12<=h<=13, -15<=k<=15, 0<=l<=17  
   
      Reflections collected / unique    13505 / 6540 [R(int) = 0.0541]  
   
      Completeness to theta = 28.30     95.3 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9948 and 0.9660  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    6540 / 0 / 329  
   
      Goodness-of-fit on F^2            0.972  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0640, wR2 = 0.1446  
   
      R indices (all data)              R1 = 0.1272, wR2 = 0.1671  
   
      Largest diff. peak and hole       0.245 and -0.251 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for DAMI.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          O(1)         9137(2)       7026(2)        401(1)       34(1)  
          O(2)        10596(2)       7149(2)       3600(1)       35(1)  
          O(3)         5760(2)       4162(2)       5951(1)       36(1)  
          N(1)        10202(2)       6227(2)       1767(2)       27(1)  
          C(1)         9046(3)       6682(2)       1360(2)       28(1)  
          C(2)         7614(2)       6775(2)       2329(2)       25(1)  
          C(3)         8129(2)       5844(2)       3211(2)       24(1)  
          C(4)         9739(2)       5860(2)       2938(2)       24(1)  
          C(5)         9576(3)       6798(2)       3652(2)       28(1)  
          N(2)         8138(2)       7156(2)       4350(2)       26(1)  
          C(6)         7307(2)       6372(2)       4360(2)       27(1)  
          C(7)         7341(3)       5396(2)       5303(2)       28(1)  
          C(8)         6721(3)       4483(2)       5193(2)       29(1)  
          C(9)         7393(2)       3953(2)       4101(2)       26(1)  
          C(10)        7384(3)       2823(2)       4039(2)       31(1)  
          C(11)        8091(3)       2261(2)       3064(2)       33(1)  
          C(12)        8791(2)       2877(2)       2128(2)       29(1)  
          C(13)        8778(2)       4023(2)       2172(2)       27(1)  
          C(14)        8091(2)       4598(2)       3164(2)       24(1)  
          C(15)       11721(3)       6245(3)       1125(2)       35(1)  
          C(16)       12896(3)       5065(2)       1214(2)       30(1)  
          C(17)       13992(3)       5015(3)       1632(2)       40(1)  
          C(18)       15110(3)       3967(3)       1689(3)       56(1)  
          C(19)       15173(3)       2952(3)       1323(2)       59(1)  
          C(20)       14083(3)       2960(3)        901(2)       50(1)  
          C(21)       12943(3)       4027(3)        850(2)       37(1)  
          C(22)        6300(2)       6805(2)       2025(2)       29(1)  
          C(23)        4900(3)       7828(2)       2526(2)       29(1)  
          O(4)         4744(2)       8450(2)       3221(2)       40(1)  
          O(5)         3844(2)       7960(2)       2098(1)       34(1)  
          C(24)        2451(3)       8955(3)       2470(3)       50(1)  
          C(25)        2627(4)      10102(3)       1840(4)       72(1)  
          C(26)        7574(3)       8092(2)       5168(2)       31(1)  
          C(27)        5869(3)       8429(2)       5676(2)       34(1)  
          C(28)        8303(3)       7590(3)       6062(2)       40(1)  
          C(29)        7940(3)       9221(2)       4565(2)       38(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for DAMI.  
           _____________________________________________________________  
   
            O(1)-C(1)                     1.223(3)  
            O(2)-C(5)                     1.225(3)  
            O(3)-C(8)                     1.223(3)  
            N(1)-C(1)                     1.354(3)  
            N(1)-C(4)                     1.457(3)  
            N(1)-C(15)                    1.463(3)  
            C(1)-C(2)                     1.518(3)  
            C(2)-C(22)                    1.511(3)  
            C(2)-C(3)                     1.539(3)  
            C(3)-C(14)                    1.514(3)  
            C(3)-C(4)                     1.544(3)  
            C(3)-C(6)                     1.550(3)  
            C(4)-C(5)                     1.516(3)  
            C(5)-N(2)                     1.361(3)  
            N(2)-C(6)                     1.465(3)  
            N(2)-C(26)                    1.501(3)  
            C(6)-C(7)                     1.528(3)  
            C(7)-C(8)                     1.492(3)  
            C(8)-C(9)                     1.489(3)  
            C(9)-C(10)                    1.369(3)  
            C(9)-C(14)                    1.412(3)  
            C(10)-C(11)                   1.374(3)  
            C(11)-C(12)                   1.393(3)  
            C(12)-C(13)                   1.374(3)  
            C(13)-C(14)                   1.400(3)  
            C(15)-C(16)                   1.492(4)  
            C(16)-C(21)                   1.387(4)  
            C(16)-C(17)                   1.386(3)  
            C(17)-C(18)                   1.358(4)  
            C(18)-C(19)                   1.356(5)  
            C(19)-C(20)                   1.403(4)  
            C(20)-C(21)                   1.382(4)  
            C(22)-C(23)                   1.512(3)  
            C(23)-O(4)                    1.211(3)  
            C(23)-O(5)                    1.331(3)  
            O(5)-C(24)                    1.458(3)  
            C(24)-C(25)                   1.491(5)  
            C(26)-C(29)                   1.523(4)  
            C(26)-C(28)                   1.523(4)  
            C(26)-C(27)                   1.529(3)  
   
            C(1)-N(1)-C(4)              113.10(18)  
            C(1)-N(1)-C(15)             123.0(2)  
            C(4)-N(1)-C(15)             123.5(2)  
            O(1)-C(1)-N(1)              126.1(2)  
            O(1)-C(1)-C(2)              126.5(2)  
            N(1)-C(1)-C(2)              107.3(2)  
            C(22)-C(2)-C(1)             114.6(2)  
            C(22)-C(2)-C(3)             120.97(19)  
            C(1)-C(2)-C(3)              104.25(19)  
            C(14)-C(3)-C(2)             114.04(19)  
            C(14)-C(3)-C(4)             112.28(19)  
            C(2)-C(3)-C(4)              101.29(18)  
            C(14)-C(3)-C(6)             114.88(19)  
            C(2)-C(3)-C(6)              109.9(2)  
            C(4)-C(3)-C(6)              103.04(18)  
            N(1)-C(4)-C(5)              112.51(19)  
            N(1)-C(4)-C(3)              104.60(18)  
            C(5)-C(4)-C(3)              104.68(18)  
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            O(2)-C(5)-N(2)              126.9(2)  
            O(2)-C(5)-C(4)              124.4(2)  
            N(2)-C(5)-C(4)              108.72(19)  
            C(5)-N(2)-C(6)              112.30(19)  
            C(5)-N(2)-C(26)             123.14(18)  
            C(6)-N(2)-C(26)             123.56(17)  
            N(2)-C(6)-C(7)              111.45(19)  
            N(2)-C(6)-C(3)              103.01(17)  
            C(7)-C(6)-C(3)              112.6(2)  
            C(8)-C(7)-C(6)              110.9(2)  
            O(3)-C(8)-C(9)              121.9(2)  
            O(3)-C(8)-C(7)              122.9(2)  
            C(9)-C(8)-C(7)              115.2(2)  
            C(10)-C(9)-C(14)            121.5(2)  
            C(10)-C(9)-C(8)             119.0(2)  
            C(14)-C(9)-C(8)             119.4(2)  
            C(9)-C(10)-C(11)            121.0(2)  
            C(10)-C(11)-C(12)           118.6(2)  
            C(13)-C(12)-C(11)           121.0(2)  
            C(12)-C(13)-C(14)           121.1(2)  
            C(13)-C(14)-C(9)            116.8(2)  
            C(13)-C(14)-C(3)            120.6(2)  
            C(9)-C(14)-C(3)             122.6(2)  
            N(1)-C(15)-C(16)            112.9(2)  
            C(21)-C(16)-C(17)           119.4(3)  
            C(21)-C(16)-C(15)           121.2(2)  
            C(17)-C(16)-C(15)           119.4(2)  
            C(18)-C(17)-C(16)           121.1(3)  
            C(19)-C(18)-C(17)           119.8(3)  
            C(18)-C(19)-C(20)           121.0(3)  
            C(21)-C(20)-C(19)           118.9(3)  
            C(20)-C(21)-C(16)           119.8(3)  
            C(23)-C(22)-C(2)            112.1(2)  
            O(4)-C(23)-O(5)             123.9(2)  
            O(4)-C(23)-C(22)            125.4(2)  
            O(5)-C(23)-C(22)            110.7(2)  
            C(23)-O(5)-C(24)            116.6(2)  
            O(5)-C(24)-C(25)            109.9(3)  
            N(2)-C(26)-C(29)            108.73(19)  
            N(2)-C(26)-C(28)            109.4(2)  
            C(29)-C(26)-C(28)           111.1(2)  
            N(2)-C(26)-C(27)            109.40(18)  
            C(29)-C(26)-C(27)           108.0(2)  
            C(28)-C(26)-C(27)           110.2(2)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for DAMI.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     33(1)      46(1)      17(1)       4(1)      -1(1)     -17(1)  
    O(2)     26(1)      40(1)      41(1)      -9(1)      -6(1)     -13(1)  
    O(3)     33(1)      44(1)      24(1)       5(1)       1(1)     -18(1)  
    N(1)     20(1)      33(1)      22(1)      -2(1)       3(1)     -11(1)  
    C(1)     31(1)      22(1)      25(1)      -2(1)      -1(1)     -10(1)  
    C(2)     23(1)      27(1)      20(1)       0(1)      -2(1)     -10(1)  
    C(3)     17(1)      30(1)      24(1)      -2(1)      -3(1)      -9(1)  
    C(4)     21(1)      25(1)      22(1)       0(1)      -1(1)     -10(1)  
    C(5)     26(1)      30(2)      25(1)       1(1)      -7(1)      -8(1)  
    N(2)     24(1)      31(1)      23(1)      -6(1)      -4(1)     -10(1)  
    C(6)     23(1)      35(2)      20(1)      -3(1)      -3(1)      -9(1)  
    C(7)     31(1)      32(2)      17(1)      -2(1)      -5(1)      -8(1)  
    C(8)     24(1)      32(2)      23(1)       6(1)      -6(1)      -5(1)  
    C(9)     21(1)      28(2)      25(1)      -3(1)      -2(1)      -7(1)  
    C(10)    26(1)      36(2)      30(1)       5(1)      -7(1)     -14(1)  
    C(11)    32(1)      31(2)      33(2)      -1(1)      -7(1)     -11(1)  
    C(12)    25(1)      32(2)      28(1)      -4(1)      -3(1)      -9(1)  
    C(13)    26(1)      27(2)      24(1)      -2(1)      -4(1)      -8(1)  
    C(14)    19(1)      29(1)      22(1)       1(1)      -4(1)      -8(1)  
    C(15)    26(1)      47(2)      28(1)      -8(1)       4(1)     -19(1)  
    C(16)    25(1)      45(2)      16(1)      -4(1)       2(1)     -14(1)  
    C(17)    26(1)      67(2)      29(2)      -2(1)      -3(1)     -24(2)  
    C(18)    31(2)      88(3)      43(2)      -1(2)     -10(1)     -17(2)  
    C(19)    32(2)      76(3)      33(2)       8(2)      -1(1)       7(2)  
    C(20)    49(2)      46(2)      34(2)      -8(1)       2(1)      -7(2)  
    C(21)    32(1)      45(2)      29(2)      -8(1)      -6(1)      -7(1)  
    C(22)    27(1)      32(2)      24(1)      -2(1)      -5(1)      -8(1)  
    C(23)    28(1)      32(2)      27(1)      -2(1)      -5(1)     -13(1)  
    O(4)     37(1)      40(1)      41(1)     -16(1)      -9(1)      -6(1)  
    O(5)     26(1)      33(1)      43(1)      -8(1)     -11(1)      -7(1)  
    C(24)    29(1)      46(2)      75(2)     -22(2)     -17(1)      -3(1)  
    C(25)    64(2)      36(2)     132(4)     -12(2)     -56(2)      -5(2)  
    C(26)    32(1)      35(2)      26(1)      -7(1)      -7(1)      -9(1)  
    C(27)    33(1)      30(2)      31(2)      -9(1)      -6(1)      -2(1)  
    C(28)    37(1)      47(2)      33(2)     -15(1)     -10(1)      -5(1)  
    C(29)    37(1)      35(2)      38(2)     -10(1)      -2(1)     -13(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for DAMI.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(2)         7316          7580          2619          30  
          H(4)        10422          5049          3102          29  
          H(6)         6246          6866          4426          32  
          H(7A)        8387          4991          5299          34  
          H(7B)        6744          5772          6015          34  
          H(10)        6881          2421          4679          37  
          H(11)        8102          1469          3030          39  
          H(12)        9284          2498          1449          35  
          H(13)        9242          4433          1519          32  
          H(15A)      11913          6880          1384          42  
          H(15B)      11793          6456           341          42  
          H(17)       13959          5725          1882          48  
          H(18)       15847          3946          1984          67  
          H(19)       15967          2225          1354          70  
          H(20)       14127          2243           654          59  
          H(21)       12195          4051           566          44  
          H(22A)       6561          6895          1213          35  
          H(22B)       6099          6029          2282          35  
          H(24A)       2189          9035          3267          59  
          H(24B)       1628          8786          2360          59  
          H(25A)       3393         10296          1993          87  
          H(25B)       1670         10756          2063          87  
          H(25C)       2934         10006          1049          87  
          H(27A)       5492          9080          6172          41  
          H(27B)       5607          7722          6093          41  
          H(27C)       5417          8701          5089          41  
          H(28A)       9396          7321          5722          48  
          H(28B)       7983          6906          6477          48  
          H(28C)       7998          8222          6564          48  
          H(29A)       7468          9872          5071          46  
          H(29B)       7560          9470          3940          46  
          H(29C)       9029          9048          4295          46  
         ________________________________________________________________  
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         Table 6.  Torsion angles [deg] for DAMI.  
         ________________________________________________________________  
   
          C(4)-N(1)-C(1)-O(1)                                -178.1(2)  
          C(15)-N(1)-C(1)-O(1)                                  9.1(4)  
          C(4)-N(1)-C(1)-C(2)                                   6.2(3)  
          C(15)-N(1)-C(1)-C(2)                               -166.7(2)  
          O(1)-C(1)-C(2)-C(22)                                 26.3(4)  
          N(1)-C(1)-C(2)-C(22)                               -157.9(2)  
          O(1)-C(1)-C(2)-C(3)                                 160.7(2)  
          N(1)-C(1)-C(2)-C(3)                                 -23.5(2)  
          C(22)-C(2)-C(3)-C(14)                                40.0(3)  
          C(1)-C(2)-C(3)-C(14)                                -90.7(2)  
          C(22)-C(2)-C(3)-C(4)                                160.8(2)  
          C(1)-C(2)-C(3)-C(4)                                  30.1(2)  
          C(22)-C(2)-C(3)-C(6)                                -90.7(2)  
          C(1)-C(2)-C(3)-C(6)                                 138.58(19)  
          C(1)-N(1)-C(4)-C(5)                                 -99.4(2)  
          C(15)-N(1)-C(4)-C(5)                                 73.4(3)  
          C(1)-N(1)-C(4)-C(3)                                  13.7(3)  
          C(15)-N(1)-C(4)-C(3)                               -173.5(2)  
          C(14)-C(3)-C(4)-N(1)                                 95.4(2)  
          C(2)-C(3)-C(4)-N(1)                                 -26.7(2)  
          C(6)-C(3)-C(4)-N(1)                                -140.46(19)  
          C(14)-C(3)-C(4)-C(5)                               -146.1(2)  
          C(2)-C(3)-C(4)-C(5)                                  91.8(2)  
          C(6)-C(3)-C(4)-C(5)                                 -21.9(2)  
          N(1)-C(4)-C(5)-O(2)                                 -60.4(3)  
          C(3)-C(4)-C(5)-O(2)                                -173.4(2)  
          N(1)-C(4)-C(5)-N(2)                                 120.4(2)  
          C(3)-C(4)-C(5)-N(2)                                   7.4(3)  
          O(2)-C(5)-N(2)-C(6)                                -167.3(2)  
          C(4)-C(5)-N(2)-C(6)                                  11.8(3)  
          O(2)-C(5)-N(2)-C(26)                                  1.6(4)  
          C(4)-C(5)-N(2)-C(26)                               -179.3(2)  
          C(5)-N(2)-C(6)-C(7)                                  95.2(2)  
          C(26)-N(2)-C(6)-C(7)                                -73.7(3)  
          C(5)-N(2)-C(6)-C(3)                                 -25.7(3)  
          C(26)-N(2)-C(6)-C(3)                                165.4(2)  
          C(14)-C(3)-C(6)-N(2)                                150.54(19)  
          C(2)-C(3)-C(6)-N(2)                                 -79.2(2)  
          C(4)-C(3)-C(6)-N(2)                                  28.1(2)  
          C(14)-C(3)-C(6)-C(7)                                 30.4(3)  
          C(2)-C(3)-C(6)-C(7)                                 160.63(18)  
          C(4)-C(3)-C(6)-C(7)                                 -92.0(2)  
          N(2)-C(6)-C(7)-C(8)                                -170.37(18)  
          C(3)-C(6)-C(7)-C(8)                                 -55.2(3)  
          C(6)-C(7)-C(8)-O(3)                                -130.0(2)  
          C(6)-C(7)-C(8)-C(9)                                  51.9(3)  
          O(3)-C(8)-C(9)-C(10)                                -24.4(4)  
          C(7)-C(8)-C(9)-C(10)                                153.7(2)  
          O(3)-C(8)-C(9)-C(14)                                158.8(2)  
          C(7)-C(8)-C(9)-C(14)                                -23.1(3)  
          C(14)-C(9)-C(10)-C(11)                                1.7(4)  
          C(8)-C(9)-C(10)-C(11)                              -175.0(2)  
          C(9)-C(10)-C(11)-C(12)                               -1.5(4)  
          C(10)-C(11)-C(12)-C(13)                               0.0(4)  
          C(11)-C(12)-C(13)-C(14)                               1.5(4)  
          C(12)-C(13)-C(14)-C(9)                               -1.3(3)  
          C(12)-C(13)-C(14)-C(3)                              177.9(2)  
          C(10)-C(9)-C(14)-C(13)                               -0.3(3)  
          C(8)-C(9)-C(14)-C(13)                               176.4(2)  
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          C(10)-C(9)-C(14)-C(3)                              -179.5(2)  
          C(8)-C(9)-C(14)-C(3)                                 -2.8(3)  
          C(2)-C(3)-C(14)-C(13)                                51.1(3)  
          C(4)-C(3)-C(14)-C(13)                               -63.4(3)  
          C(6)-C(3)-C(14)-C(13)                               179.3(2)  
          C(2)-C(3)-C(14)-C(9)                               -129.7(2)  
          C(4)-C(3)-C(14)-C(9)                                115.8(2)  
          C(6)-C(3)-C(14)-C(9)                                 -1.5(3)  
          C(1)-N(1)-C(15)-C(16)                              -134.0(2)  
          C(4)-N(1)-C(15)-C(16)                                53.9(3)  
          N(1)-C(15)-C(16)-C(21)                               62.2(3)  
          N(1)-C(15)-C(16)-C(17)                             -120.2(2)  
          C(21)-C(16)-C(17)-C(18)                               0.0(4)  
          C(15)-C(16)-C(17)-C(18)                            -177.6(2)  
          C(16)-C(17)-C(18)-C(19)                               0.6(4)  
          C(17)-C(18)-C(19)-C(20)                              -1.0(5)  
          C(18)-C(19)-C(20)-C(21)                               0.7(4)  
          C(19)-C(20)-C(21)-C(16)                               0.0(4)  
          C(17)-C(16)-C(21)-C(20)                              -0.3(4)  
          C(15)-C(16)-C(21)-C(20)                             177.3(2)  
          C(1)-C(2)-C(22)-C(23)                              -130.5(2)  
          C(3)-C(2)-C(22)-C(23)                               103.3(3)  
          C(2)-C(22)-C(23)-O(4)                               -10.6(4)  
          C(2)-C(22)-C(23)-O(5)                               169.34(19)  
          O(4)-C(23)-O(5)-C(24)                                 2.7(4)  
          C(22)-C(23)-O(5)-C(24)                             -177.2(2)  
          C(23)-O(5)-C(24)-C(25)                               82.3(3)  
          C(5)-N(2)-C(26)-C(29)                                52.9(3)  
          C(6)-N(2)-C(26)-C(29)                              -139.5(2)  
          C(5)-N(2)-C(26)-C(28)                               -68.6(3)  
          C(6)-N(2)-C(26)-C(28)                                99.0(3)  
          C(5)-N(2)-C(26)-C(27)                               170.5(2)  
          C(6)-N(2)-C(26)-C(27)                               -21.8(3)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
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5. Compound (±)-252 
 
      Table 1.  Crystal data and structure refinement for SANA.  
   
   
      Identification code               sana  
   
      Empirical formula                 C29 H32 N2 O5  
   
      Formula weight                    488.57  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Triclinic,  P-1  
   
      Unit cell dimensions              a = 6.8322(9) A   alpha = 98.068(8) 
deg.  
                                        b = 12.7786(17) A    beta = 95.054(8) 
deg.  
                                        c = 14.539(2) A   gamma = 95.450(9) 
deg.  
   
      Volume                            1244.4(3) A^3  
   
      Z, Calculated density             2,  1.304 Mg/m^3  
   
      Absorption coefficient            0.089 mm^-1  
   
      F(000)                            520  
   
      Crystal size                      0.26 x 0.13 x 0.07 mm  
   
      Theta range for data collection   1.99 to 28.40 deg.  
   
      Limiting indices                  -9<=h<=9, -17<=k<=16, 0<=l<=19  
   
      Reflections collected / unique    19072 / 6149 [R(int) = 0.0504]  
   
      Completeness to theta = 28.30     99.1 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9938 and 0.9772  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    6149 / 0 / 333  
   
      Goodness-of-fit on F^2            1.013  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0498, wR2 = 0.1077  
   
      R indices (all data)              R1 = 0.0869, wR2 = 0.1199  
   
      Largest diff. peak and hole       0.285 and -0.229 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for SANA.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)        -2213(2)      10298(1)       8182(1)       17(1)  
          C(2)        -1951(2)      10677(1)       9140(1)       21(1)  
          C(3)        -2452(2)      10023(1)       9783(1)       25(1)  
          C(4)        -3184(2)       8972(1)       9497(1)       26(1)  
          C(5)        -3431(2)       8582(1)       8560(1)       27(1)  
          C(6)        -2974(2)       9236(1)       7896(1)       20(1)  
          C(7)        -3428(2)       8786(1)       6897(1)       24(1)  
          O(1)        -3958(2)       7838(1)       6641(1)       36(1)  
          C(8)        -3284(2)       9541(1)       6233(1)       22(1)  
          C(9)        -2572(2)      10552(1)       6495(1)       20(1)  
          C(10)       -1686(2)      11018(1)       7466(1)       17(1)  
          C(11)         609(2)      11232(1)       7429(1)       17(1)  
          C(12)        1245(2)      12194(1)       8160(1)       17(1)  
          N(1)         -356(2)      12696(1)       8330(1)       17(1)  
          C(13)       -2204(2)      12169(1)       7812(1)       17(1)  
          C(14)        1804(2)      10297(1)       7481(1)       22(1)  
          C(15)        1738(2)       9634(1)       6532(1)       21(1)  
          O(2)         2052(2)      10000(1)       5833(1)       27(1)  
          O(3)         1287(2)       8601(1)       6558(1)       24(1)  
          C(16)        1145(3)       7914(1)       5658(1)       26(1)  
          C(17)         636(3)       6800(1)       5830(1)       34(1)  
          O(4)         2949(2)      12501(1)       8511(1)       21(1)  
          C(18)        -264(2)      13740(1)       8898(1)       21(1)  
          C(19)       -1054(2)      13660(1)       9828(1)       19(1)  
          C(20)       -2960(2)      13868(1)       9981(1)       24(1)  
          C(21)       -3681(3)      13740(1)      10824(1)       29(1)  
          C(22)       -2505(3)      13398(1)      11519(1)       31(1)  
          C(23)        -601(3)      13182(1)      11371(1)       29(1)  
          C(24)         116(3)      13316(1)      10530(1)       25(1)  
          C(25)       -2767(2)      12822(1)       7045(1)       17(1)  
          O(5)        -1629(2)      12980(1)       6455(1)       23(1)  
          N(2)        -4493(2)      13228(1)       7114(1)       18(1)  
          C(26)       -5234(2)      14016(1)       6554(1)       20(1)  
          C(27)       -5471(3)      13568(2)       5520(1)       32(1)  
          C(28)       -7238(2)      14226(1)       6872(1)       27(1)  
          C(29)       -3794(3)      15033(1)       6764(1)       28(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for SANA.  
           _____________________________________________________________  
   
            C(1)-C(6)                     1.398(2)  
            C(1)-C(2)                     1.399(2)  
            C(1)-C(10)                    1.527(2)  
            C(2)-C(3)                     1.382(2)  
            C(3)-C(4)                     1.381(2)  
            C(4)-C(5)                     1.373(3)  
            C(5)-C(6)                     1.398(2)  
            C(6)-C(7)                     1.479(2)  
            C(7)-O(1)                     1.226(2)  
            C(7)-C(8)                     1.460(2)  
            C(8)-C(9)                     1.328(2)  
            C(9)-C(10)                    1.503(2)  
            C(10)-C(13)                   1.569(2)  
            C(10)-C(11)                   1.573(2)  
            C(11)-C(12)                   1.509(2)  
            C(11)-C(14)                   1.516(2)  
            C(12)-O(4)                    1.2337(18)  
            C(12)-N(1)                    1.345(2)  
            N(1)-C(18)                    1.459(2)  
            N(1)-C(13)                    1.4647(19)  
            C(13)-C(25)                   1.527(2)  
            C(14)-C(15)                   1.509(2)  
            C(15)-O(2)                    1.2050(19)  
            C(15)-O(3)                    1.334(2)  
            O(3)-C(16)                    1.460(2)  
            C(16)-C(17)                   1.493(2)  
            C(18)-C(19)                   1.512(2)  
            C(19)-C(20)                   1.385(2)  
            C(19)-C(24)                   1.387(2)  
            C(20)-C(21)                   1.385(2)  
            C(21)-C(22)                   1.381(3)  
            C(22)-C(23)                   1.384(3)  
            C(23)-C(24)                   1.382(2)  
            C(25)-O(5)                    1.2321(19)  
            C(25)-N(2)                    1.339(2)  
            N(2)-C(26)                    1.480(2)  
            C(26)-C(28)                   1.519(2)  
            C(26)-C(27)                   1.520(2)  
            C(26)-C(29)                   1.530(2)  
   
            C(6)-C(1)-C(2)              118.03(15)  
            C(6)-C(1)-C(10)             120.69(15)  
            C(2)-C(1)-C(10)             121.28(14)  
            C(3)-C(2)-C(1)              120.94(16)  
            C(4)-C(3)-C(2)              120.74(17)  
            C(5)-C(4)-C(3)              119.17(16)  
            C(4)-C(5)-C(6)              120.99(16)  
            C(1)-C(6)-C(5)              120.10(16)  
            C(1)-C(6)-C(7)              121.80(15)  
            C(5)-C(6)-C(7)              118.01(15)  
            O(1)-C(7)-C(8)              121.68(16)  
            O(1)-C(7)-C(6)              122.03(16)  
            C(8)-C(7)-C(6)              116.26(14)  
            C(9)-C(8)-C(7)              122.19(16)  
            C(8)-C(9)-C(10)             124.48(16)  
            C(9)-C(10)-C(1)             112.08(13)  
            C(9)-C(10)-C(13)            114.79(13)  
            C(1)-C(10)-C(13)            109.13(13)  
            C(9)-C(10)-C(11)            106.95(13)  
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            C(1)-C(10)-C(11)            112.47(13)  
            C(13)-C(10)-C(11)           100.94(12)  
            C(12)-C(11)-C(14)           115.72(13)  
            C(12)-C(11)-C(10)           104.40(12)  
            C(14)-C(11)-C(10)           117.13(13)  
            O(4)-C(12)-N(1)             125.38(15)  
            O(4)-C(12)-C(11)            126.37(14)  
            N(1)-C(12)-C(11)            108.16(13)  
            C(12)-N(1)-C(18)            123.55(13)  
            C(12)-N(1)-C(13)            114.44(13)  
            C(18)-N(1)-C(13)            121.66(13)  
            N(1)-C(13)-C(25)            107.46(12)  
            N(1)-C(13)-C(10)            103.44(12)  
            C(25)-C(13)-C(10)           115.69(13)  
            C(15)-C(14)-C(11)           110.72(13)  
            O(2)-C(15)-O(3)             124.12(16)  
            O(2)-C(15)-C(14)            123.65(16)  
            O(3)-C(15)-C(14)            112.23(14)  
            C(15)-O(3)-C(16)            115.18(13)  
            O(3)-C(16)-C(17)            107.21(14)  
            N(1)-C(18)-C(19)            111.38(13)  
            C(20)-C(19)-C(24)           118.85(16)  
            C(20)-C(19)-C(18)           121.60(15)  
            C(24)-C(19)-C(18)           119.46(15)  
            C(19)-C(20)-C(21)           120.54(17)  
            C(22)-C(21)-C(20)           120.17(17)  
            C(21)-C(22)-C(23)           119.77(17)  
            C(24)-C(23)-C(22)           119.87(17)  
            C(23)-C(24)-C(19)           120.80(17)  
            O(5)-C(25)-N(2)             125.16(15)  
            O(5)-C(25)-C(13)            120.40(14)  
            N(2)-C(25)-C(13)            114.35(14)  
            C(25)-N(2)-C(26)            125.12(14)  
            N(2)-C(26)-C(28)            105.93(13)  
            N(2)-C(26)-C(27)            110.49(14)  
            C(28)-C(26)-C(27)           109.71(14)  
            N(2)-C(26)-C(29)            108.52(13)  
            C(28)-C(26)-C(29)           110.47(14)  
            C(27)-C(26)-C(29)           111.57(15)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for SANA.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)     15(1)      17(1)      20(1)       5(1)       3(1)       6(1)  
    C(2)     22(1)      22(1)      20(1)       4(1)       2(1)       4(1)  
    C(3)     26(1)      31(1)      20(1)       9(1)       5(1)       8(1)  
    C(4)     28(1)      25(1)      31(1)      15(1)       8(1)       7(1)  
    C(5)     27(1)      20(1)      34(1)       7(1)       5(1)       2(1)  
    C(6)     19(1)      17(1)      26(1)       4(1)       3(1)       5(1)  
    C(7)     21(1)      20(1)      29(1)      -1(1)       3(1)       2(1)  
    O(1)     48(1)      20(1)      38(1)      -3(1)       5(1)      -4(1)  
    C(8)     21(1)      24(1)      20(1)      -2(1)       0(1)       3(1)  
    C(9)     20(1)      21(1)      18(1)       3(1)       1(1)       7(1)  
    C(10)    19(1)      18(1)      14(1)       2(1)       2(1)       4(1)  
    C(11)    18(1)      20(1)      15(1)       3(1)       3(1)       4(1)  
    C(12)    20(1)      19(1)      14(1)       6(1)       3(1)       2(1)  
    N(1)     20(1)      16(1)      14(1)       0(1)       1(1)       2(1)  
    C(13)    18(1)      17(1)      15(1)       2(1)       3(1)       3(1)  
    C(14)    20(1)      27(1)      19(1)       3(1)       1(1)       7(1)  
    C(15)    16(1)      27(1)      21(1)       4(1)       5(1)       7(1)  
    O(2)     33(1)      30(1)      20(1)       4(1)       8(1)       5(1)  
    O(3)     34(1)      22(1)      17(1)       1(1)       3(1)       7(1)  
    C(16)    36(1)      25(1)      17(1)      -2(1)       3(1)       7(1)  
    C(17)    52(1)      25(1)      26(1)       2(1)       2(1)       6(1)  
    O(4)     19(1)      25(1)      19(1)       3(1)       0(1)       0(1)  
    C(18)    28(1)      16(1)      18(1)       0(1)       2(1)       1(1)  
    C(19)    26(1)      12(1)      17(1)      -1(1)       1(1)      -1(1)  
    C(20)    25(1)      24(1)      23(1)      -2(1)       0(1)       3(1)  
    C(21)    24(1)      32(1)      27(1)      -3(1)       7(1)      -2(1)  
    C(22)    39(1)      32(1)      19(1)      -1(1)       7(1)      -7(1)  
    C(23)    40(1)      26(1)      20(1)       3(1)       0(1)       1(1)  
    C(24)    27(1)      24(1)      23(1)       0(1)       2(1)       3(1)  
    C(25)    23(1)      13(1)      16(1)       0(1)       1(1)       2(1)  
    O(5)     24(1)      27(1)      20(1)       8(1)       8(1)       6(1)  
    N(2)     21(1)      17(1)      17(1)       6(1)       3(1)       4(1)  
    C(26)    24(1)      20(1)      20(1)       8(1)       4(1)       7(1)  
    C(27)    39(1)      35(1)      23(1)       7(1)      -1(1)      12(1)  
    C(28)    26(1)      26(1)      32(1)      12(1)       4(1)       9(1)  
    C(29)    34(1)      22(1)      31(1)      10(1)       5(1)       3(1)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for SANA.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(2)        -1421         11393          9352          25  
          H(3)        -2291         10301         10430          30  
          H(4)        -3512          8525          9942          32  
          H(5)        -3920          7858          8359          32  
          H(8)        -3713          9299          5593          27  
          H(9)        -2627         11014          6037          23  
          H(11)         792         11468          6812          21  
          H(13)       -3269         12137          8240          20  
          H(14A)       3193         10562          7715          26  
          H(14B)       1267          9852          7925          26  
          H(16A)       2420          7978          5384          32  
          H(16B)        108          8117          5219          32  
          H(17A)       1709          6594          6237          41  
          H(17B)        457          6320          5234          41  
          H(17C)       -590          6756          6132          41  
          H(18A)      -1048         14204          8557          25  
          H(18B)       1124         14069          9005          25  
          H(20)       -3781         14099          9505          29  
          H(21)       -4989         13889         10924          34  
          H(22)       -3001         13310         12097          37  
          H(23)         211         12943         11846          35  
          H(24)        1426         13170         10432          30  
          H(1N2)      -5170(20)     13070(13)      7603(12)      21(5)  
          H(27A)      -4169         13468          5310          38  
          H(27B)      -6104         14065          5165          38  
          H(27C)      -6294         12883          5418          38  
          H(28A)      -8143         13568          6731          33  
          H(28B)      -7772         14772          6544          33  
          H(28C)      -7091         14471          7546          33  
          H(29A)      -3650         15290          7436          34  
          H(29B)      -4306         15577          6425          34  
          H(29C)      -2504         14881          6564          34  
         ________________________________________________________________  
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         Table 6.  Torsion angles [deg] for SANA.  
         ________________________________________________________________  
   
          C(6)-C(1)-C(2)-C(3)                                  -0.7(2)  
          C(10)-C(1)-C(2)-C(3)                                179.24(14)  
          C(1)-C(2)-C(3)-C(4)                                   1.5(3)  
          C(2)-C(3)-C(4)-C(5)                                  -0.7(3)  
          C(3)-C(4)-C(5)-C(6)                                  -0.7(3)  
          C(2)-C(1)-C(6)-C(5)                                  -0.7(2)  
          C(10)-C(1)-C(6)-C(5)                                179.36(14)  
          C(2)-C(1)-C(6)-C(7)                                 175.79(15)  
          C(10)-C(1)-C(6)-C(7)                                 -4.2(2)  
          C(4)-C(5)-C(6)-C(1)                                   1.4(3)  
          C(4)-C(5)-C(6)-C(7)                                -175.18(15)  
          C(1)-C(6)-C(7)-O(1)                                 174.52(16)  
          C(5)-C(6)-C(7)-O(1)                                  -9.0(2)  
          C(1)-C(6)-C(7)-C(8)                                  -7.7(2)  
          C(5)-C(6)-C(7)-C(8)                                 168.77(15)  
          O(1)-C(7)-C(8)-C(9)                                -174.85(16)  
          C(6)-C(7)-C(8)-C(9)                                   7.4(2)  
          C(7)-C(8)-C(9)-C(10)                                  5.4(3)  
          C(8)-C(9)-C(10)-C(1)                                -16.4(2)  
          C(8)-C(9)-C(10)-C(13)                              -141.61(16)  
          C(8)-C(9)-C(10)-C(11)                               107.33(18)  
          C(6)-C(1)-C(10)-C(9)                                 15.3(2)  
          C(2)-C(1)-C(10)-C(9)                               -164.69(14)  
          C(6)-C(1)-C(10)-C(13)                               143.60(14)  
          C(2)-C(1)-C(10)-C(13)                               -36.39(19)  
          C(6)-C(1)-C(10)-C(11)                              -105.25(16)  
          C(2)-C(1)-C(10)-C(11)                                74.76(18)  
          C(9)-C(10)-C(11)-C(12)                              148.45(13)  
          C(1)-C(10)-C(11)-C(12)                              -88.08(15)  
          C(13)-C(10)-C(11)-C(12)                              28.10(15)  
          C(9)-C(10)-C(11)-C(14)                              -82.12(17)  
          C(1)-C(10)-C(11)-C(14)                               41.34(19)  
          C(13)-C(10)-C(11)-C(14)                             157.52(14)  
          C(14)-C(11)-C(12)-O(4)                               32.8(2)  
          C(10)-C(11)-C(12)-O(4)                              163.11(15)  
          C(14)-C(11)-C(12)-N(1)                             -150.30(14)  
          C(10)-C(11)-C(12)-N(1)                              -20.04(16)  
          O(4)-C(12)-N(1)-C(18)                                 6.0(2)  
          C(11)-C(12)-N(1)-C(18)                             -170.90(13)  
          O(4)-C(12)-N(1)-C(13)                               179.26(14)  
          C(11)-C(12)-N(1)-C(13)                                2.36(17)  
          C(12)-N(1)-C(13)-C(25)                             -106.53(15)  
          C(18)-N(1)-C(13)-C(25)                               66.87(17)  
          C(12)-N(1)-C(13)-C(10)                               16.32(17)  
          C(18)-N(1)-C(13)-C(10)                             -170.28(13)  
          C(9)-C(10)-C(13)-N(1)                              -141.04(13)  
          C(1)-C(10)-C(13)-N(1)                                92.19(14)  
          C(11)-C(10)-C(13)-N(1)                              -26.43(15)  
          C(9)-C(10)-C(13)-C(25)                              -23.82(19)  
          C(1)-C(10)-C(13)-C(25)                             -150.59(13)  
          C(11)-C(10)-C(13)-C(25)                              90.79(15)  
          C(12)-C(11)-C(14)-C(15)                            -153.33(14)  
          C(10)-C(11)-C(14)-C(15)                              82.82(18)  
          C(11)-C(14)-C(15)-O(2)                               48.9(2)  
          C(11)-C(14)-C(15)-O(3)                             -130.82(14)  
          O(2)-C(15)-O(3)-C(16)                                -1.3(2)  
          C(14)-C(15)-O(3)-C(16)                              178.43(13)  
          C(15)-O(3)-C(16)-C(17)                              179.93(14)  
          C(12)-N(1)-C(18)-C(19)                             -108.34(17)  
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          C(13)-N(1)-C(18)-C(19)                               78.87(18)  
          N(1)-C(18)-C(19)-C(20)                              -99.13(18)  
          N(1)-C(18)-C(19)-C(24)                               77.34(18)  
          C(24)-C(19)-C(20)-C(21)                               0.4(2)  
          C(18)-C(19)-C(20)-C(21)                             176.91(15)  
          C(19)-C(20)-C(21)-C(22)                              -0.4(3)  
          C(20)-C(21)-C(22)-C(23)                               0.0(3)  
          C(21)-C(22)-C(23)-C(24)                               0.3(3)  
          C(22)-C(23)-C(24)-C(19)                              -0.3(3)  
          C(20)-C(19)-C(24)-C(23)                              -0.1(2)  
          C(18)-C(19)-C(24)-C(23)                            -176.66(15)  
          N(1)-C(13)-C(25)-O(5)                                58.57(18)  
          C(10)-C(13)-C(25)-O(5)                              -56.38(19)  
          N(1)-C(13)-C(25)-N(2)                              -118.19(14)  
          C(10)-C(13)-C(25)-N(2)                              126.87(15)  
          O(5)-C(25)-N(2)-C(26)                                -6.3(3)  
          C(13)-C(25)-N(2)-C(26)                              170.30(13)  
          C(25)-N(2)-C(26)-C(28)                              179.59(15)  
          C(25)-N(2)-C(26)-C(27)                               60.8(2)  
          C(25)-N(2)-C(26)-C(29)                              -61.8(2)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
 
 
  Table 7.  Hydrogen bonds for SANA [A and deg.].  
 ____________________________________________________________________________  
   
 Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N2-H1N2        0.918    2.075   168.81    2.981    O4 [ x-1, y, z ] 
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6. Compound (±)-370a 
 
      Table 1.  Crystal data and structure refinement for YANT.  
   
   
      Identification code               yant  
   
      Empirical formula                 C9 H16 O6  
   
      Formula weight                    220.22  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Orthorhombic,  P212121  
   
      Unit cell dimensions              a = 9.2341(2) A   alpha = 90 deg.  
                                        b = 9.4269(2) A    beta = 90 deg.  
                                        c = 12.2070(3) A   gamma = 90 deg.  
   
      Volume                            1062.61(4) A^3  
   
      Z, Calculated density             4,  1.377 Mg/m^3  
   
      Absorption coefficient            0.116 mm^-1  
   
      F(000)                            472  
   
      Crystal size                      0.30 x 0.16 x 0.10 mm  
   
      Theta range for data collection   2.73 to 29.13 deg.  
   
      Limiting indices                  -12<=h<=12, 0<=k<=12, 0<=l<=16  
   
      Reflections collected / unique    22079 / 2846 [R(int) = 0.0409]  
   
      Completeness to theta = 28.30     100.0 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9885 and 0.9660  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    2846 / 0 / 160  
   
      Goodness-of-fit on F^2            1.033  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0310, wR2 = 0.0753  
   
      R indices (all data)              R1 = 0.0349, wR2 = 0.0775  
   
      Absolute structure parameter      -0.1(7)  
   
      Largest diff. peak and hole       0.299 and -0.174 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for YANT.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          O(1)         3728(1)      -1535(1)       7807(1)       14(1)  
          C(1)         4978(1)       -764(1)       7447(1)       13(1)  
          C(2)         4541(1)       -110(1)       6355(1)       12(1)  
          C(3)         2950(1)        225(1)       6559(1)       12(1)  
          C(4)         2476(1)      -1123(1)       7151(1)       12(1)  
          O(2)         5299(1)        359(1)       8154(1)       16(1)  
          C(5)         5981(1)        -94(1)       9156(1)       18(1)  
          C(6)         5935(2)       1105(1)       9945(1)       18(1)  
          C(7)         7092(2)       1638(2)      10428(1)       29(1)  
          O(3)         5413(1)       1041(1)       6016(1)       15(1)  
          O(4)         2175(1)        447(1)       5572(1)       16(1)  
          C(8)         1140(1)       -970(1)       7866(1)       13(1)  
          O(5)         1275(1)        130(1)       8651(1)       15(1)  
          C(9)          733(1)      -2372(1)       8403(1)       17(1)  
          O(6)         -601(1)      -2256(1)       8988(1)       18(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for YANT.  
           _____________________________________________________________  
   
            O(1)-C(1)                     1.4334(15)  
            O(1)-C(4)                     1.4588(14)  
            C(1)-O(2)                     1.3979(15)  
            C(1)-C(2)                     1.5222(17)  
            C(2)-O(3)                     1.4136(14)  
            C(2)-C(3)                     1.5239(16)  
            C(3)-O(4)                     1.4161(14)  
            C(3)-C(4)                     1.5260(16)  
            C(4)-C(8)                     1.5185(16)  
            O(2)-C(5)                     1.4404(15)  
            C(5)-C(6)                     1.4853(18)  
            C(6)-C(7)                     1.320(2)  
            C(8)-O(5)                     1.4168(14)  
            C(8)-C(9)                     1.5230(17)  
            C(9)-O(6)                     1.4283(15)  
   
            C(1)-O(1)-C(4)              109.56(9)  
            O(2)-C(1)-O(1)              111.43(10)  
            O(2)-C(1)-C(2)              106.88(9)  
            O(1)-C(1)-C(2)              105.09(9)  
            O(3)-C(2)-C(1)              114.62(10)  
            O(3)-C(2)-C(3)              115.98(9)  
            C(1)-C(2)-C(3)              101.37(9)  
            O(4)-C(3)-C(2)              112.27(9)  
            O(4)-C(3)-C(4)              112.41(10)  
            C(2)-C(3)-C(4)              100.42(9)  
            O(1)-C(4)-C(8)              110.75(9)  
            O(1)-C(4)-C(3)              104.77(9)  
            C(8)-C(4)-C(3)              115.22(10)  
            C(1)-O(2)-C(5)              113.13(9)  
            O(2)-C(5)-C(6)              108.22(10)  
            C(7)-C(6)-C(5)              123.76(13)  
            O(5)-C(8)-C(4)              112.73(10)  
            O(5)-C(8)-C(9)              111.50(10)  
            C(4)-C(8)-C(9)              111.42(10)  
            O(6)-C(9)-C(8)              111.16(10)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for YANT.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    O(1)     14(1)      14(1)      15(1)       4(1)      -1(1)       1(1)  
    C(1)     14(1)      13(1)      13(1)       0(1)       0(1)       0(1)  
    C(2)     14(1)      11(1)      12(1)       0(1)       1(1)       0(1)  
    C(3)     14(1)      12(1)      10(1)       1(1)       0(1)       1(1)  
    C(4)     13(1)      12(1)      11(1)       0(1)      -1(1)       0(1)  
    O(2)     20(1)      14(1)      12(1)       1(1)      -4(1)       0(1)  
    C(5)     21(1)      18(1)      15(1)       2(1)      -5(1)       0(1)  
    C(6)     23(1)      18(1)      14(1)       3(1)      -1(1)       0(1)  
    C(7)     37(1)      20(1)      30(1)      -2(1)     -16(1)       3(1)  
    O(3)     18(1)      15(1)      12(1)       0(1)       0(1)      -5(1)  
    O(4)     17(1)      19(1)      11(1)       1(1)      -2(1)       5(1)  
    C(8)     14(1)      14(1)      11(1)       0(1)       0(1)       0(1)  
    O(5)     18(1)      15(1)      13(1)      -3(1)      -1(1)       1(1)  
    C(9)     19(1)      16(1)      17(1)       1(1)       4(1)      -2(1)  
    O(6)     18(1)      21(1)      15(1)      -3(1)       3(1)      -7(1)  
    _______________________________________________________________________  
  
 
 
         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for YANT.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1)         5831         -1407          7358          16  
          H(2)         4597          -865          5781          15  
          H(3)         2852          1067          7052          15  
          H(4)         2290         -1878          6594          14  
          H(5A)        6997          -372          9013          22  
          H(5B)        5463          -924          9462          22  
          H(6)         5019          1510         10113          22  
          H(8)          321          -703          7371          15  
          H(9A)         641         -3114          7833          21  
          H(9B)        1511         -2663          8913          21  
          H(7A)        7020(20)      2420(20)     10961(17)      43(5)  
          H(7B)        8020(20)      1230(20)     10238(17)      45(6)  
          H(03)        5650(20)      1510(20)      6547(16)      32(5)  
          H(04)        1570(20)      1174(19)      5666(16)      30(5)  
          H(05)        1880(20)       -99(18)      9102(14)      26(4)  
          H(06)        -510(20)     -1760(20)      9481(19)      46(6)  
         ________________________________________________________________  
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         Table 6.  Torsion angles [deg] for YANT.  
         ________________________________________________________________  
   
          C(4)-O(1)-C(1)-O(2)                                 102.02(11)  
          C(4)-O(1)-C(1)-C(2)                                 -13.38(12)  
          O(2)-C(1)-C(2)-O(3)                                  42.47(13)  
          O(1)-C(1)-C(2)-O(3)                                 160.98(9)  
          O(2)-C(1)-C(2)-C(3)                                 -83.24(10)  
          O(1)-C(1)-C(2)-C(3)                                  35.27(11)  
          O(3)-C(2)-C(3)-O(4)                                  73.15(13)  
          C(1)-C(2)-C(3)-O(4)                                -162.05(9)  
          O(3)-C(2)-C(3)-C(4)                                -167.24(10)  
          C(1)-C(2)-C(3)-C(4)                                 -42.43(10)  
          C(1)-O(1)-C(4)-C(8)                                -138.89(10)  
          C(1)-O(1)-C(4)-C(3)                                 -14.06(12)  
          O(4)-C(3)-C(4)-O(1)                                 154.77(9)  
          C(2)-C(3)-C(4)-O(1)                                  35.25(11)  
          O(4)-C(3)-C(4)-C(8)                                 -83.28(12)  
          C(2)-C(3)-C(4)-C(8)                                 157.20(10)  
          O(1)-C(1)-O(2)-C(5)                                  76.32(12)  
          C(2)-C(1)-O(2)-C(5)                                -169.39(9)  
          C(1)-O(2)-C(5)-C(6)                                -166.05(10)  
          O(2)-C(5)-C(6)-C(7)                                -124.39(14)  
          O(1)-C(4)-C(8)-O(5)                                  63.68(12)  
          C(3)-C(4)-C(8)-O(5)                                 -54.99(13)  
          O(1)-C(4)-C(8)-C(9)                                 -62.56(13)  
          C(3)-C(4)-C(8)-C(9)                                 178.77(10)  
          O(5)-C(8)-C(9)-O(6)                                  58.68(14)  
          C(4)-C(8)-C(9)-O(6)                                -174.41(10)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
  
 
 
 Table 7.  Hydrogen bonds for YANT [A and deg.].  
 ____________________________________________________________________________  
   
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O3-H03         0.814    2.086   148.64    2.813    O1 [ -x+1, y+1/2, -z+3/2 ] 
 O3-H03         0.814    2.264   113.18    2.691    O2  
 
 O4-H04         0.891    1.782   170.03    2.664    O6 [ -x, y+1/2, -z+3/2 ] 
 
 O5-H05         0.813    2.023   160.09    2.801    O4 [ -x+1/2, -y, z+1/2 ] 
 
 O6-H06         0.767    1.993   161.74    2.732    O3 [ -x+1/2, -y, z+1/2 ] 
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7. Compound (±)-417 
 
      Table 1.  Crystal data and structure refinement for saat.  
   
   
      Identification code               saat  
   
      Empirical formula                 C16 H28 N2 O4  
   
      Formula weight                    312.40  
   
      Temperature                       100(2) K  
   
      Wavelength                        0.71073 A  
   
      Crystal system, space group       Monoclinic,  P21/n  
   
      Unit cell dimensions              a = 9.4522(4) A   alpha = 90 deg.  
                                        b = 15.3510(7) A    beta = 94.172(3) 
deg.  
                                        c = 13.2985(6) A   gamma = 90 deg.  
   
      Volume                            1924.51(15) A^3  
   
      Z, Calculated density             4,  1.078 Mg/m^3  
   
      Absorption coefficient            0.077 mm^-1  
   
      F(000)                            680  
   
      Crystal size                      0.25 x 0.15 x 0.10 mm  
   
      Theta range for data collection   2.03 to 28.45 deg.  
   
      Limiting indices                  -12<=h<=12, 0<=k<=20, 0<=l<=17  
   
      Reflections collected / unique    60608 / 4809 [R(int) = 0.0900]  
   
      Completeness to theta = 28.30     100.0 %  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9923 and 0.9810  
   
      Refinement method                 Full-matrix least-squares on F^2  
   
      Data / restraints / parameters    4809 / 0 / 234  
   
      Goodness-of-fit on F^2            1.150  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0785, wR2 = 0.1926  
   
      R indices (all data)              R1 = 0.1174, wR2 = 0.2106  
   
      Largest diff. peak and hole       0.396 and -0.230 e.A^-3  
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         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic  
         displacement parameters (A^2 x 10^3) for saat.  
         U(eq) is defined as one third of the trace of the orthogonalized  
         Uij tensor.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          C(1)         3281(4)      -5782(2)      10474(4)       62(1)  
          C(2)         2157(3)      -5132(2)      10164(3)       33(1)  
          O(1)         2817(2)      -4277(1)      10279(2)       28(1)  
          C(3)         1936(3)      -3594(2)      10190(2)       24(1)  
          O(2)          673(2)      -3646(1)      10032(2)       36(1)  
          C(4)         2751(3)      -2767(2)      10292(2)       23(1)  
          C(5)         2101(3)      -2003(2)      10290(2)       21(1)  
          C(6)         2928(2)      -1174(2)      10349(2)       19(1)  
          O(3)         4238(2)      -1177(1)      10347(2)       28(1)  
          N(1)         2146(2)       -451(1)      10383(2)       19(1)  
          C(7)         2760(2)        421(2)      10388(2)       20(1)  
          C(8)         2697(3)        879(2)      11427(2)       26(1)  
          C(9)         1212(3)        853(2)      11811(2)       35(1)  
          C(10)        3153(4)       1834(2)      11321(2)       37(1)  
          C(11)        3751(3)        413(2)      12175(2)       36(1)  
          C(12)        2012(2)        923(2)       9509(2)       20(1)  
          O(4)          704(2)        938(1)       9388(1)       26(1)  
          N(2)         2870(2)       1318(1)       8906(2)       23(1)  
          C(13)        2439(3)       1838(2)       8000(2)       28(1)  
          C(14)        3799(3)       2107(3)       7542(3)       53(1)  
          C(15)        1546(4)       1294(3)       7248(2)       54(1)  
          C(16)        1632(4)       2640(2)       8286(3)       56(1)  
         ________________________________________________________________  
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           Table 3.  Bond lengths [A] and angles [deg] for saat.  
           _____________________________________________________________  
   
            C(1)-C(2)                     1.494(5)  
            C(2)-O(1)                     1.458(3)  
            O(1)-C(3)                     1.339(3)  
            C(3)-O(2)                     1.199(3)  
            C(3)-C(4)                     1.485(3)  
            C(4)-C(5)                     1.324(3)  
            C(5)-C(6)                     1.492(3)  
            C(6)-O(3)                     1.238(3)  
            C(6)-N(1)                     1.336(3)  
            N(1)-C(7)                     1.460(3)  
            C(7)-C(12)                    1.529(3)  
            C(7)-C(8)                     1.555(4)  
            C(8)-C(9)                     1.528(4)  
            C(8)-C(11)                    1.532(4)  
            C(8)-C(10)                    1.538(4)  
            C(12)-O(4)                    1.236(3)  
            C(12)-N(2)                    1.328(3)  
            N(2)-C(13)                    1.477(3)  
            C(13)-C(15)                   1.512(4)  
            C(13)-C(16)                   1.512(4)  
            C(13)-C(14)                   1.519(4)  
   
            O(1)-C(2)-C(1)              106.4(3)  
            C(3)-O(1)-C(2)              115.9(2)  
            O(2)-C(3)-O(1)              124.6(2)  
            O(2)-C(3)-C(4)              125.2(2)  
            O(1)-C(3)-C(4)              110.2(2)  
            C(5)-C(4)-C(3)              121.3(2)  
            C(4)-C(5)-C(6)              120.9(2)  
            O(3)-C(6)-N(1)              123.9(2)  
            O(3)-C(6)-C(5)              121.1(2)  
            N(1)-C(6)-C(5)              114.9(2)  
            C(6)-N(1)-C(7)              122.8(2)  
            N(1)-C(7)-C(12)             107.27(19)  
            N(1)-C(7)-C(8)              112.2(2)  
            C(12)-C(7)-C(8)             114.0(2)  
            C(9)-C(8)-C(11)             109.9(2)  
            C(9)-C(8)-C(10)             109.0(2)  
            C(11)-C(8)-C(10)            109.3(2)  
            C(9)-C(8)-C(7)              112.4(2)  
            C(11)-C(8)-C(7)             107.5(2)  
            C(10)-C(8)-C(7)             108.6(2)  
            O(4)-C(12)-N(2)             124.2(2)  
            O(4)-C(12)-C(7)             120.8(2)  
            N(2)-C(12)-C(7)             115.0(2)  
            C(12)-N(2)-C(13)            126.6(2)  
            N(2)-C(13)-C(15)            110.4(2)  
            N(2)-C(13)-C(16)            110.4(2)  
            C(15)-C(13)-C(16)           110.3(3)  
            N(2)-C(13)-C(14)            106.4(2)  
            C(15)-C(13)-C(14)           109.5(3)  
            C(16)-C(13)-C(14)           109.7(3)  
           _____________________________________________________________  
   
           Symmetry transformations used to generate equivalent atoms:  
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    Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for saat.  
    The anisotropic displacement factor exponent takes the form:  
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]  
   
    _______________________________________________________________________  
   
              U11        U22        U33        U23        U13        U12  
    _______________________________________________________________________  
   
    C(1)     70(3)      18(2)      95(3)       0(2)     -20(2)       2(2)  
    C(2)     44(2)      14(1)      41(2)      -3(1)      -5(1)      -6(1)  
    O(1)     32(1)      13(1)      40(1)      -1(1)      -1(1)       0(1)  
    C(3)     29(1)      16(1)      27(1)       1(1)       1(1)      -3(1)  
    O(2)     28(1)      20(1)      59(1)      -2(1)       2(1)      -4(1)  
    C(4)     22(1)      19(1)      27(1)       1(1)       1(1)      -2(1)  
    C(5)     17(1)      17(1)      28(1)       1(1)       1(1)      -2(1)  
    C(6)     19(1)      15(1)      23(1)       3(1)       2(1)      -1(1)  
    O(3)     16(1)      19(1)      49(1)       3(1)       1(1)       0(1)  
    N(1)     13(1)      14(1)      31(1)       2(1)       2(1)      -2(1)  
    C(7)     17(1)      15(1)      28(1)       1(1)       3(1)      -1(1)  
    C(8)     31(1)      18(1)      27(1)      -2(1)       2(1)      -4(1)  
    C(9)     39(2)      31(2)      35(2)      -4(1)      12(1)       0(1)  
    C(10)    54(2)      21(1)      37(2)      -5(1)       3(1)     -10(1)  
    C(11)    44(2)      36(2)      28(2)       1(1)      -6(1)      -1(1)  
    C(12)    18(1)      15(1)      26(1)      -1(1)       1(1)       0(1)  
    O(4)     17(1)      24(1)      36(1)       8(1)       3(1)       1(1)  
    N(2)     15(1)      26(1)      29(1)       6(1)       0(1)      -3(1)  
    C(13)    27(1)      30(2)      25(1)       8(1)       0(1)      -4(1)  
    C(14)    34(2)      79(3)      47(2)      34(2)      -1(1)     -14(2)  
    C(15)    66(2)      62(2)      31(2)       9(2)      -8(2)     -31(2)  
    C(16)    79(3)      38(2)      53(2)      21(2)      14(2)      21(2)  
    _______________________________________________________________________  
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         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic  
         displacement parameters (A^2 x 10^3) for saat.  
   
         ________________________________________________________________  
   
                         x             y             z           U(eq)  
         ________________________________________________________________  
   
          H(1A)        4070         -5724         10040          74  
          H(1B)        2886         -6372         10409          74  
          H(1C)        3624         -5678         11177          74  
          H(9A)         913           246         11877          42  
          H(9B)         546          1156         11332          42  
          H(9C)        1227          1140         12470          42  
          H(10A)       3169          2121         11979          45  
          H(10B)       2479          2133         10844          45  
          H(10C)       4103          1856         11071          45  
          H(11A)       4708           456         11940          44  
          H(11B)       3484          -202         12224          44  
          H(11C)       3736           687         12840          44  
          H(14A)       4367          2472          8023          64  
          H(14B)       3566          2437          6921          64  
          H(14C)       4342          1587          7387          64  
          H(15A)       2089           784          7059          64  
          H(15B)       1284          1644          6647          64  
          H(15C)        684          1103          7553          64  
          H(16A)        783          2464          8616          67  
          H(16B)       1350          2977          7678          67  
          H(16C)       2238          2999          8750          67  
          H(2A)        1820(30)     -5200(20)      9480(20)      32(8)  
          H(2B)        1340(30)     -5160(20)     10570(20)      31(8)  
          H(4)         3780(30)     -2854(18)     10360(20)      23(7)  
          H(5)         1090(30)     -1970(20)     10220(20)      34(8)  
          H(1N1)       1240(30)      -530(20)     10380(20)      32(8)  
          H(7)         3800(20)       341(15)     10277(17)       7(6)  
          H(1N2)       3790(30)      1266(18)      9060(20)      18(7)  
         ________________________________________________________________  
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         Table 6.  Torsion angles [deg] for saat.  
         ________________________________________________________________  
   
          C(1)-C(2)-O(1)-C(3)                                -170.0(3)  
          C(2)-O(1)-C(3)-O(2)                                   0.4(4)  
          C(2)-O(1)-C(3)-C(4)                                -178.3(2)  
          O(2)-C(3)-C(4)-C(5)                                   5.4(4)  
          O(1)-C(3)-C(4)-C(5)                                -175.9(2)  
          C(3)-C(4)-C(5)-C(6)                                -177.4(2)  
          C(4)-C(5)-C(6)-O(3)                                   3.9(4)  
          C(4)-C(5)-C(6)-N(1)                                -177.3(2)  
          O(3)-C(6)-N(1)-C(7)                                   2.1(4)  
          C(5)-C(6)-N(1)-C(7)                                -176.6(2)  
          C(6)-N(1)-C(7)-C(12)                                124.7(2)  
          C(6)-N(1)-C(7)-C(8)                                -109.4(3)  
          N(1)-C(7)-C(8)-C(9)                                 -50.9(3)  
          C(12)-C(7)-C(8)-C(9)                                 71.3(3)  
          N(1)-C(7)-C(8)-C(11)                                 70.2(3)  
          C(12)-C(7)-C(8)-C(11)                              -167.6(2)  
          N(1)-C(7)-C(8)-C(10)                               -171.6(2)  
          C(12)-C(7)-C(8)-C(10)                               -49.4(3)  
          N(1)-C(7)-C(12)-O(4)                                 49.8(3)  
          C(8)-C(7)-C(12)-O(4)                                -75.0(3)  
          N(1)-C(7)-C(12)-N(2)                               -129.6(2)  
          C(8)-C(7)-C(12)-N(2)                                105.6(3)  
          O(4)-C(12)-N(2)-C(13)                                 0.0(4)  
          C(7)-C(12)-N(2)-C(13)                               179.3(2)  
          C(12)-N(2)-C(13)-C(15)                              -58.1(4)  
          C(12)-N(2)-C(13)-C(16)                               64.1(4)  
          C(12)-N(2)-C(13)-C(14)                             -176.9(3)  
         ________________________________________________________________  
   
         Symmetry transformations used to generate equivalent atoms:  
           
  
 
 
 
 Table 7.  Hydrogen bonds for saat [A and deg.].  
 ____________________________________________________________________________  
   
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1N1        0.862    1.989   165.88    2.833    O4 [ -x, -y, -z+2 ] 
 
 N2-H1N2        0.881    1.978   169.75    2.849    O3 [ -x+1, -y, -z+2 ] 
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APPENDIX VII 
 
Summary of Results 
 
♦ Efficient and environmentally benign methodology has been developed for rapid 
synthesis of small molecules. 
♦ Structural and skeletal diversity have been achieved without any extraneous additives 
except only two cases. 
♦ Microwave irradiation can influence reactivity of molecules and can be used as a 
reagent. 
♦ A new paradigm of diversity-activity relationships (DARs) has been established. 
♦ PDMAB and PMNPAB groups have been developed as novel functional handles in 
organic synthesis and orthogonal to PMB group. 
♦ Synthesis of the trisachharide unit of the repeating tetrasachharide unit of the ZPS PS 
A1 has been achieved via linear approach. 
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Figure 41. Structural and skeletal diversity from readily available starting materials 
 
Figure 42. Synthesis of the trisachharide units have been achieved 
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Date:  Mon, 26 Apr 2010 10:24:06 +0100 [04/26/2010 05:24:06 AM EDT] 
From:  David Spring <spring@ch.cam.ac.uk>  
To:  soumava@chem.wayne.edu 
Subject:  Re: Permission of Figures 
Dear Soumava 
 
Yes of course. 
 
Let me know if you want colour files of the figures 
 
Kind regards 
 
David 
 
 
 
On 26 Apr 2010, at 04:59, soumava@chem.wayne.edu wrote: 
[Hide Quoted Text]  
Dear Prof. Spring, 
                  I am Soumava Santra from the Dept. of Chemistry, Wayne State 
University. I've worked under the supervision of Prof. Peter R. Andreana and my doctoral 
research was based of MCR, DOS and Microwave. Currently, I am writing my dissertation and 
in the introduction chapter I need to include some figures from your publication. Since I 
would like to copyright my dissertation, I was wondering if you can authorize (copyright 
permission) me to include those figures into my dissertation. For your convenience, I have a 
attached a file of those figures. I am looking forward to hear from you. 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
--------------------------- 
Dept. of Chemistry 
Wayne State University 
Detroit, MI 48201 
 
<Permission of Figures from Prof. Spring.doc> 
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Date:  Tue, 27 Apr 2010 17:54:40 +0100 [04/27/2010 12:54:40 PM EDT] 
From:  David Spring <spring@ch.cam.ac.uk>  
To:  Soumava Santra <soumava@chem.wayne.edu> 
Subject:  Re: Permission of Figures 
please just take this email as permission, but as you redrew the figures, you do not need my 
permission anyway 
 
 
On 27 Apr 2010, at 17:43, Soumava Santra wrote: 
[Hide Quoted Text]  
Dear Prof. Spring, 
                Thank you very much for your reply. I actually drew the 
figures. For copyright permission, could you you provide me a letter? or 
should I contact the publisher? 
Thanking you, 
 
Sincerely, 
 
Soumava 
 
On Mon, 26 Apr 2010, David Spring wrote:  
Dear Soumava 
 
Yes of course. 
 
Let me know if you want colour files of the figures 
 
Kind regards 
 
David 
 
 
On 26 Apr 2010, at 04:59, soumava@chem.wayne.edu wrote:  
Dear Prof. Spring, 
                 I am Soumava Santra from the Dept. of Chemistry, 
Wayne State 
University. I've worked under the supervision of Prof. Peter R. 
Andreana and my doctoral research was based of MCR, DOS and 
Microwave. Currently, I am writing my dissertation and in the 
introduction chapter I need to include some figures from your 
publication. Since I would like to copyright my dissertation, I was 
wondering if you can authorize (copyright permission) me to include 
those figures into my dissertation. For your convenience, I have a 
attached a file of those figures. I am looking forward to hear from 
you. 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
--------------------------- 
Dept. of Chemistry 
Wayne State University 
Detroit, MI 48201 
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<Permission of Figures from Prof. Spring.doc> 
 
Date:  Mon, 26 Apr 2010 09:10:28 +0200 [04/26/2010 03:10:28 AM EDT] 
From:  Kappe, Christian (oliver.kappe@uni-graz.at) <oliver.kappe@uni-graz.at>  
To:  'soumava@chem.wayne.edu' <soumava@chem.wayne.edu> 
Subject:  AW: Permission of figures 
Dear Soumava, 
 
thank you very much for your mail. I am not a specialist in copyright things but I believe you 
would need permission from the publishers, not from the authors, to reproduce these figures. 
You will have my permission, but please do check with the publisher. 
 
Best regards, Oliver 
 
_____________________ 
C. Oliver Kappe 
Christian Doppler Laboratory for Microwave Chemistry 
Institute of Chemistry, Karl-Franzens-University Graz 
Heinrichstrasse 28, A-8010 Graz, Austria 
Phone: +43-316-3805352; Fax: +43-316-3809840 
email: oliver.kappe@uni-graz.at 
__________________________________ 
Microwave & Flow Chemistry Conference, Sharm el Sheikh, Egypt, February 2011 
Register and Submit Your Abstract Now! 
www.maos.net 
 
-----Ursprüngliche Nachricht----- 
Von: soumava@chem.wayne.edu [mailto:soumava@chem.wayne.edu]  
Gesendet: Sonntag, 25. April 2010 22:27 
An: Kappe, Christian (oliver.kappe@uni-graz.at) 
Betreff: Permission of figures 
 
Dear Prof. Kappe, 
                    I am Soumava Santra from the Dept. of Chemistry, Wayne State University. 
I've worked under the supervision of Prof. Peter R.   
Andreana and my doctoral research was based of MCR and Microwave.   
Currently, I am writing my dissertation and in the introduction chapter I need to include some 
figures from your publication. Since I would like to copyright my dissertation, I was 
wondering if you can authorize (copyright permission) me to include those figures into my 
dissertation. For your convenience, I have a attached a file of those figures. I am looking 
forward to hear from you. 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
--------------------------- 
Dept. of Chemistry 
Wayne State University 
Detroit, MI 48201  
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Date:  Wed, 18 Aug 2010 10:09:33 +0100 [08/18/2010 05:09:33 AM EDT] 
From:  Permission Requests - UK <permissionsuk@wiley.com> 
To:  soumava@chem.wayne.edu <soumava@chem.wayne.edu> 
Subject:  Re: Permission of figures [pfCase:1301621, pfTicket:10432525] 
Part(s):   2 Wiley Form for Permission.xls 28 KB 
Download All Attachments (in .zip file)  
 1 unnamed 6 KB 
 
Dear Soumava Santra, 
 
Thank you for your email request. Permission is granted for you to use the material 
requested for your thesis/dissertation subject to the usual acknowledgements and on the 
understanding that you will reapply for permission if you wish to distribute or publish your 
thesis/dissertation commercially. 
 
Any third party material is expressly excluded from this permission. If any material appears 
within the article with credit to another source, authorisation from that source must be 
obtained. 
 
Best wishes,  
 
 
Richard S Jones 
Permissions Assistant 
 
Wiley-Blackwell  |  9600 Garsington Road  |  Oxford  |  OX4 2DQ  |  UK 
rjones@wiley.com  
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From: soumava@chem.wayne.edu [mailto:soumava@chem.wayne.edu]  
Sent: 18 August 2010 06:22 
To: Permission Requests - UK 
Subject: Re: FW: AW: Permission of figures [pfCase:1301621, pfTicket:10432525] 
 
Dear Cassandra, 
                I've attached the completed form herewith. Please send the permission letter as 
soon as possible. 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
 
 
 
Quoting Permission Requests - UK <permissionsuk@wiley.com>: 
[Hide Quoted Text]  
Thank you for your email, however before we can proceed with your  
request we need some information from you, regarding the material you  
would like you use and how you're wishing to use it. 
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Please complete the attached form and return it to us. 
 
Many thanks. 
 
Cassandra Fryer 
 
Permissions Assistant 
Wiley-Blackwell 
9600 Garsington Road 
Oxford OX4 2DQ 
UK 
 
Email: cassandra.fryer@wiley.com 
 
 
-----Original Message----- 
From: soumava@chem.wayne.edu [mailto:soumava@chem.wayne.edu] 
Sent: 29 April 2010 06:30 
To: Permission Requests - UK 
Subject: RE: AW: Permission of figures [pfCase:1301621,  
pfTicket:10432525] 
 
Dear Sir/Madam, 
                Please see the note from Erin and Prof. Kappe below. 
I've attached a file of those figures. I hope you will do the needful  
as early as possible. Have a wonderful day!!! 
Thanking you, 
 
Sincerely, 
 
Soumava Santr 
 
Quoting cs-journals@wiley.com:  
Dear Soumava Santra 
 
Thank you for your recent communication regarding permissions. 
Please send an e-mail to permreq@wiley.com. You will receive an  
automated response that will  outline the procedures you need to  
follow in order to request permission to use printed materials from  
aour journals. 
 
 
 
 
 
Kind Regards, 
 
 
 
Erin Cabana 
Customer Services Advisor 
Journals Customer Services  for John Wiley & Sons 
 
Looking for immediate answers to your queries? Visit Online Self-Help  
<http://www.wileycustomerhelp.com/ask>  to resolve your queries 24  
hours a day, 7 days a week 
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From: soumava@chem.wayne.edu [mailto:soumava@chem.wayne.edu] 
Sent: 27 April 2010 04:16 
To: Customer Services Enquiries 
Subject: Fwd: AW: Permission of figures [pfCase:1301621,  
pfTicket:10432525] 
 
Dear Sir/Madam, 
                Please see the note from Prof. Kappe. I've attached a   
file of those figures. Could you please send me a copyright  
permission letter as early as possible? 
 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
----- Forwarded message from oliver.kappe@uni-graz.at ----- 
      Date: Mon, 26 Apr 2010 09:10:28 +0200 
      From: "Kappe, Christian (oliver.kappe@uni-graz.at)" 
<oliver.kappe@uni-graz.at> 
Reply-To: "Kappe, Christian (oliver.kappe@uni-graz.at)" 
<oliver.kappe@uni-graz.at> 
   Subject: AW: Permission of figures 
        To: "'soumava@chem.wayne.edu'" <soumava@chem.wayne.edu> 
 
Dear Soumava, 
 
thank you very much for your mail. I am not a specialist in copyright  
things but I believe you would need permission from the publishers,  
not from the authors, to reproduce these figures. You will have my  
permission, but please do check with the publisher. 
 
Best regards, Oliver 
 
_____________________ 
C. Oliver Kappe 
Christian Doppler Laboratory for Microwave Chemistry Institute of  
Chemistry, Karl-Franzens-University Graz Heinrichstrasse 28, A-8010  
Graz, Austria 
 
Phone: +43-316-3805352; Fax: +43-316-3809840 
email: oliver.kappe@uni-graz.at 
__________________________________ 
Microwave & Flow Chemistry Conference, Sharm el Sheikh, Egypt,  
February 2011 Register and Submit Your Abstract Now! 
www.maos.net 
 
-----Ursprüngliche Nachricht----- 
Von: soumava@chem.wayne.edu [mailto:soumava@chem.wayne.edu] 
Gesendet: Sonntag, 25. April 2010 22:27 
An: Kappe, Christian (oliver.kappe@uni-graz.at) 
Betreff: Permission of figures 
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Dear Prof. Kappe, 
                      I am Soumava Santra from the Dept. of Chemistry,  
Wayne State University. I've worked under the supervision of Prof. 
 
Peter R. 
Andreana and my doctoral research was based of MCR and Microwave. 
Currently, I am writing my dissertation and in the introduction  
chapter I need to include some figures from your publication. Since I  
would like to copyright my dissertation, I was wondering if you can  
authorize (copyright permission) me to include those figures into my  
dissertation. For your convenience, I have a attached a file of those  
figures. I am looking forward to hear from you. 
 
Thanking you, 
 
Sincerely, 
 
Soumava Santra 
 
--------------------------- 
Dept. of Chemistry 
Wayne State University 
Detroit, MI 48201 
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ABSTRACT 
 
I.  MICROWAVE-INFLUENCED DIVERSITY-ORIENTED 
SYNTHESIS OF BIOLOGICALLY RELEVANT SMALL AND 
NATURAL-PRODUCT-LIKE MOLECULES VIA 
MULTICOMPONENT COUPLING REACTIONS  
 
II.  SYNTHETIC STUDIES TOWARD THE TOTAL SYNTHESIS OF 
THE REPEATING TETRASACCHARIDE UNIT OF 
ZWITTERIONIC POLYSACCHARIDE PS A1  
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 Microwave-influenced diversity-oriented synthesis of biologically relevant small 
and natural-product-like molecules via multicomponent coupling reactions (MCCRs) 
have been investigated.  Cheap, readily available starting materials in conjunction of 
microwave irradiation and employment of environmentally benign solvent (e.g. water) 
provided a common platform that allowed to access a wide array of structurally and 
skeletally diverse molecules.  The investigation allowed us to establish a new paradigm 
of diversity-activity relationships (DARs) by tuning reacting components of the MCCRs 
and proved that in contrary to the conventional use of microwave as a rate accelerating 
tool, it can be used to influence reactivity of molecules.  The method was also extended 
to develop new protecting groups (PGs, PDMAB, PMNPAB) that can be useful in 
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carbohydrate as well as other areas of synthetic organic chemistry.  Additionally, the new 
p-N,N-diemethylaminobenzyl (PDMAB) PG was employed to develop an alkoxide-based 
neutral glycosylation and further extended to study entirely neutral glycosylation via 
oxocarbenium ion. 
 We also investigated the total synthesis of the repeating tetrasaccharide unit of 
zwitterionic polysaccharide PS A1 using different strategies.  PS A1 is known to 
modulate T-cell response via MHC-II pathway and shown to prevent tumor growth.  The 
synthesis is quite challenging and we have been able to construct the trisaccharide unit of 
the repeating tetrasaccharide unit of PS A1. 
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